

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :

C12N 9/00

A2

(11) International Publication Number:

WO 98/50530

(43) International Publication Date: 12 November 1998 (12.11.98)

(21) International Application Number: PCT/US98/09249

(22) International Filing Date: 5 May 1998 (05.05.98)

(30) Priority Data:

60/046,059	9 May 1997 (09.05.97)	US
60/049,002	9 June 1997 (09.06.97)	US
60/051,718	3 July 1997 (03.07.97)	US
60/056,808	22 August 1997 (22.08.97)	US
60/061,324	2 October 1997 (02.10.97)	US
60/061,321	2 October 1997 (02.10.97)	US
60/064,866	5 November 1997 (05.11.97)	US
60/068,212	19 December 1997 (19.12.97)	US

(71) Applicant (for all designated States except US): RIBOZYME PHARMACEUTICALS, INC. [US/US]; 2950 Wilderness Place, Boulder, CO 80301 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JARVIS, Thale [US/US]; 3720 Smuggler Place, Boulder, CO 80301 (US). MATULIC-ADAMIC, Jasenka [YU/YU]; 760 South 42nd Street, Boulder, CO 80303 (US). REYNOLDS, Mark [US/US]; 4184 N. Larkspout Court, Lafayette, CO 80026 (US). KISICH, Kevin [US/US]; 2451 Jonquil Circle, Lafayette, CO 80026 (US). BELLON, Laurent [FR/FR];

2946 Glenwood Drive, Boulder, CO 80301 (US). PARRY, Tom [US/US]; 12610 Utica Street, Broomfield, CO 80020 (US). BEIGELMAN, Leonid [US/US]; 5530 Colt Drive, Longmont, CO 80503 (US). MCSWIGGEN, James, A. [US/US]; 4866 Franklin Drive, Boulder, CO 80301 (US). KARPEISKY, Alexander [US/US]; 420 Vernier Avenue, Lafayette, CO 80024 (US). BURGIN, Alex [US/US]; 832 Caminito Estrella, Chula Vista, CA 91910 (US). THOMPSON, James [US/US]; 2925 Glenwood Drive #103, Boulder, CO 80301 (US). WORKMAN, Christopher, T. [US/US]; 3910 Longwood, Boulder, CO 80303 (US). BEAUDRY, Amber [US/US]; 711 E. Genesee Street, Lafayette, CO 80026 (US). SWEEDLER, David [US/US]; 956 St. Andrews Lane, Louisville, CO 80027 (US).

(74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published


Without international search report and to be republished upon receipt of that report.

(54) Title: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF EXPRESSION OF C-RAF

(57) Abstract

Nucleic acid catalysts which modulate the expression of Raf gene; method of delivery, screening, identification, synthesis, deprotection, purification, of nucleic acid catalysts and processes for identification of nucleic acid molecules is described.

Ribozyme Motifs



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION

ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF EXPRESSION OF C-RAF

Background Of The Invention

5 This invention relates to methods and reagents for the treatment of diseases or conditions relating to the levels of expression of *raf* genes.

 The following is a discussion of relevant art, none of which is admitted to be prior art to the present invention.

 The Raf family of serine/threonine kinases function as cytoplasmic signaling
10 proteins that transduce mitogenic signals in response to activation of various growth factor receptors (for reviews, see Daum, 1994 *Trends in Biochem. Sci.* 19, 474; Katz, 1997, *Curr. Opin. Genet. Devel.* 7, 75; Marais, 1996, *Cancer Surveys* 27; Naumann, 1997, *Cancer Res.* 143, 237). c-Raf is the cellular homolog of v-Raf, the transforming element of the murine sarcoma virus 3611. The Raf family consists of three highly
15 conserved isozymes in vertebrates: c-Raf-1, which is constitutively expressed in all tissues, A-Raf, which is expressed in urogenital tissue and B-Raf which is expressed in and cerebrum and testes (Storm, 1990, *Oncogene* 5, 345). Inappropriate expression of these key genes involved in cell growth and differentiation can result in uncontrolled cell proliferation and/or propagation of damaged DNA, leading to hyperproliferative disorders
20 such as cancer, restenosis, psoriasis and rheumatoid arthritis.

 Raf is one of the major downstream effectors of Ras, a member of the class of small GDP/GTP-binding proteins involved in cellular signal transduction pathways (figure 35; Marshall, 1995, *Molec. Reprod. Devel.*, 42, 493). Appropriate mitogenic signals cause an increase in levels of the GTP-bound Ras. In its GTP-bound active state,
25 Ras binds Raf and localizes it to the plasma membrane. This results in activation of the Raf kinase activity. Activated Raf in turn phosphorylates MEK, thereby activating the

MAP kinase signaling cascade leading to cell cycle progression. Amino terminal truncation of Raf leads to constitutively active protein. Expression of either constitutively active Raf or constitutively active MEK is sufficient for oncogenic transformation of fibroblasts (Cowley, 1994, *Cell* 77, 81; Mansour, 1994, *Science* 265, 966; Kolch, 1991, 5 *Nature* 349, 426). In normal cells, the expression level of Raf is limiting in cellular transformation (Cuadrado, 1993, *Oncogene* 8, 2443). The pivotal position that the Ras and Raf family of proteins occupy in cellular signal transduction pathways emphasizes their importance in the control of normal cellular growth.

Activation of Raf in mammalian cells is triggered by a variety of growth factors and cytokines. Raf activation has been observed in cardiac myocyte cultures stimulated 10 by fibroblast growth factor (FGF), endothelin or phorbol ester (Bogoyevitch, 1995, *J. Biol. Chem.* 270, 1). Activation has also been seen in Swiss 3T3 cells treated with bombesin and platelet derived growth factor (Mitchell, 1995, *J. Biol. Chem.* 270, 8623) or with colony stimulating factor or lipopolysacchride (Reimann, 1994, *J. Immun.* 153, 398), 15 in L6 myoblasts stimulated with insulin-like growth factor (Cross, 1994, *Biochem J.* 303, 21), as well as in B cells stimulated via the immunoglobulin receptor (Kumar, 1995, *Biochem J.* 307, 215).

There is growing evidence from a number of laboratories that suggests that the Ras/Raf pathway may also be involved in cell motility (Bar-Sagi and Feramisco, 1986 20 *Science* 233, 1061; Partin *et al.*, 1988 *Cancer Res.* 48-6050; Fox *et al.*, 1994 *Oncogene* 9, 3519). These studies show that cell lines transfected with activated Ras show an increase in ruffling, pseudopod extension and chemotactic response, all of which are cell-motility-related processes. Uncontrolled cell motility has been implicated in several pathological processes such as restenosis, angiogenesis and wound healing.

25 Raf activation leads to induction of several immediate early transcription factors including NF-kB and AP-1 (Bruder, 1992, *Genes Devel.* 6, 545; Finco, 1993, *J. Biol. Chem.* 268, 17676). AP-1 regulates expression of a variety of proteases (Sato, 1994 *Oncogene* 8, 395; Gaire, 1994, *J Biol Chem* 269, 2032; Lauricell-Lefebvre, 1993,

Invasion Metastasis 13, 289; Troen, 1991, *Cell Growth Differ* 2, 23). A cascade of MMP and serine proteinase expression is implicated in the acquisition of an invasive phenotype as well as in angiogenesis in tumors (MacDougall, 1995, *Cancer and Metastasis Reviews* 14, 351). Thus, Raf signaling is expected to contribute to increased invasiveness in tumor
5 cells, leading to metastasis.

Coexpression studies of Raf-1 and Bcl-2 have shown that these proteins bind and interact to synergistically suppress apoptosis (Wang, 1994, *Oncogene* 9, 2751). Thus, overexpression of Raf-1 in tumor cells is likely to contribute to malignant transformation and increased resistance to chemotherapeutic agents. Overexpression of c-Raf-1 is
10 observed in squamous cell carcinomas of the head and neck taken from patients resistant to radiation therapy (Riva, 1995, *Oral Oncol., Eur. J. Cancer* 31B, 384) and in lung carcinomas (Rapp, 1988, *The Oncogene Handbook*, 213). Activated (truncated) Raf has been detected in a number of human cancers including small-cell lung, stomach, renal, breast and laryngeal cancer (Rapp, 1988, *The Oncogene Handbook*, 213).

15 Therapeutic intervention in down-regulating Raf expression have focused on antisense oligonucleotide approaches:

Antisense oligonucleotides targeting c-Raf-1 were used to demonstrate that IL-2 stimulated growth of T cells requires c-raf (Riedel, 1993, *Eur. J. Immunol.* 23, 3146). Antisense oligonucleotides targeting c-Raf-1 in SQ-20B cells showed reduced Raf
20 expression and increased radiation sensitivity (Soldatenkov, 1997, *The Cancer J. from Scientific American* 3, 13). Rapp et al. have disclosed a method for inhibiting c-Raf-1 gene expression using a vector expressing the gene in the antisense orientation (International PCT Publication No. WO 93/04170). Antisense oligonucleotides targeting c-Raf-1 in SQ-20B cells showed reduced DNA synthesis in response to insulin
25 stimulation in rat hepatoma cells (Tomkvist, 1994, *J. Biol. Chem.* 269, 13919). Monia et al. have disclosed a method for inhibiting Raf expression using antisense oligonucleotides (U.S. Patent No. 5,563,255) and shown that antisense oligonucleotides targeting c-Raf-1 can inhibit Raf mRNA expression in cell culture, and inhibit growth of a variety of tumor

types in human tumor xenograft models (Monia *et al.*, 1996, *Proc. Natl. Acad. Sci.* 93, 15481; Monia *et al.*, 1996, *Nature Med.* 2, 668). No toxicity was observed in these studies following systemic administration of c-Raf antisense oligonucleotides, suggesting that at least partial down regulation of Raf in normal tissues is not overtly toxic.

5 It has been proposed that synthetic ribozymes can be delivered to target cells exogenously in the presence or absence of lipid delivery vehicles (Thompson *et al.*, International PCT Publication No. WO 93/23057; Sullivan *et al.*, International PCT Publication No. WO 94/02595).

10 Recently Sandberg *et al.*, 1996, Abstract, IBC USA Conferences on Angiogenesis Inhibitors and other novel therapeutics for Ocular Diseases of Neovascularization, reported pharmacokinetics of a chemically modified hammerhead ribozyme targeted against a vascular endothelial growth factor (VEGF) receptor RNA in normal and tumor bearing mice after daily bolus or continuous infusion.

15 Desjardins *et al.*, 1996, *J. Pharmacol. Exptl. Therapeutic*, 27, 8, 1419, reported pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injection.

20 The references cited above are distinct from the presently claimed invention since they do not disclose and/or contemplate the use of ribozymes to cleave Raf RNA. Furthermore, Applicant believes that the references do not disclose and/or enable the use of ribozymes to down regulate normal Raf gene expression in mammalian cells and/or whole animal.

Summary Of The Invention

25 This invention relates to identification, synthesis and use of nucleic acid catalysts to cleave RNA species that are required for cellular growth responses. In particular, applicant describes the selection and function of ribozymes capable of cleaving RNA

encoded by *c-ras* gene. Such ribozymes may be used to inhibit the hyper-proliferation of tumor cells in one or more cancers, restenosis, psoriasis, fibrosis and rheumatoid arthritis.

In the present invention, ribozymes that cleave *c-ras* RNA are described. Moreover, applicant shows that these ribozymes are able to inhibit gene expression and cell proliferation *in vitro* and *in vivo*, and that the catalytic activity of the ribozymes is required for their inhibitory effect. From those of ordinary skill in the art, it is clear from the examples described herein, that other ribozymes that cleave target RNAs required for cell proliferation may be readily designed and are within the invention.

By "inhibit" is meant that the activity of *c-ras* or level of RNAs encoded by *c-ras* is reduced below that observed in the absence of the nucleic acid, particularly, inhibition with ribozymes is preferably below that level observed in the presence of an inactive RNA molecule able to bind to the same site on the mRNA, but unable to cleave that RNA.

By "nucleic acid catalyst" is meant a nucleic acid molecule capable of catalyzing (altering the velocity and/or rate of) a variety of reactions including the ability to repeatedly cleave other separate nucleic acid molecules (endonuclease activity) in a nucleotide base sequence-specific manner. Such a molecule with endonuclease activity may have complementarity in a substrate binding region to a specified gene target, and also has an enzymatic activity that specifically cleaves RNA or DNA in that target. That is, the nucleic acid molecule with endonuclease activity is able to intramolecularly or intermolecularly cleave RNA or DNA and thereby inactivate a target RNA or DNA molecule. This complementarity functions to allow sufficient hybridization of the enzymatic RNA molecule to the target RNA or DNA to allow the cleavage to occur. 100% complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention. The nucleic acids may be modified at the base, sugar, and/or phosphate groups. The term enzymatic nucleic acid is used interchangeably with phrases such as ribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, catalytic oligonucleotides, nucleozyme, DNAzyme, RNA enzyme, endoribonuclease,

endonuclease, minizyme, leadzyme, oligozyme or DNA enzyme. All of these terminologies describe nucleic acid molecules with enzymatic activity. The specific nucleic acid catalysts described in the instant application are not limiting in the invention and those skilled in the art will recognize that all that is important in a nucleic acid catalyst of this invention is that it has a specific substrate binding site which is complementary to one or more of the target nucleic acid regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart a nucleic acid cleaving activity to the molecule.

By "substrate binding arm" or "substrate binding domain" is meant that portion/region of a ribozyme which is complementary to (*i.e.*, able to base-pair with) a portion of its substrate. Generally, such complementarity is 100%, but can be less if desired. For example, as few as 10 bases out of 14 may be base-paired. Such arms are shown generally in Figure 1 and 3. That is, these arms contain sequences within a ribozyme which are intended to bring ribozyme and target RNA together through complementary base-pairing interactions. The ribozyme of the invention may have binding arms that are contiguous or non-contiguous and may be of varying lengths. The length of the binding arm(s) are preferably greater than or equal to four nucleotides; specifically 12-100 nucleotides; more specifically 14-24 nucleotides long. If two binding arms are chosen, the design is such that the length of the binding arms are symmetrical (*i.e.*, each of the binding arms is of the same length; *e.g.*, five and five nucleotides, six and six nucleotides or seven and seven nucleotides long) or asymmetrical (*i.e.*, the binding arms are of different length; *e.g.*, six and three nucleotides; three and six nucleotides long; four and five nucleotides long; four and six nucleotides long; four and seven nucleotides long; and the like).

In one of the preferred embodiments of the inventions herein, the nucleic acid catalyst is formed in a hammerhead or hairpin motif, but may also be formed in the motif of a hepatitis d virus, group I intron, group II intron or RNaseP RNA (in association with an RNA guide sequence) or *Neurospora* VS RNA. Examples of such hammerhead motifs

are described by Dreyfus, *supra*, Rossi *et al.*, 1992, *AIDS Research and Human Retroviruses* 8, 183; of hairpin motifs by Hampel *et al.*, EP0360257, Hampel and Tritz, 1989 *Biochemistry* 28, 4929, Feldstein *et al.*, 1989, *Gene* 82, 53, Haseloff and Gerlach, 1989, *Gene*, 82, 43, and Hampel *et al.*, 1990 *Nucleic Acids Res.* 18, 299; of the hepatitis d virus motif is described by Perrotta and Been, 1992 *Biochemistry* 31, 16; of the RNaseP motif by Guerrier-Takada *et al.*, 1983 *Cell* 35, 849; Forster and Altman, 1990, *Science* 249, 783; Li and Altman, 1996, *Nucleic Acids Res.* 24, 835; *Neurospora* VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990 *Cell* 61, 685-696; Saville and Collins, 1991 *Proc. Natl. Acad. Sci. USA* 88, 8826-8830; Collins and Olive, 10 1993 *Biochemistry* 32, 2795-2799; Guo and Collins, 1995, *EMBO. J.* 14, 363); Group II introns are described by Griffin *et al.*, 1995, *Chem. Biol.* 2, 761; Michels and Pyle, 1995, *Biochemistry* 34, 2965; Pyle *et al.*, International PCT Publication No. WO 96/22689; and of the Group I intron by Cech *et al.*, U.S. Patent 4,987,071. These specific motifs are not limiting in the invention and those skilled in the art will recognize that all that is
15 important in a nucleic acid catalyst of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule.

By "equivalent" RNA to *c-raf* is meant to include those naturally occurring RNA
20 molecules associated with cancer in various animals, including human, rodent, primate, rabbit and pig. The equivalent RNA sequence also includes in addition to the coding region, regions such as 5'-untranslated region, 3'-untranslated region, introns, intron-exon junction and the like.

By "complementarity" is meant a nucleic acid that can form hydrogen bond(s) with
25 another RNA sequence by either traditional Watson-Crick or other non-traditional types (for example, Hoogsteen type) of base-paired interactions.

In a preferred embodiment the invention provides a method for producing a class of enzymatic cleaving agents which exhibit a high degree of specificity for the RNA of a

desired target. The nucleic acid catalyst is preferably targeted to a highly conserved sequence region of a target mRNAs encoding c-raf proteins such that specific treatment of a disease or condition can be provided with either one or several enzymatic nucleic acids. Such nucleic acid catalysts can be delivered exogenously to specific cells as required.

5 Alternatively, the ribozymes can be expressed from DNA/RNA vectors that are delivered to specific cells.

Such ribozymes are useful for the prevention of the diseases and conditions discussed above, and any other diseases or conditions that are related to the levels of c-Raf activity in a cell or tissue.

10 By "related" is meant that the inhibition of c-raf RNAs and thus reduction in the level of respective protein activity will relieve to some extent the symptoms of the disease or condition.

In preferred embodiments, the ribozymes have binding arms which are complementary to the target sequences in Tables XII-XIX. Examples of such ribozymes are also shown in Tables XII-XIX. Examples of such ribozymes consist essentially of

15 sequences defined in these Tables.

By "consists essentially of" is meant that the active ribozyme contains an enzymatic center or core equivalent to those in the examples, and binding arms able to bind mRNA such that cleavage at the target site occurs. Other sequences may be present

20 which do not interfere with such cleavage.

Thus, in a first aspect, the invention features ribozymes that inhibit gene expression and/or cell proliferation. These chemically or enzymatically synthesized RNA molecules contain substrate binding domains that bind to accessible regions of their target mRNAs. The RNA molecules also contain domains that catalyze the cleavage of RNA. The RNA

25 molecules are preferably ribozymes of the hammerhead or hairpin motif. Upon binding, the ribozymes cleave the target mRNAs, preventing translation and protein accumulation. In the absence of the expression of the target gene, cell proliferation is inhibited.

In a preferred embodiment, ribozymes are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through injection, infusion pump or stent, with or without their
5 incorporation in biopolymers. In another preferred embodiment, the ribozyme is administered to the site of *c-raf* expression (e.g., tumor cells) in an appropriate liposomal vehicle.

In another aspect of the invention, ribozymes that cleave target molecules and inhibit *c-raf* activity are expressed from transcription units inserted into DNA or RNA
10 vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Ribozyme expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the ribozymes are delivered as described above, and persist in target cells. Alternatively, viral vectors may be used that provide for transient
15 expression of ribozymes. Such vectors might be repeatedly administered as necessary. Once expressed, the ribozymes cleave the target mRNA. Delivery of ribozyme expressing vectors could be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction
20 into the desired target cell (for a review see Couture and Stinchcomb, 1996, *TIG.*, 12, 510). In another aspect of the invention, ribozymes that cleave target molecules and inhibit cell proliferation are expressed from transcription units inserted into DNA, RNA, or viral vectors. Preferably, the recombinant vectors capable of expressing the ribozymes are locally delivered as described above, and transiently persist in smooth muscle cells.
25 However, other mammalian cell vectors that direct the expression of RNA may be used for this purpose.

By "patient" is meant an organism which is a donor or recipient of explanted cells or the cells themselves. "Patient" also refers to an organism to which nucleic acid

catalysts can be administered. Preferably, a patient is a mammal or mammalian cells. More preferably, a patient is a human or human cells.

By "vectors" is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid.

5 These ribozymes, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed above. For example, to treat a disease or condition associated with c-ras levels, the patient may be treated, or other appropriate cells may be treated, as is evident to those skilled in the art.

10 In a further embodiment, the described ribozymes can be used in combination with other known treatments to treat conditions or diseases discussed above. For example, the described ribozymes could be used in combination with one or more known therapeutic agents to treat cancer.

15 In preferred embodiments, the ribozymes have binding arms which are complementary to the sequences in the tables, shown as Seq. I.D. Nos. 1-501, 1078-1152, 1461-1768, 1841-1912, 2354-2794 and 2846-2956. Examples of such ribozymes are shown as Seq. I.D. Nos. 502-1002, 1003-1077, 1153-1460, 1769-1840, 1913-2353 and 2795-2845. Other sequences may be present which do not interfere with such cleavage.

20 Ribozymes that cleave the specified sites in Ras mRNAs represent a novel therapeutic approach to treat tumor angiogenesis, ocular diseases, rheumatoid arthritis, psoriasis and others. Applicant indicates that ribozymes are able to inhibit the activity of Ras and that the catalytic activity of the ribozymes is required for their inhibitory effect. Those of ordinary skill in the art will find that it is clear from the examples described that other ribozymes that cleave Ras mRNAs may be readily designed and are within the invention.

25 Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Description Of The Preferred Embodiments

The drawings will first briefly be described.

Drawings:

Figure 1 shows the secondary structure model for seven different classes of nucleic acid catalysts. Arrow indicates the site of cleavage. ----- indicate the target sequence. Lines interspersed with dots are meant to indicate tertiary interactions. - is meant to indicate base-paired interaction. **Group I Intron:** P1-P9.0 represent various stem-loop structures (Cech *et al.*, 1994, *Nature Struc. Bio.*, 1, 273). **RNase P (M1RNA):** EGS represents external guide sequence (Forster *et al.*, 1990, *Science*, 249, 783; Pace *et al.*, 1990, *J. Biol. Chem.*, 265, 3587). **Group II Intron:** 5'SS means 5' splice site; 3'SS means 3'-splice site; IBS means intron binding site; EBS means exon binding site (Pyle *et al.*, 1994, *Biochemistry*, 33, 2716). **VS RNA:** I-VI are meant to indicate six stem-loop structures; shaded regions are meant to indicate tertiary interaction (Collins, International PCT Publication No. WO 96/19577). **HDV Ribozyme:** I-IV are meant to indicate four stem-loop structures (Been *et al.*, US Patent No. 5,625,047). **Hammerhead Ribozyme:** I-III are meant to indicate three stem-loop structures; stems I-III can be of any length and may be symmetrical or asymmetrical (Usman *et al.*, 1996, *Curr. Op. Struct. Bio.*, 1, 527). **Hairpin Ribozyme:** Helix 1, 4 and 5 can be of any length; Helix 2 is between 3 and 8 base-pairs long; Y is a pyrimidine; Helix 2 (H2) is provided with a least 4 base pairs (*i.e.*, n is 1, 2, 3 or 4) and helix 5 can be optionally provided of length 2 or more bases (preferably 3 - 20 bases, *i.e.*, m is from 1 - 20 or more). Helix 2 and helix 5 may be covalently linked by one or more bases (*i.e.*, r is 1 base). Helix 1, 4 or 5 may also be extended by 2 or more base pairs (*e.g.*, 4 - 20 base pairs) to stabilize the ribozyme structure, and preferably is a protein binding site. In each instance, each N and N' independently is any normal or modified base and each dash represents a potential base-pairing interaction. These nucleotides may be modified at the sugar, base or phosphate. Complete base-pairing is not required in the helices, but is preferred. Helix 1 and 4 can be of any size (*i.e.*, o and p is each independently from 0 to any number, *e.g.*, 20) as long

as some base-pairing is maintained. Essential bases are shown as specific bases in the structure, but those in the art will recognize that one or more may be modified chemically (abasic, base, sugar and/or phosphate modifications) or replaced with another base without significant effect. Helix 4 can be formed from two separate molecules, *i.e.*,
5 without a connecting loop. The connecting loop when present may be a ribonucleotide with or without modifications to its base, sugar or phosphate. "q" is 2 bases. The connecting loop can also be replaced with a non-nucleotide linker molecule. H refers to bases A, U, or C. Y refers to pyrimidine bases. "____" refers to a covalent bond. (Burke *et al.*, 1996, *Nucleic Acids & Mol. Biol.*, 10, 129; Chowrira *et al.*, US Patent No.
10 5,631,359).

Figure 2 shows a general approach to accessible site and target discovery using nucleic acid catalysts.

Figure 3 is a diagram of a hammerhead ribozyme. The consensus hammerhead cleavage site in a target RNA is a "U" followed by "H" (anything but "G"). The
15 hammerhead ribozyme cleaves after the "H." This simple di-nucleotide sequence occurs, on average, every 5 nt in a target RNA. Thus, there are approximately 400 potential hammerhead cleavage sites in a 2-Kb mRNA. Stems I and III are formed by hybridization of the hammerhead binding arms with the complementary sequence in target RNA; it is these binding arms that confer specificity to the hammerhead ribozyme
20 for its target. The binding arms of the hammerhead are interrupted by the catalytic domain that forms part of the structure responsible for cleavage.

Figure 4 shows a scheme for the design and synthesis of a Defined Library: simultaneous screen of 400 different ICAM-targeted ribozymes is used as an example. DNA oligonucleotides encoding each ICAM-targeted ribozyme are synthesized
25 individually (A), pooled (B), then cloned and converted to retroviral vectors as a pool. The resulting retroviral vector particles are used to transduce a target cell line that expresses ICAM (B). Cells expressing ribozymes that inhibit ICAM expression (ICAM-low) are sorted from cells expressing ineffective ribozymes by FACS sorting (C),

effective ribozymes enriched in the ICAM-low population of cells are identified by filter hybridization (D).

Figure 5 A) shows randomization of the binding arms of a hammerhead ribozyme to produce a Random Library. The binding arms can be of any length and any symmetry, *i.e.*, symmetrical or assymetrical. B) shows complexities of hammerhead Random Ribozyme Libraries comprising a 6-nt or a 7-nt long binding arms.

Figure 6 is a schematic overview of Target Discovery strategy. An oligonucleotide is prepared in a single reaction vessel in which all 4 standard nucleotides are incorporated in a random fashion in the target binding arm(s) of the ribozyme to produce a pool of all possible ribozymes (A). This pool is cloned into an appropriate vector in a single tube to produce the Random Library expression vector (B) and retroviral vector particles are produced from this pool in a single tube (C). The resulting Random Ribozyme Library retroviral expression vector pool is then used to transduce a cell type of interest (D). Cells exhibiting the desired phenotype are then separated from the rest of the population using a number of possible selection strategies (E and see text). Genes that are critical for expression of the selected phenotype can then be identified by sequencing the target binding arms of ribozymes contained in the selected population (F).

Figure 7 shows an example of application of Random Ribozyme Libraries to identify genes critical for the induction of ICAM expression. Human Umbilical Vein Endothelial Cells (HUVECs) are transduced with a Random Ribozyme Library (A), ICAM expression is induced using TNF-alpha (B), and cells expressing ribozymes that inhibit ICAM induction are selected from cells expressing ineffective ribozymes by sorting ICAM-low cells (C). Genes critical for ICAM induction are identified by sequencing the binding arms of the ribozymes that inhibit ICAM expression in the ICAM-low cells.

Figure 8 is an example of an efficient cloning strategy for producing a Defined or Random Ribozyme Libraries. DNA oligos encoding ribozyme coding regions and

restriction sites for cloning are designed to also contain a stem-loop structure on the 3' ends (1). This stem loop forms an intramolecular primer site for extension to form a double-stranded molecule by DNA polymerase (2). The double-stranded fragment is cleaved with appropriate restriction endonucleases to produce suitable ends for subsequent cloning (3).

Figure 9 shows molecular analysis of the PNP-targeted Defined Ribozyme Library: sequence analysis. Plasmid DNA from the PNP-targeted Defined Ribozyme Library was prepared and sequenced as a pool. The sequencing primer used reads the non-coding strand of the region encoding the ribozymes. Note that the sequence diverges at the binding arm, converges at the catalytic domain (5' - TTTCGGCCTAACGGCCTCATCAG-3'), and then diverges at the other binding arm. These results are consistent with those expected for a sequence of a heterogeneous pool of clones containing different sequences at the ribozyme binding arms.

Figure 10 shows molecular analysis of the PNP-targeted Defined Ribozyme Library: sequence analysis after propagation in Sup T1 human T cells and selection in 10 mmol 6-thioguanosine. Sup T1 cells were transduced with retroviral vector-based Defined Ribozyme Library comprised of 40 different PNP-targeted ribozyme oligos cloned into the U6+27 transcription unit (Figure 11D). The cells were propagated for 2 weeks following transduction, then subjected to 16 days of selection in 10 mmol 6-thioguanosine. Surviving cells were harvested, and ribozyme sequences present in the selected population of cells were amplified and sequenced. Note that, relative to the original Library where sequences of the binding arms were ambiguous due to the presence of 40 different ribozymes (Figure 9), the sequence of the binding arms in the selected population corresponded to only 1 of the 40 ribozymes included in the Library. These results suggest that this ribozyme was the most-potent ribozyme of 40 ribozymes tested.

Figure 11 is a schematic representation of transcription units suitable for expression ribozyme library of the instant invention. A) is a diagrammatic representation of some RNA polymerase (Pol) II and III ribozyme (RZ) transcription units. CMV

Promoter Driven is a Pol II transcript driven by a cytomegalovirus promoter; the transcript can be designed such that the ribozyme is at the 5'-region, 3'-region or somewhere in between and the transcript optionally comprises an intron. tRNA-DC is a Pol III transcript driven by a transfer RNA (tRNA) promoter, wherein the ribozyme is at the 3'-end of the transcript; the transcript optionally comprises a stem-loop structure 3' of the ribozyme. U6+27 is a Pol III transcript driven by a U6 small nuclear (snRNA) promoter; ribozyme is 3' of a sequence that is homologous to 27 nucleotides at the 5'-end of a U6 snRNA; the transcript optionally comprises a stem-loop structure at the 3'-end of the ribozyme. VAI-90 is a Pol III transcript driven by an adenovirus VA promoter; ribozyme is 3' of a sequence homologous to 90 nucleotides at the 5'-end of a VAI RNA; the transcript optionally comprises a stem-loop structure at the 3'-end of the ribozyme. VAC is a Pol III transcript driven by an adenovirus VAI promoter; the ribozyme is inserted towards the 3'-region of the VA RNA and into a S35 motif, which is a stable greater than or equal to 8 bp long intramolecular stem formed by base-paired interaction between sequences in the 5'-region and the 3'-region flanking the ribozyme (see Beigelman *et al.*, International PCT Application No. WO 96/18736); the S35 domain positions the ribozyme away from the main transcript as an independent domain. TRZ is a Pol III transcript driven by a tRNA promoter; ribozyme is inserted in the S35 domain and is positioned away from the main transcript (see Beigelman *et al.*, International PCT Application No. WO 96/18736). **B)** shows various transcription units based on the U1 small nuclear RNA (snRNA) system. **C)** is a schematic representation of a retroviral vector encoding ribozyme genes. NGFR, nerve growth factor receptor is used as a selectable marker, LTR, long terminal repeat of a retrovirus, UTR, untranslated region. **D)** shows a U6+27 hammerhead ribozyme transcription unit based on the U6 snRNA. The ribozyme transcript comprises the first 27 nt from the U6 snRNA which is reported to be necessary for the stability of the transcript. The transcript terminates with a stretch of uridine residues. The hammerhead ribozyme shown in the figure has random (N) binding arm sequence.

Figure 12. is a schematic representation of a combinatorial approach to the screening of ribozyme variants.

Figure 13 shows the sequence of a Starting Ribozyme to be used in the screening approach described in Figure 12. The Starting Ribozyme is a hammerhead (HH) ribozyme designed to cleave target RNA A (HH-A). Position 7 in HH-A is also referred to in this application as position 24 to indicate that U24 is the 24th nucleotide incorporated into the HH-A ribozyme during chemical synthesis. Similarly, positions 4 and 3 are also referred to as positions 27 and 28, respectively. s indicates phosphorothioate substitution. Lower case alphabets in the HH-A sequence indicate 2'-O-methyl nucleotides; uppercase alphabets in the sequence of HH-A at positions 5, 6, 8, 12 and 15.1 indicate ribonucleotides. Positions 3, 4 and 7 are shown as uppercase, large alphabets to indicate the positions selected for screening using the method shown in Figure 12. ● indicates base-paired interaction. iB represents abasic inverted deoxy ribose moiety.

Figure 14 shows a scheme for screening variants of HH-A ribozyme. Positions 24, 27 and 28 are selected for analysis in this scheme.

Figure 15 shows non-limiting examples of some of the nucleotide analogs that can be used to construct ribozyme libraries. 2'-O-MTM-U represents 2'-O-methylthiomethyl uridine; 2'-O-MTM-C represents 2'-O-methylthiomethyl cytidine; 6-Me-U represents 6-methyl uridine (Beigelman *et al.*, International PCT Publication No. WO 96/18736 which is incorporated by reference herein).

Figure 16 shows activity of HH-A variant ribozymes as determined in a cell-based assay. * indicates the substitution that provided the most desirable attribute in a ribozyme.

Figure 17A shows the sequence and chemical composition of ribozymes that showed the most desirable attribute in a cell.

Figure 17B shows formulae for four different novel ribozyme motifs.

Figure 18 shows the formula for a novel ribozyme motif.

Figure 19 shows the sequence of a Starting Ribozyme to be used in the screening approach described in Figure 14. A HH ribozyme targeted against RNA B (HH-B) was
5 chosen for analysis of the loop II sequence variants.

Figure 20 shows a scheme for screening loop-II sequence variants of HH-B ribozyme.

Figure 21 shows the relative catalytic rates (k_{rel}) for RNA cleavage reactions catalyzed by HH-B loop-II variant ribozymes.

10 Figure 22 is a schematic representation of HH-B ribozyme-substrate complex and the activity of HH-B ribozyme with either the 5'-GAAA-3' or the 5'-GUUA-3' loop-II sequence.

Figure 23 shows a scheme for using a combinatorial approach to identify potential ribozyme targets by varying the binding arms.

15 Figure 24 shows a scheme for using a combinatorial approach to identify novel ribozymes by the varying putative catalytic domain sequence.

Figure 25 shows a table of accessible sites within a Bcl-2 transcript ((975 nucleotides) which were found using the combinatorial in vitro screening process.

20 Figure 26 shows a table of accessible sites with a Kras transcript (796 nucleotides) which were found using the combinatorial in vitro screening process as well as a graphic depiction of relative activity of ribozymes to those sites.

Figure 27 shows a table of accessible sites with a UPA transcript (400 nucleotides) which were found using the combinatorial in vitro screening process as well as a graphic depiction of relative activity of ribozymes to those sites.

Figure 28 shows a graph displaying data from a ribonuclease protection assay (RPA) after treatment of MCF-7 cells with ribozymes targeted to site 549 of the transcript (Seq.ID #9). The Bcl-2 mRNA isolated from MCF-7 cells is normalized to GAPDH which was also probed in the RPA. The graph includes an untreated control and
5 an irrelevant ribozyme (no complementarity with Bcl-2 mRNA).

Figure 29 displays a schematic representation of NTP synthesis using nucleoside substrates.

Figure 30 depicts a scheme for the synthesis of a xylo ribonucleoside phosphoramidite.

10 Figure 31 is a diagrammatic representation of hammerhead (HH) ribozyme targeted against stromelysin RNA (site 617) with various modifications.

Figure 32 is a schematic representation of a one pot deprotection of RNA synthesized using RNA phosphoramidite chemistry.

15 Figure 33 is a comparison of a one-pot and a two-pot process for deprotection of RNA.

Figure 34 shows the results of a one-pot deprotection with different polar organic reagents.

Figure 35 is a diagrammatic representation of ras signal transduction pathway.

20 Figure 36 is a diagrammatic representation of hammerhead ribozymes targeted against c-raf RNA.

Figure 37 is a graphical representation of c-raf 2'-C-allyl 1120 hammerhead (HH) ribozyme-mediated inhibition of cell proliferation.

Figure 38 is a graphical representation of inhibition of cell proliferation mediated by c-raf 2'-C-allyl 1120 and 1251 hammerhead (HH) ribozymes.

Figure 39 shows the effects of *flt-1* ribozymes (active/inactive) on LLC-HM primary tumor growth in mice.

Figure 40 shows the effects of *flt-1* ribozymes on LLC-HM primary tumor volume immediately following the cessation of treatment.

5 Figure 41 shows the effects of *flt-1* ribozymes on lung metastatic indices (number of metastases and lung mass).

Figure 42 shows the effects of *flt-1* ribozymes (active/inactive) on LLC-HM primary tumor growth in mice.

10 Figure 43 shows the effects of *flt-1* ribozymes on LLC-HM primary tumor volume immediately following the cessation of treatment.

Figure 44 shows the effects of *flt-1* ribozymes on lung metastatic indices (number of metastases and lung mass).

Nucleic Acid Catalysts:

15 Catalytic nucleic acid molecules (ribozymes) are nucleic acid molecules capable of catalyzing one or more of a variety of reactions, including the ability to repeatedly cleave other separate nucleic acid molecules in a nucleotide base sequence-specific manner. Such nucleic acid catalysts can be used, for example, to target cleavage of virtually any RNA transcript (Zaug *et al.*, 324, *Nature* 429 1986 ; Cech, 260 *JAMA* 3030,
20 1988; and Jefferies *et al.*, 17 *Nucleic Acids Research* 1371, 1989). Catalytic nucleic acid molecules mean any nucleotide base-comprising molecule having the ability to repeatedly act on one or more types of molecules, including but not limited to nucleic acid catalysts. By way of example but not limitation, such molecules include those that are able to repeatedly cleave nucleic acid molecules, peptides, or other polymers, and those that are
25 able to cause the polymerization of such nucleic acids and other polymers. Specifically, such molecules include ribozymes, DNAzymes, external guide sequences and the like. It

is expected that such molecules will also include modified nucleotides compared to standard nucleotides found in DNA and RNA.

Because of their sequence-specificity, *trans*-cleaving nucleic acid catalysts show promise as therapeutic agents for human disease (Usman & McSwiggen, 1995 *Ann. Rep. Med. Chem.* **30**, 285-294; Christoffersen and Marr, 1995 *J. Med. Chem.* **38**, 2023-2037). Nucleic acid catalysts can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the RNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited. In addition, nucleic acid catalysts can be used to validate a therapeutic gene target and/or to determine the function of a gene in a biological system (Christoffersen, 1997, *Nature Biotech.* **15**, 483).

There are at least seven basic varieties of enzymatic RNA molecules derived from naturally occurring self-cleaving RNAs (see Table I). Each can catalyze the hydrolysis of RNA phosphodiester bonds in *trans* (and thus can cleave other RNA molecules) under physiological conditions. In general, enzymatic nucleic acids act by first binding to a substrate/target RNA. Such binding occurs through the substrate/target binding portion of an nucleic acid catalyst which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic and selective cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and thus can repeatedly bind and cleave new targets.

In addition, several *in vitro* selection (evolution) strategies (Orgel, 1979, *Proc. R. Soc. London*, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing a variety of reactions, such as cleavage and ligation of phosphodiester linkages and amide linkages, (Joyce, 1989, *Gene*, **82**, 83-87; Beaudry *et al.*, 1992, *Science* **257**,

635-641; Joyce, 1992, *Scientific American* 267, 90-97; Breaker *et al.*, 1994, *TIBTECH* 12, 268; Bartel *et al.*, 1993, *Science* 261:1411-1418; Szostak, 1993, *TIBS* 17, 89-93; Kumar *et al.*, 1995, *FASEB J.*, 9, 1183; Breaker, 1996, *Curr. Op. Biotech.*, 7, 442; Breaker, 1997, *Nature Biotech.* 15, 427).

5 There are several reports that describe the use of a variety of *in vitro* and *in vivo* selection strategies to study structure and function of catalytic nucleic acid molecules (Campbell *et al.*, 1995, *RNA* 1, 598; Joyce 1989, *Gene*, 82,83; Lieber *et al.*, 1995, *Mol Cell Biol.* 15, 540; Lieber *et al.*, International PCT Publication No. *WO 96/01314*; Szostak 1988, in *Redesigning the Molecules of Life*, Ed. S. A. Benner, pp 87, Springer-
10 Verlag, Germany; Kramer *et al.*, U.S. Patent No. 5,616,459; Draper *et al.*, US Patent No. 5,496,698; Joyce, U.S. Patent No. 5,595,873; Szostak *et al.*, U.S. Patent No. 5,631,146).

 The enzymatic nature of a ribozyme is advantageous over other technologies, since the effective concentration of ribozyme sufficient to effect a therapeutic treatment is generally lower than that of an antisense oligonucleotide. This advantage reflects the
15 ability of the ribozyme to act enzymatically. Thus, a single ribozyme (enzymatic nucleic acid) molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base-pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is
20 caused by cleavage of the RNA target and so specificity is defined as the ratio of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base-pairing. Thus, it is thought that the specificity of action of a ribozyme is greater than that of antisense oligonucleotide binding the same RNA site.

25 The development of ribozymes that are optimal for catalytic activity would contribute significantly to any strategy that employs RNA-cleaving ribozymes for the purpose of regulating gene expression. The hammerhead ribozyme, for example, functions with a catalytic rate (k_{cat}) of $\sim 1 \text{ min}^{-1}$ in the presence of saturating (10 mM)

concentrations of Mg^{2+} cofactor. However, the rate for this ribozyme in Mg^{2+} concentrations that are closer to those found inside cells (0.5 - 2 mM) can be 10- to 100-fold slower. In contrast, the RNase P holoenzyme can catalyze pre-tRNA cleavage with a k_{cat} of $\sim 30 \text{ min}^{-1}$ under optimal assay conditions. An artificial 'RNA ligase' ribozyme (Bartel *et al.*, *supra*) has been shown to catalyze the corresponding self-modification reaction with a rate of $\sim 100 \text{ min}^{-1}$. In addition, it is known that certain modified hammerhead ribozymes that have substrate binding arms made of DNA catalyze RNA cleavage with multiple turn-over rates that approach 100 min^{-1} . Finally, replacement of a specific residue within the catalytic core of the hammerhead with certain nucleotide analogues gives modified ribozymes that show as much as a 10-fold improvement in catalytic rate. These findings demonstrate that ribozymes can promote chemical transformations with catalytic rates that are significantly greater than those displayed *in vitro* by most natural self-cleaving ribozymes. It is then possible that the structures of certain self-cleaving ribozymes may not be optimized to give maximal catalytic activity, or that entirely new RNA motifs could be made that display significantly faster rates for RNA phosphoester cleavage.

By "nucleotide" as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a sugar moiety. Nucleotide generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other ; see for example, Usman and McSwiggen, *supra*; Eckstein *et al.*, International PCT Publication No. WO 92/07065; Usman *et al.*, International PCT Publication No. WO 93/15187; all hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art and has recently been summarized by Limbach *et al.*, 1994, *Nucleic Acids Res.* 22, 2183. Some of the non-limiting examples of base modifications that can be introduced into enzymatic nucleic acids without significantly effecting their catalytic activity include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl,

pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (*e.g.*, 5-methylcytidine), 5-alkyluridines (*e.g.*, ribothymidine), 5-halouridine (*e.g.*, 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (*e.g.*, 6-methyluridine) and others (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090). By "modified bases" in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents; such bases may be used within the catalytic core of the enzyme and/or in the substrate-binding regions.

In another preferred embodiment, catalytic activity of the molecules described in the instant invention can be optimized as described by Draper *et al.*, *supra*. The details will not be repeated here, but include altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications (base, sugar and/or phosphate) that prevent their degradation by serum ribonucleases and/or enhance their enzymatic activity (see *e.g.*, Eckstein *et al.*, International Publication No. WO 92/07065; Perrault *et al.*, 1990 *Nature* 344, 565; Pieken *et al.*, 1991 *Science* 253, 314; Usman and Cedergren, 1992 *Trends in Biochem. Sci.* 17, 334; Usman *et al.*, International Publication No. WO 93/15187; and Rossi *et al.*, International Publication No. WO 91/03162; Sproat, US Patent No. 5,334,711; and Burgin *et al.*, *supra*; all of these describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of enzymatic RNA molecules). Modifications which enhance their efficacy in cells, and removal of bases from stem loop structures to shorten RNA synthesis times and reduce chemical requirements are desired. (All of these publications are hereby incorporated by reference herein).

There are several examples in the art describing sugar and phosphate modifications that can be introduced into nucleic acid catalysts without significantly effecting catalysis and with significant enhancement in their nuclease stability and efficacy. Ribozymes are modified to enhance stability and/or enhance catalytic activity by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H, nucleotide base modifications (for a review see Usman and

Cedergren, 1992 *TIBS* 17, 34; Usman *et al.*, 1994 *Nucleic Acids Symp. Ser.* 31, 163; Burgin *et al.*, 1996 *Biochemistry* 35, 14090). Sugar modification of nucleic acid catalysts has been extensively described in the art (see Eckstein *et al.*, *International Publication* PCT No. WO 92/07065; Perrault *et al.* *Nature* 1990, 344, 565-568; Pieken *et al.* *Science* 1991, 253, 314-317; Usman and Cedergren, *Trends in Biochem. Sci.* 1992, 17, 334-339; Usman *et al.* *International Publication* PCT No. WO 93/15187; Sproat, *US Patent* No. 5,334,711 and Beigelman *et al.*, 1995 *J. Biol. Chem.* 270, 25702; all of the references are hereby incorporated in their totality by reference herein).

Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into ribozymes without inhibiting catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify the nucleic acid catalysts of the instant invention.

In yet another preferred embodiment, nucleic acid catalysts having chemical modifications which maintain or enhance enzymatic activity is provided. Such a nucleic acid is also, generally, more resistant to nucleases than the corresponding unmodified nucleic acid. Thus, in a cell and/or *in vivo* the activity may not be significantly lowered. As exemplified herein such ribozymes are useful in a cell and/or *in vivo* even if activity over all is reduced 10 fold (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090). Such modifications herein are said to "maintain" the enzymatic activity on all RNA ribozyme.

In a preferred embodiment, the nucleic acid catalysts of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to smooth muscle cells. The RNA or RNA complexes can be locally administered to relevant tissues through the use of a catheter, infusion pump or stent, with or without their incorporation in biopolymers. Using the methods described herein, other nucleic acid catalysts that cleave target nucleic acid may be derived and used as described above. Specific examples of nucleic acid catalysts of the instant invention are provided below in the Tables and figures.

Sullivan, *et al.*, WO 94/02595, describes the general methods for delivery of nucleic acid catalysts. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination is locally delivered by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Sullivan *et al.*, *supra* and Draper *et al.*, WO 93/23569 which have been incorporated by reference herein.

Such nucleic acid catalysts can be delivered exogenously to specific cells as required. In the preferred hammerhead motif the small size (less than 60 nucleotides, preferably between 30-40 nucleotides in length) of the molecule allows the cost of treatment to be reduced.

Therapeutic ribozymes delivered exogenously must remain stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, ribozymes must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of RNA (Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677; incorporated by reference herein) have expanded the ability to modify ribozymes by introducing nucleotide modifications to enhance their nuclease stability as described above.

Synthesis, Deprotection, and Purification of Nucleic Acid Catalysts:

Generally, RNA molecules are chemically synthesized and purified by methodologies based on the use of tetrazole to activate the RNA phosphoramidite, ethanolic-NH₄OH to remove the exocyclic amino protecting groups, tetra-*n*-butylammonium fluoride (TBAF) to remove the 2'-OH alkylsilyl protecting groups, and gel purification and analysis of the deprotected RNA. Examples of chemical synthesis, deprotection, purification and analysis procedures for RNA are provided by Usman et al., 1987 *J. Am. Chem. Soc.*, 109, 7845; Scaringe et al. *Nucleic Acids Res.* 1990, 18, 5433-5341; Perreault et al. *Biochemistry* 1991, 30 4020-4025; Slim and Gait *Nucleic Acids Res.* 1991, 19, 1183-1188. All the above noted references are all hereby incorporated by reference herein.

Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs (e.g., antisense oligonucleotides, hammerhead or the hairpin ribozymes) are used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of the mRNA structure. However, these nucleic acid molecules can also be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985 *Science* 229, 345; McGarry and Lindquist, 1986 *Proc. Natl. Acad. Sci. USA* 83, 399; SullengerScanlon et al., 1991, *Proc. Natl. Acad. Sci. USA*, 88, 10591-5; Kashani-Sabet et al., 1992 *Antisense Res. Dev.*, 2, 3-15; Dropulic et al., 1992 *J. Virol*, 66, 1432-41; Weerasinghe et al., 1991 *J. Virol*, 65, 5531-4; Ojwang et al., 1992 *Proc. Natl. Acad. Sci. USA* 89, 10802-6; Chen et al., 1992 *Nucleic Acids Res.*, 20, 4581-9; Sarver et al., 1990 *Science* 247, 1222-1225; Thompson et al., 1995 *Nucleic Acids Res.* 23, 2259). Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a ribozyme (Draper et al., PCT WO93/23569, and Sullivan et al., PCT WO94/02595, both hereby incorporated in their totality by reference herein; Ohkawa et al., 1992 *Nucleic Acids Symp. Ser.*, 27, 15-6; Taira et al., 1991, *Nucleic Acids Res.*, 19,

5125-30; Ventura *et al.*, 1993 *Nucleic Acids Res.*, 21, 3249-55; Chowrira *et al.*, 1994 *J. Biol. Chem.* 269, 25856).

The ribozymes were chemically synthesized. The method of synthesis used follows the procedure for normal RNA synthesis as described in Usman *et al.*, 1987 *J. Am. Chem. Soc.*, 109, 7845; Scaringe *et al.*, 1990 *Nucleic Acids Res.*, 18, 5433; and Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677-2684 and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. Small scale synthesis were conducted on a 394 Applied Biosystems, Inc. synthesizer using a modified 2.5 μ mol scale protocol with a 5 min coupling step for alkylsilyl protected nucleotides and 2.5 min coupling step for 2'-O-methylated nucleotides. Table II outlines the amounts, and the contact times, of the reagents used in the synthesis cycle. A 6.5-fold excess (163 μ L of 0.1 M = 16.3 μ mol) of phosphoramidite and a 24-fold excess of *S*-ethyl tetrazole (238 μ L of 0.25 M = 59.5 μ mol) relative to polymer-bound 5'-hydroxyl was used in each coupling cycle. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, were 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer: detritylation solution was 2% TCA in methylene chloride (ABI); capping was performed with 16% *N*-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution was 16.9 mM I₂, 49 mM pyridine, 9% water in THF (Millipore). B & J Synthesis Grade acetonitrile was used directly from the reagent bottle. *S*-Ethyl tetrazole solution (0.25 M in acetonitrile) was made up from the solid obtained from American International Chemical, Inc.

Deprotection of the RNA was performed as follows. The polymer-bound oligoribonucleotide, trityl-off, was transferred from the synthesis column to a 4mL glass screw top vial and suspended in a solution of methylamine (MA) at 65 °C for 10 min. After cooling to -20 °C, the supernatant was removed from the polymer support. The support was washed three times with 1.0 mL of EtOH:MeCN:H₂O/3:1:1, vortexed and

the supernatant was then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, were dried to a white powder.

The base-deprotected oligoribonucleotide was resuspended in anhydrous TEA•HF/NMP solution (250 μ L of a solution of 1.5mL *N*-methylpyrrolidinone, 750 μ L TEA and 1.0 mL TEA•3HF to provide a 1.4M HF concentration) and heated to 65°C for 1.5 h. The resulting, fully deprotected, oligomer was quenched with 50 mM TEAB (9 mL) prior to anion exchange desalting.

For anion exchange desalting of the deprotected oligomer, the TEAB solution was loaded onto a Qiagen 500[®] anion exchange cartridge (Qiagen Inc.) that was prewashed with 50 mM TEAB (10 mL). After washing the loaded cartridge with 50 mM TEAB (10 mL), the RNA was eluted with 2 M TEAB (10 mL) and dried down to a white powder.

Deprotection of RNA:

For high throughput chemical synthesis of oligoribonucleotides, it is important that the two main steps involved in the deprotection of oligoribonucleotides (i.e., aqueous basic treatment to remove exocyclic amino protecting groups and phosphate protecting groups and fluoride treatment to remove the 2'-OH alkylsilyl protecting groups such as the tButylDiMethylSilyl) are condensed.

Stinchcomb *et al.*, *supra* describe a time-efficient (~ 2 hrs) one-pot deprotection protocol based on anhydrous methylamine and triethylamine trihydrogen fluoride. Since it has recently been reported that water contamination during fluoride treatment may be detrimental to the efficiency of the desilylation reaction (Hogrefe et al, Nucleic Acids Res. (1993), 21 4739-4741), it is necessary to use an anhydrous solution of base such as a 33% methylamine in absolute ethanol followed by neat triethylamine trihydrofluoride to effectively deprotect oligoribonucleotides in a one-pot fashion. However it may be cumbersome to apply such a protocol to plate format deprotection where the solid-support is preferentially separated from the partially deprotected oligoribonucleotides prior to the 2'-hydroxyl deprotection. Indeed, because the methylamine solution used is

anhydrous, it may not be suitable to solubilize the negatively charged oligoribonucleotides obtained after basic treatment. Therefore, applicant investigated a 1:1 mixture of the ethanolic methylamine solution and different polar additives such as dimethylsulfoxide (DMSO), N,N-dimethylformamide (DMF), methanol, 5 hexamethylphosphoramide (HMPA), 1-methyl-2-pyrrolidinone (NMP) or 2-methoxyethyl ether (glyme). Of all these additives, dimethylsulfoxide is capable of efficiently solubilizing partially deprotected oligoribonucleotides (figure 34). A comparison of the one pot and two pot deprotection methods are outlined and demonstrated in figure 33.

10 The deprotection process commonly involves the deprotection of the exocyclic amino protecting groups by NH_4OH , which is time consuming (6-24 h) and inefficient. This step is then followed by treatment with TBAF to facilitate the removal of alkylsilyl protecting groups, which again is time consuming and not very effective in achieving efficient deprotection.

15 A recent modification of this two-step strategy for oligoribonucleotide deprotection has been reported by Wincott *et al.*, (*Nucleic Acids Res.*, 1995, 23, 2677-2784) and by Vinayak *et al.*, (*Nucleic Acids Symposium series*, 1995, 33, 123-125). The optimized conditions make use of aqueous methylamine at 65°C for 15 minutes in place of the ammonium hydroxide cocktail to remove exocyclic amino protecting groups while 20 the desilylation treatment needed to remove the 2'-OH alkylsilyl protecting groups utilizes a mixture of triethylamine trihydrogen fluoride (TEA.3HF), N-methylpyrrolidinone and triethylamine at 65°C for 90 minutes, thereby replacing tetrabutyl ammonium fluoride.

25 Stinchcomb *et al.*, International PCT Publication No. WO 95/23225 describe a process for one pot deprotection of RNA. On page 73, it states that:

"In an attempt to minimize the time required for deprotection and to simplify the process of deprotection of RNA synthesized on a large scale, applicant describes a one pot

deprotection protocol... According to this protocol, anhydrous methylamine is used in place of aqueous methyl amine. Base deprotection is carried out at 65 °C for 15 minutes and the reaction is allowed to cool for 10 min. Deprotection of 2'-hydroxyl groups is then carried out in the same container for 90 minutes in a TEA•3HF reagent. The reaction is
5 quenched with 16 mM TEAB solution."

This invention concerns a one-pot process for the deprotection of RNA molecules. This invention features a novel method for the removal of protecting groups from the nucleic acid base and 2'-OH groups, which accelerates the process for generating synthetic RNA in a high throughput manner (*e.g.*, in a 96 well format).

10 Chemical synthesis of RNA is generally accomplished using a traditional column format on a RNA synthesizer where only one oligoribonucleotide is synthesized at a time. Simultaneous synthesis of more than one RNA molecule in a time efficient manner requires alternate methods to the traditional column format, such as synthesis in a 96 well plate format where up to 96 RNA molecules can be synthesized at the same time. To
15 expedite this process of simultaneous synthesis of multiple RNA molecules, it is important to accelerate some of the time consuming processes such as the deprotection of RNA following synthesis (*i.e.*, removal of base protecting group, such as the exocyclic amino protecting group and the phosphate protecting groups and the removal of 2'-OH protecting groups, such as the tButylDiMethylSilyl). In a preferred embodiment, the
20 invention features a one-pot process for rapid deprotection of RNA.

Stinchcomb *et al.*, *supra* described a one-pot protocol for RNA deprotection using anhydrous methylamine and triethylamine trihydrogen fluoride. This procedure involves the use of an anhydrous solution of base such as a 33% methylamine in absolute ethanol followed by neat triethylamine trihydrofluoride to effectively deprotect
25 oligoribonucleotides in a one-pot fashion. However such a protocol may be cumbersome for deprotection of RNA synthesized on a plate format, such as a 96 well plate, because it may be necessary to separate the solid-support from the partially deprotected RNA prior to the 2'-hydroxyl deprotection. Also, since the methylamine solution used is anhydrous,

it may be difficult to solubilize the negatively charged oligoribonucleotides obtained after basic treatment. So, in a first aspect the invention features the use of a 1:1 mixture of the ethanolic methylamine solution and a polar additive, such as dimethylsulfoxide (DMSO), N,N-dimethylformamide (DMF), methanol, hexamethylphosphoramide (HMPA), 1-methyl-2-pyrrolidinone (NMP), 2-methoxyethyl ether (glyme) or the like. More specifically, dimethylsulfoxide is used to partially deprotect oligoribonucleotides (Figure 32). A comparison of the one pot and two pot deprotection methods are outlined and demonstrated in Figure 33.

This invention also concerns a rapid (high through-put) deprotection of RNA in a 96-well plate format. More specifically rapid deprotection of enzymatic RNA molecules in greater than microgram quantities with high biological activity is featured. It has been determined that the recovery of enzymatically active RNA in high yield and quantity is dependent upon certain critical steps used during its deprotection.

In a preferred embodiment, the invention features a process for one-pot deprotection of RNA molecules comprising protecting groups, comprising the steps of: a) contacting the RNA with a mixture of anhydrous alkylamine (where alkyl can be branched or unbranched, ethyl, propyl or butyl and is preferably methyl, *e.g.*, methylamine), trialkylamine (where alkyl can be branched or unbranched, methyl, propyl or butyl and is preferably ethyl, *e.g.*, ethylamine) and dimethylsulfoxide, preferably in a 10:3:13, or 1:0.3:1 proportion at temperature 20-30 °C for about 30-100 minutes, preferably 90 minutes, to remove the exocyclic amino (base) protecting groups and the phosphate protecting group (*e.g.*, 2-cyanoethyl) (*vs* 4-20 h at 55-65 °C using NH₄OH/EtOH or NH₃/EtOH, or 10-15 min at 65°C using 40% aqueous methylamine) under conditions suitable for partial deprotection of the RNA; b) contacting the partially deprotected RNA with anhydrous triethylamine•hydrogen fluoride (3HF•TEA) and heating at about 50-70 °C, preferably at 65 °C, for about 5-30 min, preferably 15 min to remove the 2'-hydroxyl protecting group (*vs* 8 - 24 h using TBAF, or TEA•3HF for 24 h (Gasparutto *et al. Nucleic Acids Res.* 1992, 20, 5159-5166) (Other alkylamine•HF

complexes may also be used, *e.g.*, trimethylamine or diisopropylethylamine) under conditions suitable for the complete deprotection of the RNA. The reaction can then be quenched by using aqueous ammonium bicarbonate (1.4 M). Although some other buffers can be used to quench the desilylation reaction (*i.e.*, triethylammonium bicarbonate, ammonium acetate), the ammonium bicarbonate buffer is perfectly suited to retain the 5'-*O*-dimethoxytrityl group at the 5'-end of the oligoribonucleotide thereby facilitating a reverse phase-based solid-phase extraction purification protocol.

By "one-pot" deprotection is meant that the process of deprotection RNA is carried out in one container instead of multiple containers as in two-pot deprotection.

10 In another preferred embodiment, the invention features a process for one pot deprotection of RNA molecules comprising protecting groups, comprising the steps of: a) contacting the RNA with a mixture of anhydrous alkylamine (where alkyl can be branched or unbranched, ethyl, propyl or butyl and is preferably methyl, *e.g.*, methylamine), and dimethylsulfoxide, preferably in a 1:1 proportion at 20-30 °C
15 temperature for about 30-100 minutes, preferably 90 minutes, to remove the exocyclic amino (base) protecting groups and the phosphate protecting group (*e.g.*, 2-cyanoethyl) (vs 4-20 h at 55-65 °C using NH₄OH/EtOH or NH₃/EtOH, or 10-15 min at 65°C using 40% aqueous methylamine) under conditions suitable for partial deprotection of the RNA; b) contacting the partially deprotected RNA with anhydrous
20 triethylamine•hydrogen fluoride (3HF•TEA) and heating at about 50-70 °C, preferably at 65 °C, for about 5-30 min, preferably 15 min to remove the 2'-hydroxyl protecting group (Other alkylamine•HF complexes may also be used, *e.g.*, trimethylamine or diisopropylethylamine) under conditions suitable for the complete deprotection of the RNA. The reaction can then be quenched by using aqueous ammonium bicarbonate (1.4
25 M). Although some other buffers can be used to quench the desilylation reaction (*i.e.*, triethylammonium bicarbonate, ammonium acetate), the ammonium bicarbonate buffer is perfectly suited to retain the 5'-*O*-dimethoxytrityl group at the 5'-end of the

oligoribonucleotide thereby facilitating a reverse phase-based solid-phase extraction purification protocol.

In another aspect the invention features a process for RNA deprotection where the exocyclic amino and phosphate deprotection reaction is performed with the ethanolic methylamine solution at room temperature for about 90 min or at 65°C for 15 min or at 45°C for 30 min or at 35°C for 60 min.

In a preferred embodiment, the process for deprotection of RNA of the present invention is used to deprotect a ribozyme synthesized using a column format as described in (Scaringe *et al.*, *supra*; Wicott *et al.*, *supra*).

Inactive hammerhead ribozymes were synthesized by substituting a U for G₅ and a U for A₁₄ (numbering from Hertel, K. J., *et al.*, 1992, *Nucleic Acids Res.*, 20, 3252).

The average stepwise coupling yields were >98% (Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677-2684).

Hairpin ribozymes are synthesized in two parts and annealed to reconstruct the active ribozyme (Chowrira and Burke, 1992 *Nucleic Acids Res.*, 20, 2835-2840). Ribozymes are also synthesized from DNA templates using bacteriophage T7 RNA polymerase (Milligan and Uhlenbeck, 1989, *Methods Enzymol.* 180, 51).

Ribozymes are modified to enhance stability and/or enhance catalytic activity by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992 *TIBS* 17, 34; Usman *et al.*, 1994 *Nucleic Acids Symp. Ser.* 31, 163; Burgin *et al.*, 1996 *Biochemistry* 6, 14090).

Ribozymes were purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; See Stinchcomb *et al.*,

International PCT Publication No. WO 95/23225, the totality of which is hereby incorporated herein by reference) and are resuspended in water.

The sequences of the ribozymes that are chemically synthesized, useful in this study, are shown in Tables XII-XIX. Those in the art will recognize that these sequences are representative only of many more such sequences where the enzymatic portion of the ribozyme (all but the binding arms) is altered to affect activity. For example, stem-loop II sequence of hammerhead ribozymes can be altered (substitution, deletion, and/or insertion) to contain any sequences provided a minimum of two base-paired stem structure can form. Similarly, stem-loop IV sequence of hairpin ribozymes, can be altered (substitution, deletion, and/or insertion) to contain any sequence, provided a minimum of two base-paired stem structure can form. Preferably, no more than 200 bases are inserted at these locations. The sequences listed in Tables XII-XIX may be formed of ribonucleotides or other nucleotides or non-nucleotides. Such ribozymes (which have enzymatic activity) are equivalent to the ribozymes described specifically in the Tables.

Nucleotide Triphosphates:

The use of modified nucleotide triphosphates would greatly assist in the combinatorial chemistry. The synthesis of nucleoside triphosphates and their incorporation into nucleic acids using polymerase enzymes has greatly assisted in the advancement of nucleic acid research. The polymerase enzyme utilizes nucleoside triphosphates as precursor molecules to assemble oligonucleotides. Each nucleotide is attached by a phosphodiester bond formed through nucleophilic attack by the 3' hydroxyl group of the oligonucleotide's last nucleotide onto the 5' triphosphate of the next nucleotide. Nucleotides are incorporated one at a time into the oligonucleotide in a 5' to 3' direction. This process allows RNA to be produced and amplified from virtually any DNA or RNA templates.

Most natural polymerase enzymes incorporate standard nucleoside triphosphates into nucleic acid. For example, a DNA polymerase incorporates dATP, dTTP, dCTP, and

dGTP into DNA and an RNA polymerase generally incorporates ATP, CTP, UTP, and GTP into RNA. There are however, certain polymerases that are capable of incorporating non-standard nucleoside triphosphates into nucleic acids (Joyce, 1997, *PNAS* 94, 1619-1622, Huang et al., *Biochemistry* 36, 8231-8242).

5 Before nucleosides can be incorporated into RNA transcripts using polymerase enzymes they must first be converted into nucleoside triphosphates which can be recognized by these enzymes. Phosphorylation of unblocked nucleosides by treatment with POCl₃ and trialkyl phosphates was shown to yield nucleoside 5'-phosphorodichloridates (Yoshikawa *et al.*, 1969, *Bull. Chem. Soc. (Japan)* 42, 3505).
10 Adenosine or 2'-deoxyadenosine 5'-triphosphate was synthesized by adding an additional step consisting of treatment with excess tri-n-butylammonium pyrophosphate in DMF followed by hydrolysis (Ludwig, 1981, *Acta Biochim. et Biophys. Acad. Sci. Hung.* 16, 131-133).

Non-standard nucleoside triphosphates are not readily incorporated into RNA
15 transcripts by traditional RNA polymerases. Mutations have been introduced into RNA polymerase to facilitate incorporation of deoxyribonucleotides into RNA (Sousa & Padilla, 1995, *EMBO J.* 14,4609-4621, Bonner *et al.*, 1992, *EMBO J.* 11, 3767-3775, Bonner et al., 1994, *J. Biol. Chem.* 42, 25120-25128, Aurup *et al.*, 1992, *Biochemistry* 31, 9636-9641).


20 McGee *et al.*, International PCT Publication No. WO 95/35102, describes the incorporation of 2'-NH₂-NTP's, 2'-F-NTP's, and 2'-deoxy-2'-benzyloxyamino UTP into RNA using bacteriophage T7 polymerase.

Wieczorek *et al.*, 1994, *Bioorganic & Medicinal Chemistry Letters* 4, 987-994, describes the incorporation of 7-deaza-adenosine triphosphate into an RNA transcript
25 using bacteriophage T7 RNA polymerase.

Lin *et al.*, 1994, *Nucleic Acids Research* 22, 5229-5234, reports the incorporation of 2'-NH₂-CTP and 2'-NH₂-UTP into RNA using bacteriophage T7 RNA polymerase and

polyethylene glycol containing buffer. The article describes the use of the polymerase synthesized RNA for *in vitro* selection of aptamers to human neutrophil elastase (HNE).

The invention features NTP's having the formula triphosphate-OR, for example the following formula I:



where R is any nucleoside; specifically the nucleosides 2'-O-methyl-2,6-diaminopurine riboside; 2'-deoxy-2'-amino-2,6-diaminopurine riboside; 2'-(N-alanyl) amino-2'-deoxy-uridine; 2'-(N-phenylalanyl)amino-2'-deoxy-uridine; 2'-deoxy-2'-(N-β-alanyl) amino ; 2'-deoxy-2'-(lysiyl) amino uridine; 2'-C-allyl uridine; 2'-O-amino-uridine; 2'-O-methylthiomethyl adenosine; 2'-O-methylthiomethyl cytidine ; 2'-O-methylthiomethyl guanosine; 2'-O-methylthiomethyl-uridine; 2'-Deoxy-2'-(N-histidyl) amino uridine; 2'-deoxy-2'-amino-5-methyl cytidine; 2'-(N-β-carboxamide-β-alanyl)amino-2'-deoxy-uridine; 2'-deoxy-2'-(N-β-alanyl)-guanosine; and 2'-O-amino-adenosine.

In a second aspect, the invention features a process for the synthesis of pyrimidine nucleotide triphosphate (such as UTP, 2'-O-MTM-UTP, dUTP and the like) including the steps of monophosphorylation where the pyrimidine nucleoside is contacted with a mixture having a phosphorylating agent (such as phosphorus oxychloride, phospho-tris-triazolides, phospho-tris-triimidazolides and the like), trialkyl phosphate (such as triethylphosphate or trimethylphosphate or the like) and dimethylaminopyridine (DMAP) under conditions suitable for the formation of pyrimidine monophosphate; and pyrophosphorylation where the pyrimidine monophosphate is contacted with a pyrophosphorylating reagent (such as tributylammonium pyrophosphate) under conditions suitable for the formation of pyrimidine triphosphates.

By "pyrimidines" is meant nucleotides comprising modified or unmodified derivatives of a six membered pyrimidine ring. An example of a pyrimidine is modified or unmodified uridine.

5 By "nucleotide triphosphate" or "NTP" is meant a nucleoside bound to three inorganic phosphate groups at the 5' hydroxyl group of the modified or unmodified ribose or deoxyribose sugar where the 1' position of the sugar may comprise a nucleic acid base or hydrogen. The triphosphate portion may be modified to include chemical moieties which do not destroy the functionality of the group (*i.e.*, allow incorporation into an RNA molecule).

10 In another preferred embodiment, nucleoside triphosphates (NTP's) of the instant invention are incorporated into an oligonucleotide using an RNA polymerase enzyme. RNA polymerases include but are not limited to mutated and wild type versions of bacteriophage T7, SP6, or T3 RNA polymerases.

15 In yet another preferred embodiment, the invention features a process for incorporating modified NTP's into an oligonucleotide including the step of incubating a mixture having a DNA template, RNA polymerase, NTP, and an enhancer of modified NTP incorporation under conditions suitable for the incorporation of the modified NTP into the oligonucleotide.

20 By "enhancer of modified NTP incorporation" is meant a reagent which facilitates the incorporation of modified nucleotides into a nucleic acid transcript by an RNA polymerase. Such reagents include but are not limited to methanol; LiCl; polyethylene glycol (PEG); diethyl ether; propanol; methyl amine; ethanol and the like.

25 In another preferred embodiment, the modified nucleoside triphosphates can be incorporated by transcription into a nucleic acid molecules including enzymatic nucleic acid, antisense, 2-5A antisense chimera, oligonucleotides, triplex forming oligonucleotide (TFO), aptamers and the like (Stull *et al.*, 1995 *Pharmaceutical Res.* 12, 465).

By "antisense" it is meant a non-nucleic acid catalyst that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm *et al.*, 1993 *Nature* 365, 566) interactions and alters the activity of the target RNA (for a review see Stein and Cheng, 1993 *Science* 261, 1004; Agrawal *et al.*, U.S. Patent No. 5,591,721; 5 Agrawal, U.S. Patent No. 5,652,356).

By "2-5A antisense chimera" it is meant, an antisense oligonucleotide containing a 5' phosphorylated 2'-5'-linked adenylate residues. These chimeras bind to target RNA in a sequence-specific manner and activate a cellular 2-5A-dependent ribonuclease which, in turn, cleaves the target RNA (Torrence *et al.*, 1993 *Proc. Natl. Acad. Sci. USA* 90, 1300).

10 By "triplex forming oligonucleotides (TFO)" it is meant an oligonucleotide that can bind to a double-stranded DNA in a sequence-specific manner to form a triple-strand helix. Formation of such triple helix structure has been shown to inhibit transcription of the targeted gene (Duval-Valentin *et al.*, 1992 *Proc. Natl. Acad. Sci. USA* 89, 504).

By "oligonucleotide" as used herein is meant a molecule having two or more 15 nucleotides. The polynucleotide can be single, double or multiple stranded and may have modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof.

In yet another preferred embodiment, the modified nucleoside triphosphates of the instant invention can be used for combinatorial chemistry or *in vitro* selection of nucleic 20 acid molecules with novel function. Modified oligonucleotides can be enzymatically synthesized to generate libraries for screening.

Nucleoside modifications of bases and sugars, have been discovered in a variety of naturally occurring RNA (*e.g.*, tRNA, mRNA, rRNA; reviewed by Hall, 1971 *The Modified Nucleosides in Nucleic Acids*, Columbia University Press, New York; Limbach 25 *et al.*, 1994 *Nucleic Acids Res.* 22, 2183). In an attempt to understand the biological significance, structural and thermodynamic properties, and nuclease resistance of these nucleoside modifications in nucleic acids, several investigators have chemically

synthesized nucleosides, nucleotides and phosphoramidites with various base and sugar modifications and incorporated them into oligonucleotides.

Uhlmann and Peyman, 1990, *Chem. Reviews* 90, 543, review the use of certain nucleoside modifications to stabilize antisense oligonucleotides.

- 5 Usman *et al.*, International PCT Publication Nos. *WO/93/15187*; and *WO 95/13378*; describe the use of sugar, base and backbone modifications to enhance the nuclease stability of nucleic acid catalysts.

- Eckstein *et al.*, International PCT Publication No. *WO 92/07065* describe the use of sugar, base and backbone modifications to enhance the nuclease stability of nucleic
10 acid catalysts.

Grasby *et al.*, 1994, *Proc. Indian Acad. Sci.*, 106, 1003, review the "applications of synthetic oligoribonucleotide analogues in studies of RNA structure and function".

Eaton and Pieken, 1995, *Annu. Rev. Biochem.*, 64, 837, review sugar, base and backbone modifications that enhance the nuclease stability of RNA molecules.

- 15 Rosemeyer *et al.*, 1991, *Helvetica Chem. Acta*, 74, 748, describe the synthesis of 1-(2'-deoxy- β -D-xylofuranosyl) thymine-containing oligodeoxynucleotides.

Seela *et al.*, 1994, *Helvetica Chem. Acta*, 77, 883, describe the synthesis of 1-(2'-deoxy- β -D-xylofuranosyl) cytosine-containing oligodeoxynucleotides.

- Seela *et al.*, 1996, *Helvetica Chem. Acta*, 79, 1451, describe the synthesis xylose-
20 DNA containing the four natural bases.

In another preferred embodiment, catalytic activity of the molecules described in the instant invention can be optimized as described by Draper *et al.*, *supra*. The details will not be repeated here, but include altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications (base, sugar and/or phosphate) that

prevent their degradation by serum ribonucleases and/or enhance their enzymatic activity (see *e.g.*, Eckstein *et al.*, International Publication No. WO 92/07065; Perrault *et al.*, 1990 *Nature* 344, 565; Pieken *et al.*, 1991 *Science* 253, 314; Usman and Cedergren, 1992 *Trends in Biochem. Sci.* 17, 334; Usman *et al.*, International Publication No. WO 93/15187; and Rossi *et al.*, International Publication No. WO 91/03162; Sproat, US Patent No. 5,334,711; and Burgin *et al.*, *supra*; all of these describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of enzymatic RNA molecules). Modifications which enhance their efficacy in cells, and removal of bases from stem loop structures to shorten RNA synthesis times and reduce chemical requirements are desired. (All these publications are hereby incorporated by reference herein.).

By "enhanced enzymatic activity" is meant to include activity measured in cells and/or *in vivo* where the activity is a reflection of both catalytic activity and ribozyme stability. In this invention, the product of these properties is increased or not significantly (less than 10 fold) decreased *in vivo* compared to an all RNA ribozyme.

In yet another preferred embodiment, nucleic acid catalysts having chemical modifications which maintain or enhance enzymatic activity is provided. Such nucleic acid is also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or *in vivo* the activity may not be significantly lowered. As exemplified herein such ribozymes are useful in a cell and/or *in vivo* even if activity over all is reduced 10 fold (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090). Such ribozymes herein are said to "maintain" the enzymatic activity on all RNA ribozyme.

In a most preferred embodiment the invention features a method of synthesizing ribozyme libraries of various sizes. This invention describes methods to chemically synthesize ribozyme libraries of various sizes from suitable nucleoside analogs.

Considerations for the selection of nucleotide building blocks and determination of coupling efficiency: In addition to structural considerations (hydrogen bond donors and

acceptors, stacking properties, pucker orientation of sugars, hydrophobicity or hydrophilicity of some subgroups constitutive of the nucleotides) that may lead to the selection of a specific nucleotide to be included in the design of a ribozyme library, one of the important features that needs to be considered when selecting nucleotide building blocks is the chemical compatibility of such building blocks with ribozyme synthesis. A "nucleotide building block" is a nucleoside or nucleoside analog that possess a suitably protected phosphorus atom at the oxidation state V reacting readily, upon activation, to give a P^V-containing internucleoside linkage. A suitable nucleoside building block may also contain a phosphorus atom at the oxidation state III reacting readily, upon activation, to give a P^{III}-containing internucleoside linkage that can be oxidized to the desired P^V-containing internucleoside linkage. Applicant has found that the phosphoramidite chemistry (P^{III}) is a preferred coupling method for ribozyme library synthesis. There are several other considerations while designing and synthesizing certain ribozyme libraries, such as: a) the coupling efficiencies of the nucleotide building blocks considered for a ribozyme library should not fall below 90% to provide a majority of full-length ribozyme; b) the nucleotide building blocks should be chemically stable to the selected synthesis and deprotection conditions of the particular ribozyme library; c) the deprotection schemes for the nucleotide building blocks incorporated into a ribozyme library, should be relatively similar and be fully compatible with ribozyme deprotection protocols. In particular, nucleoside building blocks requiring extended deprotection or that cannot sustain harsh treatment should be avoided in the synthesis of a ribozyme library. Typically, the reactivity of the nucleotide building blocks should be optimum when diluted to 100 mM to 200 mM in non-protic and relatively polar solvent. Also the deprotection condition using 3:1 mixture of ethanol and concentrated aqueous ammonia at 65 degrees C. for 4 hours followed by a fluoride treatment as exemplified in Wincott *et al. supra*, is particularly useful for ribozyme synthesis and is a preferred deprotection pathway for such nucleotide building blocks.

In one preferred embodiment, a "nucleotide building block mixing" approach to generate ribozyme libraries is described. This method involves mixing various nucleotide

building blocks together in proportions necessary to ensure equal representation of each of the nucleotide building blocks in the mixture. This mixture is incorporated into the ribozyme at position(s) selected for randomization.

The nucleotide building blocks selected for incorporation into a ribozyme library, are typically mixed together in appropriate concentrations, in reagents, such as anhydrous acetonitrile, to form a mixture with a desired phosphoramidite concentration. This approach for combinatorial synthesis of a ribozyme library with one or more random positions within the ribozyme (X as described above) is particularly useful since a standard DNA synthesizer can handle a building block mixture similar to a building block solution containing a single building block. Such a nucleotide building block mixture is coupled to a solid support or to a growing ribozyme sequence attached to a solid-support. To ensure that the ribozyme library synthesized achieves the desired complexity, the scale of the synthesis is increased substantially above that of the total complexity of the library. For example, a 2.5 μ mole ribozyme synthesis provides $\sim 3 \times 10^{17}$ ribozyme molecules corresponding to sub-nanomolar amounts of each member of a billion compounds ribozyme library.

Divinylbenzene highly cross-linked polystyrene solid-support constitutes the preferred stationary phase for ribozyme library synthesis. However, other solid-support systems utilized in DNA or RNA synthesis can also be used for ribozyme library synthesis. This includes silica-based solid-supports such as controlled-pore glass (CPG) or polymeric solid-supports such as all types of derivatized polystyrene resins, grafted polymers of chloromethylated polystyrene crosslinked with ethylene glycol, oligoethylene glycol.

Because of different coupling kinetics of the nucleotide building blocks present in a mixture, it is necessary to evaluate the relative incorporation of each of the members of the mixture and to adjust, if needed, the relative concentration of the building blocks in the mixture to get equimolar representation, compensating thereby the kinetic parameter. Typically a building block that presents a slow coupling kinetic will be over-represented

in the mixture and vice versa for a building block that presents a fast coupling kinetic. When equimolar incorporation is sought, acceptable limits for unequal incorporation may generally be +/-10%.

Synthesis of a random ribozyme library can be performed either with the mixture
5 of desired nucleotide building blocks, or with a combination of certain random positions (obtained by using one or more building block mixtures) and one or more fixed positions that can be introduced through the incorporation of a single nucleotide building block reagent. For instance, in the oligonucleotide model 5'-TT XXXX TTB-3' used in
example 2 *infra*, the positions from 3'-end 1 is fixed as 2'-deoxy-inverted abasic ribose
10 (B), positions 2, 3, 8 and 9 have been fixed as 2'-deoxy-thymidine (T) while the X positions 4-7 correspond to an approximately equimolar distribution of all the nucleotide building blocks that make up the X mixture.

In another preferred embodiment, a "mix and split" approach to generate ribozyme libraries is described. This method is particularly useful when the number of selected
15 nucleotide building blocks to be included in the library is large and diverse (greater than 5 nucleotide building blocks) and/or when the coupling kinetics of the selected nucleotide building blocks do not allow competitive coupling even after relative concentration adjustments and optimization. This method involves a multi-step process wherein the solid support used for ribozyme library synthesis is "split" (divided) into equal portions,
20 (the number of portions is equal to the number of different nucleotide building blocks (n) chosen for incorporation at one or more random positions within the ribozyme). For example, if there are 10 different nucleotide building blocks chosen for incorporation at one or more positions in the ribozyme library, then the solid support is divided into 10 different portions. Each portion is independently coupled to one of the selected
25 nucleotide building blocks followed by mixing of all the portions of solid support. The ribozyme synthesis is then resumed as before the division of the building blocks. This enables the synthesis of a ribozyme library wherein one or more positions within the ribozyme is random. The number of "splitting" and "mixing" steps is dependent on the

number of positions that are random within the ribozyme. For example if three positions are desired to be random then three different splitting and mixing steps are necessary to synthesize the ribozyme library.

Random ribozyme libraries are synthesized using a non-competitive coupling
5 procedure where each of the selected nucleotide analogs "n" separately couple to an
inverse "n" (1/n) number of aliquots of solid-support or of a growing ribozyme chain on
the solid-support. A very convenient way to verify completeness of the coupling reaction
is the use of a standard spectrophotometric DMT assay (Oligonucleotide Synthesis, A
Practical Approach, ed. M. Gait, pp 48, IRC Press, Oxford, UK; incorporated by reference
10 herein). These aliquots may be subsequently combined, mixed and split into one new
aliquot. A similar approach to making oligonucleotide libraries has recently been
described by Cook *et al.*, (US Patent No. 5,587,471) and is incorporated by reference
herein.

Nucleotide Synthesis

15 Addition of dimethylaminopyridine (DMAP) to the phosphorylation protocols
known in the art can greatly increase the yield of nucleoside monophosphates while
decreasing the reaction time (Fig. 29). Synthesis of the nucleosides of the invention have
been described in several publications and Applicants previous applications (Beigelman *et al.*,
International PCT publication No. WO 96/18736; Dudzcy *et al.*, Int. PCT Pub. No.
20 WO 95/11910; Usman *et al.*, Int. PCT Pub. No. WO 95/13378; Matulic-Adamic *et al.*,
1997, *Tetrahedron Lett.* 38, 203; Matulic-Adamic *et al.*, 1997, *Tetrahedron Lett.* 38,
1669; all of which are incorporated herein by reference). These nucleosides are dissolved
in triethyl phosphate and chilled in an ice bath. Phosphorus oxychloride (POCl₃) is then
added followed by the introduction of DMAP. The reaction is then warmed to room
25 temperature and allowed to proceed for 5 hours. This reaction allows the formation of
nucleoside monophosphates which can then be used in the formation of nucleoside
triphosphates. Tributylamine is added followed by the addition of anhydrous acetonitrile
and tributylammonium pyrophosphate. The reaction is then quenched with TEAB and

stirred overnight at room temperature (about 20C). The triphosphate is purified using column purification and HPLC and the chemical structure is confirmed using NMR analysis. Those skilled in the art will recognize that the reagents, temperatures of the reaction, and purification methods can easily be alternated with substitutes and equivalents and still obtain the desired product.

The invention provides nucleoside triphosphates which can be used for a number of different functions. The nucleoside triphosphates formed from nucleosides found in table III are unique and distinct from other nucleoside triphosphates known in the art. Incorporation of modified nucleotides into DNA or RNA oligonucleotides can alter the properties of the molecule. For example, modified nucleotides can hinder binding of nucleases, thus increasing the chemical half-life of the molecule. This is especially important if the molecule is to be used for cell culture or *in vivo*. It is known in the art that the introduction of modified nucleotides into these molecules can greatly increase the stability and thereby the effectiveness of the molecules (Burgin *et al.*, 1996, *Biochemistry* 35, 14090-14097; Usman *et al.*, 1996, *Curr. Opin. Struct. Biol.* 6, 527-533).

Modified nucleotides are incorporated using either wild type and mutant polymerases. For example, mutant T7 polymerase is used in the presence of modified nucleotide triphosphate(s), DNA template and suitable buffers. Those skilled in the art will recognize that other polymerases and their respective mutant versions can also be utilized for the incorporation of NTP's of the invention. Nucleic acid transcripts were detected by incorporating radiolabelled nucleotides (α -³²P NTP). The radiolabeled NTP contained the same base as the modified triphosphate being tested. The effects of methanol, PEG and LiCl were tested by adding these compounds independently or in combination. Detection and quantitation of the nucleic acid transcripts was performed using a Molecular Dynamics PhosphorImager. Efficiency of transcription was assessed by comparing modified nucleotide triphosphate incorporation with all-ribonucleotide incorporation control. Wild type polymerase was used to incorporate NTP's using the manufacturers buffers and instructions (Boehringer Mannheim).


Transcription Conditions

Incorporation rates of modified nucleoside triphosphates into oligonucleotides can be increased by adding to traditional buffer conditions, several different enhancers of modified NTP incorporation. Applicant has utilized methanol and LiCl in an attempt to increase incorporation rates of dNTP using RNA polymerase. These enhancers of modified NTP incorporation can be used in different combinations and ratios to optimize transcription. Optimal reaction conditions differ between nucleoside triphosphates and can readily be determined by standard experimentation. Overall however, inclusion of enhancers of modified NTP incorporation such as methanol or inorganic compound such as lithium chloride, have been shown by the applicant to increase the mean transcription rates.

Administration of Nucleoside mono, di or triphosphates

The nucleotide monophosphates, diphosphates, or triphosphates can be used as a therapeutic agent either independently or in combination with other pharmaceutical components. These molecules of the inventions can be administered to patients using the methods of Sullivan *et al.*, PCT WO 94/02595. Molecules of the invention may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles. Alternatively, the modified nucleotide triphosphate, diphosphate or monophosphate/vehicle combination is locally delivered by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of delivery and administration are provided in Sullivan *et al.*, *supra* and Draper *et al.*, PCT WO93/23569 which have been incorporated by reference herein.

This invention further relates to a compound having the Formula II:



wherein, R_1 is OH, O- R_3 , where R_3 is independently a moiety selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; C- R_3 , where R_3 is independently a moiety selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; halo, NHR_4 (R_4 =alkyl (C1-22), acyl (C1-22), substituted or unsubstituted aryl), or OCH_2SCH_3 (methylthiomethyl), $ONHR_5$ where R_5 is independently H, aminoacyl group, peptidyl group, biotinyl group, cholesteryl group, lipoic acid residue, retinoic acid residue, folic acid residue, ascorbic acid residue, nicotinic acid residue, 6-aminopenicillanic acid residue, 7-aminocephalosporanic acid residue, alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide or ester, $ON=R_6$, where R_6 is independently pyridoxal residue, pyridoxal-5-phosphate residue, 13-cis-retinal residue, 9-cis-retinal residue, alkyl, alkenyl, alkynyl, alkylaryl, carbocyclic alkylaryl, or heterocyclic alkylaryl; B is independently a nucleotide base or its analog or hydrogen; X is independently a phosphorus-containing group; and R_2 is independently blocking group or a phosphorus-containing group.

Specifically, an "alkyl" group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxy, cyano, alkoxy, NO_2 or $N(CH_3)_2$, amino, or SH.

The term "alkenyl" group refers to unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic

groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, NO₂, halogen, N(CH₃)₂, amino, or SH.

5 The term "alkynyl" refers to an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably,
10 hydroxyl, cyano, alkoxy, =O, =S, NO₂ or N(CH₃)₂, amino or SH.

 An "aryl" group refers to an aromatic group which has at least one ring having a conjugated p electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The preferred substituent(s) on aryl groups are halogen, trihalomethyl, hydroxyl, SH, cyano, alkoxy, alkyl, alkenyl, alkynyl,
15 and amino groups.

 An "alkylaryl" group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above).

 "Carbocyclic aryl" groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted.

20 "Heterocyclic aryl" groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted.

 An "amide" refers to an -C(O)-NH-R, where R is either alkyl, aryl, alkylaryl or
25 hydrogen.

An "ester" refers to an -C(O)-OR', where R is either alkyl, aryl, or alkylaryl.

A "blocking group" is a group which is able to be removed after polynucleotide synthesis and/or which is compatible with solid phase polynucleotide synthesis.

A "phosphorus containing group" can include phosphorus in forms such as dithioates, phosphoramidites and/or as part of an oligonucleotide.

In a preferred embodiment, the invention features a process for synthesis of the compounds of formula II.

In a preferred embodiment the invention features a process for the synthesis of a xylofuranosyl nucleoside phosphoramidite comprising the steps of: a) oxidation of a 2' and 5'-protected ribonucleoside with a an oxidant such as chromium oxide/pyridine/aceticanhydride, dimethylsulfoxide/aceticanhydride, or Dess-Martin reagent (periodinane) followed by reduction with a reducing agent such as, triacetoxysodium borohydride, sodium borohydride, or lithium borohydride, under conditions suitable for the formation of 2' and 5'-protected xylofuranosyl nucleoside; b) phosphitylation under conditions suitable for the formation of xylofuranosyl nucleoside phosphoramidite.

In yet another preferred embodiment, the invention features the incorporation of the compounds of Formula II into polynucleotides. These compounds can be incorporated into polynucleotides enzymatically. For example by using bacteriophage T7 RNA polymerase, these novel nucleotide analogs can be incorporated into RNA at one or more positions (Milligan *et al.*, 1989, *Methods Enzymol.*, 180, 51). Alternatively, novel nucleoside analogs can be incorporated into polynucleotides using solid phase synthesis (Brown and Brown, 1991, in *Oligonucleotides and Analogues: A Practical Approach*, p. 1, ed. F. Eckstein, Oxford University Press, New York; Wincott *et al.*, 1995, *Nucleic Acids Res.*, 23, 2677; Beaucage & Caruthers, 1996, in *Bioorganic Chemistry: Nucleic Acids*, p 36, ed. S. M. Hecht, Oxford University Press, New York).

The compounds of Formula II can be used for chemical synthesis of nucleotide-tri-phosphates and/or phosphoramidites as building blocks for selective incorporation into oligonucleotides. These oligonucleotides can be used as an antisense molecule, 2-5A antisense chimera, triplex forming oligonucleotides (TFO) or as a nucleic acid catalyst.

- 5 The oligonucleotides can also be used as probes or primers for synthesis and/or sequencing of RNA or DNA.

The compounds of the instant invention can be readily converted into nucleotide diphosphate and nucleotide triphosphates using standard protocols (for a review see Hutchinson, 1991, in *Chemistry of Nucleosides and Nucleotides*, v.2, pp 81-160, Ed. L. B.

- 10 Townsend, Plenum Press, New York, USA; incorporated by reference herein).


The compounds of Formula II can also be independently or in combination used as an antiviral, anticancer or an antitumor agent. These compounds can also be independently or in combination used with other antiviral, anticancer or antitumor agents.

- 15 In one of the preferred embodiments of the inventions herein, the nucleic acid catalyst is formed in a hammerhead or hairpin motif, but may also be formed in the motif of a hepatitis d virus, group I intron, group II intron or RNaseP RNA (in association with an RNA guide sequence) or *Neurospora* VS RNA. Examples of such hammerhead motifs are described by Dreyfus, *supra*, Rossi *et al.*, 1992, *AIDS Research and Human*
20 *Retroviruses* 8, 183; of hairpin motifs by Hampel *et al.*, EP0360257, Hampel and Tritz, 1989 *Biochemistry* 28, 4929, Feldstein *et al.*, 1989, *Gene* 82, 53, Haseloff and Gerlach, 1989, *Gene*, 82, 43, and Hampel *et al.*, 1990 *Nucleic Acids Res.* 18, 299; of the hepatitis d virus motif is described by Perrotta and Been, 1992 *Biochemistry* 31, 16; of the RNaseP motif by Guerrier-Takada *et al.*, 1983 *Cell* 35, 849; Forster and Altman, 1990, *Science*
25 249, 783; Li and Altman, 1996, *Nucleic Acids Res.* 24, 835; *Neurospora* VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990 *Cell* 61, 685-696; Saville and Collins, 1991 *Proc. Natl. Acad. Sci. USA* 88, 8826-8830; Collins and Olive, 1993 *Biochemistry* 32, 2795-2799; Guo and Collins, 1995, *EMBO. J.* 14, 363); Group II


introns are described by Griffin *et al.*, 1995, *Chem. Biol.* 2, 761; Michels and Pyle, 1995, *Biochemistry* 34, 2965; Pyle *et al.*, International PCT Publication No. *WO 96/22689*; and of the Group I intron by Cech *et al.*, U.S. Patent 4,987,071. These specific motifs are not limiting in the invention and those skilled in the art will recognize that all that is important in a nucleic acid catalyst of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule.

In a preferred embodiment, a polynucleotide of the invention would bear one or more 2'-hydroxylamino functionalities attached directly to the monomeric unit or through the use of an appropriate spacer. Since oligonucleotides have neither aldehyde nor hydroxylamino groups, the formation of an oxime would occur selectively using oligo as a polymeric template. This approach would facilitate the attachment of practically any molecule of interest (peptides, polyamines, coenzymes, oligosaccharides, lipids, etc.) directly to the oligonucleotide using either aldehyde or carboxylic function in the molecule of interest.

Scheme 1. Post synthetic Oxime Bond Formation



Scheme 2. Chemical Ligation of Oligonucleotides




5 Advantages of oxime bond formation:

- The oximation reaction proceeds in water
- Quantitative yields
- Hydrolytic stability in a wide pH range (5 - 8)
- The amphoteric nature of oximes allows them to act either as weak acids or weak bases.
- Oximes exhibit a great tendency to complex with metal ions

10

In yet another preferred embodiment, the aminooxy “tether” in oligonucleotides, such as a ribozyme, is reacted with different compounds bearing carboxylic groups (e.g., aminoacids, peptides, “cap” structures ,etc.) resulting in the formation of oxyamides as shown below.

15

Scheme 3. Post synthetic oxamide bond formation**Target Discovery:**

5 Applicant has developed an efficient and rapid method for screening libraries of catalytic nucleic acid molecules capable of performing a desired function in a cell. The invention also features the use of a catalytic nucleic acid library to modulate certain attributes or processes in a biological system, such as a mammalian cell, and to identify and isolate a) nucleic acid catalysts from the library involved in modulating the cellular
10 process/attribute of interest; and b) modulators of the desired cellular process/attribute using the sequence of the nucleic acid catalyst.

More specifically, the method of the instant invention involves designing and constructing a catalytic nucleic acid library, where the catalytic nucleic acid includes a catalytic and a substrate binding domain, and the substrate binding domain (arms) are
15 randomized. This library of catalytic nucleic acid molecules with randomized binding arm(s) are used to modulate certain processes/attributes in a biological system. The method described in this application involves simultaneous screening of a library or pool of catalytic nucleic acid molecules with various substitutions at one or more positions and selecting for ribozymes with desired function or characteristics or attributes. This
20 invention also features a method for constructing and selecting for catalytic nucleic acid molecules for their ability to cleave a given target nucleic acid molecule or an unknown target nucleic acid molecule (*e.g.*, RNA), and to inhibit the biological function of that target molecule or any protein encoded by it.

It is not necessary to know either the sequence or the structure of the target nucleic
25 acid molecule in order to select for catalytic nucleic acid molecules capable of cleaving the target in this cellular system. The cell-based screening protocol described in the

instant invention (*i.e.*, one which takes place inside a cell) offers many advantages over extracellular systems, because the synthesis of large quantities of RNA by enzymatic or chemical methods prior to assessing the efficacy of the catalytic nucleic acid molecules is not necessary. The invention further describes a rapid method of using catalytic nucleic acid molecule libraries to identify the biological function of a gene sequence inside a cell. Applicant describes a method of using catalytic nucleic acid molecule libraries to identify a nucleic acid molecule, such as a gene, involved in a biological process; this nucleic acid molecule may be a known molecule with a known function, or a known molecule with a previously undefined function or an entirely novel molecule. This is a rapid means for identifying, for example, genes involved in a cellular pathway, such as cell proliferation, cell migration, cell death, and others. This method of gene discovery is not only a novel approach to studying a desired biological process but also a means to identify active reagents that can modulate this cellular process in a precise manner.

Applicant describes herein, a general approach for simultaneously assaying the ability of one or more members of a catalytic nucleic acid molecule library to modulate certain attributes/process(es) in a biological system, such as plants, animals or bacteria, involving introduction of the library into a desired cell and assaying for changes in a specific "attribute," "characteristic" or "process." The specific attributes may include cell proliferation, cell survival, cell death, cell migration, angiogenesis, tumor volume, tumor metastasis, levels of a specific mRNA(s) in a cell, levels of a specific protein(s) in a cell, levels of a specific protein secreted, cell surface markers, cell morphology, cell differentiation pattern, cartilage degradation, transplantation, restenosis, viral replication, viral load, and the like. By modulating a specific biological pathway using a catalytic nucleic acid molecule library, it is possible to identify the gene(s) involved in that pathway, which may lead to the discovery of novel genes, or genes with novel function. This method provides a powerful tool to study gene function inside a cell. This approach also offers the potential for designing novel catalytic oligonucleotides, identifying ribozyme accessible sites within a target, and for identifying new nucleic acid targets for ribozyme-mediated modulation of gene expression.

In another aspect the invention involves synthesizing a Random Binding Arm Nucleic Acid Catalyst Library (Random Library) and simultaneously testing all members of the Random Library in cells. This library has ribozymes with random substrate binding arm(s) and a defined catalytic domain. Cells with an altered attribute (such as inhibition of cell proliferation) as a result of interaction with the members of the Random Library are selected and the sequences of the ribozymes from these cells are determined. Sequence information from the binding arm(s) of these ribozymes can be used to isolate nucleic acid molecules that are likely to be involved in the pathway responsible for the desired cellular attribute using standard technology known in the art, *e.g.*, nucleic acid amplification using techniques such as polymerase chain reaction (PCR). This method is a powerful means to isolate new genes or genes with new function.

By "Random Library" as used herein is meant ribozyme libraries comprising all possible variants in the binding arm (s) of a given ribozyme motif. Here the complexity and the content of the library is not defined. The Random Library is expected to comprise sequences complementary to every potential target sequence, for the ribozyme motif chosen, in the genome of an organism. This Random Library can be used to screen for ribozyme cleavage sites in a known target sequence or in a unknown target. In the first instance, the Random Library is introduced into the cell of choice and the expression of the known target gene is assayed. Cells with an altered expression of the target will yield the most effective ribozyme against the known target. In the second instance, the Random Library is introduced into the cell of choice and the cells are assayed for a specific attribute, for example, survival of cells. Cells that survive the interaction with the Random Library are isolated and the ribozyme sequence from these cells is determined. The sequence of the binding arm of the ribozyme can then be used as probes to isolate the gene(s) involved in cell death. Because, the ribozyme(s) from the Random Library is able to modulate (*e.g.*, down regulate) the expression of the gene(s) involved in cell death, the cells are able to survive under conditions where they would have otherwise died. This is a novel method of gene discovery. This approach not only provides the information about mediators of certain cellular processes, but also provides a means to modulate the

expression of these modulators. This method can be used to identify modulators of any cell process in any organism, including but not limited to mammals, plants and bacteria.

The invention provides a method for producing a class of enzymatic cleaving agents which exhibit a high degree of specificity for the nucleic acid sequence of a desired target. The nucleic acid catalyst is preferably targeted to a highly conserved sequence region of a target such that specific diagnosis and/or treatment of a disease or condition can be provided with a single enzymatic nucleic acid.

In a first aspect the invention features a method for identifying one or more nucleic acid molecules, such as gene(s), involved in a process (such as, cell growth, proliferation, apoptosis, morphology, angiogenesis, differentiation, migration, viral multiplication, drug resistance, signal transduction, cell cycle regulation, temperature sensitivity, chemical sensitivity and others) in a biological system, such as a cell. The method involves the steps of: a) providing a random library of nucleic acid catalysts, with a substrate binding domain and a catalytic domain, where the substrate binding domain has a random sequence, to the biological system under conditions suitable for the process to be altered; b) identifying any nucleic acid catalyst present in that biological system where the process has been altered by any nucleic acid catalyst; and c) determining the nucleotide sequence of at least a portion of the binding arm of such a nucleic acid catalyst to allow identification of the nucleic acid molecule involved in the process in that biological system.

In a related aspect the invention features a method for identification of a nucleic acid molecule capable of modulating a process in a biological system. The method includes: a) introducing a library of nucleic acid catalysts with a substrate binding domain and a catalytic domain, where the substrate binding domain has a random sequence, into the biological system under conditions suitable for modulating the process; and b) determining the nucleotide sequence of at least a portion of the substrate binding domain of any nucleic acid catalyst from a biological system where the process has been

modulated to allow said identification of the nucleic acid molecule capable of modulating said process in that biological system.

In a second aspect, the invention the invention further concerns a method for identification of a nucleic acid catalyst capable of modulating a process in a biological system. This involves: a) introducing a library of nucleic acid catalysts with a substrate binding domain and a catalytic domain, where the substrate binding domain has a random sequence, into the biological system under conditions suitable for modulating the process; and b) identifying any nucleic acid catalyst from a biological system where the process has been modulated.

By "enzymatic portion" or "catalytic domain" is meant that portion/region of the ribozyme essential for cleavage of a nucleic acid substrate (for example see Figure 3).

By "nucleic acid molecule" as used herein is meant a molecule having nucleotides. The nucleic acid can be single, double or multiple stranded and may comprise modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof. An example of a nucleic acid molecule according to the invention is a gene which encodes for macromolecule such as a protein.

The "biological system" as used herein may be a eukaryotic system or a prokaryotic system, may be a bacterial cell, plant cell or a mammalian cell, or may be of plant origin, mammalian origin, yeast origin, Drosophila origin, or archebacterial origin.

This invention further relates to novel nucleic acid molecules with catalytic activity, which are particularly useful for cleavage of RNA or DNA. The nucleic acid catalysts of the instant invention are distinct from other nucleic acid catalysts known in the art. This invention also relates to a method of screening variants of nucleic acid catalysts using standard nucleotides or modified nucleotides. Applicant has determined an efficient method for screening libraries of catalytic nucleic acid molecules, particularly those with chemical modifications at one or more positions. The method described in this application involves systematic screening of a library or pool of ribozymes with various

substitutions at one or more positions and selecting for ribozymes with desired function or characteristic or attribute.

In one preferred embodiment, a method for identifying a nucleic acid molecule involved in a process in a cell is described, including the steps of: a) synthesizing a library
5 of nucleic acid catalysts, having a substrate binding domain and a catalytic domain, where the substrate binding domain has a random sequence; b) testing the library in the cell under conditions suitable to cause the process in the cell to be altered (such as: inhibition of cell proliferation, inhibition of angiogenesis, modulation of growth and /or differentiation, and others); c) isolating and enriching the cell with the altered process; d)
10 identifying and isolating the nucleic acid catalyst in the altered cell; e) using an oligonucleotide, having the sequence homologous to the sequence of the substrate binding domain of the nucleic acid catalyst isolated from the altered cell, as a probe to isolate the nucleic acid molecule from the cell or the altered cell. Those nucleic acid molecules identified using the selection/screening method described above are likely to be involved
15 in the process that was being assayed for alteration by the member(s) of the ribozyme library. These nucleic acid molecules may be new gene sequences, or known gene sequences, with a novel function. One of the advantages of this method is that nucleic acid sequences, such as genes, involved in a biological process, such as differentiation, cell growth, disease processes including cancer, tumor angiogenesis, arthritis,
20 cardiovascular disease, inflammation, restenosis, vascular disease and the like, can be readily identified using the Random Library approach. Thus theoretically, one Random Library for a given ribozyme motif can be used to assay any process in any biological system.

In another preferred embodiment the invention involves synthesizing a Defined
25 Arm Nucleic Acid Catalyst Library (Defined Library) and simultaneously testing it against known targets in a cell. The library includes ribozymes with binding arm(s) of known complexity (Defined) and a defined catalytic domain. Modulation of expression of the target gene by ribozymes in the library will cause the cells to have an altered

phenotype. Such cells are isolated and the ribozymes in these cells are the ones most suited for modulating the expression of the desired gene in the cell.

By "Defined Library" as used herein is meant a library of nucleic acid catalysts, wherein each member nucleic acid catalyst is designed and produced independently, then
5 added to the library. Thus, the content, complexity (number of different ribozymes contained in the library) and ratios of library members are defined at the outset. Defined Library comprises ≥ 2 ribozymes. The process involves screening the sequence of the known target RNA for all possible sites that can be cleaved by a given ribozyme motif and as described, for example in McSwiggen, US Patent No. 5,525,468, incorporated by
10 reference herein. Synthesizing a representative number of different ribozymes against the target sequence. Combining the ribozymes and introducing the pooled ribozymes into a biological system comprising the target RNA under conditions suitable to facilitate modulation of the expression of the target RNA in said biological system.

Screening of Nucleic Acid Catalysts

15 Applicant describes herein, a general combinatorial approach for assaying ribozyme variants based on ribozyme activity and/or a specific "attribute" of a ribozyme, such as the cleavage rate, cellular efficacy, stability, delivery, localization and the like. Variations of this approach also offer the potential for designing novel catalytic oligonucleotides, identifying ribozyme accessible sites within a target, and for identifying
20 new nucleic acid targets for ribozyme-mediated modulation of gene expression.

In one preferred embodiment, the method relies upon testing mixtures (libraries) of ribozymes with various nucleotides, nucleotide analogs, or other analog substitutions, rather than individual ribozymes, to rapidly identify the nucleotide, nucleotide analog, or other analog that is variable at one or more positions within a ribozyme. In the first step
25 (step 1, Figure 2), a desired number of positions (for example, 3 positions as shown in Figure 2) are chosen for variation in a first ribozyme motif (Starting Ribozyme); there is no requirement on the number of positions that can be varied and these positions may or

may not be phylogenetically conserved for the ribozyme. In addition, these position may reside within the catalytic core, binding arms, or accessory domains. The number of positions that are chosen to be varied defines the number of "Classes" of ribozyme libraries that will be synthesized. In the example illustrated in Figure 2, three positions

5 (designated positions 1, 2 and 3) are varied, so three different Classes of ribozyme pool are synthesized. In the next step (step 2), ribozyme pools are synthesized containing a random mixture of different nucleotides, nucleotide analogs, or other analogs at all of the desired positions (designated "X") to be varied except one, which is the "fixed" position (designated "F"). The fixed position contains a specific nucleotide, nucleotide analog or

10 other analog. There is no requirement for the number of nucleotides, or analogs be used. The number of nucleotides or analogs defines the number of pools (designated n) in each Class. For example if ten different nucleotides or analogs are chosen, ten different pools (n=10) will be synthesized for each Class; each of the pools will contain a specific modification at one fixed position (designated F) but will contain an equal mixture of all

15 ten modifications at the other positions (designated X). In a subsequent step (step 3), the different pools of ribozymes are tested for desired activity, phenotype, characteristic or attribute. For example, the testing may be determining *in vitro* rates of target nucleic acid cleavage for each pool, testing ribozyme-substrate binding affinities, testing nuclease resistance, determining pharmacodynamic properties, or determining which pool is most

20 efficacious in a cellular or animal model system. Following testing, a particular pool is identified as a desired variant (designated "Desired Variant-1") and the nucleotide or the analog present at the fixed position within the Desired Variant-1 is made constant (designated "Z") for all subsequent experiments; a single position within a ribozyme is therefore varied, *i.e.*, the variable nucleotide or analog at a single position, when all other

25 X positions are random, is identified within a ribozyme motif. Subsequently, new ribozyme pools (Classes 2, 3 *etc.*) are synthesized containing an equal mixture of all nucleotides or analogs at the remaining positions to be optimized except one fixed position and one or more constant positions. Again, a specific nucleotide or analog is "fixed" at a single position that is not randomized and the pools are assayed for a

particular phenotype or attribute (step 4). This process is repeated until all desired positions have been varied and screened. For example if three positions are chosen for optimization, the synthesis and testing will need to be repeated three times (3 Classes). In the first two Classes, pools will be synthesized; in the final Class, specific ribozymes will be synthesized and tested. When the final position is analyzed (step 5), no random positions will remain and therefore only individual ribozymes are synthesized and tested. The resulting ribozyme or ribozymes (designated "second ribozyme motif") will have a defined chemical composition which will likely be distinct from the Starting Ribozyme motif (first ribozyme motif). This is a rapid method of screening for variability of one or more positions within a ribozyme motif.

In another preferred embodiment, the invention involves screening of chemical modifications at one or more positions within a hammerhead ribozyme motif. More specifically, the invention involves variability in the catalytic core sequence of a hammerhead ribozyme. Particularly, the invention describes screening for variability of positions 3, 4 and 7 within a hammerhead ribozyme. The invention also features screening for optimal loop II sequence in a hammerhead ribozyme.

In yet another preferred embodiment, the invention features a rapid method for screening accessible ribozyme cleavage sites within a target sequence. This method involves screening of all possible sequences in the binding arm of a ribozyme. The sequence of the binding arms determines the site of action of certain ribozymes. The combinatorial approach can be used to identify desirable and/or accessible sites within a target sequence by essentially testing all possible arm sequences. The difficulty with this approach is that ribozymes require a certain number of base pairs (for example, for hammerhead ribozymes the binding arm length is approximately 12-16 nucleotides) in order to bind functionally and sequence-specifically. This would require, for example 12-16 different groups of hammerhead ribozyme pools; 12-16 positions would have to be optimized which would require 12-16 different groups being synthesized and tested. Each pool would contain the four different nucleotides (A, C, U and G) or nucleotide

analogs ($p = 4$ for nucleotides). It would be very time consuming to test each group, identify the best pool, synthesize another group of ribozyme pools with one additional position constant, and then repeat the procedure until all 12-16 groups had been tested. However it is possible to decrease the number of Classes by testing multiple positions within a single Class. In this case, the number of pools within a Class equals the number of nucleotides or analogs in the random mixture (i.e., n) to the w power, where w equals the number of positions fixed in each Class. The number of Classes that need to be synthesized to optimize the final ribozyme equals the total number of positions to be optimized divided by the number of positions (w) tested within each Class. The number of pools in each Class = n^w . The number of Class = total number of positions / w .

In another preferred embodiment, the invention features a rapid method of screening for new catalytic nucleic acid motifs by keeping the binding arms constant and varying one or more positions in a putative catalytic domain. Applicant describes a method to vary positions within the catalytic domain, without changing positions within the binding arms, in order to identify new catalytic motifs. An example is illustrated in Figure 24. It is unclear how many positions are required to obtain a functional catalytic domain in a nucleic acid molecule, however it is reasonable to presume that if a large number of functionally diverse nucleotide analogs can be used to construct the pools, a relatively small number of positions could constitute a functional catalytic domain. This may especially be true if analogs are chosen that one would expect to participate in catalysis (e.g., acid/base catalysts, metal binding, etc.). In the example illustrated, four positions (designated 1, 2, 3 and 4) are chosen. In the first step, ribozyme libraries (Class 1) are constructed: position 1 is fixed (F_1) and positions 2, 3 and 4 are random (X_2 , X_3 and X_4 , respectively). In step 2, the pools (the number of pools tested depends on the number of analogs used; n) are assayed for activity. This testing may be performed *in vitro* or in a cellular or animal model. Whatever assay that is used, the pool with the desired characteristic is identified and libraries (class 2) are again synthesized with position 1 now constant (Z_1) with the analog that was identified in class 1. In class 2, position 2 is fixed (F_2) and positions 3 and 4 are random (X_3 and X_4). This process is repeated until

every position has been made constant and the chemical composition of the catalytic domain is determined. If the number of positions in the catalytic domain to be varied are large, then it is possible to decrease the number of Classes by testing multiple positions within a single Class. The number of pools within a Class equals the number of nucleotides or analogs in the random mixture (i.e., n) to the w power, where w equals the number of positions fixed in each Class. The number of Classes that need to be synthesized to optimize the final ribozyme equals the total number of positions to be optimized divided by the number of positions (w) tested within each Class. The number of pools in each Class = n^w . The number of Classes = total number of positions / w .

In a preferred embodiment a method for identifying variants of a nucleic acid catalyst is described comprising the steps of: a) selecting at least three (3) positions, preferably 3-12, specifically 4-10, within said nucleic acid catalyst to be varied with a predetermined group of different nucleotides, these nucleotides are modified or unmodified (non-limiting examples of nucleotides that can be used in this method are shown in Figure 15); b) synthesizing a first class of different pools of said nucleic acid catalyst, wherein the number of pools synthesized is equal to the number of nucleotides in the predetermined group of different nucleotides (for example if 10 different nucleotides are selected to be in the group of predetermined nucleotides then 10 different pools of nucleic acid catalysts have to be synthesized), wherein at least one of the positions to be varied in each pool comprises a defined nucleotide (fixed position; F) selected from the predetermined group of different nucleotides and the remaining positions to be varied comprise a random mixture of nucleotides (X positions) selected from the predetermined group of different nucleotides; c) testing the different pools of said nucleic acid catalyst under conditions suitable for said pools to show a desired attribute (including but not limited to improved cleavage rate, cellular and animal efficacy, nuclease stability, enhanced delivery, desirable localization) and identifying the pool with said desired attribute and wherein the position with the defined nucleotide (F) in the pool with the desired attribute is made constant (Z position) in subsequent steps; d) synthesizing a second class of different pools of nucleic acid catalyst, wherein at least one of the


positions to be varied in each of the second class of different pools comprises a defined nucleotide (F) selected from the predetermined group of different nucleotides and the remaining positions to be varied comprise a random mixture (X) of nucleotides selected from the predetermined group of different nucleotides (this second class of pools therefore has F, X and Z positions); e) testing the second class of different pools of said nucleic acid catalyst under conditions suitable for showing desired attribute and identifying the pool with said desired attribute and wherein the position with the defined nucleotide in the pool with the desired attribute is made constant (Z) in subsequent steps; and f) this process is repeated until every position selected in said nucleic acid catalyst to be varied is made constant.

In yet another preferred embodiment, a method for identifying novel nucleic acid molecules in a biological system is described, comprising the steps of: a) synthesizing a pool of nucleic acid catalyst with a substrate binding domain and a catalytic domain, wherein said substrate binding domain comprises a random sequence; b) testing the pools of nucleic acid catalyst under conditions suitable for showing a desired effect (such as inhibition of cell proliferation, inhibition of angiogenesis, modulation of growth and/or differentiation, and others) and identifying the catalyst with said desired attribute;

c) using an oligonucleotide, comprising the sequence of the substrate binding domain of the nucleic acid catalyst showing said desired effect, as a probe, screening said biological system for nucleic acid molecules complementary to said probe; and d) isolating and sequencing said complementary nucleic acid molecules. These nucleic acid molecules identified using a nucleic acid screening method described above may be new gene sequences, or known gene sequences. The advantage of this method is that nucleic acid sequences, such as genes, involved in a biological process, such as differentiation, cell growth, disease processes including cancer, tumor angiogenesis, arthritis, cardiovascular disease, inflammation, restenosis, vascular disease and the like, can be readily identified.


In a preferred embodiment, the invention features a nucleic acid molecule with catalytic activity having one of the formulae **III-VII**:

Formula III



5



Formula IV




Z3= 2'-O-MTM-U

Z4= 2'-C-Allyl-U

Z7= 6-Methyl-U

Formula VFormula VI

Formula VII

In each of the above formulae, N represents independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of length sufficient to stably interact (*e.g.*, by forming hydrogen bonds with complementary nucleotides in the target) with a target nucleic acid molecule (the target can be an RNA, DNA or RNA/DNA mixed polymers); preferably the length of Q is greater than or equal to 3 nucleotides and the length of M is preferably greater than or equal to 5 nucleotides; o and n are integers greater than or equal to 1 and preferably less than about 100, wherein if (N)_o and (N)_n are nucleotides, (N)_o and (N)_n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent (*i.e.*, the molecule is assembled from two separate molecules), but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; and \bullet represents a chemical linkage (*e.g.*, a phosphate ester linkage, amide linkage or others known in the art). 2'-O-MTM-U and 2'-O-MTM-C refers to 2'-O-methylthiomethyl uridine and 2'-O-methylthiomethyl-cytidine, respectively. A, C, U and G represent adenosine, cytidine, uridine and guanosine nucleotides, respectively. The nucleotides in the formulae are unmodified or modified at the sugar, base, and/or phosphate portions as known in the art.

In yet another embodiment, the nucleotide linker (L) is a nucleic acid aptamer, such as an ATP aptamer, HIV Rev aptamer (RRE), HIV Tat aptamer (TAR) and others (for a review see Gold *et al.*, 1995, *Annu. Rev. Biochem.*, 64, 763; and Szostak & Ellington, 1993, in *The RNA World*, ed. Gesteland and Atkins, pp 511, CSH Laboratory Press). A “nucleic acid aptamer” as used herein is meant to indicate nucleic acid sequence capable of interacting with a ligand. The ligand can be any natural or a synthetic molecule, including but not limited to a resin, metabolites, nucleosides, nucleotides, drugs, toxins, transition state analogs, peptides, lipids, proteins, aminoacids, nucleic acid molecules, hormones, carbohydrates, receptors, cells, viruses, bacteria and others.

In yet another embodiment, the non-nucleotide linker (L) is as defined herein.

In particular, the invention features modified ribozymes having a base substitution selected from pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyluracil, dihydrouracil, naphthyl, 6-methyl-uracil and aminophenyl.

In yet another embodiment, the non-nucleotide linker (L) is as defined herein. The term “non-nucleotide” as used herein include either abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, or polyhydrocarbon compounds. Specific examples include those described by Seela and Kaiser, *Nucleic Acids Res.* 1990, 18:6353 and *Nucleic Acids Res.* 1987, 15:3113; Cload and Schepartz, *J. Am. Chem. Soc.* 1991, 113:6324; Richardson and Schepartz, *J. Am. Chem. Soc.* 1991, 113:5109; Ma et al., *Nucleic Acids Res.* 1993, 21:2585 and *Biochemistry* 1993, 32:1751; Durand et al., *Nucleic Acids Res.* 1990, 18:6353; McCurdy et al., *Nucleosides & Nucleotides* 1991, 10:287; Jschke et al., *Tetrahedron Lett.* 1993, 34:301; Ono et al., *Biochemistry* 1991, 30:9914; Arnold *et al.*, International Publication No. WO 89/02439; Usman *et al.*, International Publication No. WO 95/06731; Dudycz *et al.*, International Publication No. WO 95/11910 and Ferentz and Verdine, *J. Am. Chem. Soc.* 1991, 113:4000, all hereby incorporated by reference herein. Thus, in a preferred embodiment, the invention features a nucleic acid catalyst having one or more non-nucleotide moieties, and having enzymatic

activity to cleave an RNA or DNA molecule. By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is
5 abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine. The terms "abasic" or "abasic nucleotide" as used herein encompass sugar moieties lacking a base or having other chemical groups in place of base at the 1' position.

In preferred embodiments, the enzymatic nucleic acid includes one or more
10 stretches of RNA, which provide the enzymatic activity of the molecule, linked to the non-nucleotide moiety. The necessary RNA components are known in the art, see, e.g., Usman, *supra*. By RNA is meant a molecule comprising at least one ribonucleotide residue.

As the term is used in this application, non-nucleotide-containing enzymatic
15 nucleic acid means a nucleic acid molecule that contains at least one non-nucleotide component which replaces a portion of a ribozyme, e.g., but not limited to, a double-stranded stem, a single-stranded "catalytic core" sequence, a single-stranded loop or a single-stranded recognition sequence. These molecules are able to cleave (preferably, repeatedly cleave) separate RNA or DNA molecules in a nucleotide base sequence
20 specific manner. Such molecules can also act to cleave intramolecularly if that is desired. Such enzymatic molecules can be targeted to virtually any RNA transcript.

The specific nucleic acid catalysts described in the instant application are not limiting in the invention and those skilled in the art will recognize that all that is important in a nucleic acid catalyst of this invention is that it has a specific substrate
25 binding site (e.g., M and/or Q of Formulae III-VII above) which is complementary to one or more of the target nucleic acid regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart a nucleic acid cleaving activity to the molecule.

Vector Expression of Enzymatic Nucleic Acid

The nucleic acid catalysts of the instant invention can be expressed within cells from eukaryotic promoters (*e.g.*, Izant and Weintraub, 1985 *Science* 229, 345; McGarry and Lindquist, 1986 *Proc. Natl. Acad. Sci. USA* 83, 399; Scanlon *et al.*, 1991, *Proc. Natl. Acad. Sci. USA*, 88, 10591-5; Kashani-Sabet *et al.*, 1992 *Antisense Res. Dev.*, 2, 3-15; Dropulic *et al.*, 1992 *J. Virol.*, 66, 1432-41; Weerasinghe *et al.*, 1991 *J. Virol.*, 65, 5531-4; Ojwang *et al.*, 1992 *Proc. Natl. Acad. Sci. USA* 89, 10802-6; Chen *et al.*, 1992 *Nucleic Acids Res.*, 20, 4581-9; Sarver *et al.*, 1990 *Science* 247, 1222-1225; Thompson *et al.*, 1995 *Nucleic Acids Res.* 23, 2259; Good *et al.*, 1997, *Gene Therapy*, 4, 45; all of the references are hereby incorporated in their totality by reference herein). Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a ribozyme (Draper *et al.*, PCT WO 93/23569, and Sullivan *et al.*, PCT WO 94/02595; Ohkawa *et al.*, 1992 *Nucleic Acids Symp. Ser.*, 27, 15-6; Taira *et al.*, 1991, *Nucleic Acids Res.*, 19, 5125-30; Ventura *et al.*, 1993 *Nucleic Acids Res.*, 21, 3249-55; Chowrira *et al.*, 1994 *J. Biol. Chem.* 269, 25856; all of the references are hereby incorporated in their totality by reference herein).

In another aspect of the invention, nucleic acid catalysts that cleave target molecules are expressed from transcription units (see for example Figure 11) inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Ribozyme expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the ribozymes are delivered as described above, and persist in target cells. Alternatively, viral vectors may be used that provide for transient expression of ribozymes. Such vectors might be repeatedly administered as necessary. Once expressed, the ribozymes cleave the target mRNA. The active ribozyme contains an enzymatic center or core equivalent to those in the examples, and binding arms able to bind target nucleic acid molecules such that cleavage at the target site occurs. Other

sequences may be present which do not interfere with such cleavage. Delivery of ribozyme expressing vectors could be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction
5 into the desired target cell (for a review see Couture and Stinchcomb, 1996, *TIG.*, 12, 510).

In a preferred embodiment, an expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid catalyst of the instant invention is disclosed. The nucleic acid sequence encoding the nucleic acid catalyst of the instant invention is
10 operable linked in a manner which allows expression of that nucleic acid molecule.

In one embodiment, the expression vector comprises: a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); c) a gene encoding at least one of the nucleic acid catalyst of the instant invention; and wherein said gene is operably
15 linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. The vector may optionally include an open reading frame (ORF) for a protein operably linked on the 5' side or the 3'-side of the gene encoding the nucleic acid catalyst of the invention; and/or an intron (intervening sequences).

20 Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA
25 polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990 *Proc. Natl. Acad. Sci. U S A*, 87, 6743-7; Gao and Huang 1993 *Nucleic Acids Res.*, 21, 2867-72; Lieber et al., 1993 *Methods Enzymol.*, 217, 47-66; Zhou et al., 1990 *Mol. Cell. Biol.*, 10,

4529-37). Several investigators have demonstrated that ribozymes expressed from such promoters can function in mammalian cells (e.g., Kashani-Sabet et al., 1992 *Antisense Res. Dev.*, 2, 3-15; Ojwang et al., 1992 *Proc. Natl. Acad. Sci. U S A*, 89, 10802-6; Chen et al., 1992 *Nucleic Acids Res.*, 20, 4581-9; Yu et al., 1993 *Proc. Natl. Acad. Sci. U S A*, 90, 6340-4; L'Huillier et al., 1992 *EMBO J.* 11, 4411-8; Lisiewicz et al., 1993 *Proc. Natl. Acad. Sci. U. S. A.*, 90, 8000-4; Thompson et al., 1995 *Nucleic Acids Res.* 23, 2259; Sullenger & Cech, 1993, *Science*, 262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as ribozymes in cells (Thompson et al., *supra*; Couture and Stinchcomb, 1996, *supra*; Noonberg et al., 1994, *Nucleic Acid Res.*, 22, 2830; Noonberg et al., US Patent No. 5,624,803; Good et al., 1997, *Gene Ther.* 4, 45; Beigelman et al., International PCT Publication No. *WO 96/18736*; all of these publications are incorporated by reference herein. Examples of transcription units suitable for expression of ribozymes of the instant invention are shown in Figure 11. The above ribozyme transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, *supra*).

In a preferred embodiment an expression vector comprising nucleic acid sequence encoding at least one of the catalytic nucleic acid molecule of the invention, in a manner which allows expression of that nucleic acid molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; c) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another preferred embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a gene encoding at least one

said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In yet another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; e) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

Delivery of Nucleic Acid Catalysts:

In a preferred embodiment, the nucleic acid catalysts are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to smooth muscle cells. The RNA or RNA complexes can be locally administered to relevant tissues through the use of a catheter, infusion pump or stent, with or without their incorporation in biopolymers. Using the methods described herein, other nucleic acid catalysts that cleave target nucleic acid may be derived and used as described above. Specific examples of nucleic acid catalysts of the instant invention are provided below in the Tables and figures.

Sullivan, *et al.*, *supra*, describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications,

ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the
aforementioned vehicles. Alternatively, the RNA/vehicle combination is locally
delivered by direct injection or by use of a catheter, infusion pump or stent. Other routes
of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or
5 joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular,
intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme
delivery and administration are provided in Sullivan *et al.*, *supra* and Draper *et al.*, *supra*
which have been incorporated by reference herein.

The present invention also includes pharmaceutically acceptable formulations of
10 the compounds described. These formulations include salts of the above compounds, *e.g.*,
ammonium, sodium, calcium, magnesium, lithium, and potassium salts.

A pharmacological composition or formulation refers to a composition or
formulation in a form suitable for administration, *e.g.*, systemic administration, into a cell
or patient, preferably a human. Suitable forms, in part, depend upon the use or the route
15 of entry, for example oral, transdermal, or by injection. Such forms should not prevent
the composition or formulation to reach a target cell (*i.e.*, a cell to which the negatively
charged polymer is desired to be delivered to). For example, pharmacological
compositions injected into the blood stream should be soluble. Other factors are known
in the art, and include considerations such as toxicity and forms which prevent the
20 composition or formulation from exerting its effect.

By "systemic administration" is meant *in vivo* systemic absorption or
accumulation of drugs in the blood stream followed by distribution throughout the entire
body. Administration routes which lead to systemic absorption include, without
limitations: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary
25 and intramuscular. Each of these administration routes expose the desired negatively
charged polymers, *e.g.*, NTP's, to an accessible diseased tissue. The rate of entry of a
drug into the circulation has been shown to be a function of molecular weight or size.
The use of a liposome or other drug carrier comprising the compounds of the instant

invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation which can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach may provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as the cancer cells.

The invention also features the use of the a composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer an method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic *et al. Chem. Rev.* 1995, **95**, 2601-2627; Ishiwata *et al., Chem. Pharm. Bull.* 1995, **43**, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic *et al., Science* 1995, **267**, 1275-1276; Oku *et al., 1995, Biochim. Biophys. Acta*, **1238**, 86-90). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of drugs, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu *et al., J. Biol. Chem.* 1995, **42**, 24864-24870; Choi *et al., International PCT Publication No. WO 96/10391*; Ansell *et al., International PCT Publication No. WO 96/10390*; Holland *et al., International PCT Publication No. WO 96/10392*; all of these are incorporated by reference herein). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen. All of these references are incorporated by reference herein.

The present invention also includes compositions prepared for storage or administration which include a pharmaceutically effective amount of the desired

compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co. (A.R. Gennaro edit. 1985) hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents may be provided. *Id.* at 1449. These include sodium benzoate, sorbic acid and esters of *p*-hydroxybenzoic acid. In addition, antioxidants and suspending agents may be used.

A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors which those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer. In one aspect, the invention provides nucleic acid catalysts that can be delivered exogenously to specific cells as required.

Local ribozyme administration offers the advantages of achieving high tissue concentrations of ribozymes and limiting their exposure to catabolic and excretory mechanisms. Although local routes of administration provide access to pathologies involving a number of organ systems, systemic administration would make ribozyme treatment of several other major human diseases feasible.

It has been demonstrated that certain tissues accumulate oligonucleotides and/or oligonucleotide formulations following systemic administration. These tissues include sites of inflammation (Wu *et al.* 1993, *Cancer Res.* 53: 3765-3767), solid tumors (Yuan *et al.* 1994, *Cancer Res.* 54: 3352-3356), kidney (Cossum *et al.* 1993, *J. Pharmacol. and Exp. Ther.* 267: 1181-1190), brain (Wu *et al.* 1996, *J. Pharmacol. Exp. Ther.* 276: 206-11) and those rich in reticulo-endothelial cells (liver, spleen, lymphatics; Litzinger *et al.*

1994, *Biochim. Biophys. Acta* **1190**: 99-107; Agrawal *et al.* 1991, *Proc. Natl. Acad. Sci. USA* **88**: 7595-7599; Agrawal *et al.* 1995, *Clin. Pharmacology* **28**: 7-16; Sands *et al.* 1994, *Molecular Pharmacol.* **45**: 932-943; Saijo *et al.* 1994, *Oncology Research* **6**: 243-249).

- 5 The kidney, as well as organs of the reticulo-endothelial system (RES), are mainly responsible for clearance of ribozymes following intravenous (*i.v.*) administration. Diseases involving these tissues are good candidates for systemic ribozyme therapy by virtue of their tendency to accumulate ribozymes.

- 10 In one preferred embodiment, the invention features method of treating inflammation using ribozymes. Inflammatory processes underlie the pathology of a large number of human diseases. Many of these processes can be blocked by inhibiting the expression of inflammatory mediators and/or their receptors (Cohen *et al.* 1995, *Am. J. Med.* **99**: 45S-52S). Systemic administration of monoclonal antibodies specific to these mediators have been shown to be efficacious in animal models of rheumatoid arthritis, inflammatory
15 bowel disease, and acute respiratory distress syndrome (Arend *et al.* 1990, *Arthritis and Rheumatism* **33**: 305-315). One potential way for systemic administration of ribozymes to impact systemic inflammatory disease is through inhibition of TNF- α production by macrophages. TNF- α has been shown participate in a variety of inflammatory processes and is produced mainly by macrophages which are known to accumulate cationic lipid-
20 formulated ribozymes (Masahiro *et al.* 1990, *J. Immunology.* **144**: 1425-1431). Anti-mouse TNF- α ribozymes were effective in cell culture, thus, it may be possible that systemic delivery of ribozymes by a liposome formulation could be an effective therapeutic in the above mentioned inflammatory disease states.

- 25 In another preferred embodiment, the invention features methods of treating diseases involving RES using ribozymes. A number of studies have shown that systemically administered oligonucleotides distribute to RES tissues (liver, spleen and lymphatics). Several studies with cationic lipid complexed oligonucleotides have also shown specific biodistribution to these. Pathology involving the RES includes a number of infectious

diseases of major importance, such as human immunodeficiency virus (HIV), mycobacterium infections including tuberculosis (TB), avium, and leprae (leprosy). These diseases are all associated with, for example, overproduction of interleukin-10 (IL-10), a potent immunosuppressive cytokine (Barnes *et al.* 1993, *Infect. Immun.* 61: 3482-9). Some of these infections can potentially be ameliorated by administration of neutralizing antibodies to IL-10.

In yet another preferred embodiment, the invention features method of treating cancer using ribozymes. As evidence of the potential use of systemic oligonucleotides as anticancer agents, antisense phosphorothioates have been have been reported to exhibit antitumor efficacy in a murine model of Burkitt's lymphoma (Huang *et al.* 1995, *Mol. Med.* 1: 647-658). The molecular targets of systemic antineoplastic ribozymes could include oncogenes, protooncogenes, or angiogenic factors and receptors. Although the link between oncogenes and tumorigenesis is now well established, the specific mutations that lead to activation of a proto-oncogene can be widely diverse. Upregulation of protooncogene products is also common in human cancer. Reducing the levels of these gene products may be beneficial in treatment of cancer. In addition, since many tumors are highly vascularized, angiogenic factors or receptors may provide good alternate or adjunct targets to oncogenes for the therapy of solid tumors and their metastases. Applicant, in a non-limiting example *infra*, show ribozymes targeting angiogenic mediators.

The potential number of molecular targets in cancer is quite large. Among these targets are oncogenes, protooncogenes, metalloproteinases, growth factors, and angiogenic factors. However, a common denominator in many forms of metastatic solid tumors is extensive vascularization of the tumor. As tumors exceed about 1 mm in diameter, they require neovascularization for continued growth (Gimbrone *et al.*, 1972, *J. Exp. Med.*, 136, 261). In addition, the appearance of new blood vessels within a tumor correlates with the initiation of the process of metastasis (Martiny-Baron and Marmé, 1995). It is possible that by using a systemically administered ribozyme targeting a key

player in the process of angiogenesis would reduce both primary tumor growth, tumor progression and tumor metastasis.

“Angiogenesis” refers to formation of new blood vessels from existing blood vessels which is an essential process in reproduction, development and wound repair.

5 “Tumor angiogenesis” refers to the induction of the growth of blood vessels from surrounding tissue into a solid tumor. Tumor growth and tumor metastasis are dependent on angiogenesis (for a review see Folkman, 1985, *Nature Med.* 1: 27-31; Folkman 1990 *J. Natl. Cancer Inst.*, 82, 4; Folkman and Shing, 1992 *J. Biol. Chem.* 267, 10931).

10 “Tumor metastasis” refers to the transfer and/or migration of tumor cells, originating from a primary tumor, from one part of the body or organ to another. Most malignant tumors have the capacity to metastasize.

“Tumor” refers to a new growth of tissue wherein the cells multiply, divide and grow uncontrolled.

15 In a preferred embodiment, the invention features a method of treating non-hepatic ascites using ribozymes. Nonhepatic ascites or peritoneal fluid accumulation resulting from abdominal cancer and ovarian hyperstimulation syndrome (OHSS) can result in significant fluid loss from the intravascular space and hypovolemia. If ascites volumes are large, abdominal pain, hypovolemic hypotension, electrolyte abnormalities and respiratory difficulties can ensue. Thus, if ascites is left untreated, it can be life
20 threatening. Evidence is now accumulating that nonhepatic ascites may be induced, at least in part, by vascular endothelial growth factor (VEGF). For this reason, nonhepatic ascites may be a potential therapeutic indication for ribozymes directed against vascular endothelial growth factor (VEGF) receptors delivered either systemically or regionally to the peritoneum.

25 Ovaries can be overstimulated by hormonal therapy during fertility treatment. As a result, women can experience ovarian hyperstimulation syndrome which is associated

with grossly enlarged ovaries and extreme ascites fluid accumulation. This fluid accumulation is thought to be induced by the release of a vascular permeability agent which may interact with vessels of the peritoneal cavity leading to plasma extravasation. Abramov and co-workers (1997, *Fertil. Steril.* 67: 261) have shown that plasma VEGF
5 levels are elevated in OHSS and return to normal upon resolution of the syndrome. An earlier study has shown that VEGF is elevated in the serum and follicular fluid of OHSS patients and that the source of this VEGF may be the luteinizing granulosa cells of the ovary (Krasnow et al., 1996, *Fertil. Steril.* 65: 552). McClure et al. (1994, *Lancet* 344, 235) concluded that VEGF is the key mediator of OHSS ascites production since rhVEGF
10 increases OHSS ascites but not liver ascites and that this increase is reversible by rhVEGF antiserum. Thus, reducing the expression of VEGF receptors in the vasculature of the peritoneum may have a therapeutic benefit in OHSS by substantially reducing OHSS-stimulated ascites production. Since VEGF can interact with VEGF receptors on vessels throughout the peritoneum from ovarian release of VEGF into systemic circulation,
15 systemic treatment may represent the best option for treating this syndrome.

Malignant ascites: Another form of ascites can be induced by malignancies of the peritoneum including breast, pancreatic, uterine and colorectal cancers. It is thought that certain cancers produce factors which influence peritoneal vascular permeability leading to plasma extravasation (Garrison et al., 1986; *Ann. Surg.* 203: 644; Garrison et al., 1987,
20 *J. Surg. Res.* 42: 126; Nagy et al., 1993, *Cancer Res.* 53: 2631). Several solid tumors including some colorectal and breast carcinomas are known to secrete VEGF to recruit blood vessels for sustained growth and metastasis. This secreted VEGF may also serve to increase local vasculature permeability. In support of this hypothesis, Nagy et al. (*supra*) showed in mice that peritoneal fluid resulting from MOT and TTA3/St carcinomas
25 contained elevated levels of VEGF whose concentration correlated directly with fluid accumulation and development of hyperpermeable microvessels. Therefore, ribozymes directed against VEGF receptors administered systemically may impact both the tumor growth and metastases of VEGF secreting tumors as well as ascites induced by VEGF interacting with the vasculature of the peritoneum.

Strategies for Systemic Delivery

Methods to enhance tissue accumulation

Tissue accumulation of ribozymes can be improved by formulation, conjugation, or further chemical stabilization of the ribozyme. Elimination due to glomerular filtration
5 can be slowed by increasing the apparent molecular weight of the ribozyme, *e.g.*, by liposome encapsulation or bioconjugation to PEG. Applicant has observed that the rate of catabolism can be slowed by a factor of 100 and lung accumulation increased 500 fold by formulation with DMRIE/DOPE reagents. Liposomal encapsulation is likely to have a similar effect on the rate of catabolism. The rate of clearance into non-target tissues could
10 also be reduced by encapsulation into liposomes, provided that the liposomes were surface modified with PEG such that RES clearance were avoided. Increasing the rate of uptake by target tissues can also be enhanced, for example, by conjugation of cholesterol to the ribozymes. Applicant has also observed that in tissues of the RES, accumulation has been increased several hundred fold by complexation with a cationic lipid carrier.

15 *Sustained release as a means to increase exposure*

Sustained or continuous delivery devices, such as ALZET[®] osmotic mini-pumps, may also enhance accumulation in target tissues by increasing exposure relative to bolus *i.v.* administration. Sustained delivery from ALZET[®] pumps has been shown to be an effective way of administering a phosphorothioate antisense molecule for inhibition of
20 tumor growth in mice (Huang *et al.* 1995, *supra*). Applicant has observed that the rate of ribozyme catabolism in and rate of clearance from the circulation is concentration dependent and may relate to the equilibrium plasma protein binding of the ribozyme. Phosphorothioate DNA is rapidly cleared from circulation when its concentration exceeds the plasma protein binding constant, as is the case after *i.v.* bolus administration.
25 Osmotic pumps administer oligonucleotides at a slower and constant rate, and therefore may maintain plasma levels near the equilibrium binding capacity. This would result in less of the administered dose being lost to glomerular filtration (elimination) and hepatic

extraction (catabolism); more of the administered dose may be available for uptake into target tissues.

Animal Models

Use of murine models

- 5 For a typical systemic study involving 10 mice (20 g each) per dose group, 5 doses (1, 3, 10, 30 and 100 mg/kg daily over 14 days continuous administration), approximately 400 mg of ribozyme, formulated in saline would be used. A similar study in young adult rats (200 g) would require over 4 g. Parallel pharmacokinetic studies may involve the use of similar quantities of ribozymes further justifying the use of murine models.

10 *Ribozymes and Lewis lung carcinoma and B-16 melanoma murine models*

Identifying a common animal model for systemic efficacy testing of ribozymes is an efficient way of screening ribozymes for systemic efficacy.

- The Lewis lung carcinoma and B-16 murine melanoma models are well accepted models of primary and metastatic cancer and are used for initial screening of anti-cancer.
- 15 These murine models are not dependent upon the use of immunodeficient mice, are relatively inexpensive, and minimize housing concerns. Both the Lewis lung and B-16 melanoma models involve subcutaneous implantation of approximately 10^6 tumor cells from metastatically aggressive tumor cell lines (Lewis lung lines 3LL or D122, LLc-LN7; B-16-BL6 melanoma) in C57BL/6J mice. Alternatively, the Lewis lung model can be
- 20 produced by the surgical implantation of tumor spheres (approximately 0.8 mm in diameter). Metastasis also may be modeled by injecting the tumor cells directly *i.v.*. In the Lewis lung model, microscopic metastases can be observed approximately 14 days following implantation with quantifiable macroscopic metastatic tumors developing within 21-25 days. The B-16 melanoma exhibits a similar time course with tumor
- 25 neovascularization beginning 4 days following implantation. Since both primary and metastatic tumors exist in these models after 21-25 days in the same animal, multiple

measurements can be taken as indices of efficacy. Primary tumor volume and growth latency as well as the number of micro- and macroscopic metastatic lung foci or number of animals exhibiting metastases can be quantitated. The percent increase in lifespan can also be measured. Thus, these models would provide suitable primary efficacy assays for
5 screening systemically administered ribozymes/ribozyme formulations.

In the Lewis lung and B-16 melanoma models, systemic pharmacotherapy with a wide variety of agents usually begins 1-7 days following tumor implantation/inoculation with either continuous or multiple administration regimens. Concurrent pharmacokinetic studies can be performed to determine whether sufficient tissue levels of ribozymes can
10 be achieved for pharmacodynamic effect to be expected. Furthermore, primary tumors and secondary lung metastases can be removed and subjected to a variety of *in vitro* studies (*i.e.*, target mRNA reduction).

Anti-VEGF receptor ribozymes

Sustained tumor growth and metastasis depend upon angiogenesis. In fact, the
15 appearance of vessels in a growing tumor is correlated with the beginning of metastatic potential. Several studies have shown that antiangiogenic agents alone or in combination with cytotoxic agents reduce lung metastases and/or primary tumor volume in the Lewis lung and B-16 melanoma models (Borgstrom *et al.* 1995, *Anticancer Res.* 15: 719-728; Kato *et al.* 1994, *Cancer Res.* 54: 5143-5147; O'Reilly *et al.* 1994, *Cell* 79: 315-328;
20 Sato *et al.* 1995, *Jpn. J. Cancer Res.* 86: 374-382).

A major factor implicated in the induction of solid tumor angiogenesis is vascular endothelial growth factor (VEGF; Folkman, 1995, *supra*). Several human tumors have been shown to synthesize and secrete. With regard to treating lung metastasis, VEGF and VEGF receptors of both subtypes and their expression are upregulated in the lung under
25 conditions of hypoxia (Tuder *et al.* 1994, *J. Clin. Invest.* 95: 1798-1807). This may lead to neovascularization which provides the means by which tumor cells gain access to

circulation (Mariny-Baron and Marmé, 1995). Thus, VEGF and its receptors may be important targets in the treatment of metastatic disease.

Applicant has shown that a catalytically active ribozyme targeting *flt-1* RNA inhibits VEGF-induced neovascularization in a dose-dependent manner in a rat corneal model of angiogenesis. Testing with cytotoxic agents in combination with antiangiogenic ribozymes may also prove useful.

Anti-K- and H-ras ribozymes

Mutations involving *ras* underlie a number of human cancers. *Ras* also plays a role in metastatic potential (Shekhar and Miller, 1994, *Invasion Metastasis* 14: 27-37) and may do so, in part, by influencing endothelial cell migration (Fox *et al.* 1994, *Oncogene* 9: 3519-26). With regard to lung cancer, *ras* has been shown to induce abnormal mitoses in lung fibroblasts (Lyubuski *et al.* 1994, *Cytobios* 80: 161-178) and is a clinical marker in non-small cell lung tumors (Niklinski and Furman, 1995, *Eur. J. Cancer Prev.* 4: 129-138). Studies in cells cultured from human small cell lung tumor xenografts demonstrated overexpression of K-*ras* (Arvelo *et al.* 1994, *Anticancer Res.* 14: 1893-1901). This evidence provides ample support for the systemic testing of ribozymes directed against H- and K-*ras* in the murine cancer models (primary and secondary metastasis) discussed above.

Four of the current synthetic ribozymes directed against human K- *ras* will cleave homologous mouse K-*ras* targets at four sites and inhibit cultured rat aortic smooth muscle cell proliferation.

Anti-c-fos ribozymes

The protein product of the proto-oncogene *c-fos* is a nuclear transcription factor which is involved in tumorigenesis. In support of the possible use of systemically administered ribozymes directed against *c-fos*, null mouse mutations of *c-fos* have been shown to result in viable mice. Using this mouse model, it has been shown that *c-fos* is

important in malignant conversion of papillomas. Additionally, *c-fos* has been shown to up-regulate tumor metalloproteinases (Schonthal *et al.* 1988, *Cell* **54**: 325-334). It is possible that *c-fos* may play a role in tumor angiogenesis as evidenced by VEGF mRNA levels being significantly reduced in *c-fos* deficient tumors. It has also been shown that *c-fos* is highly expressed in some B-16 cell and human melanoma cell lines (Kroumpouzos *et al.* 1994, *Pigment Cell Res.* **7**: 348-353; Nakayama *et al.* 1995, *J. Dermatol.* **22**: 549-559; Peris *et al.* 1991, *Arch. Dermatol. Res.* **283**: 500-505). The expression of *c-fos* may be directly proportional to metastatic potential in B-16 melanoma cell lines. With this evidence, it is reasonable to conclude that *c-fos* represents a suitable systemic ribozyme target in either the Lewis lung, B-16 melanoma, or human melanoma models.

Delivery of ribozymes and ribozyme formulations in the Lewis lung model

Several ribozyme formulations, including cationic lipid complexes which may be useful for inflammatory diseases (*e.g.*, DIMRIE/DOPE, *etc.*) and RES evading liposomes which may be used to enhance vascular exposure of the ribozymes, are of interest in cancer models due to their presumed biodistribution to the lung. Thus, liposome formulations can be used for delivering ribozymes to sites of pathology linked to an angiogenic response.

The sequences of the ribozymes that are chemically synthesized, useful in this study, are non-limiting examples. Those in the art will recognize that these sequences are representative only of many more such sequences where the enzymatic portion of the ribozyme (all but the binding arms) is altered to affect activity. For example, stem-loop II sequence of hammerhead ribozymes can be altered (substitution, deletion, and/or insertion) to contain any sequences provided a minimum of two base-paired stem structure can form. Similarly, stem-loop IV sequence of hairpin ribozymes listed in Tables IV (5'-CACGUUGUG-3') can be altered (substitution, deletion, and/or insertion) to contain any sequence, provided a minimum of two base-paired stem structure can form. Preferably, no more than 200 bases are inserted at these locations. The sequences listed in Tables III and IV may be formed of ribonucleotides or other nucleotides or non-

nucleotides. Such ribozymes (which have enzymatic activity) are equivalent to the ribozymes described specifically in the Tables.

Target sites

Targets for useful ribozymes can be determined as disclosed in Draper *et al.*, WO 93/23569; Sullivan *et al.*, WO 93/23057; Thompson *et al.*, WO 94/02595; Draper *et al.*,
5 WO 95/04818; McSwiggen *et al.*, US Patent No. 5,525,468 and hereby incorporated by reference herein in totality. Rather than repeat the guidance provided in those documents here, below are provided specific examples of such methods, not limiting to those in the art. Ribozymes to such targets are designed as described in those applications and
10 synthesized to be tested *in vitro* and *in vivo*, as also described. Such ribozymes can also be optimized and delivered as described therein.

The sequence of human *c-raf* mRNAs were screened for optimal ribozyme target sites using a computer folding algorithm. Hammerhead or hairpin ribozyme cleavage sites were identified. These sites are shown in Tables XII-XIX (All sequences are 5' to 3'
15 in the tables) The nucleotide base position is noted in the Tables as that site to be cleaved by the designated type of ribozyme. The nucleotide base position is noted in the Tables as that site to be cleaved by the designated type of ribozyme.

Because Raf RNAs are highly homologous in certain regions, some ribozyme target sites are also homologous (see Table XVIII and XIX). In this case, a single ribozyme
20 will target different classes of Raf RNA. The advantage of one ribozyme that targets several classes of Raf RNA is clear, especially in cases where one or more of these RNAs may contribute to the disease state.

Hammerhead or hairpin ribozymes were designed that could bind and were individually analyzed by computer folding (Jaeger *et al.*, 1989 *Proc. Natl. Acad. Sci. USA*,
25 86, 7706) to assess whether the ribozyme sequences fold into the appropriate secondary structure. Those ribozymes with unfavorable intramolecular interactions between the binding arms and the catalytic core are eliminated from consideration. Varying binding

arm lengths can be chosen to optimize activity. Generally, at least 5 bases on each arm are able to bind to, or otherwise interact with, the target RNA. Ribozymes of the hammerhead or hairpin motif were designed to anneal to various sites in the mRNA message. The binding arms are complementary to the target site sequences described
5 above.

Examples

The following are non-limiting examples showing the selection, isolation, synthesis and activity of enzymatic nucleic acids of the instant invention.

The following examples demonstrate the selection of ribozymes that cleave c-raf
10 RNA. The methods described herein represent a scheme by which ribozymes may be derived that cleave other RNA targets required for cell division. Also provided is a description of how such ribozymes may be delivered to cells. The examples demonstrate that upon delivery, the ribozymes inhibit cell proliferation in culture and modulate gene expression *in vivo*. Moreover, significantly reduced inhibition is observed if mutated
15 ribozymes that are catalytically inactive are applied to the cells. Thus, inhibition requires the catalytic activity of the ribozymes.

Example 1: Identification of Potential Ribozyme Cleavage Sites in Human *c-raf* RNA

The sequence of human c-raf RNA was screened for accessible sites using a computer folding algorithm. Regions of the mRNA that did not form secondary folding
20 structures and contained potential hammerhead and/or hairpin ribozyme cleavage sites were identified. The sequences of these cleavage sites are shown in **tables XII-XIX**.

Example 2: Selection of Ribozyme Cleavage Sites in Human *c-raf* RNA

To test whether the sites predicted by the computer-based RNA folding algorithm corresponded to accessible sites in c-raf RNA, 20 hammerhead sites were selected for
25 analysis. Ribozyme target sites were chosen by analyzing genomic sequences of human c-raf (GenBank Accession No. X03484; Bonner *et al.*, 1986, *Nucleic Acids Research*, 14,

1009-1015) and prioritizing the sites on the basis of folding. Hammerhead ribozymes were designed that could bind each target (see Figure 1) and were individually analyzed by computer folding (Christoffersen *et al.*, 1994 *J. Mol. Struct. Theochem*, 311, 273; Jaeger *et al.*, 1989, *Proc. Natl. Acad. Sci. USA*, 86, 7706) to assess whether the ribozyme
5 sequences fold into the appropriate secondary structure. Those ribozymes with unfavorable intramolecular interactions between the binding arms and the catalytic core were eliminated from consideration. As noted below, varying binding arm lengths can be chosen to optimize activity. Generally, at least 5 bases on each arm are able to bind to, or otherwise interact with, the target RNA. Ribozyme target sites within A-Raf were chosen
10 by analyzing genomic sequences of human A-raf-1 (GenBank Accession No. X04790; Beck *et al.*, 1987, *Nucleic Acids Research*, 115, 595-609). Ribozyme target sites within B-Raf were chosen by analyzing genomic sequences of human B-raf-1 (GenBank Accession No. M95712 M95720 X54072; Sitanandam *et al.*, 1990, *Oncogene*, 5, 1775-1780).

15 Example 3: Chemical Synthesis and Purification of Ribozymes for Efficient Cleavage of c-raf RNA

Ribozymes of the hammerhead or hairpin motif were designed to anneal to various sites in the RNA message. The binding arms are complementary to the target site sequences described above. The ribozymes were chemically synthesized. The method of
20 synthesis used followed the procedure for normal RNA synthesis as described in Usman *et al.*, (1987 *J. Am. Chem. Soc.*, 109, 7845), Scaringe *et al.*, (1990 *Nucleic Acids Res.*, 18, 5433) and Wincott *et al.*, *supra*, and made use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. The average stepwise coupling yields were >98%.

25 Inactive ribozymes were synthesized by substituting a U for G5 and a U for A14 (numbering from Hertel *et al.*, 1992 *Nucleic Acids Res.*, 20, 3252). Hairpin ribozymes were synthesized in two parts and annealed to reconstruct the active ribozyme (Chowrira and Burke, 1992 *Nucleic Acids Res.*, 20, 2835-2840). Ribozymes were also synthesized

from DNA templates using bacteriophage T7 RNA polymerase (Milligan and Uhlenbeck, 1989, Methods Enzymol. 180, 51). Ribozymes were modified to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H (for a review see Usman and Cedergren, 1992 TIBS 17, 34).

- 5 Ribozymes were purified by gel electrophoresis using general methods or were purified by high pressure liquid chromatography (HPLC; See Wincott et al., supra; the totality of which is hereby incorporated herein by reference) and were resuspended in water. The sequences of the chemically synthesized ribozymes used in this study are shown below in Table XII-XIX.

10 Example 4: Ribozyme Cleavage of c-raf RNA Target *in vitro*

Ribozymes targeted to the human c-raf RNA are designed and synthesized as described above. These ribozymes can be tested for cleavage activity *in vitro*, for example using the following procedure. The target sequences and the nucleotide location within the c-raf mRNA are given in Table XII.

- 15 *Cleavage Reactions:* Full-length or partially full-length, internally-labeled target RNA for ribozyme cleavage assay is prepared by *in vitro* transcription in the presence of [α - 32 P] CTP, passed over a G 50 Sephadex column by spin chromatography and used as substrate RNA without further purification. Alternately, substrates are 5'- 32 P-end labeled using T4 polynucleotide kinase enzyme. Assays are performed by pre-warming a 2X
- 20 concentration of purified ribozyme in ribozyme cleavage buffer (50 mM Tris-HCl, pH 7.5 at 37°C, 10 mM MgCl₂) and the cleavage reaction was initiated by adding the 2X ribozyme mix to an equal volume of substrate RNA (maximum of 1-5 nM) that was also pre-warmed in cleavage buffer. As an initial screen, assays are carried out for 1 hour at 37°C using a final concentration of either 40 nM or 1 mM ribozyme, *i.e.*, ribozyme
- 25 excess. The reaction is quenched by the addition of an equal volume of 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol after which the sample is heated to 95°C for 2 minutes, quick chilled and loaded onto a denaturing

polyacrylamide gel. Substrate RNA and the specific RNA cleavage products generated by ribozyme cleavage are visualized on an autoradiograph of the gel. The percentage of cleavage is determined by Phosphor Imager[®] quantitation of bands representing the intact substrate and the cleavage products.

5 Example 5: Ability of c-raf Ribozymes to Inhibit Smooth Muscle Cell Proliferation:

Ribozymes targeting sites in c-Raf mRNA were synthesized using modifications that confer nuclease resistance (Beigelman, 1995, *J. Biol. Chem.* 270, 25702). The ribozymes were screened for their ability to inhibit cell proliferation in serum-starved primary rat aortic smooth muscle cells as described by Jarvis et al. (1996, *RNA* 2, 419; incorporated by reference herein). The ribozyme targeting site represented by Seq ID Nos 175 and 198 showed particularly high activity in inhibiting cell proliferation. An inactive control ribozyme was synthesized which had identical substrate binding arms but contained mutations in the catalytic core that eliminate cleavage activity. Inhibition of cell proliferation by active versus inactive c-Raf ribozymes is shown in Figures 37 and 38. The data are presented as proliferation relative to the serum-stimulated untreated control cells. Clearly the active ribozyme is showing substantial inhibition relative to both the untreated control and its corresponding inactive control, thus indicating that the inhibition of proliferation is mediated by ribozyme-mediated cleavage of c-Raf.

In several other systems, cationic lipids have been shown to enhance the bioavailability of oligonucleotides to cells in culture (Bennet, C. F., et al., 1992, *Mol. Pharmacology*, 41, 1023-1033). In many of the following experiments, ribozymes were complexed with cationic lipids. The cationic lipid, Lipofectamine (a 3:1 (w/w) formulation of DOSPA (2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate) and dioleoyl phosphatidylethanolamine (DOPE)), was purchased from Life Technologies, Inc. DMRIE (N-[1-(2,3-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide) was obtained from VICAL. DMRIE was resuspended in CHCl₃ and mixed at a 1:1 molar ratio with dioleoyl phosphatidylethanolamine (DOPE). The CHCl₃ was evaporated, the lipid was

resuspended in water, vortexed for 1 minute and bath sonicated for 5 minutes. Ribozyme and cationic lipid mixtures were prepared in serum-free DMEM immediately prior to addition to the cells. DMEM plus additives was warmed to room temperature (about 20-25°C), cationic lipid was added to the final desired concentration and the solution was
5 vortexed briefly. RNA oligonucleotides were added to the final desired concentration and the solution was again vortexed briefly and incubated for 10 minutes at room temperature. In dose response experiments, the RNA/lipid complex was serially diluted into DMEM following the 10 minute incubation.

Serum-starved smooth muscle cells were washed twice with PBS, and the
10 RNA/lipid complex was added. The plates were incubated for 4 hours at 37°C. The medium was then removed and DMEM containing 10% FBS, additives and 10 µM bromodeoxyuridine (BrdU) was added. In some wells, FBS was omitted to determine the baseline of unstimulated proliferation.

The plates were incubated at 37°C for 20-24 hours, fixed with 0.3% H₂O₂ in
15 100% methanol, and stained for BrdU incorporation by standard methods. In this procedure, cells that have proliferated and incorporated BrdU stain brown; non-proliferating cells are counter-stained a light purple. Both BrdU positive and BrdU negative cells were counted under the microscope. 300-600 total cells per well were counted. In the following experiments, the percentage of the total cells that have
20 incorporated BrdU (% cell proliferation) is presented. Errors represent the range of duplicate wells. Percent inhibition then is calculated from the % cell proliferation values as follows: % inhibition = 100 - 100((Ribozyme - 0% serum)/(Control - 0% serum)).

From this initial screen, hammerhead ribozyme targeted against c-raf site 1120 (Figure 36) was further tested. The active ribozyme was able to inhibit proliferation of
25 smooth muscle cell, whereas, the control inactive ribozyme, that cannot cleave c-raf RNA due to alterations in their catalytic core sequence, fails to inhibit smooth muscle cell proliferation (Figure 37). Thus, inhibition of cell proliferation by these hammerhead

sequences is due to their ability to cleave c-ras RNA, and not because of any non-ribozyme activity.

Example 6: Oligonucleotide design and preparation for cloning Defined and Random Libraries

5 The DNA oligonucleotides used in this study to construct Defined and Random Ribozyme Libraries were purchased from Life Technologies (BRL). A schematic of the oligonucleotide design used to construct said Defined or Comprehensive Ribozyme Libraries is shown in Figure 8. This example is meant to illustrate one possible means to construct such libraries. The methods described herein are not meant to be inclusive of all possible methods for constructing such libraries. The oligonucleotides used to construct the hammerhead ribozyme libraries were designed as follows:

5'-CGAAATCAATTG-(N1)_x-{CatalyticCore}-(N2)_x-CGTACGACACGAAAGTATCG-3'

Where N1 = the Stem I target-specific binding arm of length x, Catalytic Core = the hammerhead catalytic domain 5'-CTGATGAGGCCGUUAGGCCGAAA-3', and N2 = the Stem III target specific binding arm of length x. The oligonucleotides were designed to self-prime via formation of a stem-loop structure encoded at the 3' ends of the oligos (Figure 8A). This intramolecular interaction favored an unbiased extension of complex pools of ribozyme-encoding oligonucleotides. In the case of Defined Ribozyme Library described below (Figures 9-10), N1 and N2 were 8 nt each and were designed to be complimentary to the RNA encoded by the purine nucleoside phosphorylase (PNP) gene. In the case of Random Ribozyme Libraries, N1 and N2 were randomized during synthesis to produce a single pool of all possible hammerhead ribozymes.

In the example shown (Figures 9-10), oligonucleotides encoding 40 different PNP-specific hammerhead ribozymes (greater than 40 ribozymes can be used) were pooled to a final concentration of 1 μ M total oligonucleotides (2.5 nM each individual oligo). Oligos were heated to 68°C for 30 min and then cooled to ambient temperature to promote formation of the 3' stem-loop for self-priming (Figure 8A). The

3' stem loop was extended (Figure 8B) using Klenow DNA polymerase (1 μ M total oligonucleotides in 1 ml of 50 mM Tris pH 7.5, 10mM MgCl₂, 100 μ g/ml BSA, 25 μ g M dNTP mix, and 200 U Klenow) by incubating for 30 min at 37°C. The reaction mixtures were then heated to 65°C for 15 min to inactivate the polymerase. The double-stranded
5 oligos (approximately 30 μ g) were digested with the 100 U of the 5' restriction endonuclease Mfe I (NEB) as described by the manufacturer, then similarly digested with the 3' restriction endonuclease BsiWI (Figure 8C). To reduce the incidence of multiple ribozyme inserts during the cloning steps, the cleaved products were treated with Calf Intestinal Phosphatase (CIP, Boehringer Mannheim) as described by the manufacturer to
10 remove the phosphate groups at the 5' ends. This step inhibits intra- and intermolecular ligation of the ribozyme-encoding fragments. Full-length product corresponding to the double-stranded, restriction digested and phosphatase-treated products was gel-purified following electrophoresis through 10% non-denaturing acrylamide gels prior to cloning to enrich for full-length material.

15 Example 7: Cloning of Defined and Random Libraries

The cloning vectors used contained the following cloning sites: 5'- MfeI - Cla I - BsiWI -3'. Vectors were digested with Mfe I and BsiWI prior to use. Thus, vectors cleaved with both enzymes should lack the Cla I site present between the sites, while vectors cleaved with only one of the enzymes should still retain the Cla I site. Pooled
20 oligos were ligated to vector using a 2:1 or 5:1 molar ratio of double-stranded oligo to vector in 50-mL reactions containing 500 ng vector and 5 U ligase in 1x ligase buffer (Boehringer Mannheim). Ligation reactions were incubated over night at 16°C, then heated to 65°C 10 min to inactivate the ligase enzyme. The desired products contain a single ribozyme insert and lack the original Cla I site included between the Mfe I and
25 BsiWI cloning sites. Any unwanted, background vector lacking ribozyme inserts and thus still containing the Cla I sites were inactivated by cleaving the product with 5 U of the restriction endonuclease Cla I for 1 h at 37°C. Approximately 150 ng of ligated vector

was used to transform 100 µl XL-2 Blue competent bacteria as described by the supplier (Stratagene).

Example 8: Simultaneous screening of 40 different ribozymes targeting PNP using Defined Ribozyme Libraries.

5 A Defined Ribozyme Library containing 40 different hammerhead ribozymes targeting PNP was constructed as described above (Figures 8-10). PNP is an enzyme that plays a critical role in the purine metabolic/salvage pathways. PNP was chosen as a target because cells with reduced PNP activity can be readily selected from cells with wild-type activity levels using the drug 6-thioguanosine. This agent is not toxic to cells until it is
10 converted to 6-thioguanine by PNP. Thus, cells with reduced PNP activity are more resistant to this drug and can be selectively grown in concentrations of 6-thioguanosine that are toxic to cells with wild-type activity levels.

 The PNP-targeted Defined Ribozyme Library expression vectors were converted into retroviral vector particles, and the resulting particles were used to
15 transduce the Sup T1 human T cell line. A T-cell line was chosen for study because T lymphocytes are more dependent on the purine salvage pathway and thus are highly susceptible to 6-thioguanosine killing. Two weeks after transduction, the cells were challenged with 10 mmol 6-thioguanosine. Resistant cells began to emerge two weeks after initiation of selection. 6-Thioguanosine-resistant cells were harvested, and the
20 ribozyme-encoding region of the expression vector was amplified using PCR and sequenced. The sequence pattern of the ribozyme region in the selected cells was significantly different from that produced from the starting library shown in Figure 9. In the original library, sequences of the binding arms were ambiguous due to the presence of all 40 PNP-targeted ribozymes (Figure 9). However, the sequence of the ribozyme-
25 encoding regions from the 6-thioguanosine selected cells was clearly weighted towards one of the ribozymes contained in the original pool - the ribozyme designed to cleave at nucleotide #32 of PNP mRNA. These data suggests that the ribozyme targeting position

32 of the PNP mRNA appears to be more active than the other 39 PNP-targeted ribozymes included in the pool.

Example 9: Optimizing Loop II sequence of a Hammerhead Ribozyme (HH-B) for Enhanced Catalytic Rates

5 To test the feasibility of the combinatorial approach described in Figure 12 approach, Applicant chose to optimize the sequence of loop-II of a hammerhead ribozyme (HH-B) (see Figure 22). Previous studies had demonstrated that a variety of chemical modifications and different sequences within loop-II may have significant effects on the rate of cleavage *in vitro*, despite the fact that this sequence is not phylogenetically
10 conserved and can in fact be deleted completely. According to the standard numbering system for the hammerhead ribozyme, the four positions within loop II are numbered 12.1, 12.2, 12.3, and 12.4. The Starting Ribozyme (HH-B) contained the sequence G_{12.1} A_{12.2} A_{12.3} A_{12.4}. For simplicity, the four positions will be numbered 5' to 3': G_{12.1}= 1; A_{12.2}= 2; A_{12.3}=3; A_{12.4}= 4. The remainder of the hammerhead ribozyme "template" remained
15 constant and is based on a previously described hammerhead motif (Draper *et al.*, International PCT Publication No. WO 95/13380, incorporated by reference herein).

A strategy for optimizing the four (number of Classes = 4) loop-II positions is illustrated in Figure 180. The four standard ribose nucleotides (A, C, U and G) were chosen to construct the ribozyme pools (n = 4). In the first step, four different pools were
20 synthesized by the nucleotide building block mixing approach described herein. Applicant first chose to "fix" (designated F) position 3 because preliminary experiments indicated that the identity of the base at this position had the most profound effects on activity; positions 1, 2 and 4 are random. The four pools were assayed under stoichiometric conditions (1μM ribozyme; 1μM substrate), to help ensure that the entire
25 population of ribozymes in each pool was assayed. Substrate and ribozyme were pre-annealed and the reactions were initiated with the addition of 10mM MgCl₂. The rate of cleavage for each library was derived from plots of fraction of substrate cleaved as a function of time. Reactions were also performed simultaneously with the starting

ribozyme (i.e., homogenous, loop-II = GAAA). The relative rate of cleavage for each library (k_{rel}) was calculated by dividing the observed rate of the library by the rate of the control/starting ribozyme and is plotted in Figure 21. The error bars indicate the standard error derived from the curve fits. The results show that all four pools had similar rates (k_{rel}); however, the library possessing "U" at position 3 was slightly faster.

Ribozyme pools were again synthesized (Class 2) with position 3 being made constant (U_3), position 4 was fixed (F_4) and positions 1 and 2 were random (X). The four pools were assayed as before; the pool containing "A" at position 4 was identified as the most desirable pool. Therefore, during the synthesis of the next pool (Class 3), positions 3 and 4 were constant with U_3 and A_4 , position 2 was fixed (F_2) and position 1 was random (X). The four pools were again assayed; all four pools showed very similar, but substantially elevated rates of cleavage. The pool containing U at position 2 was identified as the fastest. Therefore, during the synthesis of the final four ribozymes (Class 4), position 3, 4 and 2 were made constant with U_3 , A_4 and U_2 ; position 1 was fixed with A, U, C or G. The final ribozyme containing G at position 4 was clearly identified as the fastest ribozyme, allowing the identification of $G_{12,1} U_{12,2} U_{12,3} A_{12,4}$ as the optimized ribozyme motif.

To confirm that the final ribozyme ($G_{12,1} U_{12,2} U_{12,3} A_{12,4}$) was indeed faster than the starting ribozyme ($G_{12,1} A_{12,2} A_{12,3} A_{12,4}$), we compared the two ribozymes (illustrated in Figure 22) under single-turnover conditions at saturating ribozyme concentrations. The observed rates should therefore measure the rate of the chemical step, k_2 . The fraction of substrate remaining uncleaved as a function of time is shown in Figure 22 (lower panel), and the derived rate constants are shown. The results show that the optimized ribozyme cleaves >10 times faster (3.7 min^{-1} vs. 0.35 min^{-1}) than the starting ribozyme.

Example 10: Optimizing Core Chemistry of a Hammerhead Ribozyme (HH-A)

To further test the feasibility of the approach described in Figure 12, we chose to optimize the three pyrimidine residues within the core of a hammerhead ribozyme (HH-

A). These three positions (shown in Figure 13 as U7, U4 and C3) were chosen because previous studies indicated that these positions are critical for both stability (Beigelman *et al.*, 1995, *supra*) and activity (Ruffner *et al.*, 1990, *supra*; Burgin *et al.*, 1996, *supra*) of the ribozyme. According to the standard numbering system for the hammerhead
5 ribozyme, the three pyrimidine positions are 7, 4 and 3. For construction of the libraries, the ribozyme positions are numbered 3' to 5': position 24 = 7, position 27 = 4, and position 28 = 3 (see Figure 13). The remainder of the hammerhead ribozyme "template" remained constant and is based on a previously described hammerhead motif (Thompson
10 *et al.*, US Patent No. 5,610,052, incorporated by reference herein). The starting ribozyme template is targeted against nucleotide position 823 of k-ras mRNA (Site A). Down regulation of this message, as a result of ribozyme action, results in the inability of the cells to proliferate. Therefore in order to optimize a ribozyme, we chose to identify "variants" which were successful in inhibiting cell proliferation.

Cell Culture Assay:

15 *Ribozyme:lipid complex formation*

Ribozymes and LipofectAMINE were combined DMEM at final concentrations of 100 nM and 3.6 μ M, respectively. Complexes were allowed to form for 15 min at 37 C in the absence of serum and antibiotics.

Proliferation Assay

20 Primary rat aortic smooth muscle cells (RASMC) were seeded at a density of 2500 cells/well in 48 well plates. Cells were incubated overnight in DMEM, supplemented with 20% fetal bovine serum (FBS), Na-pyruvate, penicillin (50 U/ml), and streptomycin (50 μ g/ml). Subsequently cells were rendered quiescent by a 48 h incubation in DMEM with 0.5% FBS.

25 Cells were incubated for 1.5 h with serum-free DMEM ribozyme:lipid complexes. The medium was replaced and cells were incubated for 24 h in DMEM with 0.25% FCS.

Cells were then stimulated with 10% FBS for 24 h. ^3H -thymidine (0.3 $\mu\text{Ci}/\text{well}$) was present for the last 12 h of serum stimulation.

At the end of the stimulation period the medium was aspirated and cells were fixed in icecold TCA (10%) for 15 min. The TCA solution was removed and wells were
5 washed once with water. DNA was extracted by incubation with 0.1 N NaOH at RT for 15 min. Solubilized DNA was quantitatively transferred to minivials. Plates were washed once with water. Finally, ^3H -thymidine incorporation was determined by liquid scintillation counting.

A strategy for optimizing the three (number of Class = 3) pyrimidine residues is
10 illustrated in Figure 20. Ten different nucleotide analogs (illustrated in Figure 15) were chosen to construct the ribozyme library ($n = 10$). In the first step, ten different pools (Class 1) were synthesized by the mix and split approach described herein. Positions 24 and 27 were random and position 28 was fixed with each of the ten different analogs. The ten different pools were formulated with a cationic lipid (Jarvis *et al.*, 1996, *RNA*, 2,419;
15 incorporated by reference herein), delivered to cells *in vitro*, and cell proliferation was subsequently assayed (see Figure 16). A positive control (active ribozyme) inhibited cell proliferation by ~50% and an inactive control (inactive) resulted in a less than 25% reduction in cell proliferation. The ten ribozyme pools resulted in intermediate levels of reduction. However, the best pool could be identified as $X_{24} X_{27} 2'\text{-MTM-U}_{28}$ (positions
20 24 and 27 random; $2'\text{-O-MTM-U}$ at position 28). Therefore, a second ribozyme library (Class 2) was synthesized with position 28 constant ($2'\text{-O-MTM-U}$); position 24 was random (X_{24}) and position 27 was fixed with each of the ten different analogs (F_{27}). Again, the ten pools were assayed for their ability to inhibit cell proliferation. Among Class 2, two pools inhibited proliferation equally well: $X_{24} 2'\text{-C-allyl-U}_{27} 2'\text{-O-MTM-U}_{28}$
25 and $X_{24} 2'\text{-O-MTM-C}_{27} 2'\text{-O-MTM-U}_{28}$. Because a single "winner" could not be identified in Class 2, position 27 was made constant with either $2'\text{-C-allyl-U}$ or with $2'\text{-O-MTM-C}$ and the ten analogs were placed individually at position 24 (Class 3). Therefore in Class 3, twenty different ribozymes were assayed for their ability to inhibit

cell proliferation. Because both positions 27 and 28 are constant, the final twenty ribozymes contain no random positions. Thus in the final group (Class 3), pure ribozymes and not pools were assayed. Among the final groups four ribozymes inhibited cell proliferation to a greater extent than the control ribozyme (Figure 22). These four winners are illustrated in Figure 23A. Figure 23B shows general formula for four different motifs. A formula for a novel ribozyme motif is shown in Figure 18.

Example 11: Identifying Accessible Sites for Ribozyme Action in a target

In the previous two examples (9 and 10), positions within the catalytic domain of the hammerhead ribozyme were optimized. The number of groups that needed to be tested equals = the total number of positions within the ribozyme that were chosen to be tested. A similar procedure can be used on the binding arms of the ribozyme. The sequence of the binding arms determines the site of action of the ribozyme. The combinatorial approach can be used to identify those sites by essentially testing all possible arm sequences. The difficulty with this approach is that ribozymes require a certain number of base pairs (12-16) in order bind tightly and specifically. According to the procedure outlined above, this would require 12-16 different groups of ribozyme pools; 12-16 positions would have to be optimized which would require 12-16 different groups being synthesized and tested. Each pool would contain the four different nucleotides (A, C, U and G) or nucleotide analogs ($n = 4$). It would be very time consuming to test each group, identify the best pool, synthesize another group of ribozyme pools with one additional position constant, and then repeat the procedure until all 12-16 groups had been tested. However it is possible to decrease the number of groups by testing multiple positions within a single group. In this case, the number of pools within a group equals the number of nucleotides or analogs in the random mixture (i.e., n) to the w power, where w equals the number of positions fixed in each group. The number of groups that need to be synthesized to optimize the final ribozyme equals the total number of positions to be optimized divided by the number of positions (w) tested

within each group. The number of pools in each group = n^w . The number of groups = total number of positions / w .

For example, Figure 23 illustrates this concept on a hammerhead ribozyme containing 12 base pair binding arms. Each of the two binding arms form 6 base pairs with it's corresponding RNA target. It is important to note that for the hammerhead ribozyme one residue (A15.1) must remain constant; A15.1 forms a base pair with a substrate nucleotide (U16.1) but is also absolutely required for ribozyme activity. It is the only residue within the hammerhead ribozyme that is part of both the catalytic domain, and the binding domain (arms). In the example this position is not optimized. In the first
5 Group, three positions are fixed (designated F) with the four different 2'-O-methyl nucleotides (A, C, U and G). The 2'-O-methyl modification stabilizes the ribozyme against nuclease degradation and increases the binding affinity with it's substrate. The total number of pools in each group does not equal n , as in the previous examples. The number of pools in each group equals $4^3 = (\text{four analogs})^{(\text{number of positions fixed; } 3)} =$
10 64. In all 64 pools, all other positions in the arm are made random (designated X) by the nucleotide mixing building block approach. The catalytic domain is not considered in this example and therefore remains part of the ribozyme template (i.e., constant).

In the first step, all 64 ribozyme pools are tested. This test may be cleavage *in vitro* (see Example 9), or efficacy in a cellular (see Example 10) or animal model, or any
20 other assayable end-point. This end-point however, should be specific to a particular RNA target. For example, if one wishes to identify accessible sites within the mRNA of GeneB, a suitable end-point would be to look for decreased levels of GeneB mRNA after ribozyme treatment. After a winning pool is identified, since each pool specifies the identity of three positions (w), three positions can be made constant for the next group
25 (Class 2). Class 2 is synthesized containing 64 different pools; three positions that were fixed in Class 1 are now constant (designated Z), three more positions are fixed (F), and the remaining positions (X) are a random mix of the four nucleotides. The 64 pools are assayed as before, a winning pool is identified, allowing three more positions to be

constant in the next Class of ribozyme pools (Class 3) and the process is repeated again. In the final Class of ribozymes (Class 4), only two positions are fixed, all other positions have been previously fixed. The total number of ribozymes is therefore $n^* = 4^2 = 16$; these ribozymes also contain no random positions. In the final step (step 4), the 16
5 ribozymes are tested; the winning ribozyme defines the sequence of the binding arms for a particular target.

Fixing multiple positions within a single group it is possible to decrease the overall number of groups that need to be tested. As mentioned, this is particularly useful when a large number of different positions need to be optimized. A second advantage to
10 this approach is that it decreases the complexity of molecules in each pool. If one would expect that many combinations within a given pool will be inactive, by decreasing the number of different ribozymes in each pool, it will be easier to identify the "winning" pool. In this approach, a larger number of pools have to be tested in each group, however, the number of groups is smaller and the complexity of each ribozyme pool is smaller.
15 Finally, it should be emphasized there is not a restriction on the number of positions or analogs that can be tested. There is also no restriction on how many positions are tested in each group.

Example 12: Identifying new RNA targets for Ribozymes

As described above for identifying ribozyme-accessible sites, the assay used to
20 identify the "winning" pool of ribozymes is not defined and may be cleavage *in vitro* (see Example 8), or efficacy in a cellular (see Example 9) or animal model, or any other assayable end-point. For identifying accessible sites, this end-point should be specific to a particular RNA target (e.g., mRNA levels). However, the end-point could also be nonspecific. For example, one could choose a disease model and simply identify the
25 winning ribozyme pool based on the ability to provide a desired effect. In this case, it is not even necessary to know what the cellular target that is being acted upon by the ribozyme is. One can simply identify a ribozyme that has a desired effect. The advantage to this approach is that the sequence of the binding arms will be complementary to the

RNA target. It is therefore possible to identify gene products that are involved in a disease process or any other assayable phenotype. One does not have to know what the target is prior to starting the study. The process of identifying an optimized ribozyme (arm combinatorial) identifies both the drug (ribozyme) and the RNA target, which may
5 be a known RNA sequence or a novel sequence leading to the discovery of new genes.

Example 13: Identifying New Ribozyme Catalytic Domains

In the previous two examples, positions within the binding domain of the hammerhead ribozyme were varied and positions within the catalytic domain were not changed. Conversely, it is possible to vary positions within the catalytic domain, without
10 changing positions within the binding arms, in order to identify new catalytic motifs. An example is illustrated in Figure 24. The hammerhead ribozyme, for example comprises about 23 residues within the catalytic domain. It is unclear how many of these 23 positions are required to obtain a functional catalytic domain, however it is reasonable to presume that if a large number of functionally diverse nucleotide analogs can be used to
15 construct the pools, a relatively small number of positions could constitute a functional catalytic domain. This may especially be true if analogs are chosen that one would expect to participate in catalysis (e.g., acid/base catalysts, metal binding, etc.). In the example illustrated in Figure 24, four positions (designated 1, 2, 3 and 4) are chosen. In the first step, ribozyme libraries (Class 1) are constructed: position 1 is fixed (F_1) and positions 2,
20 3 and 4 are random (X_2 , X_3 and X_4 , respectively). In step 2, the pools (the number of pools tested depends on the number of analogs used; n) are assayed for activity. This testing may be performed *in vitro* or in a cellular or animal model. Whatever assay that is used, the pool with the most activity is identified and libraries (class 2) are again synthesized with position 1 now constant (Z_1) with the analog that was identified in class
25 1. In class 2, position 2 is fixed (F_2) and positions 3 and 4 are random (X_3 and X_4). This process is repeated until every position has been made constant, thus identifying the catalytic domain or a new motif.

EXAMPLE 14: Determination of Coupling Efficiency of the phosphoramidite derivatives of 2'-C-allyl-uridine, 1; 4'-thio-cytidine, 2; 2'-methylthiomethyl-uridine, 3; 2'-methylthiomethyl-cytidine, 4; 2'-amino-uridine, 5; N3-methyl-uridine, 6; 1-b-D-(ribofuranosyl)-pyridin-4-one, 7; 1-b-D-(ribofuranosyl)-pyridin-2-one, 8; 1-b-D-(ribofuranosyl)-phenyl, 9; 6-methyl-uridine, 10 to be used in a split and mix approach.

The determination of the coupling efficiency of amidites 1 to 10 was assessed using ten model sequences agacXGAuGa (where upper case represents ribonucleotide residues, lower case represents 2'-O-methyl ribonucleotide residues and X is amidites 1 to 10, to be used in the construction of a hammerhead ribozyme library wherein the modified amidites 1 to 10 would be incorporated. Ten model sequences were synthesized using ten 0.112 g aliquots of 5'-O-DMT-2'-O-Me-Adenosine Polystyrene (PS) solid-support loaded at 22.3 $\mu\text{mol/g}$ and equivalent to a 2.5 μmol scale synthesis. Synthesis of these ten decamers were performed on ABI 394 DNA synthesizer (Applied Biosystems, Foster City, Calif.) using standard nucleic acid synthesis reagents and synthesis protocols, with the exception of an extended (7.5 min) coupling time for the ribonucleoside phosphoramidites and phosphoramidites 1, 2, 3, 4, 6, 7, 8, 9, 10, 12.5 min coupling time for the 2'-amino-uridine phosphoramidite, amidite 5 and 2.5 min coupling time for the 2'-O-methyl nucleoside phosphoramidites.

Oligomers were cleaved from the solid support by treatment with a 3:1 mixture of ammonium hydroxide: absolute ethanol at 65 degree C for 4 hrs followed by a desilylation treatment and butanol precipitation as described in Wincott et al. (Wincott et al, *Nucleic Acids Res*, 1995, 23, 2677-2684; incorporated by reference herein). Oligonucleotides were analyzed directly on an anion-exchange HPLC column (Dionex, Nucleopac, PA-100, 4x250 mm) using a gradient of 50% to 80% of B over 12 minutes (A = 10 mM sodium perchlorate, 1 mM Tris, pH 9.43; B = 300 mM sodium perchlorate, 1 mM Tris, pH 9.36) and a Hewlett-Packard 1090 HPLC system.

The average stepwise yield (ASWY), indicating the coupling efficiency of phosphoramidites, 1 to 10, were calculated from peak-area percentages according to the

equation $ASWY = (FLP\%)^{1/n}$ where FLP% is the percentage full-length product in the crude chromatogram and n the number of synthesis cycles. ASWY ranging from of 96.5% to 97.5% were obtained for phosphoramidites, 1 to 10. The experimental coupling efficiencies of the phosphoramidites 1 to 10, as determined using a standard spectrophotometric dimethoxytrityl assay were in complete agreement with the ASWY and were judged satisfactory to proceed with the X24, X27, X28 ribozyme library synthesis.

EXAMPLE 15: Determination of optimal relative concentration of a mixture of 2'-O-methyl-guanosine, cytidine, uridine and adenosine providing equal representation of the four nucleotides.

A mixture N, composed of an equimolar mixture of the four 2'-O-Me- nucleoside phosphoramidites (mG=2'-O-methyl guanosine; mA=2'-O-methyl adenosine; mC=2'-O-methyl cytidine; mU=2'-O-methyl uridine) was used in the synthesis of a model sequence TXXXXTTB, where T is 2'-deoxy-thymidine and B is a 2'-deoxy-inverted abasic polystyrene solid-support as described in Example 14. After standard deprotection (Wincott *et al.*, *supra*), the crude nonamer was analyzed on an anion-exchange HPLC column (see example 6). From the HPLC analysis, an averaged stepwise yield (ASWY) of 99.3% was calculated (see example 14) indicating that the overall coupling efficiency of the mixture N was comparable to that of 2'-deoxythymidine. To further assess the relative incorporation of each of the components within the mixture, N, the full-length product TXXXXTTB (over 94.3% at the crude stage) was further purified and subjected to base composition analysis as described herein. Purification of the FLP from the failures is desired to get accurate base composition.

Base composition analysis summary:

A standard digestion/HPLC analysis was performed: To a dried sample containing 0.5 A.sub.260 units of TXXXXTTB, 50 μ l mixture, containing 1 mg of nuclease P1 (550 units/mg), 2.85 ml of 30 mM sodium acetate and 0.3 ml of 20 mM aqueous zinc chloride, was added. The reaction mixture was incubated at 50 degrees C overnight.

Next, 50 μ l of a mixture comprising 500 μ l of alkaline phosphatase (1 units/ μ l), 312 μ l of 500 mM Tris pH 7.5 and 2316 μ l water was added to the reaction mixture and incubated at 37 degrees C for 4 hours. After incubation, the samples were centrifuged to remove sediments and the supernatant was analyzed by HPLC on a reversed-phase C18 column
 5 equilibrated with 25 mM KH₂PO₄. Samples were analyzed with a 5% acetonitrile isocratic gradient for 8 min followed by a 5% to 70% acetonitrile gradient over 8 min.

The HPLC percentage areas of the different nucleoside peaks, once corrected for the extinction coefficient of the individual nucleosides, are directly proportional to their molar ratios.

10 The results of these couplings are shown in Table IV.

Nucleoside	dT 0.1 M	2'-OMe-C 0.025M	2'-OMe-U 0.025M	2'-OMe-G 0.025M	2'-OMe-A 0.025M
% area	43.81	6.04	14.07	18.54	17.54
Epsilon 260 nm	8800	7400	10100	11800	14900
moles	0.00498	0.00082	0.00139	0.00157	0.00118
equivalent	4	0.656	1.119	1.262	0.946

As can be seen in Table IV, the use of an equimolar mixture of the four 2'-O-methyl phosphoramidites does not provide an equal incorporation of all four amidites, but favors 2'-O-methyl-U and G and incorporates 2'-O-methyl-A and C to a lower efficiency.

15 To alleviate this, the relative concentrations of 2'-O-methyl-A, G, U and C amidite were adjusted using the inverse of the relative incorporation as a guide line. After several iterations, the optimized mixture providing nearly identical incorporation of all four amidites was obtained as shown in Table V below. The relative representation do not exceed 12% difference between the most and least incorporated residue corresponding to
 20 a +/- 6% deviation from equimolar incorporation.

Nucleoside	dT	2'-OMe-C	2'-OMe-U	2'-OMe-G	2'-OMe-A
	0.1M	0.032M	0.022M	0.019M	0.027M
% area	44.47	8.91	11.81	15.53	19.28
Epsilon 260 nm	8800	7400	10100	11800	14900
moles	0.00505	0.00120	0.00117	0.00132	0.00129
equivalent	4	0.953	0.926	1.042	1.024

EXAMPLE 16: A Non-competitive coupling method for the preparation of the X24, X27 and N28 ribozyme library 5'-a₂c₂a₂a₂ag aFX GAX Gag gcg aaa gcc Gaa Agc ccu cB -3' wherein 2'-C-allyl-uridine, 1; 4'-thio-cytidine, 2; 2'-methylthiomethyl-uridine, 3; 2'-methylthiomethyl-cytidine, 4; 2'-amino-uridine, 5; N3-methyl-uridine, 6; 1-b-D-(ribofuranosyl)-pyrimidine-4-one, 7; 1-b-D-(ribofuranosyl)-pyrimidine-2-one, 8; 1-b-D-(ribofuranosyl)-phenyl, 9; and/or 6-methyl-uridine, 10 are incorporated at the X24, X27 and F28 positions through the mix and split approach.

The synthesis of ten different batches of 2.5 µmol scale Gag gcg aaa gcc Gaa Agc ccu cB sequence was performed on 2'-deoxy inverted abasic polystyrene solid support **B** on a 394 ABI DNA synthesizer (Applied Biosystems, Foster City, CA). These ten aliquots were then separately reacted with phosphoramidite building blocks **1** to **10** according to the conditions described in example 11. After completion of the individual incorporation of amidites **1** to **10**, their coupling efficiencies were determined to be above 95 % as judged by trityl monitoring. The 10 different aliquots bearing the ten different sequences were mixed thoroughly and divided into ten equal subsets. Each of these aliquots were then successively reacted with ribo-A, ribo-G amidites and one of the amidites **1** to **10**. The ten aliquots were combined, mixed and split again in 10 subsets. At that point, the 10 different polystyrene aliquots, exhibiting the following sequence: *X* GAX Gag gcg aaa gcc Gaa Agc ccu cB, were reacted again with amidites **1** to **10** separately. The aliquots were not mixed, but kept separate to obtain a unique residue at

the 28th position of each of the ten pools. The ribozyme synthesis was then finished independently to yield ten random ribozymes pools. Each pool comprises a 3'-terminal inverted abasic residue **B**, followed by the sequence Gag gcg aaa gcc Gaa Agc ccu c, followed with one random position **X** in the 24th position corresponding to a mixture of
 5 amidites 1 to 10, followed by the sequence GA, followed one random position **X** in the 27th position corresponding to a mixture of amidites 1 to 10, followed by a fixed monomer **F** (one of the amidites 1 to 10) in the 28th position and finally the 5'-terminal sequence a₅c₅a₅a₅a g a. This is represented by the sequence notation 5'- a₅c₅a₅a₅ag a**FX** GAX Gag gcg aaa gcc Gaa Agc ccu c**B**-3', in which **X** are random positions and **F** is a
 10 unique fixed position. The total complexity of such a ribozyme library was 10³ or 1,000 members separated in 10 pools of 100 different ribozyme sequences each.

EXAMPLE 17: Competitive coupling method (monomer mixing approach) for the preparation of the x₂₋₆ and X₃₀₋₃₅ "binding arms" ribozyme library

Synthesis of 5'-x₅x₅x xFF cuG Au G Agg ccg uua ggc cGA AAF xxx x**B**-3' is
 15 described, with F being a defined 2'-O-methyl-ribonucleoside chosen among 2'-O-methyl-ribo-adenosine (mA), -guanosine (mG), -cytidine (mC), -uridine (mU) and x being an equal mixture of 2'-O-methyl-ribo-adenosine, -guanosine, -cytidine, -uridine.

The syntheses of this ribozyme library was performed with an ABI 394 DNA synthesizer (Applied Biosystems, Foster City, Calif.) using standard nucleic acid
 20 synthesis reagents and synthesis protocols, with the exception of an extended (7.5 min) coupling time for the ribonucleoside phosphoramidites (upper case) and 2'-amino-uridine phosphoramidite, **u**, (2.5 min) coupling time for the 2'-O-methyl-ribonucleoside phosphoramidites (lower case) and the 2'-O-methyl-ribonucleoside phosphoramidites mixture, n.

25 Sixty four (64) batches of 0.086 g aliquots of 3'-O-DMT-2'-deoxy-inverted abasic-Polystyrene (**B**) solid-support loaded at 29 µmol/g and equivalent to a 2.5 µmol

scale synthesis were individually reacted with a 27:32:19:22 / v:v:v:v mixture, x, of mA:mC:mG:mU diluted in dry acetonitrile to 0.1 M as described in example 7. This synthesis cycle was repeated for a total of four times. The 64 aliquots were then grouped into four subsets of sixteen aliquots (Class 1) that were reacted with either mA, mG, mC, mU to synthesize the n6 position. This accomplished, the sequence: 5'- cuG Au G Agg ccg uua ggc cGA AA was added onto the 6 position of the 64 aliquots constituting Class 1. Each subset of Class 1 was then divided into four subsets of four aliquots (Class 2) that were reacted with either mA, mG, mC, mU to synthesize the F30 position. Each subset of Class 2 was then divided into four subsets of one aliquot (Class 3) that were reacted with either mA, mG, mC, mU to synthesize the F31 position. Finally, the random sequence 5'- x₅x₅x x was added onto each of the 64 aliquots.

The ribozyme library yielded sixty four random ribozymes pools each having an equal mixture of the four 2'-O-methyl-nucleoside at the position x2 to 6 and x30 to 35, and a defined 2'-O-methyl-nucleoside chosen among mA, mC, mG, mU at the positions F6, F30 and F31. The total complexity of such a "binding arms" ribozyme library was 4¹¹ or 4,194,304 members separated in 64 pools of 65,536 different ribozyme sequences each.

EXAMPLE 18: Competitive coupling method (monomer mixing approach) for the preparation of the position 15 to 18 "loop II" ribozyme library

Synthesis of 5' UCU CCA UCU GAU GAG GCC XXF XGG CCG AAA AUC CCU 3' is described, with F being a defined ribonucleoside chosen among adenosine (A), guanosine (G), cytidine (C), uridine (U) and X being an equal mixture of adenosine (A), guanosine (G), cytidine (C), uridine (U).

The syntheses of this ribozyme library was performed with an ABI 394 DNA synthesizer (Applied Biosystems, Foster City, Calif.) using standard nucleic acid synthesis reagents and synthesis protocols, with the exception of an extended (7.5 min)

coupling time for the ribonucleoside phosphoramidites (A, G, C, U) and the ribonucleoside phosphoramidite mixture, X.

Four batches (4) of 2.5 μ mol scale of GG CCG AAA AUC CCU sequence were synthesized on 0.085 g samples of 5'-O-DMT-2'-O-TBDMS-3'-succinyl-uridine-Polystyrene (U) solid-support loaded at 29.8 μ mol/g. To synthesize the position X15, the four aliquots of solid-supports were individually reacted with a 30:26:24:20 / v:v:v:v mixture, X, of A:C:G:U diluted in dry acetonitrile to 0.1 M according to the optimized conditions for the DNA phosphoramidites mixed-base coupling as described in the DNA Synthesis Course Manual published by Perkin-Elmer-Applied Biosystem Division. (DNA Synthesis Course Manual : Evaluating and isolating synthetic oligonucleotides, the complete guide, p. 2-4, Alex Andrus, August 1995). The four aliquots of solid-supports were then individually reacted with either of the four ribonucleoside phosphoramidites (A, G, C, U) to create the F16 position. The position X17 and X18 were then added onto the F16 (either A, G, C or U) of the four aliquots of solid-supports by repeating twice the same procedure used for the position X15.

The synthesis of the ribozyme library was then ended by adding the sequence 5'-UCU CCA UCU GAU GAG GCC on the position X18 of each of the four subsets of the ribozyme library. The ribozyme library yielded four random ribozymes pools that each have an equal mixture of the four ribonucleoside (A, G, C and U) at the position X15, X17 and X18, and a discrete ribonucleoside chosen among A, C, G or U at the positions F16. The total complexity of such a loop II ribozyme library was 256 members separated in 4 pools of 64 different ribozyme sequences.

Example 19: Arm-Combinatorial Library Screening For Bcl-2, K-ras and Urokinase plasminogen Activator (UPA)

Substrate synthesis through in vitro transcription: Run-off transcripts for Bcl-2 and Kras were prepared using linearized plasmids (975 and 796 nucleotides respectively). Transcripts for UPA were produced from a PCR generated DNA fragment containing a T7 promoter (400 nucleotides). Transcription was performed using the T7 Megascript

transcription kit (Ambion, Inc.) with the following conditions: a 50ul reaction volume containing 7.5mM each of ATP, CTP, UTP, and GTP, 2mM guanosine, 5ul 10x T7 reaction buffer, 5ul T7 enzyme mix, and 0.5ug of linearized plasmid or PCR'd DNA template. The mixture was incubated at 37°C for 4 hours (6 hours for transcripts < 500 bases). Guanosine was added to the transcription reactions so that the final transcript could be efficiently 5'-end labeled without prior phosphatase treatment. Transcription volume was then increased to 200ul with buffer containing 50mM TRIS pH 7.5, 100mM KCl, and 2mM MgCl₂ and spin column purified over Bio-Gel P-60 (BioRad) equilibrated in the same buffer. 100ul of transcript was then applied to 750ul of packed resin. Spin column flow-through was used directly in a 5'-end labeling reaction as follows (100ul final volume): 82ul of P-60 spin column purified transcript, 10ul 10x polynucleotide kinase buffer, 4ul 10U/ul Polynucleotide Kinase (Boehringer/Mannheim) and 4ul 150uCi/ul Gamma-32P-ATP (NEN) were incubated together at 37°C for one hour. The reaction volume was increased to 200ul with buffer containing 50mM TRIS pH 7.5, 100mM KCl and 2mM MgCl₂ and the sample was then purified over Bio-Gel P-60 packed spin column as described above. Approximate specific activities of the 5'-end labeled transcripts were determined via BioScan and stored frozen at -20°C.

Synthesis of Ribozyme pools:

In vitro ribozyme-transcript cleavage reactions: Cleavage reactions were carried out as follows: 5'-end labeled transcript (~2-4 x 10⁴ dpm/ul final) was incubated with 10uM ribozyme pool in 50mM TRIS pH 7.5, 50mM NaCl, 2mM MgCl₂ and 0.01% SDS for 24-48 hours at room temperature (~22°C). An equal volume of gel loading dye (95% formamide, 0.01M EDTA, 0.0375% bromophenol blue, and 0.0375% xylene cyanol) was added to stop the reaction and the samples are heated to 95°C. Reactions (1-2 x 10⁵ dpm per lane) were run on a 5% denaturing polyacrylamide gel containing 7M urea and 1x TBE. Gels are dried and imaged using the PhosphorImager system (Molecular Dynamics). Ambion, Inc. RNA Century Marker Plus RNA standards body labeled in a T7 Megascript reaction as described above using 3ul of 10mCi/ml Alpha-³²P-ATP (BioRad) and 0.5ug Century RNA template and subsequently spin column purified over

Bio-Gel P-6 (Bio-Rad) were used as a size reference on the gel. Cleavage product sizes were determined using the RNA standards which provided an approximate site of cleavage (est. Size in Figure). Because each of the ribozyme pools has three positions within the binding arms fixed, it is possible to identify all of the potential ribozyme sites that can potentially be cleaved by that pool. The estimated size of the cleavage product is therefore compared with the potential sites to identify the exact site of cleavage.

This protocol has been completed on three different transcripts: Bcl-2 (figure 25), Kras (figure 26), and UPA (figure 27). The data is summarized in the figures. All potential hammerhead ribozyme cleavage sites are indicated in the graph with a short vertical line.

The actual sites identified are indicated in the graph. The size of the bar reflects the intensity of the cleavage product from the cleavage reaction. The combinatorial pool used to identify each site, the actual sequence of each site, the position of cleavage within the transcript (based on the known sequence), and the estimated size of the cleavage product (based on gel analysis) are listed.

Example 20: Reduction of Bcl-2 mRNA using Optimized Ribozymes

Two ribozymes targeted against the same site in the bcl-2 transcript (Seq.ID#9, figure 25) were synthesized, but the two ribozymes were stabilized using two different chemistries (U4/U7 amino and U4 c-allyl). Ribozymes (200 nM) were delivered using lipofectamine (7.2 mM) for 3 hours into MCF-7 cells (50% confluency). Cellular RNA was harvested 24 hours after delivery, analyzed by RNase protection analysis (RPA) and normalized to GAPDH mRNA in triplicate samples. Both ribozymes gave a reduction in bcl-2 mRNA (see Figure 28). A ribozyme targeted against an irrelevant mRNA (c-myc) had no effect on the ratio of bcl-2 mRNA to GAPDH mRNA. All reduction of bcl-2 RNA was statistically significant with respect to untreated samples and samples treated with the irrelevant ribozyme.

Example 21: Synthesis of purine nucleoside triphosphates: 2'-O-methyl-guanosine-5'-triphosphate

2'-O-methyl guanosine nucleoside (0.25 grams, 0.84 mmol) was dissolved in triethyl phosphate (5.0) ml by heating to 100 C for 5 minutes. The resulting clear,

colorless solution was cooled to 0 C using an ice bath under an argon atmosphere. Phosphorous oxychloride (1.8 eq., 0.141 ml) was then added to the reaction mixture with vigorous stirring. The reaction was monitored by HPLC, using a sodium perchlorate gradient. After 5 hours at 0 C, tributylamine (0.65 ml) was added followed by the
5 addition of anhydrous acetonitrile (10.0 ml), and after 5 minutes (reequilibration to 0 C) tributylammonium pyrophosphate (4.0 eq., 1.53 g) was added. The reaction mixture was quenched with 20 ml of 2M TEAB after 15 minutes at 0 C (HPLC analysis with above conditions showed consumption of monophosphate at 10 minutes) then stirred overnight at room temperature, the mixture was evaporated *in vacuo* with methanol co-evaporation
10 (4x) then diluted in 50 ml 0.05M TEAB. DEAE sephadex purification was used with a gradient of 0.05 to 0.6 M TEAB to obtain pure triphosphate (0.52 g, 66.0% yield) (elutes around 0.3M TEAB); the purity was confirmed by HPLC and NMR analysis.

Example 22: Synthesis of Pyrimidine nucleoside triphosphates: 2'-O-methylthiomethyl-uridine-5'-triphosphate

15 2'-O-methylthiomethyl uridine nucleoside (0.27 grams, 1.0 mmol) was dissolved in triethyl phosphate (5.0 ml). The resulting clear, colorless solution was cooled to 0 C with an ice bath under an argon atmosphere. Phosphorus oxychloride (2.0 eq., 0.190 ml) was then added to the reaction mixture with vigorous stirring. Dimethylaminopyridine (DMAP, 0.2eq., 25 mg) was added, the solution warmed to room temperature and the
20 reaction was monitored by HPLC, using a sodium perchlorate gradient. After 5 hours at 20 C, tributylamine (1.0 ml) was added followed by anhydrous acetonitrile (10.0 ml), and after 5 minutes tributylammonium pyrophosphate (4.0 eq., 1.8 g) was added. The reaction mixture was quenched with 20 ml of 2M TEAB after 15 minutes at 20 C (HPLC analysis with above conditions showed consumption of monophosphate at 10 minutes)
25 then stirred overnight at room temperature. The mixture was evaporated *in vacuo* with methanol co-evaporation (4x) then diluted in 50 ml 0.05M TEAB. DEAE fast flow Sepharose purification with a gradient of 0.05 to 1.0 M TEAB was used to obtain pure triphosphate (0.40 g, 44% yield) (elutes around 0.3M TEAB) as determined by HPLC and NMR analysis.

Example 23: Utilization of DMAP in Uridine 5'-Triphosphate Synthesis

The reactions were performed on 20 mg aliquots of nucleoside dissolved in 1 ml of triethyl phosphate and 19 ul of phosphorus oxychloride. The reactions were monitored at 40 minute intervals automatically by HPLC to generate yield-of-product curves at times up to 18 hours. A reverse phase column and ammonium acetate/ sodium acetate buffer system (50mM & 100mM respectively at pH 4.2) was used to separate the 5', 3', 2' monophosphates (the monophosphates elute in that order) from the 5'-triphosphate and the starting nucleoside. The data is shown in table VI. These conditions doubled the product yield and resulted in a 10-fold improvement in the reaction time to maximum yield (1200 minutes down to 120 minutes for a 90% yield). Selectivity for 5'-monophosphorylation was observed for all reactions. Subsequent triphosphorylation occurred in nearly quantitative yield.

Materials Used in Bacteriophage T7 RNA Polymerase Reactions

BUFFER 1: Reagents are mixed together to form a 10X stock solution of buffer 1 (400 mM Tris-Cl (pH 8.1), 200 mM MgCl₂, 100 mM DTT, 50 mM spermidine, and 0.1% triton X-100. Prior to initiation of the polymerase reaction methanol, LiCl is added and the buffer is diluted such that the final reaction conditions for condition 1 consisted of : 40mM tris pH (8.1), 20mM MgCl₂, 10 mM DTT, 5 mM spermidine, 0.01% triton X-100, 10% methanol, and 1 mM LiCl.

BUFFER 2: Reagents are mixed together to form a 10X stock solution of buffer 2 (400 mM Tris-Cl (pH 8.1), 200 mM MgCl₂, 100 mM DTT, 50 mM spermidine, and 0.1% triton X-100. Prior to initiation of the polymerase reaction PEG, LiCl is added and the buffer is diluted such that the final reaction conditions for buffer 2 consisted of : 40mM tris pH (8.1), 20mM MgCl₂, 10 mM DTT, 5 mM spermidine, 0.01% triton X-100, 4% PEG, and 1 mM LiCl.

BUFFER 3: Reagents are mixed together to form a 10X stock solution of buffer 3 (400 mM Tris-Cl (pH 8.0), 120 mM MgCl₂, 50 mM DTT, 10 mM spermidine and 0.02% triton X-100. Prior to initiation of the polymerase reaction PEG is added and the buffer is

diluted such that the final reaction conditions for buffer 3 consisted of : 40mM tris pH (8.0), 12 mM MgCl₂, 5 mM DTT, 1 mM spermidine, 0.002% triton X-100, and 4% PEG.

BUFFER 4: Reagents are mixed together to form a 10X stock solution of buffer 4 (400 mM Tris-Cl (pH 8.0), 120 mM MgCl₂, 50 mM DTT, 10 mM spermidine and 0.02% triton X-100. Prior to initiation of the polymerase reaction PEG, methanol is added and the buffer is diluted such that the final reaction conditions for buffer 4 consisted of : 40mM tris pH (8.0), 12 mM MgCl₂, 5 mM DTT, 1 mM spermidine, 0.002% triton X-100, 10% methanol, and 4% PEG.

BUFFER 5: Reagents are mixed together to form a 10X stock solution of buffer 5 (400 mM Tris-Cl (pH 8.0), 120 mM MgCl₂, 50 mM DTT, 10 mM spermidine and 0.02% triton X-100. Prior to initiation of the polymerase reaction PEG, LiCl is added and the buffer is diluted such that the final reaction conditions for buffer 5 consisted of : 40mM tris pH (8.0), 12 mM MgCl₂, 5 mM DTT, 1 mM spermidine, 0.002% triton X-100, 1 mM LiCl and 4% PEG.

BUFFER 6: Reagents are mixed together to form a 10X stock solution of buffer 6 (400 mM Tris-Cl (pH 8.0), 120 mM MgCl₂, 50 mM DTT, 10 mM spermidine and 0.02% triton X-100. Prior to initiation of the polymerase reaction PEG, methanol is added and the buffer is diluted such that the final reaction conditions for buffer 6 consisted of : 40mM tris pH (8.0), 12 mM MgCl₂, 5 mM DTT, 1 mM spermidine, 0.002% triton X-100, 10% methanol, and 4% PEG.

Example 24: Screening of Modified Nucleoside triphosphates with Mutant T7 RNA Polymerase

Each modified nucleotide triphosphate was individually tested in buffers 1 through 6 at two different temperatures (25 and 37°C). Buffers 1-6 tested at 25°C were designated conditions 1-6 and buffers 1-6 test at 37°C were designated conditions 7-12 (table VII). In each condition, Y639F mutant T7 polymerase (Sousa and Padilla, *Supra*) (0.3-2 mg/20 ml reaction), NTP's (2 mM each), DNA template (10 pmol), inorganic pyrophosphatase (5U/ml) and α -³²P NTP(0.8 mCi/pmol template) were combined and heated at the designated temperatures for 1-2 hours. The radiolabeled NTP used was different from the

modified triphosphate being testing. The samples were resolved by polyacrylamide gel electrophoresis. Using a phosphorImager (Molecular Dynamics, Sunnyvale, CA), the amount of full-length transcript was quantified and compared with an all-RNA control reaction. The data is presented in **Table VIII**; results in each reaction is expressed as a percent compared to the all-ribonucleotide triphosphate (rNTP) control. The control was run with the mutant T7 polymerase using commercially available polymerase buffer (Boehringer Mannheim, Indianapolis, IN).

Example 25: Incorporation of Modified NTP's using Wild-type T7 RNA polymerase

Bacteriophage T7 RNA polymerase was purchased from Boehringer Mannheim at 0.4 U/ μ L concentration. Applicant used the commercial buffer supplied with the enzyme and 0.2 μ Ci alpha-³²P NTP in a 50 μ L reaction with nucleotides triphosphates at 2 mM each. The template was double-stranded PCR fragment, which was used in previous screens. Reactions were carried out at 37°C for 1 hour. 10 μ L of the sample was run on a 7.5% analytical PAGE and bands were quantitated using a PhosphorImager. Results are calculated as a comparison to an "all ribo" control (non-modified nucleoside triphosphates) and the results are in **Table IX**.

Example 26: Incorporation of Multiple Modified Nucleoside triphosphates Into Oligonucleotides

Combinations of modified nucleoside triphosphates were tested with the transcription protocol described in example 9, to determine the rates of incorporation of two or more of these triphosphates. Incorporation 2'-Deoxy-2'-(L-histidine) amino uridine (2'-his-NH₂-UTP) was tested with unmodified cytidine nucleoside triphosphates, rATP and rGTP in reaction condition number 9. The data is presented as a percentage of incorporation of modified NTP's compared to the all rNTP control and is shown in **Table Xa**.

Two modified cytidines (2'-NH₂-CTP or 2'dCTP) were incorporated along with 2'-his-NH₂-UTP with identical efficiencies. 2'-his-NH₂-UTP and 2'-NH₂-CTP were then tested with various unmodified and modified adenosine triphosphates in the same buffer

(Table Xb). The best modified adenosine triphosphate for incorporation with both 2'-his-NH₂-UTP and 2'-NH₂-CTP was 2'-NH₂-DAPTP.

EXAMPLE 27: Optimization of Reaction conditions for Incorporation of Modified Nucleotide Triphosphate

5 The combination of 2'-his-NH₂-UTP, 2'-NH₂-CTP, 2'-NH₂-DAP, and rGTP was tested in several reaction conditions (Table XI) using the incorporation protocol described in example 14. The results demonstrate that of the buffer conditions tested, incorporation of these modified nucleoside triphosphates occur in the presence of both methanol and LiCl.

10 Example 28: Deprotection of Ribozyme in a 96 Well Plate

A ribozyme sequence (200nmole) was synthesized as described herein on a polystyrene solid support in a well of a 96 well plate. A 10:3:13 mixture (800 µL) of anhydrous methylamine (308µL), triethylamine (92µL) and dimethylsulfoxide (DMSO) (400 µL) was prepared of which half (400 µL) was added to the well and incubated at room
15 temperature for 45 minutes. Following the reaction the solution was replaced with the remaining 400 µL and incubated as before. At the end of the reaction, the solid support was filtered off, all 800 µL of MA/TEA/DMSO solution was collected together and 100 µL of TEA.3HF was added. The reaction was then heated at 65°C for 15 minutes and then cooled to room temperature. The solution was then quenched with aqueous
20 NH₄⁺HCO₃⁻ (1mL) (see Figure 30). HPLC chromatography of the reaction mixture afforded 32 O. D.u_{260 nm} of which 46% was full length ribozyme.

Example 29: Column Deprotection of Ribozyme

A ribozyme was synthesized using the column format as described herein. The polystyrene solid-support with protected oligoribonucleotide or modified
25 oligoribonucleotide (200 nmole) was transferred into a glass vial equipped with a screw cap. A 10:3:13 mixture of anhydrous methylamine (308 µL), triethylamine (92 µL) and dimethylsulfoxide (DMSO) (400 µL) was added followed by vortexing of the glass vial. After allowing the reaction for 1.5 hours, the solid support was filtered off. 100 µL of TEA.3HF was added at room temperature to the vial and the reaction was mixed causing

the solution to gel. The reaction was then heated at 65 °C for 15 minutes and then cooled to room temperature. The solution was then quenched with 1.5 M aqueous $\text{NH}_4^+\text{HCO}_3^-$ (1mL). HPLC chromatography of the reaction mixture afforded 32 O. D.u_{260 nm} of which 46% was full length ribozyme.

5 Example 30: Column Deprotection of Ribozyme with anhydrous ethanolic methylamine

A ribozyme was synthesized using the column format as described herein. The polystyrene solid-support with protected oligoribonucleotide or modified oligoribonucleotide (200 nmole) was transferred into a glass vial equipped with a screw cap. A 1:1 mixture of anhydrous ethanolic methylamine (400 µL) and dimethylsulfoxide
10 (DMSO) (400 µL) was added followed by vortexing of the glass vial. After allowing the reaction for 1.5 hours, the solid support was filtered off. 100 µL of TEA.3HF was added at room temperature to the vial and the reaction was mixed causing the solution to gel. The reaction was then heated at 65 °C for 15 minutes and then cooled to room temperature. The solution was then quenched with 1.5 M aqueous $\text{NH}_4^+\text{HCO}_3^-$ (1mL).
15 HPLC chromatography of the reaction mixture afforded 32 O. D.u_{260 nm} of which 46% was full length ribozyme.

Example 31. Large-scale One-Pot Deprotection of Ribozyme

A ribozyme was synthesized at the 0.5 mmol scale using the column format as described herein. The polystyrene solid-support (24 grs) with protected
20 oligoribonucleotide or modified oligoribonucleotide (500 µmole) was transferred into a 1L Schott bottle equipped with a screw cap. A 1:1.3 mixture of anhydrous ethanolic methylamine (150 mL) and dimethylsulfoxide (DMSO) (200 mL) was added followed by vortexing (200 rpm) of the glass bottle for 1.5 hours. The reaction mixture was then frozen at -70 °C for 30 minutes. 50 mL of neat TEA.3HF was then added at room
25 temperature to the reaction mixture and the reaction was placed in a shaking oven (200 rpm) where it was heated at 65 °C for 60 minutes and subsequently frozen at -70 °C for 30 minutes. The solution was then quenched with 1.5 M aqueous $\text{NH}_4^+\text{HCO}_3^-$ (200 mL).

The reaction mixture was separated from the polystyrene solid-support by filtration on a sintered glass funnel (10-20 μm porosity). U.V. spectrophotometric quantification and HPLC chromatography of the reaction mixture afforded 160,000 O.D._{260 nm} of which 46.4% was full length ribozyme. After allowing the reaction for 1.5 hours, the solid support was filtered off

Example 32: Antitumor and antimetastatic efficacy of ribozymes directed against the mRNA encoding the two VEGF receptor subtypes, *flt-1* and *flk-1* in the mouse Lewis lung-HM carcinoma model of primary tumor growth and metastasis

The Lewis lung carcinoma (LLC) model is a syngeneic mouse model of metastatic cancer commonly used for antitumor agent efficacy screening. According to Folkman (1995, *supra*), primary tumor growth and metastasis in this model is dependent upon VEGF-induced angiogenesis. Two variants of the LLC model exist. The low metastatic form involves the implantation of a tumor, usually subcutaneous, which sends micrometastases to the lungs whose growth is suppressed by the presence of the primary tumor. The highly metastatic (HM) form differs from the low metastatic variant in that the growth of metastases is not suppressed by the presence of the primary tumor. Thus, the HM form is a model in which it is possible to measure pharmacologic efficacy on both primary tumor growth and metastasis in the same mouse without excision of the primary tumor.

Applicant selected the highly metastatic variant of the Lewis lung model for antitumor/metastatic screening of ribozymes directed against VEGF receptor (*flt-1* and *flk-1*) mRNA. These ribozymes have been shown to reduce VEGF binding and VEGF-stimulated proliferation in cultured MVEC's as well as VEGF-induced neovascularization of the rat cornea (Cushman et al., 1996, Angiogenesis Inhibitors and Other Novel Therapeutic Strategies for Ocular Diseases of Neovascularization, IBC Conference Abstract). Pharmacokinetically, Applicant has found that ribozymes distribute systemically following continuous i.v. infusion (*via* Alzet osmotic minipumps) at significant concentrations within most tissues including subcutaneously implanted

tumors. This study examines the antitumor/antimetastatic efficacy of *flt-1* and *flk-1* ribozymes continuously infused i.v. in the LLC-HM mouse model.

Methods

Ribozymes

5 The ribozymes used in this study were hammerhead ribozymes comprising a 4 base pair stem II, four phosphorothioate linkages at the 5'-end, a 2'-C-allyl substitution at position 4 (see Figure 1), and an inverted abasic nucleotide substitution at the 3'-end. The catalytically active and inactive ribozymes were RPI.4610/4611 (active/inactive) and RPI.4733/4734 directed against *flt-1* and *flk-1* messages, respectively. Ribozymes
10 solutions were prepared in normal saline (USP).

Test solutions (ribozymes or saline control) were dispensed into Alzet® osmotic minipumps (Model # 1002--total volume capacity including excess = 200 µl) which dispense 0.5 µl/h at 37 °C when exposed to interstitial water. Pumps were either filled with normal saline (USP) or 167.0, 50.0, 16.7, 5.0, or 1.7 mg/ml ribozyme solutions.
15 Prior to animal implantation, osmotic minipumps were placed in 37 °C sterile water for at least four hours to activate pumping.

Tumor inoculation

All animal procedures in this study were performed in accordance with the National Research Council's Guide for the Care and Use of Laboratory Animals (1996), USDA
20 regulations, and the policies and procedures of the RPI Institutional Animal Care and Use Committee. A total of 210 female C57BL/6J mice weighing between 20-25 g were used in this study. All animals were housed under 12 h on/12 h off light cycles and received *ad libitum* food and water.

Highly metastatic variant Lewis lung carcinoma (LLC-HM) tumors were
25 propagated *in vivo* from an LLC-HM cell line. These tumors needed to be propagated *in vivo* because they can revert to the low metastatic phenotype in culture. LLC-HM cells

were initially cultured in DMEM + 10% FCS + 1 % GPS. For *in vivo* propagation, 5×10^6 cells were injected subcutaneously in mice. Tumors were allowed to grow for 25 days at which time animals were euthanized by CO₂ inhalation and lung macrometastases were counted. Animals with the most macrometastases (approximately 15-20) were selected for preparation of tumor breis and propagation. When tumors in animals selected for propagation reached a volume of approximately 1500 mm³, animals were euthanized by CO₂ inhalation and tumors were excised. Tumors were sieved through a 100 µm pore size sterile nylon mesh. LLC-HM cells were resuspended in normal saline to a final concentration of 5×10^6 viable cells/ml (*via* hemocytometer). Three days prior to ribozyme dosing, all animals were subcutaneously inoculated on the right flank with 5×10^5 cells (in a volume of 100 µl).

Ribozyme or saline dosing

Each ribozyme solution was prepared to deliver 100, 30, 10, 3, or 1 mg/kg/day in a volume of 12 ml. A total of 10 animals per dose or saline control group were surgically implanted on the left flank with osmotic minipumps pre-filled with the respective test solution three days following tumor inoculation. Pumps were attached to indwelling jugular vein catheters. The specifications for the model #1002 Alzet osmotic minipump show that they accurately deliver aqueous solutions at 0.5 µl/h for 14 days. Table III summarizes the experimental groups.

Tumor volume and metastatic index quantitation

Beginning four days and ending 24 days following tumor inoculation, the length and width of all primary tumors were measured every other day using microcalipers. Tumor volumes were calculated using the standard formula for an ellipsoid volume, $(L \cdot W^2)/2$. Tumor volumes were calculated in triplicate for each animal. A mean tumor volume was calculated for each animal. Group means and standard error of the group means were calculated from individual animal mean tumor volumes.

Twenty-five days following tumor inoculation, all animals were euthanized by CO₂ inhalation and lungs and primary tumors harvested. Lung macrometastases were counted under a dissecting microscope (2.5 X magnification). Lungs and primary tumors were also weighed on an analytical balance. Lung weights served as an index of total lung metastatic burden.

Statistical analysis

For all treatment groups, group tumor volume means on day 18 (end of treatment) as well as means of primary tumor and lung weight and numbers of lung metastases were evaluated for normality and subjected to analysis of variance. Statistical differences between group means were evaluated using the Tukey-Kramer post-hoc test ($\alpha = 0.05$). Comparisons with the control group (saline control) were made using the Dunnett's test ($\alpha = 0.05$).

Results

Flt-1

The effects of several doses of active and inactive *Flt-1* ribozymes (RPI.4610/4611, respectively) on primary LLC-HM tumor growth are summarized in Figure 39 (A-E). At the lowest dose (Figure 39A), both active and inactive reduce primary tumor growth similarly throughout the entire time course compared to saline controls. However, with increasing dose, active ribozyme reduces primary tumor growth to a greater extent than the inactive ribozyme, with the largest difference observed at 30 mg/kg/day (Figure 39D). The magnitude of the maximal reduction compared to saline was approximately four fold with the active ribozyme RPI.4610 at 30 mg/kg/day. It should be noted that this observed four fold reduction is still present at day 24 even though treatment ended 7 days earlier.

The growth curve data was subjected to exponential regression. The curve fits show that the tumor growth data fits an exponential curve with a high correlation coefficient ($R > 0.95$). Thus, there appears to be no long lasting toxic effect on tumor growth. Since

the calculated slope of the exponential curve at any point indicates the rate of tumor growth, it should be possible to compare rates of growth between treatments. Since the curve fits do not assume that the tumor growth starts from the same point (which is a correct assumption since the all tumors start with the same tumor cell inoculum concentration), an accurate calculation of the slope of the exponential curve is not possible since the curve fitting algorithm extrapolates a $t = 0$ tumor size which is then used to calculate the slope. In the analysis, the saline tumor size at $t = 0$ is much greater than the other treatment groups, thus comparisons with saline are not necessarily accurate. If the curve fit algorithm is restricted to the same tumor size, a dose-dependent reduction in the rate of tumor growth is observed with the active ribozyme. However, the curve fits show lower correlation coefficients in some cases.

In order to see whether the ribozyme treatments statistically reduce primary tumor growth, primary tumor volume measurements at each dose immediately following treatment (day 18) were compared (Figure 40). Active ribozyme RPI.4610 produced a statistically significant ($p < 0.05$) and dose-dependent reduction in primary tumor volume. Although the inactive ribozyme (RPI.4611) showed some reduction in primary tumor volume at the lowest and highest doses, there was no dose-dependent reduction observed. At doses between 3 and 30 mg/kg/day, the inactive ribozyme showed no significant reduction in primary tumor volume. There was a significant difference ($p < 0.05$) between active and inactive ribozymes (Tukey-Kramer test) at doses of 10 and 30 mg/kg/day.

Applicant has also observed that the active ribozyme RPI.4610 produced a significant reduction in primary tumor mass at all doses tested (1-100 mg/kg/day) 25 days following inoculation.

Figures 41 A and B illustrate that the active ribozyme reduced both the number of lung metastases and lung mass in a dose-dependent manner. The active *flt-1* ribozyme showed a significant reduction ($p < 0.05$ by Dunnetts) in the number of lung metastases at the 30 and 100 mg/kg/day doses compared to saline. There was also a significant

the calculated slope of the exponential curve at any point indicates the rate of tumor growth, it should be possible to compare rates of growth between treatments. Since the curve fits do not assume that the tumor growth starts from the same point (which is a correct assumption since the all tumors start with the same tumor cell inoculum concentration), an accurate calculation of the slope of the exponential curve is not possible since the curve fitting algorithm extrapolates a $t = 0$ tumor size which is then used to calculate the slope. In the analysis, the saline tumor size at $t = 0$ is much greater than the other treatment groups, thus comparisons with saline are not necessarily accurate. If the curve fit algorithm is restricted to the same tumor size, a dose-dependent reduction in the rate of tumor growth is observed with the active ribozyme. However, the curve fits show lower correlation coefficients in some cases.

In order to see whether a the ribozyme treatments statistically reduce primary tumor growth, primary tumor volume measurements at each dose immediately following treatment (day 18) were compared (Figure 40). Active ribozyme RPI.4610 produced a statistically significant ($p < 0.05$) and dose-dependent reduction in primary tumor volume. Although the inactive ribozyme (RPI.4611) showed some reduction in primary tumor volume at the lowest and highest doses, there was no dose-dependent reduction observed. At doses between 3 and 30 mg/kg/day, the inactive ribozyme showed no significant reduction in primary tumor volume. There was a significant difference ($p < 0.05$) between active and inactive ribozymes (Tukey-Kramer test) at doses of 10 and 30 mg/kg/day.

Applicant has also observed that the active ribozyme RPI.4610 produced a significant reduction in primary tumor mass at all doses tested (1-100 mg/kg/day) 25 days following inoculation.

Figures 41 A and B illustrate that the active ribozyme reduced both the number of lung metastases and lung mass in a dose-dependent manner. The active *flt-1* ribozyme showed a significant reduction ($p < 0.05$ by Dunnetts) in the number of lung metastases at the 30 and 100 mg/kg/day doses compared to saline. There was also a significant

difference between active and inactive ribozymes at these doses ($p < 0.05$ by Student's t). RPI.4610 reduced the lung weight to almost normal levels at the highest dose (100 mg/kg/day). There was no observable dose-related effect of the inactive ribozyme on either the number of lung metastases or lung weight. A significant reduction ($p < 0.05$, Student's t) in lung mass, an index of metastatic burden, was observed between saline and the active ribozyme. The lack of significance using more stringent statistical tests (Dunnett's or Tukey-Kramer), which take into account the variance within all groups, was due to high variability, especially in the inactive ribozyme group. However, since five doses were tested, it is possible to say that there is a dose-dependent trend in the reduction of lung metastases/lung weight.

Example 33: Effects of *flk-1* ribozymes (active/inactive) on LLC-HM primary tumor growth in mice.

The dose-related effects of active and inactive *flk-1* directed ribozymes (RPI.4733/4734, respectively) on primary LLCare shown in Figure 38 A-E.

The dose-related effects of active and inactive *flk-1* directed ribozymes (RPI.4733/4734, respectively) on primary LLCare shown in Figure 42 A-E. At the lowest dose, there was no observable effect on primary tumor growth with the active *flk-1* ribozyme (Figure 42A). The inactive ribozyme showed a modest reduction in primary tumor growth. At higher doses (3-100 mg/kg/day, Figure 42B-E), the active *flk-1* ribozyme reduced primary tumor growth while the inactive ribozyme showed little, if any, antitumor efficacy over the dose range between 10 and 100 mg/kg/day (Figures 42C-E). The antitumor efficacy of both active and inactive *flk-1* ribozymes are similar at 3 mg/kg/day (Figure 42B).

As in the case of the *flt-1* ribozymes, tumor growth followed exponential growth kinetics. Again, since the $t = 0$ tumor size could not accurately be estimated by the curve fit program, it is not possible to calculate the slope of the exponential curve fits for the *flk-1* ribozymes.

Immediately following the cessation of treatment (day 18), the active *flk-1* ribozyme showed a significant reduction in primary tumor volume from 3 to 100 mg/kg/day (Figure 43). The magnitude of the reduction is approximately four fold and appeared to be maximal at 3 mg/kg/day. The lowest dose had no significant effect on primary tumor volume. The inactive *flk-1* ribozyme had a significant antitumor effect at doses of 1 and 3 mg/kg/day; however, this effect disappeared between 10 and 100 mg/kg/day.

The antimetastatic effects of the *flk-1* ribozymes are illustrated in Figure 44 A and B. Although neither ribozyme showed a statistically significant effect on the number of lung metastases at any dose, it appears that the active *flk-1* ribozyme showed a significant reduction in lung mass over the dose range between 3 and 100 mg/kg/day.

Applicant has further observed that the lung mass was reduced to normal over the entire dose range. The inactive ribozyme reduced lung mass at 1 and 3 mg/kg/day (Figure 41C); however, this trend was not observed at higher doses (3-100 mg/kg/day).

Example 34: Ribozyme-mediated decrease in vascularity of tumor

Three tumors from each of three treatment groups (saline controls, inactive RPI.4611 and active RPI.4610, 30 mg/kg/day dose only) were analyzed for vascularity using an immunohistochemical assay which stains endothelial cells for CD31 (PECAM). The vascularity was quantitated in a blinded fashion. From the raw data the average number of vessels per high magnification field (400X) were calculated. They are as follows: SALINE CONTROL = 24.1; RPI.4611 (Inactive) = 27.6; RPI.4610 (Active) = 16.0.

It is suggestive that ribozyme-specific antiangiogenic effect is exhibited by the active Flt-1 ribozyme in Lewis lung tumors. Thus, the mechanism of action for the observed reduction in the primary tumor volumes may be due to an antiangiogenic effect. Similar delivery strategies can be used to deliver c-raf ribozymes to treat a variety of diseases.

Use of Ribozymes Targeting *c-raf*

Overexpression of the *c-raf* oncogene has been reported in a number of cancers (see above). Thus, inhibition of *c-raf* expression (for example using ribozymes) can reduce cell proliferation of a number of cancers, *in vitro* and *in vivo* and can reduce their proliferative potential. A cascade of MMP and serine proteinase expression is implicated in the acquisition of an invasive phenotype as well as in angiogenesis in tumors (MacDougall & Matrisian, 1995, *Cancer & Metastasis Reviews* 14, 351; Ritchlin & Winchester, 1989, *Springer Semin Immunopathol.*, 11, 219).

A number of human diseases are characterized by the inappropriate proliferation of cells at sites of injury or damage to the normal tissue architecture. These diseases include restenosis, caused by the local proliferation of medial smooth muscle cells at sites of arterial wall disruption by surgery; psoriasis, caused by proliferation of keratinocytes at regions of endothelial cell damage in the skin, and various fibrosis, caused by the inappropriate replication of cells during wound healing processes. In certain inflammatory processes, cell proliferation may not be causative, yet it exacerbates the disease pathology. For example, in rheumatoid arthritis, synovial hyperplasia leads to accelerated cartilage damage due to secretion of proteases by the expanding population of synovial fibroblasts. Any number of these diseases and others which involve cellular proliferation or the loss of proliferative control, such as cancer, could be treated using ribozymes which inhibit the expression of the cellular *Raf* gene products. Alternatively, ribozyme inhibition of the cellular growth factor receptors could be used to inhibit downstream signalling pathways. The specific growth factors involved would depend upon the cell type indicated in the proliferative event.

Ribozymes, with their catalytic activity and increased site specificity (see above), are likely to represent a potent and safe therapeutic molecule for the treatment of cancer. In the present invention, ribozymes are shown to inhibit smooth muscle cell proliferation. From those practiced in the art, it is clear from the examples described, that the same

ribozymes may be delivered in a similar fashion to cancer cells to block their proliferation.

Diagnostic uses

Ribozymes of this invention may be used as diagnostic tools to examine genetic
5 drift and mutations within diseased cells or to detect the presence of *c-raf* RNA in a cell. The close relationship between ribozyme activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple ribozymes described in this invention, one may map nucleotide changes which are important to RNA
10 structure and function *in vitro*, as well as in cells and tissues. Cleavage of target RNAs with ribozymes may be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets may be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of
15 combinational therapies (e.g., multiple ribozymes targeted to different genes, ribozymes coupled with known small molecule inhibitors, or intermittent treatment with combinations of ribozymes and/or other chemical or biological molecules). Other *in vitro* uses of ribozymes of this invention are well known in the art, and include detection of the presence of mRNAs associated with *c-raf* related condition. Such RNA is detected by
20 determining the presence of a cleavage product after treatment with a ribozyme using standard methodology.

In a specific example, ribozymes which can cleave only wild-type or mutant forms of the target RNA are used for the assay. The first ribozyme is used to identify wild-type RNA present in the sample and the second ribozyme will be used to identify mutant RNA
25 in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA will be cleaved by both ribozymes to demonstrate the relative ribozyme efficiencies in the reactions and the absence of cleavage of the "non-targeted" RNA species. The cleavage products from the synthetic substrates will also serve to generate size markers

for the analysis of wild-type and mutant RNAs in the sample population. Thus each analysis will require two ribozymes, two substrates and one unknown sample which will be combined into six reactions. The presence of cleavage products will be determined using an RNase protection assay so that full-length and cleavage fragments of each RNA
5 can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (*i.e.*, *c-raf*) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts,
10 then a qualitative comparison of RNA levels will be adequate and will decrease the cost of the initial diagnosis. Higher mutant form to wild-type ratios will be correlated with higher risk whether RNA levels are compared qualitatively or quantitatively.

Additional Uses

Potential usefulness of sequence-specific nucleic acid catalysts of the instant
15 invention might have many of the same applications for the study of RNA that DNA restriction endonucleases have for the study of DNA (Nathans *et al.*, 1975 *Ann. Rev. Biochem.* 44:273). For example, the pattern of restriction fragments could be used to establish sequence relationships between two related RNAs, and large RNAs could be specifically cleaved to fragments of a size more useful for study. The ability to engineer
20 sequence specificity of the ribozyme is ideal for cleavage of RNAs of unknown sequence.

The use of NTP's described in this invention have several research and commercial applications. These modified nucleoside triphosphates can be used for *in vitro* selection (evolution) of oligonucleotides with novel functions. Examples of *in vitro* selection protocols are incorporated herein by reference (Joyce, 1989, *Gene*, 82, 83-87;
25 Beaudry *et al.*, 1992, *Science* 257, 635-641; Joyce, 1992, *Scientific American* 267, 90-97; Breaker *et al.*, 1994, *TIBTECH* 12, 268; Bartel *et al.*, 1993, *Science* 261:1411-1418; Szostak, 1993, *TIBS* 17, 89-93; Kumar *et al.*, 1995, *FASEB J.*, 9, 1183; Breaker, 1996, *Curr. Op. Biotech.*, 7, 442).

Additionally, these modified nucleoside triphosphates can be employed to generate modified oligonucleotide combinatorial chemistry libraries. Several references for this technology exist (Brenner *et al.*, 1992, *PNAS* 89, 5381-5383, Eaton, 1997, *Curr. Opin. Chem. Biol.* 1, 10-16) which are all incorporated herein by reference.

5 Nucleic acid molecules of the instant invention might have many of the same applications for the study of RNA that DNA restriction endonucleases have for the study of DNA (Nathans *et al.*, 1975 *Ann. Rev. Biochem.* 44:273). For example, the pattern of restriction fragments could be used to establish sequence relationships between two related RNAs, and large RNAs could be specifically cleaved to fragments of a size more
10 useful for study. The ability to engineer sequence specificity of the ribozyme is ideal for cleavage of RNAs of unknown sequence. Nucleic acid molecules (*e.g.*, ribozymes) of the invention can be used, for example, to target cleavage of virtually any RNA transcript (Zaug *et al.*, 324, *Nature* 429 1986 ; Cech, 260 *JAMA* 3030, 1988; and Jefferies *et al.*, 17 *Nucleic Acids Research* 1371, 1989). Such nucleic acids can be used as a therapeutic or
15 to validate a therapeutic gene target and/or to determine the function of a gene in a biological system (Christoffersen, 1997, *Nature Biotech.* 15, 483).

Various ligands can be attached to oligonucleotides using the compounds containing
zylo modification for the purposes of cellular delivery, nuclease resistance, cellular
trafficking and localization, chemical ligation of oligonucleotide fragments.
20 Incorporation of one or more compounds of Formula II into a ribozyme may increase its effectiveness. Compounds of Formula II can be used as potential antiviral agents.

Other embodiments are within the following claims.

TABLE I

Characteristics of naturally occurring ribozymes**Group I Introns**

- 5 • Size: ~150 to >1000 nucleotides.
- Requires a U in the target sequence immediately 5' of the cleavage site.
- Binds 4-6 nucleotides at the 5'-side of the cleavage site.
- Reaction mechanism: attack by the 3'-OH of guanosine to generate cleavage products with 3'-OH and 5'-guanosine.
- 10 • Additional protein cofactors required in some cases to help folding and maintenance of the active structure.
- Over 300 known members of this class. Found as an intervening sequence in *Tetrahymena thermophila* rRNA, fungal mitochondria, chloroplasts, phage T4, blue-green algae, and others.
- 15 • Major structural features largely established through phylogenetic comparisons, mutagenesis, and biochemical studies [^{1,2}].
- Complete kinetic framework established for one ribozyme [^{3,4,5,6}].
- Studies of ribozyme folding and substrate docking underway [^{7,8,9}].
- Chemical modification investigation of important residues well established [^{10,11}].

¹. Michel, Francois; Westhof, Eric. Slippery substrates. *Nat. Struct. Biol.* (1994), 1(1), 5-7.

². Lisacek, Frederique; Diaz, Yolande; Michel, Francois. Automatic identification of group I intron cores in genomic DNA sequences. *J. Mol. Biol.* (1994), 235(4), 1206-17.

³. Herschlag, Daniel; Cech, Thomas R.. Catalysis of RNA cleavage by the *Tetrahymena thermophila* ribozyme. 1. Kinetic description of the reaction of an RNA substrate complementary to the active site. *Biochemistry* (1990), 29(44), 10159-71.

⁴. Herschlag, Daniel; Cech, Thomas R.. Catalysis of RNA cleavage by the *Tetrahymena thermophila* ribozyme. 2. Kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. *Biochemistry* (1990), 29(44), 10172-80.

⁵. Knitt, Deborah S.; Herschlag, Daniel. pH Dependencies of the *Tetrahymena* Ribozyme Reveal an Unconventional Origin of an Apparent pKa. *Biochemistry* (1996), 35(5), 1560-70.

⁶. Bevilacqua, Philip C.; Sugimoto, Naoki; Turner, Douglas H.. A mechanistic framework for the second step of splicing catalyzed by the *Tetrahymena* ribozyme. *Biochemistry* (1996), 35(2), 648-58.

⁷. Li, Yi; Bevilacqua, Philip C.; Mathews, David; Turner, Douglas H.. Thermodynamic and activation parameters for binding of a pyrene-labeled substrate by the *Tetrahymena* ribozyme: docking is not diffusion-controlled and is driven by a favorable entropy change. *Biochemistry* (1995), 34(44), 14394-9.

⁸. Banerjee, Alope Raj; Turner, Douglas H.. The time dependence of chemical modification reveals slow steps in the folding of a group I ribozyme. *Biochemistry* (1995), 34(19), 6504-12.

⁹. Zarrinkar, Patrick P.; Williamson, James R.. The P9.1-P9.2 peripheral extension helps guide folding of the *Tetrahymena* ribozyme. *Nucleic Acids Res.* (1996), 24(5), 854-8.

¹⁰. Strobel, Scott A.; Cech, Thomas R.. Minor groove recognition of the conserved G.cntdot.U pair at the *Tetrahymena* ribozyme reaction site. *Science* (Washington, D. C.) (1995), 267(5198),

- The small (4-6 nt) binding site may make this ribozyme too non-specific for targeted RNA cleavage, however, the Tetrahymena group I intron has been used to repair a "defective" β -galactosidase message by the ligation of new β -galactosidase sequences onto the defective message [12].

5

RNase P RNA (M1 RNA)

- Size: ~290 to 400 nucleotides.
- RNA portion of a ubiquitous ribonucleoprotein enzyme.
- 10 • Cleaves tRNA precursors to form mature tRNA [13].
- Reaction mechanism: possible attack by M^{2+} -OH to generate cleavage products with 3'-OH and 5'-phosphate.
- RNase P is found throughout the prokaryotes and eukaryotes. The RNA subunit has been sequenced from bacteria, yeast, rodents, and primates.
- 15 • Recruitment of endogenous RNase P for therapeutic applications is possible through hybridization of an External Guide Sequence (EGS) to the target RNA [14, 15]
- Important phosphate and 2' OH contacts recently identified [16, 17]

Group II Introns

20

- Size: >1000 nucleotides.
- Trans cleavage of target RNAs recently demonstrated [18, 19].
- Sequence requirements not fully determined.
- Reaction mechanism: 2'-OH of an internal adenosine generates cleavage products with 3'-OH and a "lariat" RNA containing a 3'-5' and a 2'-5' branch point.

25

675-9.

¹¹. Strobel, Scott A.; Cech, Thomas R.. Exocyclic Amine of the Conserved G.cntdot.U Pair at the Cleavage Site of the Tetrahymena Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization. *Biochemistry* (1996), 35(4), 1201-11.

¹². Sullenger, Bruce A.; Cech, Thomas R.. Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. *Nature* (London) (1994), 371(6498), 619-22.

¹³. Robertson, H.D.; Altman, S.; Smith, J.D. *J. Biol. Chem.*, **247**, 5243-5251 (1972).

¹⁴. Forster, Anthony C.; Altman, Sidney. External guide sequences for an RNA enzyme. *Science* (Washington, D. C., 1883-) (1990), 249(4970), 783-6.

¹⁵. Yuan, Y.; Hwang, E. S.; Altman, S. Targeted cleavage of mRNA by human RNase P. *Proc. Natl. Acad. Sci. USA* (1992) 89, 8006-10.

¹⁶. Harris, Michael E.; Pace, Norman R.. Identification of phosphates involved in catalysis by the ribozyme RNase P RNA. *RNA* (1995), 1(2), 210-18.

¹⁷. Pan, Tao; Loria, Andrew; Zhong, Kun. Probing of tertiary interactions in RNA: 2'-hydroxyl-base contacts between the RNase P RNA and pre-tRNA. *Proc. Natl. Acad. Sci. U. S. A.* (1995), 92(26), 12510-14.

¹⁸. Pyle, Anna Marie; Green, Justin B.. Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate. *Biochemistry* (1994), 33(9), 2716-25.

¹⁹. Michels, William J. Jr.; Pyle, Anna Marie. Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships. *Biochemistry* (1995), 34(9), 2965-77.

- Only natural ribozyme with demonstrated participation in DNA cleavage [^{20,21}] in addition to RNA cleavage and ligation.
- Major structural features largely established through phylogenetic comparisons [²²].
- Important 2' OH contacts beginning to be identified [²³]
- 5 • Kinetic framework under development [²⁴]

Neurospora VS RNA

- Size: ~144 nucleotides.
- 10 • Trans cleavage of hairpin target RNAs recently demonstrated [²⁵].
- Sequence requirements not fully determined.
- Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends.
- Binding sites and structural requirements not fully determined.
- 15 • Only 1 known member of this class. Found in Neurospora VS RNA.

Hammerhead Ribozyme

(see text for references)

- Size: ~13 to 40 nucleotides.
- 20 • Requires the target sequence UH immediately 5' of the cleavage site.
- Binds a variable number nucleotides on both sides of the cleavage site.
- Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends.
- 14 known members of this class. Found in a number of plant pathogens (virusoids) that use RNA as the infectious agent.
- 25 • Essential structural features largely defined, including 2 crystal structures [^{26,27}]
- Minimal ligation activity demonstrated (for engineering through *in vitro* selection) [²⁸]

²⁰ . Zimmerly, Steven; Guo, Huatao; Eskes, Robert; Yang, Jian; Perlman, Philip S.; Lambowitz, Alan M.. A group II intron RNA is a catalytic component of a DNA endonuclease involved in intron mobility. *Cell* (Cambridge, Mass.) (1995), 83(4), 529-38.

²¹ . Griffin, Edmund A., Jr.; Qin, Zhifeng; Michels, Williams J., Jr.; Pyle, Anna Marie. Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups. *Chem. Biol.* (1995), 2(11), 761-70.

²² . Michel, Francois; Ferat, Jean Luc. Structure and activities of group II introns. *Annu. Rev. Biochem.* (1995), 64, 435-61.

²³ . Abramovitz, Dana L.; Friedman, Richard A.; Pyle, Anna Marie. Catalytic role of 2'-hydroxyl groups within a group II intron active site. *Science* (Washington, D. C.) (1996), 271(5254), 1410-13.

²⁴ . Daniels, Danette L.; Michels, William J., Jr.; Pyle, Anna Marie. Two competing pathways for self-splicing by group II introns: a quantitative analysis of *in vitro* reaction rates and products. *J. Mol. Biol.* (1996), 256(1), 31-49.

²⁵ . Guo, Hans C. T.; Collins, Richard A.. Efficient trans-cleavage of a stem-loop RNA substrate by a ribozyme derived from Neurospora VS RNA. *EMBO J.* (1995), 14(2), 368-76.

²⁶ . Scott, W.G., Finch, J.T., Aaron, K. The crystal structure of an all RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage. *Cell*, (1995), 81, 991-1002.

²⁷ . McKay, Structure and function of the hammerhead ribozyme: an unfinished story. *RNA*, (1996), 2, 395-403.

²⁸ . Long, D., Uhlenbeck, O., Hertel, K. Ligation with hammerhead ribozymes. US Patent No.

- Complete kinetic framework established for two or more ribozymes [²⁹].
- Chemical modification investigation of important residues well established [³⁰].

Hairpin Ribozyme

- 5
 - Size: ~50 nucleotides.
 - Requires the target sequence GUC immediately 3' of the cleavage site.
 - Binds 4-6 nucleotides at the 5'-side of the cleavage site and a variable number to the 3'-side of the cleavage site.
- 10
 - Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends.
 - 3 known members of this class. Found in three plant pathogen (satellite RNAs of the tobacco ringspot virus, arabis mosaic virus and chicory yellow mottle virus) which uses RNA as the infectious agent.
- 15
 - Essential structural features largely defined [³¹, ³², ³³, ³⁴]
 - Ligation activity (in addition to cleavage activity) makes ribozyme amenable to engineering through *in vitro* selection [³⁵]
 - Complete kinetic framework established for one ribozyme [³⁶].
 - Chemical modification investigation of important residues begun [³⁷, ³⁸].
- 20

5,633,133.

²⁹. Hertel, K.J., Herschlag, D., Uhlenbeck, O. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. *Biochemistry*, (1994) 33, 3374-3385. Beigelman, L., *et al.*, Chemical modifications of hammerhead ribozymes. *J. Biol. Chem.*, (1995) 270, 25702-25708.

³⁰. Beigelman, L., *et al.*, Chemical modifications of hammerhead ribozymes. *J. Biol. Chem.*, (1995) 270, 25702-25708.

³¹. Hampel, Arnold; Tritz, Richard; Hicks, Margaret; Cruz, Phillip. 'Hairpin' catalytic RNA model: evidence for helices and sequence requirement for substrate RNA. *Nucleic Acids Res.* (1990), 18(2), 299-304.

³². Chowrira, Bharat M.; Berzal-Herranz, Alfredo; Burke, John M.. Novel guanosine requirement for catalysis by the hairpin ribozyme. *Nature (London)* (1991), 354(6351), 320-2.

³³. Berzal-Herranz, Alfredo; Joseph, Simpson; Chowrira, Bharat M.; Butcher, Samuel E.; Burke, John M.. Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. *EMBO J.* (1993), 12(6), 2567-73.

³⁴. Joseph, Simpson; Berzal-Herranz, Alfredo; Chowrira, Bharat M.; Butcher, Samuel E.. Substrate selection rules for the hairpin ribozyme determined by *in vitro* selection, mutation, and analysis of mismatched substrates. *Genes Dev.* (1993), 7(1), 130-8.

³⁵. Berzal-Herranz, Alfredo; Joseph, Simpson; Burke, John M.. *In vitro* selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions. *Genes Dev.* (1992), 6(1), 129-34.

³⁶. Hegg, Lisa A.; Fedor, Martha J.. Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes. *Biochemistry* (1995), 34(48), 15813-28.

³⁷. Grasby, Jane A.; Mersmann, Karin; Singh, Mohinder; Gait, Michael J.. Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA. *Biochemistry* (1995), 34(12), 4068-76.

³⁸. Schmidt, Sabine; Beigelman, Leonid; Karpeisky, Alexander; Usman, Nassim; Sorensen, Ulrik S.; Gait, Michael J.. Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure. *Nucleic Acids Res.* (1996), 24(4), 573-81.

Hepatitis Delta Virus (HDV) Ribozyme

- Size: ~60 nucleotides.
- Trans cleavage of target RNAs demonstrated [³⁹].
- 5 • Binding sites and structural requirements not fully determined, although no sequences 5' of cleavage site are required. Folded ribozyme contains a pseudoknot structure [⁴⁰].
- Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends.
- Only 2 known members of this class. Found in human HDV.
- 10 • Circular form of HDV is active and shows increased nuclease stability [⁴¹]

³⁹ . Perrotta, Anne T.; Been, Michael D.. Cleavage of oligoribonucleotides by a ribozyme derived from the hepatitis .delta. virus RNA sequence. *Biochemistry* (1992), 31(1), 16-21.

⁴⁰ . Perrotta, Anne T.; Been, Michael D.. A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. *Nature (London)* (1991), 350(6317), 434-6.





⁴¹ . Puttaraju, M.; Perrotta, Anne T.; Been, Michael D.. A circular trans-acting hepatitis delta virus ribozyme. *Nucleic Acids Res.* (1993), 21(18), 4253-8.





Table II: 2.5 μ mol RNA Synthesis Cycle




Reagent	Equivalents	Amount	Wait Time*
Phosphoramidites	6.5	163 μ L	2.5
S-Ethyl Tetrazole	23.8	238 μ L	2.5
Acetic Anhydride	100	233 μ L	5 sec
N-Methyl Imidazole	186	233 μ L	5 sec
TCA	83.2	1.73 mL	21 sec
Iodine	8.0	1.18 mL	45 sec
Acetonitrile	NA	6.67 mL	NA

* Wait time does not include contact time during delivery.

TABLE III. NUCLEOSIDES USED FOR CHEMICAL SYNTHESIS
OF MODIFIED NUCLEOTIDE TRIPHOSPHATES

	NUCLEOSIDES	Abbreviation	CHEMICAL STRUCTURE
1	2'-O-methyl-2,6-diaminopurine riboside	2'-O-Me-DAP	
2	2'-deoxy-2'-amino-2,6-diaminopurine riboside	2'-NH ₂ -DAP	
3	2'-(N-alanyl)amino-2'-deoxy-uridine	ala-2'-NH ₂ U	
4	2'-(N-phenylalanyl)amino-2'-deoxy-uridine	phe-2'-NH ₂ -U	

	NUCLEOSIDES	Abbreviation	CHEMICAL STRUCTURE
5	2'-(<i>N</i> -β-alanyl) amino-2'-deoxy uridine	2'-β-Ala-NH ₂ -U	
6	2'-Deoxy-2'-(lysiyl) amino uridine	2'-L-lys-NH ₂ .U	
7	2'-C-allyl uridine	2'-C-allyl-U	
8	2'-O-amino-uridine	2'-O-NH ₂ -U	

	NUCLEOSIDES	Abbreviation	CHEMICAL STRUCTURE
9	2'- <i>O</i> -methylthiomethyl adenosine	2'- <i>O</i> -MTM-A	
10	2'- <i>O</i> -methylthiomethyl cytidine	2'- <i>O</i> -MTM-C	
11	2'- <i>O</i> -methylthiomethyl guanosine	2'- <i>O</i> -MTM-G	

	NUCLEOSIDES	Abbreviation	CHEMICAL STRUCTURE
12	2'- <i>O</i> -methylthiomethyl-uridine	2'- <i>O</i> -MTM-U	
13	2'-(<i>N</i> -histidyl) amino uridine	2'-his-NH ₂ -U	
14	2'-Deoxy-2'-amino-5-methyl cytidine	5-Me-2'-NH ₂ -C	
15	2'-(<i>N</i> -β-carboxamidine-β-alanyl)amino-2'-deoxy-uridine	β-ala-CA-NH ₂ -U	



	NUCLEOSIDES	Abbreviation	CHEMICAL STRUCTURE
16	2'-(<i>N</i> - β -alanyl) guanosine	β -Ala-NH ₂ -G	
17	2'- <i>O</i> -Amino-Adenosine	2'- <i>O</i> -NH ₂ -A	

Table VI. PHOSPHORYLATION OF URIDINE IN THE PRESENCE OF DMAP

0 equiv. DMAP		0.2 equiv. DMAP		0.5 equiv. DMAP		1.0 equiv. DMAP	
Time (min)	Product %	Time (min)	Product %	Time (min)	Product %	Time (min)	Product %
0	1	0	0	0	0	0	0
40	7	10	8	20	27	30	74
80	10	50	24	60	46	70	77
120	12	90	33	100	57	110	84
160	14	130	39	140	63	150	83
200	17	170	43	180	63	190	84
240	19	210	47	220	64	230	77
320	20	250	48	260	68	270	79
1130	48	290	49	300	64	310	77
1200	46	1140	68	1150	76	1160	72
		1210	69	1220	76	1230	74

Condition No.	TRIS-HCL (mM)	MgCl ₂ (mM)	DTT (mM)	Spermidine (mM)	Triton X-100 (%)	METHANOL (%)	LiCl (mM)	PEG (%)	Temp(°C)
1	40 (pH 8.0)	20	10	5	0.01	10	1	-	25
2	40 (pH 8.0)	20	10	5	0.01	10	1	4	25
3	40 (pH 8.1)	12	5	1	0.002	-	-	4	25
4	40 (pH 8.1)	12	5	1	0.002	10	-	4	25
5	40 (pH 8.1)	12	5	1	0.002	-	1	4	25
6	40 (pH 8.1)	12	5	1	0.002	10	1	4	25
7	40 (pH 8.0)	20	10	5	0.01	10	1	-	37
8	40 (pH 8.0)	20	10	5	0.01	10	1	4	37
9	40 (pH 8.1)	12	5	1	0.002	-	-	4	37
10	40 (pH 8.1)	12	5	1	0.002	10	-	4	37
11	40 (pH 8.1)	12	5	1	0.002	-	1	4	37
12	40 (pH 8.1)	12	5	1	0.002	10	1	4	37

Table VII. Detailed Description of the NTP Incorporation Reaction Conditions

Modification	COND# 1	COND# 2	COND# 3	COND# 4	COND# 5	COND# 6	COND# 7	COND# 8	COND# 9	COND# 10	COND# 11	COND# 12
2'-NH ₂ -ATP	1	2	3	5	2	4	1	2	10	11	5	9
2'-NH ₂ -CTP	11	37	45	64	25	70	26	54	292	264	109	244
2'-NH ₂ -GTP	4	7	6	14	5	17	3	16	10	21	9	16
2'-NH ₂ -UTP	14	45	4	100	85	82	48	88	20	418	429	440
2'-dATP	9	3	19	23	9	24	6	3	84	70	28	51
2'-dCTP	1	10	43	46	35	47	27	127	204	212	230	235
2'-dGTP	6	10	9	15	9	12	8	34	38	122	31	46
2'-dTTP	9	9	14	18	13	18	8	15	116	114	59	130
2'-O-Me-ATP	0	0	0	0	0	0	1	1	2	2	2	2
2'-O-Me-CTP	no data compared to ribo; incorporates at low level											
2'-O-Me-GTP	4	3	4	4	4	4	2	4	4	5	4	5
2'-O-Me-UTP	55	52	39	38	41	48	55	71	93	103	81	77
2'-O-Me-DAP	4	4	3	4	4	5	4	3	4	5	5	5
2'-NH ₂ -DAP	0	0	1	1	1	1	1	0	0	0	0	0
ala-2'-NH ₂ -UTP	2	2	2	2	3	4	14	18	15	20	13	14
phe-2'-NH ₂ -UTP	8	12	7	7	8	8	4	10	6	6	10	6
2'-β-NH ₂ -ala-UTP	65	48	25	17	21	21	220	223	265	300	275	248
2'-F-ATP	227	252	98	103	100	116	288	278	471	198	317	185
2'-F-GTP	39	44	17	30	17	26	172	130	375	447	377	438
2'-C-allyl-UTP	3	2	2	3	3	2	3	3	3	2	3	3
2'-O-NH ₂ -UTP	6	8	5	5	4	5	16	23	24	24	19	24
2'-O-MTM-ATP	0	1	0	0	0	0	1	0	0	0	0	0
2'-O-MTM-CTP	2	2	1	1	1	1	3	4	5	4	5	3
2'-O-MTM-GTP	6	1	1	3	1	2	0	1	1	3	1	4

Table VIII. INCORPORATION OF MODIFIED NUCLEOTIDE TRIPHOSPHATES

**Table IX: INCORPORATION OF MODIFIED
NUCLEOTIDE TRIPHOSPHATES USING WILD TYPE
BACTERIOPHAGE T7 POLYMERASE**

Modification	label	% ribo control
2'-NH ₂ -GTP	ATP	4%
2'-dGTP	ATP	3%
2'-O-Me-GTP	ATP	3%
2'-F-GTP	ATP	4%
2'-O-MTM-GTP	ATP	3%
2'-NH ₂ -UTP	ATP	39%
2'-dTTP	ATP	5%
2'-O-Me-UTP	ATP	3%
ala-2'-NH ₂ -UTP	ATP	2%
phe-2'-NH ₂ - UTP	ATP	1%
2'-β-ala-NH ₂ UTP	ATP	3%
2'-C-allyl-UTP	ATP	2%
2'-O-NH ₂ -UTP	ATP	1%
2'-O-MTM-UTP	ATP	64%
2'-NH ₂ -ATP	GTP	1%
2'-O-MTM-ATP	GTP	1%
2'-NH ₂ -CTP	GTP	59%
2'-dCTP	GTP	40%

Table Xa: Incorporation of 2'-his-UTP and Modified CTP's

modification	2'-his-UTP	rUTP
CTP	16.1	100
2'-amino-CTP	9.5*	232.7
2'-deoxy-CTP	9.6*	130.1
2'-OMe-CTP	1.9	6.2
2'-MTM-CTP	5.9	5.1
control	1.2	

5

Table Xb: Incorporation of 2'-his-UTP, 2-amino CTP, and Modified ATP's

modification	2'-his-UTP and 2'-amino-CTP	rUTP and rCTP
ATP	15.7	100
2'-amino-ATP	2.4	28.9
2'-deoxy-ATP	2.3	146.3
2'-OMe-ATP	2.7	15
2'-F-ATP	4	222.6
2'-MTM-ATP	4.7	15.3
2'-OMe-DAP	1.9	5.7
2'-amino-DAP	8.9*	9.6

10 Numbers shown are a percentage of incorporation compared to the all-RNA control

* -Bold number indicates best observed rate of modified nucleotide triphosphate incorporation

**Table XI. INCORPORATION OF 2'-his-UTP, 2'-NH₂-CTP, 2'-NH₂-DAP,
and rGTP USING VARIOUS REACTION CONDITIONS**

Conditions	compared to all rNTP
7	8.7*
8	7*
9	2.3
10	2.7
11	1.6
12	2.5

5 Numbers shown are a percentage of incorporation compared to the all-RNA control

* Two highest levels of incorporation contained both methanol and LiCl

Table XII: Human *C-raf* Hammerhead Ribozyme and Target Sequences

nt position	Target Site	SEQ ID. No.	Ribozyme Sequence	SEQ ID. No.
17	GACCGCCUC CCGCUC	1	GGGAGCGG CUGAUGAG X CGAA AGGCGGUC	502
23	CUCCCGCUC CCUCACCC	2	GGGUGAGG CUGAUGAG X CGAA AGCGGGAG	503
27	CGCUCGCCUC ACCCGCCG	3	CGGCGGGU CUGAUGAG X CGAA AGGGAGCG	504
82	CAGGACGUU GGGGCGGC	4	GCCGCCCC CUGAUGAG X CGAA ACGUCCUG	505
97	GCCUGGCUC CCUCAGGU	5	ACCUGAGG CUGAUGAG X CGAA AGCCAGGC	506
101	GGCUCGCCUC AGGUUUAA	6	UUAACCUU CUGAUGAG X CGAA AGGGAGCC	507
106	CCUCAGGUU UAAGAAUU	7	AAUUCUUA CUGAUGAG X CGAA ACCUGAGG	508
107	CUCAGGUUU AAGAAUUG	8	CAAUUCUU CUGAUGAG X CGAA AACUGAG	509
108	UCAGGUUUA AGAAUUGU	9	ACAAUUCU CUGAUGAG X CGAA AAACCUGA	510
114	UUAAGAAUU GUUUAAGC	10	GCUUAAAC CUGAUGAG X CGAA AUUCUUA	511
117	AGAAUUGUU UAAGCUGC	11	GCAGCUUA CUGAUGAG X CGAA ACAAUUUC	512
118	GAAUUGUUU AAGCUGCA	12	UGCAGCUU CUGAUGAG X CGAA AACAAUUC	513
119	AAUUGUUUA AGCUGCAU	13	AUGCAGCU CUGAUGAG X CGAA AAACAAUU	514
128	AGCUGCAUC AAUGGAGC	14	GCUCCAUU CUGAUGAG X CGAA AUGCAGCU	515
141	GAGCACAUA CAGGGAGC	15	GCUCCUG CUGAUGAG X CGAA AUGUGCUC	516
151	AGGGAGCUU GGAAGACG	16	CGUCUCC CUGAUGAG X CGAA AGCUCUCC	517
162	AAGACGAUC AGCAAUGG	17	CCAUGCU CUGAUGAG X CGAA AUCGUCU	518
172	GCAAUGGUU UUGGAUUC	18	GAAUCCAA CUGAUGAG X CGAA ACCAUUGC	519
173	CAAUGGUUU UGGAUUCA	19	UGAAUCCA CUGAUGAG X CGAA AACCAUUG	520
174	AAUGGUUUU GGAUUCAA	20	UUGAAUCC CUGAUGAG X CGAA AAACCAUU	521
179	UUUUGGAUU CAAAGAUG	21	CAUCUUUG CUGAUGAG X CGAA AUCCAAAA	522
180	UUUGGAUUC AAAGAUGC	22	GCAUCUUU CUGAUGAG X CGAA AAUCCAAA	523
194	UGCCGUGUU UGAUGGCU	23	AGCCAUCA CUGAUGAG X CGAA ACACGGCA	524
195	GCCGUGUUU GAUGGCUC	24	GAGCCAUC CUGAUGAG X CGAA AACACGGC	525
203	UGAUGGCUC CAGCUGCA	25	UGCAGCUG CUGAUGAG X CGAA AGCCAUCA	526
213	AGCUGCAUC UCUCUAC	26	GUAGGAGA CUGAUGAG X CGAA AUGCAGCU	527
215	CUGCAUCUC UCCUACAA	27	UUGUAGGA CUGAUGAG X CGAA AGAUGCAG	528
217	GCAUCUCUC CUACAUA	28	UAUUGUAG CUGAUGAG X CGAA AGAGAUGC	529
220	UCUCUCCUA CAAUAGUU	29	AACUUAUUG CUGAUGAG X CGAA AGGAGAGA	530
225	CCUACAAUA GUUCAGCA	30	UGCUGAAC CUGAUGAG X CGAA AUUGUAGG	531
228	ACAAUAGUU CAGCAGUU	31	AACUGCUG CUGAUGAG X CGAA ACUAUUGU	532
229	CAAUAGUUC AGCAGUUU	32	AAACUGCU CUGAUGAG X CGAA AACUAUUG	533
236	UCAGCAGUU UGGCUAUC	33	GAUAGCCA CUGAUGAG X CGAA ACUGCUGA	534
237	CAGCAGUUU GGCUAUC	34	UGAUAGCC CUGAUGAG X CGAA AACUGCUG	535
242	GUUUGGCUA UCAGCGCC	35	GGCGCUGA CUGAUGAG X CGAA AGCCAAAC	536
244	UUGGCUAUC AGCGCCGG	36	CCGGCGCU CUGAUGAG X CGAA AUAGCCAA	537
257	CCGGGCAUC AGAUGAUG	37	CAUCAUCU CUGAUGAG X CGAA AUGCCCGG	538
273	GGCAACUC ACAGAUCC	38	GGAUCUGU CUGAUGAG X CGAA AGUUUGCC	539
280	UCACAGAU CCUCUAG	39	CUUAGAAG CUGAUGAG X CGAA AUCUGUGA	540
283	CAGAUCCUU CUAGACA	40	UGUCUAG CUGAUGAG X CGAA AGGAUCUG	541
284	AGAUCUUC UAAGACAA	41	UUGUCUUA CUGAUGAG X CGAA AAGGAUCU	542
286	AUCCUUCUA AGACAAGC	42	GCUUGUCU CUGAUGAG X CGAA AGAAGGAU	543
301	GCAACUAU UCCGUGUU	43	AACACGGA CUGAUGAG X CGAA AGUGUUGC	544
303	AACACUAUC CGUGUUU	44	AAAACACG CUGAUGAG X CGAA AUAGUGUU	545
309	AUCCGUGUU UUCUUGCC	45	GGCAAGAA CUGAUGAG X CGAA ACACGGAU	546
310	UCCGUGUUU UCUUGCCG	46	CGGCAAGA CUGAUGAG X CGAA AACACGGA	547
311	CCGUGUUUU CUUGCCGA	47	UCGGCAAG CUGAUGAG X CGAA AAACACGG	548
312	CGUGUUUUC UUGCCGAA	48	UUCGGCAA CUGAUGAG X CGAA AAAACACG	549
314	UGUUUUCUU GCCGAACA	49	UGUUCGGC CUGAUGAG X CGAA AGAAAACA	550
339	ACAGUGGUC AAUGUGCG	50	CGCACAUA CUGAUGAG X CGAA ACCACUGU	551
362	AAUGAGCUU GCAUGACU	51	AGUCAUGC CUGAUGAG X CGAA AGCUCAUU	552
375	GACUGCCUU AUGAAAGC	52	GCUUUCAU CUGAUGAG X CGAA AGGCAGUC	553
376	ACUGCCUUA UGAAAGCA	53	UGCUUUCA CUGAUGAG X CGAA AAGGCAGU	554
387	AAAGCACUC AAGGUGAG	54	CUCACCUU CUGAUGAG X CGAA AGUGCUUU	555
425	UGCAGUGUU CAGACUUC	55	GAAGUCUG CUGAUGAG X CGAA ACACUGCA	556
426	GCAGUGUUC AGACUUCU	56	AGAAGUCU CUGAUGAG X CGAA AACACUGC	557
432	UUCAGACUU CUCCACGA	57	UCGUGGAG CUGAUGAG X CGAA AGUCUGAA	558

nt position	Target Site	SEQ ID. No.	Ribozyme Sequence	SEQ ID. No.
433	UCAGACUUC UCCACGAA	58	UUCGUGGA CUGAUGAG X CGAA AAGUCUGA	559
435	AGACUUCUC CACGAACA	59	UGUUCGUG CUGAUGAG X CGAA AGAAGUCU	560
451	ACAAAGGUA AAAAAGCA	60	UGCUIUUU CUGAUGAG X CGAA ACCUUGU	561
464	AGCACGCUU AGAUUGGA	61	UCCAAUCU CUGAUGAG X CGAA AGCGUGCU	562
465	GCACGCUUA GAUUGGAA	62	UUCCAAUC CUGAUGAG X CGAA AAGCGUGC	563
469	GUUAGAUU GGAAUACU	63	AGUAUUCC CUGAUGAG X CGAA AUCUAAGC	564
475	AUUGGAAUA CUGAUGCU	64	AGCAUCAG CUGAUGAG X CGAA AUUCCAAU	565
488	UGCUGCGUC UUUGAUUG	65	CAAUCAAA CUGAUGAG X CGAA ACGCAGCA	566
490	CUGCGUCUU UGAUUGGA	66	UCCAAUCA CUGAUGAG X CGAA AGACGCAG	567
491	UGCUGUUUU GAUUGGAG	67	CUCCAAUC CUGAUGAG X CGAA AAGACGCA	568
495	UCUUUGAUU GGAGAAGA	68	UCUUCUCC CUGAUGAG X CGAA AUCAAAGA	569
507	GAAGAACUU CAAGUAGA	69	UCUACUUG CUGAUGAG X CGAA AGUUCUUC	570
508	AAGAACUUC AAGUAGAU	70	AUCUACUU CUGAUGAG X CGAA AAGUUCUU	571
513	CUUCAAGUA GAUUUCCU	71	AGGAAAUC CUGAUGAG X CGAA ACUUGAAG	572
517	AAGUAGAUU UCCUGGAU	72	AUCCAGGA CUGAUGAG X CGAA AUCUACUU	573
518	AGUAGAUUU CCUGGAUC	73	GAUCCAGG CUGAUGAG X CGAA AAUCUACU	574
519	GUAGAUUUC CUGGAUCA	74	UGAUCCAG CUGAUGAG X CGAA AAAUCUAC	575
526	UCCUGGAUC AUGUUCUU	75	GGGAACAU CUGAUGAG X CGAA AUCCAGGA	576
531	GAUCAUGUU CCCUCAC	76	GUGAGGGG CUGAUGAG X CGAA ACAUGAUC	577
532	AUCAUGUUC CCCUCACA	77	UGUGAGGG CUGAUGAG X CGAA AACAUAGU	578
537	GUUCCCUUC ACAACACA	78	UGUGUUGU CUGAUGAG X CGAA AGGGGAAC	579
551	ACACAACUU UGCUCGGA	79	UCCGAGCA CUGAUGAG X CGAA AGUUGUGU	580
552	CACAACUUU GCUCGGAA	80	UUCGAGGC CUGAUGAG X CGAA AAGUUGUG	581
556	ACUUUGCUC GGAAGACG	81	CGUCUUC CUGAUGAG X CGAA AGCAAAGU	582
566	GAAGACGUU CCUGAAGC	82	GCUUCAGG CUGAUGAG X CGAA ACGUCUUC	583
567	AAGACGUUC CUGAAGCU	83	AGCUUCAG CUGAUGAG X CGAA AACGUCUU	584
576	CUGAAGCUU GCCUUCUG	84	CAGAAGGC CUGAUGAG X CGAA AGCUUCAG	585
581	GCUUGCCUU CUGUGACA	85	UGUCACAG CUGAUGAG X CGAA AGGCAAGC	586
582	CUUGCCUUC UGUGACAU	86	AUGUCACA CUGAUGAG X CGAA AAGGCAAG	587
591	UGUGACAUU UGUCAGAA	87	UUCUGACA CUGAUGAG X CGAA AUGUCACA	588
595	ACAUCUGUC AGAAAUUC	88	GAAUUCU CUGAUGAG X CGAA ACAGAUGU	589
602	UCAGAAAUU CCUGCUC	89	UGAGCAGG CUGAUGAG X CGAA AUUUCUGA	590
603	CAGAAAUUC CUGCUC	90	UUGAGCAG CUGAUGAG X CGAA AAUUCUG	591
609	UUCUGCUC AAUGGAUU	91	AAUCCAUC CUGAUGAG X CGAA AGCAGGAA	592
617	CAUUGGAUU UCGAUGUC	92	GACAUCGA CUGAUGAG X CGAA AUCCAUG	593
618	AAUGGAUUU CGAUGUCA	93	UGACAUCG CUGAUGAG X CGAA AAUCCAUC	594
619	AUGGAUUUC GAUGUCAG	94	CUGACAUC CUGAUGAG X CGAA AAUCCAUC	595
625	UUCGAUGUC AGACUUGU	95	ACAAGUCU CUGAUGAG X CGAA ACAUCGAA	596
631	GUCAGACUU GUGGCUAC	96	GUGGCCAC CUGAUGAG X CGAA AGUCUGAC	597
638	UUGUGGCUA CAAAUUUC	97	GAAAUUUG CUGAUGAG X CGAA AGCCACAA	598
644	CUACAAAUU UCAUGAGC	98	GCUCAUGA CUGAUGAG X CGAA AUUUGUAG	599
645	UACAAAUUU CAUGAGCA	99	UGCUC AUG CUGAUGAG X CGAA AAUUGUA	600
646	ACAAAUUUC AUGAGCAC	100	GUGCUCAU CUGAUGAG X CGAA AAUUGU	601
658	AGCACUGUA GCACCAA	101	UUUGGUGC CUGAUGAG X CGAA ACAGUGCU	602
669	ACCAAAGUA CCUACU	102	AUAGUAGG CUGAUGAG X CGAA ACUUGGU	603
673	AAGUACCUA CUAUGUGU	103	ACACAUAG CUGAUGAG X CGAA AGGUACUU	604
676	UACCUACUA UGUGUGUG	104	CACACACA CUGAUGAG X CGAA AGUAGGUA	605
694	ACUGGAGUA ACAUCAGA	105	UCUGAUGU CUGAUGAG X CGAA ACUCCAGU	606
699	AGUACAUUC AGACAACU	106	AGUUGUCU CUGAUGAG X CGAA AUGUACU	607
708	AGACAACUC UUAUUGUU	107	AACAAUAA CUGAUGAG X CGAA AGUUGUCU	608
710	ACAACUCUU AUUGUUUC	108	GAAACAAU CUGAUGAG X CGAA AGAGUUGU	609
711	CAACUCUUA UUGUUUCC	109	GGAAACAA CUGAUGAG X CGAA AAGAGUUG	610
713	ACUCUUAUU GUUCCAA	110	UUGGAAAC CUGAUGAG X CGAA AUAAGAGU	611
716	CUUAUUGUU UCCAAAUU	111	AAUUGGGA CUGAUGAG X CGAA ACAAUUAG	612
717	UAUUGUUU CCAAUUC	112	GAAUUGG CUGAUGAG X CGAA AACAAUAA	613
718	UAUUGUUU CAAAUUCC	113	GGAAUUG CUGAUGAG X CGAA AAACAAUA	614
724	UCCAAAUU CCACU	114	AAUAGUGG CUGAUGAG X CGAA AUUUGGAA	615
725	UCCAAAUU CACU	115	CAUAGUG CUGAUGAG X CGAA AAUUGGAA	616
730	AUUCACUA UUGUGAU	116	AUCACCAA CUGAUGAG X CGAA AGUGGAAU	617

nt position	Target Site	SEQ ID. No.	Ribozyme Sequence	SEQ ID. No.
732	UCCACUAUU GGUGAUAG	117	CUAUCACC CUGAUGAG X CGAA AUAGUGGA	618
739	UUGGUGAUA GUGGAGUC	118	GACUCCAC CUGAUGAG X CGAA AUCACCAA	619
747	AGUGGAGUC CCAGCACU	119	AGUGCUGG CUGAUGAG X CGAA ACUCCACU	620
756	CCAGCACUA CCUUCUUU	120	AAAGAAGG CUGAUGAG X CGAA AGUGCUGG	621
760	CACUACCUU CUUUGACU	121	AGUCAAG CUGAUGAG X CGAA AGGUAGUG	622
761	ACUACCUUC UUUGACUA	122	UAGUCAAA CUGAUGAG X CGAA AAGGUAGU	623
763	UACCUUCUU UGACUAUG	123	CAUAGUCA CUGAUGAG X CGAA AGAAGGUA	624
764	ACCUUCUUU GACUAUGC	124	GCAUAGUC CUGAUGAG X CGAA AAGAAGGU	625
769	CUUUGACUA UGCUCGU	125	ACGACGCA CUGAUGAG X CGAA AGUCAAG	626
775	CUAUGCGUC GUAUGCGA	126	UCGCAUAC CUGAUGAG X CGAA ACGCAUAG	627
778	UGCGUCGUA UGCAGAG	127	CUCUCGCA CUGAUGAG X CGAA ACGACGCA	628
788	GCGAGAGUC UGUUCCA	128	UGGAAACA CUGAUGAG X CGAA ACUCUCGC	629
792	GAGUCUGUU UCCAGGAU	129	AUCCUGGA CUGAUGAG X CGAA ACAGACUC	630
793	AGUCUGUUU CCAGGAUG	130	CAUCCUGG CUGAUGAG X CGAA AACAGACU	631
794	GUCUGUUUC CAGGAUGC	131	GCAUCCUG CUGAUGAG X CGAA AACAGAC	632
807	AUGCCUGUU AGUUCUA	132	UGAGAACU CUGAUGAG X CGAA ACAGGCAU	633
808	UGCCUGUUA GUUCACAG	133	CUGAGAAC CUGAUGAG X CGAA AACAGGCA	634
811	CUGUAGUUU CUCAGCAC	134	GUGCUGAG CUGAUGAG X CGAA ACUAAACAG	635
812	UGUUAUUC UCAGCACA	135	UGUGCUGA CUGAUGAG X CGAA AACUAACA	636
814	UUAGUUCUC AGCACAGA	136	UCUGUGCU CUGAUGAG X CGAA AGAACUA	637
824	GCACAGUAU UUCUACAC	137	GUGUAGAA CUGAUGAG X CGAA AUCUGUGC	638
826	ACAGAUUUU CUACACCU	138	AGGUGUAG CUGAUGAG X CGAA AUUUCUGU	639
827	CAGAUUUUC UACACCUC	139	GAGGUGUA CUGAUGAG X CGAA AAUAUCUG	640
829	GAUAUUUUA CACCUCAC	140	GUGAGGUG CUGAUGAG X CGAA AGAAUAUC	641
835	CUACACCUC ACGCCUUC	141	GAAGGCGU CUGAUGAG X CGAA AGGUGUAG	642
842	UCACGCCUU CACCUUUA	142	UAAAGGUG CUGAUGAG X CGAA AGGCGUGA	643
843	CACGCCUUC ACCUUUAA	143	UUAAGGUG CUGAUGAG X CGAA AAGGCGUG	644
848	CUUCACCUU UAACACCU	144	AGGUGUUA CUGAUGAG X CGAA AGGUGAAG	645
849	UUCACCUUU AACACCUC	145	GAGGUGUU CUGAUGAG X CGAA AAGGUGAA	646
850	UAACCUUUA ACACCUC	146	GGAGGUGU CUGAUGAG X CGAA AAAGGUGA	647
857	UAACACCUC CAGUCCCU	147	AGGGACUG CUGAUGAG X CGAA AGGUGUUA	648
862	CCUCCAGUC CCUCAUCU	148	AGAUGAGG CUGAUGAG X CGAA ACUGGAGG	649
866	CAGUCCCUU AUCUGAAG	149	CUUCAGAU CUGAUGAG X CGAA AGGGACUG	650
869	UCCCUCAUC UGAAGGUU	150	AACCUUCA CUGAUGAG X CGAA AUGAGGGA	651
877	CUGAAGGUU CCCUCUCC	151	GGAGAGGG CUGAUGAG X CGAA ACCUUCAG	652
878	UGAAGGUUC CCUCUCCC	152	GGGAGAGG CUGAUGAG X CGAA AACCUUCA	653
882	GGUUCUCCU UCCAGAG	153	CUCUGGGA CUGAUGAG X CGAA AGGGAACC	654
884	UUCUCCUUC CCAGAGGC	154	GCCUCUGG CUGAUGAG X CGAA AGAGGGAA	655
899	GCAGAGGUC GACAUCCA	155	UGGAUGUC CUGAUGAG X CGAA ACCUCUGC	656
905	GUCGACAU CACACCUA	156	UAGGUGUG CUGAUGAG X CGAA AUGUCGAC	657
913	CCACACCUA AUGUCCAC	157	GUGGACAU CUGAUGAG X CGAA AGGUGUGG	658
918	CCUAAUGUC CACAUGGU	158	ACCAUGUG CUGAUGAG X CGAA ACAUUGAG	659
927	CACAUGGUC AGCACCAC	159	GUGGUGCU CUGAUGAG X CGAA ACCAUGUG	660
960	AGGAUGAUU GAGGAUGC	160	GCAUCCUC CUGAUGAG X CGAA AUCAUCCU	661
972	GAUGCAAUU CGAAGUCA	161	UGACUUCG CUGAUGAG X CGAA AUUGCAUC	662
973	AUGCAAUUC GAAGUCAC	162	GUGACUUC CUGAUGAG X CGAA AAUUGCAU	663
979	UUCGAAGUC ACAGCGAA	163	UUCGUGU CUGAUGAG X CGAA ACUUCGAA	664
989	CAGCGAAUC AGCCUCAC	164	GUGAGGCU CUGAUGAG X CGAA AUUCGUG	665
995	AUCAGCCUC ACCUUCAG	165	CUGAAGGU CUGAUGAG X CGAA AGGCUGAU	666
1000	CCUACCUU CAGCCUUG	166	CAGGCGUG CUGAUGAG X CGAA AGGUGAGG	667
1001	CUCACCUUC AGCCUUGU	167	ACAGGCGU CUGAUGAG X CGAA AAGGUGAG	668
1010	AGCCUUGUC CAGUAGCC	168	GGCUACUG CUGAUGAG X CGAA ACAGGCGU	669
1015	UGUCCAGUA GCCCAAC	169	GUUGGGGC CUGAUGAG X CGAA ACUGGACA	670
1027	CCAACAUC UGAGCCCA	170	UGGGCUCA CUGAUGAG X CGAA AUUGUUGG	671
1046	AGGUGGUC ACAGCCGA	171	UCGGCUGU CUGAUGAG X CGAA ACCAGCCU	672
1092	GCACAGUA UCUGGGAC	172	GUCCGAGA CUGAUGAG X CGAA ACUGGUGC	673
1094	ACCAGUAUC UGGGACCC	173	GGGUCCCA CUGAUGAG X CGAA AUACUGGU	674
1119	AACAAAUAU AGGCCUCG	174	CGAGGCCU CUGAUGAG X CGAA AUUUUGUU	675
1120	ACAAAUAUA GGCCUCGU	175	ACGAGGCC CUGAUGAG X CGAA AAUUUUGU	676

nt position	Target Site	SEQ ID. No.	Ribozyme Sequence	SEQ ID. No.
1126	UUAGGCCUC GUGGACAG	176	CUGUCCAC CUGAUGAG X CGAA AGGCCUAA	677
1141	AGAGAGAUU CAAGCUAU	177	AUAGCUUG CUGAUGAG X CGAA AUCUCUCU	678
1142	GAGAGAUUC AAGCUAUU	178	AAUAGCUU CUGAUGAG X CGAA AAUCUCUC	679
1148	UUCAAGCUA UUAUUGGG	179	CCCAAUAA CUGAUGAG X CGAA AGCUUGAA	680
1150	CAAGCUAUU AUUGGGAA	180	UUCCCAAU CUGAUGAG X CGAA AUAGCUUG	681
1151	AAGCUAUUA UUGGGAAA	181	UUUCCCAA CUGAUGAG X CGAA AAUAGCUU	682
1153	GCUAUUUUU GGGAAUA	182	UAUUUCCC CUGAUGAG X CGAA AUAAUAGC	683
1161	UGGGAAUA GAAGCCAG	183	CUGGCUUC CUGAUGAG X CGAA AUUUCCCA	684
1184	GAUGCUGUC CACUCGGA	184	UCCGAGUG CUGAUGAG X CGAA ACAGCAUC	685
1189	UGUCCACUC GGAUUGGG	185	CCCAAUCC CUGAUGAG X CGAA AGUGGACA	686
1194	ACUCGGAUU GGGUCAGG	186	CCUGACCC CUGAUGAG X CGAA AUCCGAGU	687
1199	GAUUGGGUC AGGCUCUU	187	AAGAGCCU CUGAUGAG X CGAA ACCCAAUC	688
1205	GUCAGGCUC UUUUGGAA	188	UUCCAAUA CUGAUGAG X CGAA AGCCUGAC	689
1207	CAGGCUCUU UUGGAACU	189	AGUUCCAA CUGAUGAG X CGAA AGAGCCUG	690
1208	AGGCUCUUU UGGAACUG	190	CAGUUGCA CUGAUGAG X CGAA AAGAGCCU	691
1209	GGCUCUUUU GGAACUGU	191	ACAGUUCU CUGAUGAG X CGAA AAAGAGCC	692
1218	GGAACUGUU UUAAGGG	192	CCCUUAUA CUGAUGAG X CGAA ACAGUUCU	693
1219	GAACUGUUU AUAAGGGU	193	ACCCUUAU CUGAUGAG X CGAA AACAGUUC	694
1220	AACUGUUUA UAAGGGUA	194	UACCCUUA CUGAUGAG X CGAA AAACAGUU	695
1222	CUGUUUAUA AGGGUAAA	195	UUUACCCU CUGAUGAG X CGAA AUAAACAG	696
1228	AUAAGGGUA AAUGGCAC	196	GUGCCAUU CUGAUGAG X CGAA ACCCUUAU	697
1245	GGAGAUGUU GCAGUAAA	197	UUUACUGC CUGAUGAG X CGAA ACAUCUCC	698
1251	GUUGCAGUA AAGAUCCU	198	AGGAUCUU CUGAUGAG X CGAA ACUGCAAC	699
1257	GUAAAGAUC CUAAGGU	199	ACCUUAG CUGAUGAG X CGAA AUCUUUAC	700
1260	AAGAUCCUA AAGGUUGU	200	ACAACCUU CUGAUGAG X CGAA AGGAUCUU	701
1266	CUAAAGGUU GUCGACCC	201	GGGUCGAC CUGAUGAG X CGAA ACCUUUAG	702
1269	AAGGUUGUC GACCCAAC	202	GUUGGGUC CUGAUGAG X CGAA ACAACCUU	703
1289	AGAGCAAUU CCAGGCCU	203	AGGCCUGG CUGAUGAG X CGAA AUUGCUCU	704
1290	GAGCAAUUU CAGGCCUU	204	AAGGCCUG CUGAUGAG X CGAA AAUUGCUC	705
1298	CCAGCCUUU CAGGAUUG	205	CAUUCUG CUGAUGAG X CGAA AGGCCUGG	706
1299	CAGGCCUUC AGGAAUGA	206	UCAUCCU CUGAUGAG X CGAA AAGGCCUG	707
1317	GUGGCUGUU CUGCGCAA	207	UUGCGCAG CUGAUGAG X CGAA ACAGCCAC	708
1318	UGGCUGUUC UGCGCAA	208	UUUGCGCA CUGAUGAG X CGAA AACAGCCA	709
1344	GUGAACAUU CUGCUUUU	209	AAAAGCAG CUGAUGAG X CGAA AUGUUCAC	710
1345	UGAACAUUC UGCUUUUC	210	GAAAGCA CUGAUGAG X CGAA AAUGUUCA	711
1350	AUUCUGCUU UUCAUGGG	211	CCCAUGAA CUGAUGAG X CGAA AGCAGAAU	712
1351	UUCUGCUUU UCAUGGGG	212	CCCAUGA CUGAUGAG X CGAA AAGCAGAA	713
1352	UCUGCUUUU CAUGGGGU	213	ACCCCAUG CUGAUGAG X CGAA AAAGCAGA	714
1353	CUGCUUUUC AUGGGGUA	214	UACCCCAU CUGAUGAG X CGAA AAAAGCAG	715
1361	CAUGGGGUA CAUGACAA	215	UUGUCAUG CUGAUGAG X CGAA ACCCCAUG	716
1386	CUGGCAAUU GUGACCCA	216	UGGGUCAC CUGAUGAG X CGAA AUUGCCAG	717
1416	AGCAGCCUC UACAAACA	217	UGUUUGUA CUGAUGAG X CGAA AGGCUGCU	718
1418	CAGCCUCUA CAAACACC	218	GGUGUUUG CUGAUGAG X CGAA AGAGGCUG	719
1434	CUGCAUGUC CAGGAGAC	219	GUCUCCUG CUGAUGAG X CGAA ACAUGCAG	720
1448	GACCAAGUU UCAGAUGU	220	ACAUCUGA CUGAUGAG X CGAA ACUUGGUC	721
1449	ACCAAGUUU CAGAUGUU	221	AACAUCUG CUGAUGAG X CGAA AACUUGGU	722
1450	CCAAGUUUC AGAUGUUC	222	GAACAUCU CUGAUGAG X CGAA AAACUUGG	723
1457	UCAGAUGUU CCAGCUAA	223	UUAGCUGG CUGAUGAG X CGAA ACAUCUGA	724
1458	CAGAUGUUC CAGCUAAU	224	AUUAGCUG CUGAUGAG X CGAA AACUUCUG	725
1464	UUCAGCUA AUUGACAU	225	AUGUCAAU CUGAUGAG X CGAA AGCUGGAA	726
1467	CAGCUAAUU GACAUUGC	226	GCAUUGUC CUGAUGAG X CGAA AUUAGCUG	727
1473	AUUGACAUU GCCCGGCA	227	UGCCGGGC CUGAUGAG X CGAA AUGUCAAU	728
1489	AGACGGCUC AGGGAAUG	228	CAUUCUUU CUGAUGAG X CGAA AGCCGUCU	729
1502	AAUGGACUA UUGCAUG	229	CAUGCAAA CUGAUGAG X CGAA AGUCCAUA	730
1504	UGGACUAUU UGCAUGCA	230	UGCAUGCA CUGAUGAG X CGAA AUAGUCCA	731
1505	GGACUAUUU GCAUGCAA	231	UUGCAUGC CUGAUGAG X CGAA AAUAGUCC	732
1521	AAGAACAUC AUCCAUA	232	CUAUGGAU CUGAUGAG X CGAA AUGUUCUU	733
1524	AACAUAUC CAUAGAGA	233	UCUCUAUG CUGAUGAG X CGAA AUGAUGUU	734
1528	UCAUCCAUA GAGACAUG	234	CAUGUCUC CUGAUGAG X CGAA AUGGAUGA	735

nt position	Target Site	SEQ ID. No.	Ribozyme Sequence	SEQ ID. No.
1541	CAUGAAAUC CAACAAUA	235	UAUUGUUG CUGAUGAG X CGAA AUUUCAUG	736
1549	CCAACAAUA UAUUUCUC	236	GAGAAAUA CUGAUGAG X CGAA AUUGUUGG	737
1551	AACAAUAUA UUUCUCCA	237	UGGAGAAA CUGAUGAG X CGAA AUAUUGUU	738
1553	CAAUUAUUA UCUCCAUG	238	CAUGGAGA CUGAUGAG X CGAA AUAUAUUG	739
1554	AAUAUAUUU CUCCAUGA	239	UCAUGGAG CUGAUGAG X CGAA AAUAUAUU	740
1555	AUAUAUUUC UCCAUGAA	240	UUAUGGGA CUGAUGAG X CGAA AAUAUAUU	741
1557	AUAUUUCUC CAUGAAGG	241	CCUUCAUG CUGAUGAG X CGAA AGAAUAUU	742
1568	UGAAGGCUU AACAGUGA	242	UCACUGUU CUGAUGAG X CGAA AGCCUUCA	743
1569	GAAGGCUUA ACAGUGAA	243	UUCACUGU CUGAUGAG X CGAA AAGCCUUC	744
1581	GUGAAAAUU GGAGAUUU	244	AAAUCUCC CUGAUGAG X CGAA AUUUUCAC	745
1588	UUGGAGAUU UGGUUUG	245	CAAACCAA CUGAUGAG X CGAA AUCUCCA	746
1589	UGGAGAUUU UGGUUUGG	246	CAAACCAA CUGAUGAG X CGAA AAUCUCCA	747
1590	GGAGAUUUU GGUUUGGC	247	GCCAAACC CUGAUGAG X CGAA AAAUCUCC	748
1594	AUUUUGGUU UGGCAACA	248	UGUUGCCA CUGAUGAG X CGAA ACCAAAAU	749
1595	UUUUGGUUU GGCAACAG	249	CUGUUGCC CUGAUGAG X CGAA AACCAAAA	750
1605	GCAACAGUA AAGUCACG	250	CGUGACUU CUGAUGAG X CGAA ACUGUUGC	751
1610	AGUAAAGUC ACGCUGGA	251	UCCAGCGU CUGAUGAG X CGAA ACUUUACU	752
1624	GGAGUGGUU CUCAGCAG	252	CUGCUGAG CUGAUGAG X CGAA ACCACUCC	753
1625	GAGUGGUUC UCAGCAGG	253	CCUGCUGA CUGAUGAG X CGAA AACCACUC	754
1627	GUGGUUCUC AGCAGGUU	254	AACCUGCU CUGAUGAG X CGAA AGAACCAC	755
1635	CAGCAGGUU GAACAACC	255	GGUUGUUC CUGAUGAG X CGAA ACCUGCUG	756
1645	AACAACCUA CUGGCUCU	256	AGAGCCAG CUGAUGAG X CGAA AGGUUGUU	757
1652	UACUGGCUC UGUCCUCU	257	AGAGGACA CUGAUGAG X CGAA AGCCAGUA	758
1656	GGCUCUGUC CUCUGGAU	258	AUCCAGAG CUGAUGAG X CGAA ACAGAGCC	759
1659	UCUGUCCUC UGGAUGGC	259	GCCAUCCA CUGAUGAG X CGAA AGGACAGA	760
1680	GAGGUGAUC CGAAUGCA	260	UGCAUUCG CUGAUGAG X CGAA AUCACCUC	761
1693	UGCAGGAUA ACAACCCA	261	UGGGUUGU CUGAUGAG X CGAA AUCCUGCA	762
1703	CAACCCAUA CAGUUUCC	262	GGAAACUG CUGAUGAG X CGAA AUGGGUUG	763
1704	AACCCAUAU AGUUUCCA	263	UGGAAACU CUGAUGAG X CGAA AAUGGGUU	764
1708	CAUUCAGUU UCCAGUCG	264	CGACUGGA CUGAUGAG X CGAA ACUGAAUG	765
1709	AUUCAGUUU CCAGUCGG	265	CCGACUGG CUGAUGAG X CGAA AACUGAAU	766
1710	UUCAGUUUC CAGUCGGA	266	UCCGACUG CUGAUGAG X CGAA AACUGGAA	767
1715	UUUCCAGUC GGAUGUCU	267	AGACAUCU CUGAUGAG X CGAA ACUGGAAA	768
1722	UCGGAUGUC UACUCCUA	268	UAGGAGUA CUGAUGAG X CGAA ACAUCCGA	769
1724	GGAUGUCUA CUCCUAUG	269	CAUAGGAG CUGAUGAG X CGAA AGACAUCU	770
1727	UGUCUACUC CUAUGGCA	270	UGCCAUAU CUGAUGAG X CGAA AGUAGACA	771
1730	CUACUCCUA UGGCAUCG	271	CGAUGCCA CUGAUGAG X CGAA AGGAGUAG	772
1737	UAUGGCAUC GUUAUGUA	272	UACAAUAC CUGAUGAG X CGAA AUGCCAUA	773
1740	GGCAUCGUA UUGUAUGA	273	UCAUACAA CUGAUGAG X CGAA ACGAUGCC	774
1742	CAUCGUUUU GUUGAAGC	274	GUUCAUAC CUGAUGAG X CGAA AUACGAUG	775
1745	CGUAUUGUA UGAACUGA	275	UCAGUUCA CUGAUGAG X CGAA ACAAUACG	776
1767	GGGGAGCUU CCUUAUUC	276	GAAUAAGG CUGAUGAG X CGAA AGCUCCCC	777
1768	GGGAGCUUC CUUAUUCU	277	AGAAUAAG CUGAUGAG X CGAA AAGCUCCC	778
1771	AGCUUCCUU AUUCUCAC	278	GUGAGAAU CUGAUGAG X CGAA AGGAAGCU	779
1772	GCUUCCUUA UUCUCACA	279	UGUGAGAA CUGAUGAG X CGAA AAGGAAGC	780
1774	UUCUUAUUU CUCACAUC	280	GAUGUGAG CUGAUGAG X CGAA AUAAGGAA	781
1775	UCCUUAUUC UCACAUCA	281	UGAUGUGA CUGAUGAG X CGAA AAUAAGGA	782
1777	CUUAUUCUC ACAUCAAC	282	GUUGAUGU CUGAUGAG X CGAA AGAAUAAG	783
1782	UCUACAUC AACCAACG	283	CGGUUGUU CUGAUGAG X CGAA AUGUGAGA	784
1795	ACCGAGAUU AGAUAUC	284	GAUGAUCU CUGAUGAG X CGAA AUCUCGGU	785
1800	GAUCAGAUU AUCUUCAU	285	AUGAAGAU CUGAUGAG X CGAA AUCUGAUC	786
1803	CAGAUCAUC UUAUGGU	286	ACCAUGAA CUGAUGAG X CGAA AUGAUCUG	787
1805	GAUCAUCUU CAUGGUGG	287	CCACCAUG CUGAUGAG X CGAA AGAUGAUC	788
1806	AUCAUCUUC AUGGUGGG	288	CCCACCAU CUGAUGAG X CGAA AAGAUGAU	789
1823	CCGAGGAUA UGCCUCCC	289	GGGAGGCA CUGAUGAG X CGAA AUCCUCGG	790
1829	AUAUGCCUC CCCAGAUC	290	GAUCUGGG CUGAUGAG X CGAA AGGCAUUA	791
1837	CCCCAGAUC UUAGUAAG	291	CUUACUAA CUGAUGAG X CGAA AUCUGGGG	792
1839	CCAGAUCUU AGUAAGCU	292	AGCUUACU CUGAUGAG X CGAA AGAUCUGG	793
1840	CAGAUCUUA GUAAGCUA	293	UAGCUUAC CUGAUGAG X CGAA AAGAUCUG	794

nt position	Target Site	SEQ ID. No.	Ribozyme Sequence	SEQ ID. No.
1843	AUCUUAGUA AGCUAUAU	294	AUAUAGCU CUGAUGAG X CGAA ACUAAGAU	795
1848	AGUAAGCUA UAUAAGAA	295	UUCUUUAU CUGAUGAG X CGAA AGCUUACU	796
1850	UAAGCUAUA UAAGAACU	296	AGUUCUUA CUGAUGAG X CGAA AUAGCUUA	797
1852	AGCUAUUAU AGAACUGC	297	GCAGUUCU CUGAUGAG X CGAA AUAUAGCU	798
1884	AGGUGGUA GCUGACUG	298	CAGUCAGC CUGAUGAG X CGAA ACCAGCCU	799
1905	AAGAAAGUA AAGGAAGA	299	UCUCCCUU CUGAUGAG X CGAA ACUUCUUU	800
1921	AGAGGCCUC UUUUCCCC	300	GGGAAAAA CUGAUGAG X CGAA AGGCCUCU	801
1923	AGGCCUCUU UUUCCCCA	301	UGGGGAAA CUGAUGAG X CGAA AGAGGCCU	802
1924	GGCCUCUUU UCCCCAG	302	CUGGGGAA CUGAUGAG X CGAA AAGAGGCC	803
1925	GCCUCUUUU UCCCCAGA	303	UCUGGGGA CUGAUGAG X CGAA AAAGAGGC	804
1926	CCUCUUUUU CCCCAGAU	304	AUCUGGGG CUGAUGAG X CGAA AAAAGAGG	805
1927	CUCUUUUUC CCCAGAUC	305	GAUCUGGG CUGAUGAG X CGAA AAAAAGAG	806
1935	CCCAGAUUC CUGUCUUC	306	GAAGACAG CUGAUGAG X CGAA AUCUGGGG	807
1940	GAUCUGUC UUCAUUG	307	CAAUGGAA CUGAUGAG X CGAA ACAGGAUC	808
1942	UCCUGUCUU CCAUUGAG	308	CUCAAUGG CUGAUGAG X CGAA AGACAGGA	809
1943	CCUGUCUUC CAUUGAGC	309	GCUCAAUG CUGAUGAG X CGAA AAGACAGG	810
1947	UCUCCAUU GAGCUGCU	310	AGCAGCUC CUGAUGAG X CGAA AUGGAAGA	811
1956	GAGCUGCUC CAACACUC	311	GAGUGUUG CUGAUGAG X CGAA AGCAGCUC	812
1964	CCAACACUC UCUACCGA	312	UCGGUAGA CUGAUGAG X CGAA AGUGUUGG	813
1966	AACACUCUC UACCGAAG	313	CUUCGGUA CUGAUGAG X CGAA AGAGUGUU	814
1968	CACUCUCUA CCGAAGAU	314	AUCUUCGG CUGAUGAG X CGAA AGAGAGUG	815
1977	CCGAAGAUU AACCGGAG	315	CUCCGGUU CUGAUGAG X CGAA AUCUUCGG	816
1990	GGAGCGCUU CCGAGCCA	316	UGGCUCGG CUGAUGAG X CGAA AGCGCUCC	817
1991	GAGCGCUUC CGAGCCAU	317	AUGGCUCG CUGAUGAG X CGAA AAGCGCUC	818
2000	CGAGCCAUU CUUGCAUC	318	GAUGCAAG CUGAUGAG X CGAA AUGGCUCG	819
2003	GCCAUCUUU GCAUCGGG	319	CCCGAUGC CUGAUGAG X CGAA AGGAUGGC	820
2008	CCUUGCAUC GGGCAGCC	320	GGCUGCCC CUGAUGAG X CGAA AUGCAAGG	821
2029	CUGAGGAUA UCAAUGCU	321	AGCAUUGA CUGAUGAG X CGAA AUCUCACG	822
2031	GAGGAUAUC AAUGCUUG	322	CAAGCAUU CUGAUGAG X CGAA AUAUCCUC	823
2038	UCAUUGCUU GCACGUCG	323	CAGCGUGC CUGAUGAG X CGAA AGCAUUGA	824
2054	GACCACGUC CCCGAGGC	324	GCCUCGGG CUGAUGAG X CGAA ACGUGGUC	825
2070	CUGCCUGUC UUCUAGUU	325	AACUAGAA CUGAUGAG X CGAA ACAGGCAG	826
2072	GCCUGUCUU CUAGUUGA	326	UCAACUAG CUGAUGAG X CGAA AGACAGGC	827
2073	CCUGUCUUC UAGUUGAC	327	GUCAACUA CUGAUGAG X CGAA AAGACAGG	828
2075	UGUCUUCUA GUUGACUU	328	AAGUCAAC CUGAUGAG X CGAA AGAAGACA	829
2078	CUUCUAGUU GACUUUGC	329	GCAAAGUC CUGAUGAG X CGAA ACUAGAAG	830
2083	AGUUGACUU UGCACUG	330	CAGGUGCA CUGAUGAG X CGAA AGUCAACU	831
2084	GUUGACUUU GCACCUGU	331	ACAGGUGC CUGAUGAG X CGAA AAGUCAAC	832
2093	GCACUGUC UUCAGGCU	332	AGCCUGAA CUGAUGAG X CGAA ACAGGUGC	833
2095	ACCUGUCUU CAGGCGUC	333	GCAGCCUG CUGAUGAG X CGAA AGACAGGU	834
2096	CCUGUCUUC AGGCUGCC	334	GGCAGCCU CUGAUGAG X CGAA AAGACAGG	835
2136	GCACCACUU UUCUGCUC	335	GAGCAGAA CUGAUGAG X CGAA AGUGGUGC	836
2137	CACCACUUU UCUGCUCC	336	GGAGCAGA CUGAUGAG X CGAA AAGUGGUG	837
2138	ACCACUUUU CUGCUCCC	337	GGGAGCAG CUGAUGAG X CGAA AAAGUGGU	838
2139	CCACUUUUC UGCUCCCU	338	AGGGAGCA CUGAUGAG X CGAA AAAAGUGG	839
2144	UUUCUGCUC CCUUCUC	339	GAGAAAGG CUGAUGAG X CGAA AGCAGAAA	840
2148	UGCUCUUU UCUCACAG	340	UCUGGAGA CUGAUGAG X CGAA AGGGAGCA	841
2149	GCUCUUUU CUCCAGAG	341	CUCUGGAG CUGAUGAG X CGAA AAGGGAGC	842
2150	CUCCUUUUC UCCAGAGG	342	CCUCUGGA CUGAUGAG X CGAA AAAGGGAG	843
2152	CCUUUUCUC CAGAGGCA	343	UGCCUCUG CUGAUGAG X CGAA AGAAAGGG	844
2171	ACACAUUUU UUCAGAGA	344	UCUCUGAA CUGAUGAG X CGAA ACAUGUGU	845
2172	CACAUUUUU UCAGAGAA	345	UUCUCUGA CUGAUGAG X CGAA AACAUUGU	846
2173	ACAUGUUUU CAGAGAAG	346	CUUCUCUG CUGAUGAG X CGAA AAACAUGU	847
2174	CAUGUUUUC AGAGAAGC	347	GCUUCUCU CUGAUGAG X CGAA AAAACAUG	848
2184	GAGAAGCUC UGUUAAGG	348	CCUUAAGC CUGAUGAG X CGAA AGCUUCUC	849
2189	GCUCUGCUA AGGACCUU	349	AAGGUCCU CUGAUGAG X CGAA AGCAGAGC	850
2197	AAGGACCUU CUAGACUG	350	CAGUCUAG CUGAUGAG X CGAA AGGUCCUU	851
2198	AGGACCUUC UAGACUGC	351	GCAGUCUA CUGAUGAG X CGAA AAGGUCCU	852
2200	GACCUUCUA GACUGCUC	352	GAGCAGUC CUGAUGAG X CGAA AGAAGGUC	853

nt position	Target Site	SEQ ID. No.	Ribozyme Sequence	SEQ ID. No.
2208	AGACUGCUC ACAGGGCC	353	GGCCUGU CUGAUGAG X CGAA AGCAGUCU	854
2218	CAGGGCCUU AACUUCAU	354	AUGAAGUU CUGAUGAG X CGAA AGGCCUG	855
2219	AGGGCCUUA ACUUCAUG	355	CAUGAAGU CUGAUGAG X CGAA AAGGCCU	856
2223	CCUUAACUU CAUGUUGC	356	GCAACAUG CUGAUGAG X CGAA AGUUAAGG	857
2224	CUUAACUUC AUGUUGCC	357	GGCAACAU CUGAUGAG X CGAA AAGUUAAG	858
2229	CUUCAUGUU GCCUUCUU	358	AAGAAGGC CUGAUGAG X CGAA ACAUGAAG	859
2234	UGUUGCCUU CUUUUCUA	359	UAGAAAAG CUGAUGAG X CGAA AGGCAACA	860
2235	GUUGCCUUC UUUUCUAU	360	AUAGAAAA CUGAUGAG X CGAA AAGGCAAC	861
2237	UGCCUUCUU UUCUAUCC	361	GGAUAGAA CUGAUGAG X CGAA AGAAGGCA	862
2238	GCCUUCUUU UCUAUCCC	362	GGGAUAGA CUGAUGAG X CGAA AAGAAGGC	863
2239	CCUUCUUUU CUAUCCCU	363	AGGGAUAG CUGAUGAG X CGAA AAAGAAGG	864
2240	CUUCUUUUC UAUCCCUU	364	AAGGGAUA CUGAUGAG X CGAA AAAAGAAG	865
2242	UCUUUUCUA UCCCUUUG	365	CAAAGGGA CUGAUGAG X CGAA AGAAAAGA	866
2244	UUUUCUAUC CCUUUGGG	366	CCCAAAGG CUGAUGAG X CGAA AUAGAAAA	867
2248	CUAUCCCUU UGGGCCCU	367	AGGGCCCA CUGAUGAG X CGAA AGGGAUAG	868
2249	UGCUCCCUU GGGCCCUG	368	CAGGGCCC CUGAUGAG X CGAA AAGGGAUA	869
2273	GAAGCCAUU UGCAGUGC	369	GCACUGCA CUGAUGAG X CGAA AUGGCUUC	870
2274	AAGCCAUUU GCAGUGCU	370	AGCACUGC CUGAUGAG X CGAA AAUGGCUU	871
2290	UGGUGUGUC CUGCUCCC	371	GGGAGCAG CUGAUGAG X CGAA ACACACCA	872
2296	GUCCUGCUC CCUCCCCA	372	UGGGGAGG CUGAUGAG X CGAA AGCAGGAC	873
2300	UGCUCUCCU CCCACAUU	373	AAUGUGGG CUGAUGAG X CGAA AGGGAGCA	874
2308	CCCCACAUU CCCCAUGC	374	GCAUGGGG CUGAUGAG X CGAA AUGUGGGG	875
2309	CCCACAUUC CCCAUGCU	375	AGCAUGGG CUGAUGAG X CGAA AAUGUGGG	876
2318	CCCAUGCUC AAGGCCCA	376	UGGGCCUU CUGAUGAG X CGAA AGCAUGGG	877
2331	CCCAGCUU CUGUAGAU	377	AUCUACAG CUGAUGAG X CGAA AGGCUGGG	878
2332	CCAGCCUUC UGUAGAUG	378	CAUCUACA CUGAUGAG X CGAA AAGGCUGG	879
2336	CCUUCUGUA GAUGCGCA	379	UGCGCAUC CUGAUGAG X CGAA ACAGAAGG	880
2354	GUGGAUGUU GAUGGUAG	380	CUACCAUC CUGAUGAG X CGAA ACAUCCAC	881
2361	UUGAUGGUA GUACAAAA	381	UUUUGUAC CUGAUGAG X CGAA ACCAUCAA	882
2364	AUGGUAGUA CAAAAAGC	382	GCUUUUUG CUGAUGAG X CGAA ACUACCAU	883
2393	CCAGCUGUU GGCUACAU	383	AUGUAGCC CUGAUGAG X CGAA ACAGCUGG	884
2398	UGUUGGCUA CAUGAGUA	384	UACUCAUG CUGAUGAG X CGAA AGCCAACA	885
2406	ACAUGAGUA UUUAGAGG	385	CCUCUAAA CUGAUGAG X CGAA ACUCAUGU	886
2408	AUGAGUAUU UAGAGGAA	386	UCCUCUA CUGAUGAG X CGAA AUACUCAU	887
2409	UGAGUAUUU AGAGGAAG	387	CUCCUCU CUGAUGAG X CGAA AAUACUCA	888
2410	GAGUAUUUA GAGGAAGU	388	ACUUCUC CUGAUGAG X CGAA AAUACUCU	889
2419	GAGGAAGUA AGGUAGCA	389	UGCUAACU CUGAUGAG X CGAA ACUUCUCU	890
2424	AGUAAGGUA GCAGGCAG	390	CUGCCUGC CUGAUGAG X CGAA ACCUUAUC	891
2434	CAGGCAGUC CAGCCCUG	391	CAGGGCUG CUGAUGAG X CGAA ACUGCCUG	892
2462	CAUGGGAUU UUGGAAAU	392	AUUUCCAA CUGAUGAG X CGAA AUCCCAUG	893
2463	AUGGGAUUU UGGAAAUU	393	GAUUUCCA CUGAUGAG X CGAA AAUCCCAU	894
2464	UGGGAUUUU GGAAAUCA	394	UGAUUUCC CUGAUGAG X CGAA AAUCCCAA	895
2471	UUGGAAAUU AGCUUCUG	395	CAGAAGCU CUGAUGAG X CGAA AUUCCCAA	896
2476	AAUCAGCUU CUGGAGGA	396	UCCUCCAG CUGAUGAG X CGAA AGCUGAUU	897
2477	AUCAGCUUC UGGAGGAA	397	UUCUCCA CUGAUGAG X CGAA AAGCUGAU	898
2493	AUGCAUGUC ACAGGCGG	398	CCGCCUGU CUGAUGAG X CGAA ACAUGCAU	899
2506	GCGGGACUU UCUUCAGA	399	UCUGAAGA CUGAUGAG X CGAA AGUCCCGC	900
2507	CGGGACUUU CUUCAGAG	400	CUCUGAAG CUGAUGAG X CGAA AAGUCCCG	901
2508	GGGACUUUC UUCAGAGA	401	UCUCUGAA CUGAUGAG X CGAA AAAGUCCC	902
2510	GACUUUCUU CAGAGAGU	402	ACUCUCUG CUGAUGAG X CGAA AGAAAGUC	903
2511	ACUUUCUUC AGAGAGUG	403	CACUCUCU CUGAUGAG X CGAA AAGAAAGU	904
2536	CCAGACAUU UUGCACAU	404	AUGUGCAA CUGAUGAG X CGAA AUGUCUGG	905
2537	CAGACAUUU UGCACAUU	405	UAUGUGCA CUGAUGAG X CGAA AAUGUCUG	906
2538	AGACAUUUU GCACAUAA	406	UUAUGUGC CUGAUGAG X CGAA AAAUGUCU	907
2545	UUGCACAUU AGGCACCA	407	UGUGGCCU CUGAUGAG X CGAA AUGUGCAA	908
2577	CCGAGACUC UGGCCGCC	408	GGCGGCCA CUGAUGAG X CGAA AGUCUCGG	909
2600	AGCCUGCUU UGGUACUA	409	UAGUACCA CUGAUGAG X CGAA AGCAGGCU	910
2601	GCCUGCUUU GGUACUAU	410	AUAGUACC CUGAUGAG X CGAA AAGCAGGC	911
2605	GCUUUGGUA CUAUGGAA	411	UUCCAUAG CUGAUGAG X CGAA ACCAAAGC	912

nt position	Target Site	SEQ ID. No.	Ribozyme Sequence	SEQ ID. No.
2608	UUGGUACUA UGGAACUU	412	AAGUUGCA CUGAUGAG X CGAA AGUACCAA	913
2616	AUGGAACUU UUCUUAGG	413	CCUAAGAA CUGAUGAG X CGAA AGUUGCCAU	914
2617	UGGAACUUU UCUUAGGG	414	CCCUAAGA CUGAUGAG X CGAA AAGUUGCA	915
2618	GGAACUUUU CUUAGGGG	415	CCCCUAG CUGAUGAG X CGAA AAAGUUGCC	916
2619	GAACUUUUC UUAGGGGA	416	UCCCCUAA CUGAUGAG X CGAA AAAAGUUC	917
2621	ACUUUUCUU AGGGGACA	417	UGUCCCCU CUGAUGAG X CGAA AGAAAAGU	918
2622	CUUUUCUUA GGGGACAC	418	GUGUCCCC CUGAUGAG X CGAA AAGAAAAG	919
2633	GGACACGUC CUCCUUUC	419	GAAAGGAG CUGAUGAG X CGAA ACGUGUCC	920
2636	CACGUCCUC CUUUCACA	420	UGUGAAAG CUGAUGAG X CGAA AGGACGUG	921
2639	GUCCUCCUU UCACAGCU	421	AGCUGUGA CUGAUGAG X CGAA AGGAGGAC	922
2640	UCCUCCUUU CACAGCUU	422	AAGCUGUG CUGAUGAG X CGAA AAGGAGGA	923
2641	CCUCCUUUC ACAGCUUC	423	GAAGCUGU CUGAUGAG X CGAA AAAGGAGG	924
2648	UCACAGCUU CUAAGGUG	424	CACCUUAG CUGAUGAG X CGAA AGCUGUGA	925
2649	CACAGCUUC UAAGGUGU	425	ACACCUUA CUGAUGAG X CGAA AAGCUGUG	926
2651	CAGCUUCUA AGGUGUCC	426	GGACACCU CUGAUGAG X CGAA AGAAGCUG	927
2658	UAAGGUGUC CAGUGCAU	427	AUGCACUG CUGAUGAG X CGAA ACACCUUA	928
2667	CAGUGCAUU GGAUGGU	428	ACCAUCCC CUGAUGAG X CGAA AUGCACUG	929
2676	GGGAUGGUU UCCAGGC	429	GCCUGGAA CUGAUGAG X CGAA ACCAUCCC	930
2677	GGAUGGUUU UCCAGGCA	430	UGCCUGGA CUGAUGAG X CGAA AACCAUCC	931
2678	GAUGGUUUU CCAGGCAA	431	UUGCCUGG CUGAUGAG X CGAA AAACCAUC	932
2679	AUGGUUUUC CAGGCAAG	432	CUUGCCUG CUGAUGAG X CGAA AAAACCAU	933
2693	AAGGCACUC GGCCAAUC	433	GAUUGGCC CUGAUGAG X CGAA AGUGCCUU	934
2701	CGGCCAAUC CGCAUCUC	434	GAGAUGCG CUGAUGAG X CGAA AUUGGCCG	935
2707	AUCCGCAUC UCAGCCCU	435	AGGGCUGA CUGAUGAG X CGAA AUGCGGAU	936
2709	CCGCAUCUC AGCCUCU	436	AGAGGGCU CUGAUGAG X CGAA AGAUGCGG	937
2716	UCAGCCUC UCAGGAGC	437	GCUCUGA CUGAUGAG X CGAA AGGGCUGA	938
2718	AGCCUCUC AGGAGCAG	438	CUGCUCCU CUGAUGAG X CGAA AGAGGGCU	939
2728	GGAGCAGUC UUCAUCA	439	UGAUGGAA CUGAUGAG X CGAA ACUGCUCC	940
2730	AGCAGUCUU CCAUCAUG	440	CAUGAUGG CUGAUGAG X CGAA AGACUGCU	941
2731	GCAGUCUUC CAUCAUGC	441	GCAUGAUG CUGAUGAG X CGAA AAGACUGC	942
2735	UCUCCACUC AUGCUGAA	442	UUCAGCAU CUGAUGAG X CGAA AUGGAAGA	943
2745	UGCUGAAUU UUGUCUUC	443	GAAGACAA CUGAUGAG X CGAA AUUCAGCA	944
2746	GCUGAAUUU UGUCUUC	444	GGAAGACA CUGAUGAG X CGAA AAUUCAGC	945
2747	CUGAAUUUU GUCUUGCA	445	UGGAAGAC CUGAUGAG X CGAA AAUUCAGC	946
2750	AAUUUUGUC UUCAGGA	446	UCCUGGAA CUGAUGAG X CGAA ACAAAAUU	947
2752	UUUUGUCUU CCAGGAGC	447	GCUCUGG CUGAUGAG X CGAA AGACAAA	948
2753	UUUGUCUUC CAGGAGCU	448	AGCUCCUG CUGAUGAG X CGAA AAGACAAA	949
2768	CUGCCCCUA UGGGGCGG	449	CCGCCCA CUGAUGAG X CGAA AGGGGCAG	950
2795	CAGCCUGUU UCUCUAAC	450	GUUAGAGA CUGAUGAG X CGAA ACAGGCUG	951
2796	AGCCUGUUU CUCUAACA	451	UGUUAGAG CUGAUGAG X CGAA AACAGGCU	952
2797	GCCUGUUUC UCUAACAA	452	UUGUUAGA CUGAUGAG X CGAA AAACAGGC	953
2799	CUGUUUCUC UAACAAAC	453	GUUUGUUA CUGAUGAG X CGAA AGAAACAG	954
2801	GUUUCUCUA ACAACAA	454	UUGUUUGU CUGAUGAG X CGAA AGAGAAAC	955
2825	AACAGCCUU GUUUCUCU	455	AGAGAAAC CUGAUGAG X CGAA AGGCUGUU	956
2828	AGCCUUGUU UCUCUAGU	456	ACUAGAGA CUGAUGAG X CGAA ACAAGGCU	957
2829	GCCUUGUUU CUCUAGUC	457	GACUAGAG CUGAUGAG X CGAA AACAGGCU	958
2830	CCUUGUUUC UCUAGUCA	458	UGACUAGA CUGAUGAG X CGAA AAACAAGG	959
2832	UUGUUUCUC UAGUCACA	459	UGUGACUA CUGAUGAG X CGAA AGAAACAA	960
2834	GUUUCUCUA GUCACAUC	460	GAUGUGAC CUGAUGAG X CGAA AGAGAAAC	961
2837	UCUCUAGUC ACAUCAUG	461	CAUGAUGU CUGAUGAG X CGAA ACUAGAGA	962
2842	AGUCACAUC AUGUGUAU	462	AUACACAU CUGAUGAG X CGAA AUGUGACU	963
2849	UCAUGUGUA UACAAGGA	463	UCCUUGUA CUGAUGAG X CGAA ACACAUGA	964
2851	AUGUGUAUA CAAGGAAG	464	CUUCCUUG CUGAUGAG X CGAA AUACACAU	965
2868	CCAGGAUA CAGGUUUU	465	AAAACCUG CUGAUGAG X CGAA AUUCCUGG	966
2874	AUACAGGUU UUCUUGAU	466	AUCAAGAA CUGAUGAG X CGAA ACCUGUAU	967
2875	UACAGGUUU UCUGAUG	467	CAUCAAGA CUGAUGAG X CGAA AACUGUA	968
2876	ACAGGUUUU CUUGAUGA	468	UCAUCAAG CUGAUGAG X CGAA AAACCUGU	969
2877	CAGGUUUUC UUGAUGAU	469	AUCAACAA CUGAUGAG X CGAA AAAACCUG	970
2879	GGUUUUCUU GAUGAUUU	470	AAAUCAUC CUGAUGAG X CGAA AGAAACC	971

nt position	Target Site	SEQ ID. No.	Ribozyme Sequence	SEQ ID. No.
2886	UUGAUGAUU UGGGUUUU	471	AAAACCCA CUGAUGAG X CGAA AUCAUCA	972
2887	UGAUGAUUU GGGUUUUU	472	UAAAACCC CUGAUGAG X CGAA AAUCAUCA	973
2892	AUUUGGGUU UUAUUUUU	473	AAAAUUAA CUGAUGAG X CGAA ACCCAAU	974
2893	UUUGGGUUU UAAUUUUU	474	CAAAAUUA CUGAUGAG X CGAA AACCCTAA	975
2894	UUGGGUUUU AAUUUUUU	475	ACAAAAUU CUGAUGAG X CGAA AAACCCAA	976
2895	UGGGUUUUU AUUUUUUU	476	AACAAAAU CUGAUGAG X CGAA AAAACCCA	977
2898	GUUUUAAUU UUGUUUUU	477	AAAAACAA CUGAUGAG X CGAA AUUAAAAC	978
2899	UUUUAAUUU UGUUUUUU	478	UAAAAACA CUGAUGAG X CGAA AAUUAAAA	979
2900	UUUAAUUUU GUUUUUUU	479	AUAAAAAC CUGAUGAG X CGAA AAAUUAAA	980
2903	AAUUUUUUU UUUUUUUG	480	GCAAUAAA CUGAUGAG X CGAA ACAAAAUU	981
2904	AUUUUUUUU UUAUUUGC	481	UGCAAUAA CUGAUGAG X CGAA AACAAAUU	982
2905	UUUUGUUUU UAUUGCAC	482	GUGCAAUA CUGAUGAG X CGAA AAACAAAA	983
2906	UUUGUUUUU AUUGCACC	483	GGUGCAAU CUGAUGAG X CGAA AAAACAAA	984
2907	UUGUUUUUU UUGCACCU	484	AGGUGCAA CUGAUGAG X CGAA AAAAACAA	985
2909	GUUUUUUUU GCACCUGA	485	UCAGGUGC CUGAUGAG X CGAA AUAAAAAC	986
2924	GACAAAAUA CAGUUAUC	486	GAUAACUG CUGAUGAG X CGAA AUUUUGUC	987
2929	AAUACAGUU AUCUGAUG	487	CAUCAGAU CUGAUGAG X CGAA ACUGUAUU	988
2930	AUACAGUUA UCUGAUGG	488	CCAUCAGA CUGAUGAG X CGAA AACUGUAU	989
2932	ACAGUUAUC UGAUGGUC	489	GACCAUCA CUGAUGAG X CGAA AUAACUGU	990
2940	CUGAUGGUC CCUCAAUU	490	AAUUGAGG CUGAUGAG X CGAA ACCAUCAG	991
2944	UGGUCCUCU AAUUUAUU	491	ACAUAUUU CUGAUGAG X CGAA AGGGACCA	992
2948	CCUCAAUU AUGUUUUU	492	AAUAACAU CUGAUGAG X CGAA AUUGAGGG	993
2949	CCUCAAUU UGUUUUUU	493	AAUAACA CUGAUGAG X CGAA AAUUGAGG	994
2953	AAUUAUGUU AUUUUUUU	494	AUUAAAAU CUGAUGAG X CGAA ACAUAAUU	995
2954	AUUUAUGUU UUUUAAUA	495	UAUUAAAA CUGAUGAG X CGAA AACAUAAU	996
2956	UAUGUUUUU UUAUUAAA	496	UUUAUUAA CUGAUGAG X CGAA AUAACAUA	997
2957	AUGUUUUUU UAAUAAAA	497	UUUUUUUA CUGAUGAG X CGAA AAUAACAU	998
2958	UGUUUUUUU AAUAAAAU	498	AUUUUUUU CUGAUGAG X CGAA AAUAACA	999
2959	GUUAUUUUU AUAAAAUA	499	UAUUUUUU CUGAUGAG X CGAA AAAAUAAU	1000
2962	AUUUUAAUA AAAUAAAU	500	AUUUUUUU CUGAUGAG X CGAA AUUAAAAU	1001
2967	AAUAAAAUA AAUUAAAU	501	AUUUAAUU CUGAUGAG X CGAA AUUUUAUU	1002

Table XIII: Human *C-ras* Hairpin Ribozyme and Target Sequence

nt. Position	Ribozyme Sequence	SEQ ID. No.	Target Sequence	SEQ ID. No.
12	GCGGA AGAA GUCA ACCAGAGAACA X GUACAUUACUGGUA	1003	UGACC GCC UCCCGC	1078
19	UGAGGG AGAA GGAG ACCAGAGAACA X GUACAUUACUGGUA	1004	UCCCC GCU CCUCU	1079
31	CCCGC AGAA GGUG ACCAGAGAACA X GUACAUUACUGGUA	1005	CACCC GCC GCGGG	1080
61	UUCGC AGAA GCUU ACCAGAGAACA X GUACAUUACUGGUA	1006	AGCU GCC GCGAA	1081
64	UCGUU AGAA GCAG ACCAGAGAACA X GUACAUUACUGGUA	1007	CUGCC GCC GAACGA	1082
88	GAGCA AGAA GCCC ACCAGAGAACA X GUACAUUACUGGUA	1008	GGCG GCC UGGUC	1083
205	AGAUC AGAA GGAG ACCAGAGAACA X GUACAUUACUGGUA	1009	CUCCA GCU GCAUCU	1084
233	UAGCA AGAA GCUG ACCAGAGAACA X GUACAUUACUGGUA	1010	CAGCA GUU UGGCUA	1085
258	GCCAUC AGAA GAUG ACCAGAGAACA X GUACAUUACUGGUA	1011	CAUCA GAU GAUGGC	1086
276	AGRAG AGAA GUGA ACCAGAGAACA X GUACAUUACUGGUA	1012	UCACA GAU CCUUCU	1087
370	UCAUA AGAA GUCA ACCAGAGAACA X GUACAUUACUGGUA	1013	UGACU GCC UUAUGA	1088
427	GGAGN AGAA GRAC ACCAGAGAACA X GUACAUUACUGGUA	1014	GUUCA GAC UUCUC	1089
477	CGRAG AGAA GUAU ACCAGAGAACA X GUACAUUACUGGUA	1015	AUACU GAU GCUGCG	1090
605	CCAUU AGAA GGA ACCAGAGAACA X GUACAUUACUGGUA	1016	UUCU GCU CRAUGG	1091
626	CCCAA AGAA GACA ACCAGAGAACA X GUACAUUACUGGUA	1017	UGUCA GAC UUGUGG	1092
655	UGGUC AGAA GUGC ACCAGAGAACA X GUACAUUACUGGUA	1018	GCACU GUA GCACCA	1093
789	CCUGA AGAA GACU ACCAGAGAACA X GUACAUUACUGGUA	1019	AGUCU GUU UCCAGG	1094
859	AUGAG AGAA GGAG ACCAGAGAACA X GUACAUUACUGGUA	1020	CUCCA GUC CCUCU	1095
938	UCCACA AGAA GCGU ACCAGAGAACA X GUACAUUACUGGUA	1021	ACGUU GCC UGUGGA	1096
990	AGGUG AGAA GAUU ACCAGAGAACA X GUACAUUACUGGUA	1022	AUACA GCC UCACCU	1097
1002	GGACAG AGAA GAAG ACCAGAGAACA X GUACAUUACUGGUA	1023	CUUCA GCC CUGUC	1098
1007	CUACUG AGAA GGGC ACCAGAGAACA X GUACAUUACUGGUA	1024	GCCU GUC CAGUAG	1099
1012	UGGGC AGAA GGAC ACCAGAGAACA X GUACAUUACUGGUA	1025	GUCCA GUA GCCCCA	1100
1049	GUUUC AGAA GUGA ACCAGAGAACA X GUACAUUACUGGUA	1026	UCACA GCC GAAAC	1101
1089	CCAGA AGAA GGUG ACCAGAGAACA X GUACAUUACUGGUA	1027	CAGCA GUA UCUGGG	1102
1181	CGAGU AGAA GCAU ACCAGAGAACA X GUACAUUACUGGUA	1028	AUGCU GUC CACUG	1103
1190	GACCA AGAA GAGU ACCAGAGAACA X GUACAUUACUGGUA	1029	ACUGG GAU UGGUC	1104
1215	CUAUA AGAA GUDC ACCAGAGAACA X GUACAUUACUGGUA	1030	GAACU GUU UAUAG	1105
1314	GCGAG AGAA GCCA ACCAGAGAACA X GUACAUUACUGGUA	1031	UGGCU GUU CUGCG	1106
1346	AUGAA AGAA GAU ACCAGAGAACA X GUACAUUACUGGUA	1032	AUUCU GCU UUDCAU	1107
1411	UGAGA AGAA GCUG ACCAGAGAACA X GUACAUUACUGGUA	1033	CAGCA GCC UCACA	1108
1451	UGAAC AGAA GAA ACCAGAGAACA X GUACAUUACUGGUA	1034	UUUCA GAU GUUCA	1109
1481	UGGCC AGAA GCCG ACCAGAGAACA X GUACAUUACUGGUA	1035	CGCA GAC GGCUA	1110
1485	UCCUG AGAA GUCU ACCAGAGAACA X GUACAUUACUGGUA	1036	AGAG GCU CAGGA	1111
1653	CCAGAG AGAA GAGC ACCAGAGAACA X GUACAUUACUGGUA	1037	GCUCU GUC CUCUG	1112
1705	ACUGA AGAA GAU ACCAGAGAACA X GUACAUUACUGGUA	1038	AUACA GUU UCCAGU	1113
1712	ACUCC AGAA GGA ACCAGAGAACA X GUACAUUACUGGUA	1039	UUCCA GUC GGAUGU	1114

nt. Position	Ribozyme Sequence	SEQ ID. No.	Target Sequence	SEQ ID. No.
1716	GUAGAC AGAA GACU ACCAGAGAAACA X GUACAUUACCCUGGUA	1040	AGUCG GAU GUCUAC	1115
1751	CCCGUC AGAA GUUC ACCAGAGAAACA X GUACAUUACCCUGGUA	1041	GAUCU GAU GACGGG	1116
1796	AGAUG AGAA GAUC ACCAGAGAAACA X GUACAUUACCCUGGUA	1042	GAUCA GAU CACUUC	1117
1833	ACUAG AGAA GGG ACCAGAGAAACA X GUACAUUACCCUGGUA	1043	CCCCA GAU CUUAGU	1118
1858	CUUUG AGAA GUUC ACCAGAGAAACA X GUACAUUACCCUGGUA	1044	GAUCU GCC CCAAG	1119
1887	CACACA AGAA GCUA ACCAGAGAAACA X GUACAUUACCCUGGUA	1045	UAGCU GAC UGUGUG	1120
1931	GACAGG AGAA GGG ACCAGAGAAACA X GUACAUUACCCUGGUA	1046	CCCCA GAU CCUGUC	1121
1937	AUGGAA AGAA GGAU ACCAGAGAAACA X GUACAUUACCCUGGUA	1047	AUCUUC GUC UUCUAC	1122
1952	UGUUG AGAA GCUC ACCAGAGAAACA X GUACAUUACCCUGGUA	1048	GAGCU GCU CCAACA	1123
2013	AGUGUG AGAA GCCC ACCAGAGAAACA X GUACAUUACCCUGGUA	1049	GGGCA GCC CACACU	1124
2045	GACGUG AGAA GCGU ACCAGAGAAACA X GUACAUUACCCUGGUA	1050	ACGCU GAC CACGUC	1125
2063	AGACA AGAA GCCU ACCAGAGAAACA X GUACAUUACCCUGGUA	1051	AGGCU GCC UGUCUU	1126
2067	CUAGAA AGAA GGCA ACCAGAGAAACA X GUACAUUACCCUGGUA	1052	UGCCU GUC UUCUAG	1127
2090	CCUGAA AGAA GGUG ACCAGAGAAACA X GUACAUUACCCUGGUA	1053	CACCU GUC UUCAGG	1128
2140	AAAGGG AGAA GAAA ACCAGAGAAACA X GUACAUUACCCUGGUA	1054	UUUCU GCU CCCUUU	1129
2204	CCUGUG AGAA GUCU ACCAGAGAAACA X GUACAUUACCCUGGUA	1055	AGACU GCU CACAGG	1130
2292	GGAGGG AGAA GGAC ACCAGAGAAACA X GUACAUUACCCUGGUA	1056	GUCCU GCU CCCUCC	1131
2326	ACAGAA AGAA GGGC ACCAGAGAAACA X GUACAUUACCCUGGUA	1057	GGCCA GCC UUCUGU	1132
2333	GGCAUC AGAA GAAG ACCAGAGAAACA X GUACAUUACCCUGGUA	1058	CUUCU GUA GAUGCG	1133
2381	AGCUG AGAA GGGC ACCAGAGAAACA X GUACAUUACCCUGGUA	1059	GGCCA GCC CCAGCU	1134
2387	GCCAC AGAA GGGG ACCAGAGAAACA X GUACAUUACCCUGGUA	1060	CCCCA GCU GUUGGC	1135
2390	GUAGCC AGAA GCUG ACCAGAGAAACA X GUACAUUACCCUGGUA	1061	CAGCU GUU GGCUAC	1136
2431	GGGUG AGAA GCCU ACCAGAGAAACA X GUACAUUACCCUGGUA	1062	AGGCA GUC CAGCCC	1137
2436	CAUCAG AGAA GGAC ACCAGAGAAACA X GUACAUUACCCUGGUA	1063	GUCCA GCC CUGAUG	1138
2441	CUCCAC AGAA GGGC ACCAGAGAAACA X GUACAUUACCCUGGUA	1064	GCCCU GAU GUGGAG	1139
2472	UCCAGA AGAA GAUU ACCAGAGAAACA X GUACAUUACCCUGGUA	1065	AAUCA GCU UCUGGA	1140
2557	GUCCUG AGAA GUUU ACCAGAGAAACA X GUACAUUACCCUGGUA	1066	AAACA GCC CAGGAC	1141
2567	AGUCUC AGAA GUCC ACCAGAGAAACA X GUACAUUACCCUGGUA	1067	GGACU GCC GAGACU	1142
2582	CCUUC AGAA GCCA ACCAGAGAAACA X GUACAUUACCCUGGUA	1068	UGGCC GCC CGAAGG	1143
2596	UACCA AGAA GCGU ACCAGAGAAACA X GUACAUUACCCUGGUA	1069	AGCCU GCU UUGGUA	1144
2644	CUUAGA AGAA GUGA ACCAGAGAAACA X GUACAUUACCCUGGUA	1070	UCACA GCU UCUAAG	1145
2710	UGAGAG AGAA GAGA ACCAGAGAAACA X GUACAUUACCCUGGUA	1071	UCUCA GCC CUCUCA	1146
2725	AUGGAA AGAA GCUC ACCAGAGAAACA X GUACAUUACCCUGGUA	1072	GAGCA GUC UUCUAC	1147
2761	CUAAGG AGAA GCUC ACCAGAGAAACA X GUACAUUACCCUGGUA	1073	GAGCU GCC CCUAUG	1148
2788	GAAACA AGAA GGCC ACCAGAGAAACA X GUACAUUACCCUGGUA	1074	GGCCA GCC UGUUUC	1149
2792	UAGAGA AGAA GCGU ACCAGAGAAACA X GUACAUUACCCUGGUA	1075	AGCCU GUU UCUCUA	1150
2820	AAACAA AGAA GUUU ACCAGAGAAACA X GUACAUUACCCUGGUA	1076	AAACA GCC UUGUUC	1151
2933	GGGACC AGAA GAUA ACCAGAGAAACA X GUACAUUACCCUGGUA	1077	UAUCU GAU GGUCCC	1152

Where "X" represents stem IV region of a Hairpin ribozyme. The length of stem IV may be 2 base-pairs.

Table XIV. Hammerhead Ribozyme Sites for A-Raf

Pos	RZ	SEQ ID. No.	Substrate	SEQ ID. No.
10	UCCACCCU CUGAUGAG X CGAA AUUGGGUC	1153	GACCCAAUA AGGGUGGA	1461
28	CUCUGCGG CUGAUGAG X CGAA ACUCAGCC	1154	GGCUGAGUC CCGCAGAG	1462
42	ACUCUCGU CUGAUGAG X CGAA AUUGGCUC	1155	GAGCCAAUA ACGAGAGU	1463
51	GCCUCUCG CUGAUGAG X CGAA ACUCUCGU	1156	ACGAGAGUC CGAGAGGC	1464
74	UCCUCACA CUGAUGAG X CGAA AGUCCGCC	1157	GGCGGACUC UGUGAGGA	1465
123	CACGCCGC CUGAUGAG X CGAA ACAGCCGC	1158	GCGGCUGUA GCGGCGUG	1466
166	GAUGGGCU CUGAUGAG X CGAA AGGUGGGG	1159	CCCCACCUC AGCCCAUC	1467
174	UUUGUCAA CUGAUGAG X CGAA AUGGGCUG	1160	CAGCCCAUC UUGACAAA	1468
176	AUUUUGUC CUGAUGAG X CGAA AGAUGGGC	1161	GCCCAUCUU GACAAAAU	1469
185	GAGCCUUA CUGAUGAG X CGAA AUUUUGUC	1162	GACAAAAUC UAAGGCUC	1470
187	UGGAGCCU CUGAUGAG X CGAA AGAUUUUG	1163	CAAAAUCUA AGGCUCCA	1471
193	GUCCAUG CUGAUGAG X CGAA AGCCUUAG	1164	CUAAGGCUC CAUGGAGC	1472
238	CUGCCCGG CUGAUGAG X CGAA AUGGCUCG	1165	CGAGCCAUC CCGGGCAG	1473
257	UAUACUUU CUGAUGAG X CGAA ACGGUGCC	1166	GGCACCGUC AAAGUUAU	1474
263	GGCAGGUA CUGAUGAG X CGAA ACUUUGAC	1167	GUCAAAGUA UACCUGCC	1475
265	UGGGCAGG CUGAUGAG X CGAA AUACUUUG	1168	CAAAGUAUA CCUGCCCA	1476
299	CCAUCCCG CUGAUGAG X CGAA ACAGUCAC	1169	GUGACUGUC CGGGAUGG	1477
317	GAGUCGUA CUGAUGAG X CGAA ACACUCAU	1170	AUGAGUGUC UACGACUC	1478
319	GAGAGUCG CUGAUGAG X CGAA AGACACUC	1171	GAGUGUCUA CGACUCUC	1479
325	UGUCUAGA CUGAUGAG X CGAA AGUCGUAG	1172	CUACGACUC UCUAGACA	1480
327	CUUGUCUA CUGAUGAG X CGAA AGAGUCGU	1173	ACGACUCUC UAGACAAG	1481
329	GCCUUGUC CUGAUGAG X CGAA AGAGAGUC	1174	GACUCUCUA GACAAGGC	1482
354	CUGAUUUA CUGAUGAG X CGAA ACCCCGCA	1175	UGCgggguc UAAUUCAG	1483
356	UCCUGAUU CUGAUGAG X CGAA AGACCCCG	1176	CGGGGUCUA AAUCAGGA	1484
360	GCAGUCCU CUGAUGAG X CGAA AUUUAGAC	1177	GUCUAAUUC AGGACUGC	1485
377	AGUCGGUA CUGAUGAG X CGAA ACCACACA	1178	UGUGUGGUC UACCGACU	1486
379	UGAGUCGG CUGAUGAG X CGAA AGACCACA	1179	UGUGGUCUA CCGACUCA	1487
386	CCCUUGAU CUGAUGAG X CGAA AGUCGGUA	1180	UACCGACUC AUCAGGGG	1488
389	CGUCCCUU CUGAUGAG X CGAA AUGAGUCG	1181	CGACUCAUC AAGGGACG	1489
407	CAGGCAGU CUGAUGAG X CGAA ACCGUCUU	1182	AAGACGGUC ACUGCCUG	1490
428	AGGGGAGC CUGAUGAG X CGAA AUGGCUGU	1183	ACAGCCAUU GCUCCCCU	1491
432	AUCCAGGG CUGAUGAG X CGAA AGCAAUGG	1184	CCAUUGCUC CCCUGGAU	1492
452	UCGACAAU CUGAUGAG X CGAA AGCUCCUC	1185	GAGGAGCUC AUUGUCGA	1493
455	ACCUCGAC CUGAUGAG X CGAA AUGAGCUC	1186	GAGCUCAUU GUCGAGGU	1494
458	AGGACCUC CUGAUGAG X CGAA ACAAUAG	1187	CUCAUUGUC GAGGUCCU	1495
464	UCUUCAAG CUGAUGAG X CGAA ACCUCGAC	1188	GUCGAGGUC CUUGAAGA	1496
467	ACAUCUUC CUGAUGAG X CGAA AGGACCUC	1189	GAGGUCCUU GAAGAUGU	1497
476	GUCAGCGG CUGAUGAG X CGAA ACAUCUUC	1190	GAAGAUGUC CCGCUGAC	1498
495	CCGUACAA CUGAUGAG X CGAA AUUGUGCA	1191	UGCACAAUU UUGUACGG	1499
496	UCCGUACA CUGAUGAG X CGAA AAUUGUGC	1192	GCACAAUUU UGUACGGA	1500
497	UCCCGUAC CUGAUGAG X CGAA AAUUGUG	1193	CACAAUUUU GUACGGAA	1501
500	GUCUCCG CUGAUGAG X CGAA ACAAUUU	1194	AAUUUUGUA CGGAAGAC	1502
511	GGCUGAAG CUGAUGAG X CGAA AGGUCUUC	1195	GAAGACCUU CUUCAGCC	1503
512	AGGCUGAA CUGAUGAG X CGAA AAGGUCUU	1196	AAGACCUUC UUCAGCCU	1504
514	CCAGGCUG CUGAUGAG X CGAA AGAAGGUC	1197	GACCUUCUU CAGCCUGG	1505
515	GCCAGGCU CUGAUGAG X CGAA AAGAAGGU	1198	ACCUUCUUC AGCCUGGC	1506
526	AGUCACAG CUGAUGAG X CGAA ACGCCAGG	1199	CCUGGCGUU CUGGACU	1507
527	AAGUCACA CUGAUGAG X CGAA AACGCCAG	1200	CUGGCGUUC UGUGACUU	1508
535	UAAGGCAG CUGAUGAG X CGAA AGUCACAG	1201	CUGUGACUU CUGCCUUA	1509
536	UUAAGGCA CUGAUGAG X CGAA AAGUCACA	1202	UGUGACUUC UGCCUUA	1510
542	AGAAACUU CUGAUGAG X CGAA AGGCAGAA	1203	UUCUGCCUU AAGUUCU	1511
543	CAGAAACU CUGAUGAG X CGAA AAGGCAGA	1204	UCUGCCUUA AGUUCUG	1512

Pos	RZ	SEQ ID. No.	Substrate	SEQ ID. No.
547	GGAACAGA CUGAUGAG X CGAA ACUUAAGG	1205	CCUUAAGUU UCUGUUC	1513
548	UGGAACAG CUGAUGAG X CGAA AACUUAAG	1206	CUUAAGUUU CUGUCCA	1514
549	AUGGAACA CUGAUGAG X CGAA AAACUUA	1207	UUAAGUUUC UGUCCA	1515
553	AGCCAUGG CUGAUGAG X CGAA ACAGAAA	1208	GUUUCUGUU CCAUGCU	1516
554	AAGCCAUG CUGAUGAG X CGAA AACAGAAA	1209	UUUCUGUUC CAUGCUU	1517
562	GGCAACGG CUGAUGAG X CGAA AGCCAUGG	1210	CCAUGGCUU CCGUGCC	1518
563	UGGCAACG CUGAUGAG X CGAA AAGCCAUG	1211	CAUGGCUUC CGUUGCCA	1519
567	GGUUUGGC CUGAUGAG X CGAA ACGGAAGC	1212	GCUUCCGUU GCCAAACC	1520
583	GGAACUUG CUGAUGAG X CGAA AGCCACAG	1213	CUGUGGCUA CAAGUUC	1521
589	GCUGGUGG CUGAUGAG X CGAA ACUUGUAG	1214	CUACAAGUU CCACCAGC	1522
590	UGCUGGUG CUGAUGAG X CGAA AACUUGUA	1215	UACAAGUUC CACCAGCA	1523
600	GGAGGAAC CUGAUGAG X CGAA AUGCUGGU	1216	ACCAGCAUU GUUCCUCC	1524
603	CUUGGAGG CUGAUGAG X CGAA ACAAUVCU	1217	AGCAUUGUU CCUCCAAG	1525
604	CCUUGGAG CUGAUGAG X CGAA AACAAUGC	1218	GCAUUGUUC CUCCAAGG	1526
607	GGACCUUG CUGAUGAG X CGAA AGGAACAA	1219	UUGUCCUC CAAGUCC	1527
614	ACUGUGGG CUGAUGAG X CGAA ACCUUGGA	1220	UCCAAGGUC CCCACAGU	1528
623	UCAACACA CUGAUGAG X CGAA ACUGUGGG	1221	CCCACAGUC UGUUGUA	1529
629	CUCUGGUC CUGAUGAG X CGAA ACACAGAC	1222	GUCUGUGUU GACAUGAG	1530
639	GCGGUUGG CUGAUGAG X CGAA ACUCAUGU	1223	ACAUGAGUA CCAACCGC	1531
655	UGUGGUAG CUGAUGAG X CGAA ACUGUUGG	1224	CCAACAGUU CUACCACA	1532
656	CUGUGGUA CUGAUGAG X CGAA AACUGUUG	1225	CAACAGUUC UACCACAG	1533
658	CACUGUGG CUGAUGAG X CGAA AGAACUGU	1226	ACAGUUCUA CCACAGUG	1534
668	AAAUCCUG CUGAUGAG X CGAA ACACUGUG	1227	CACAGUGUC CAGGAUUU	1535
675	UCCGGACA CUGAUGAG X CGAA AUCCUGGA	1228	UCCAGGAUU UGUCCGGA	1536
676	CUCCGGAC CUGAUGAG X CGAA AAUCCUGG	1229	CCAGGAUUU GUCCGAG	1537
679	AGCCUCCG CUGAUGAG X CGAA ACAAAUCC	1230	GGAUUUGUC CGGAGGCU	1538
688	GCUGUCUG CUGAUGAG X CGAA AGCCUCCG	1231	CGGAGGCUC CAGACAGC	1539
705	GUUCGAGG CUGAUGAG X CGAA AGCCUCAU	1232	AUGAGGCUC CCUCGAAC	1540
709	GGCGGUUC CUGAUGAG X CGAA AGGGAGCC	1233	GGCUCCUC GAACCGCC	1541
730	GGGUUAGC CUGAUGAG X CGAA ACUCAUUC	1234	GAAUGAGUU GCUAACCC	1542
734	UGGGGGGU CUGAUGAG X CGAA AGCAACUC	1235	GAGUUGCUA ACCCCCA	1543
747	GGGGCUGG CUGAUGAG X CGAA ACCCUGGG	1236	CCCAGGGUC CCAGCCCC	1544
784	GGAAGGGG CUGAUGAG X CGAA AGUGCUCC	1237	GGAGCACUU CCCCUUCC	1545
785	GGAAGGG CUGAUGAG X CGAA AAGUGCUC	1238	GAGCACUUC CCCUCC	1546
790	GGGCAGGG CUGAUGAG X CGAA AGGGGAAG	1239	CUUCCCCU CCCUGCCC	1547
791	GGGGCAGG CUGAUGAG X CGAA AAGGGGAA	1240	UUCCCCUUC CCUGCCCC	1548
815	AUGCGCUG CUGAUGAG X CGAA AGGGGGG	1241	GCCCCCUA CAGCGCAU	1549
824	GUGGAGCG CUGAUGAG X CGAA AUGCGCUG	1242	CAGCGCAUC CGCUCAC	1550
829	UGGACGUG CUGAUGAG X CGAA AGCGGAUG	1243	CAUCCGCUC CACGUCCA	1551
835	UGGGAGUG CUGAUGAG X CGAA ACGUGGAG	1244	CUCCACGUC CACUCCA	1552
840	GACGUUGG CUGAUGAG X CGAA AGUGGACG	1245	CGUCCACUC CCAACGUC	1553
848	ACCAUAUG CUGAUGAG X CGAA ACGUUGGG	1246	CCCAACGUC CAUAUGGU	1554
852	GCUGACCA CUGAUGAG X CGAA AUGGACGU	1247	ACGUCCAUA UGGUCAGC	1555
857	GUGGUGCU CUGAUGAG X CGAA ACCAUAUG	1248	CAUAUGGUC AGCACAC	1556
880	UGAGGUUG CUGAUGAG X CGAA AGUCCAUG	1249	CAUGGACUC CAACCUCA	1557
887	AGCUGGAU CUGAUGAG X CGAA AGGUUGGA	1250	UCCAACCUC AUCCAGCU	1558
890	GUGAGCUG CUGAUGAG X CGAA AUGAGGUU	1251	AACCUCAUC CAGCUCAC	1559
896	UGGCCAGU CUGAUGAG X CGAA AGCUGGAU	1252	AUCCAGCUC ACUGCCA	1560
909	AGUGCUGA CUGAUGAG X CGAA ACUCUGGC	1253	GCCAGAGUU UCAGACU	1561
910	CAGUGCUG CUGAUGAG X CGAA AACUCUGG	1254	CCAGAGUUU CAGCACUG	1562
911	UCAGUGCU CUGAUGAG X CGAA AAACUCUG	1255	CAGAGUUUC AGCACUGA	1563
930	UCCUCUAC CUGAUGAG X CGAA ACCGGCAG	1256	CUGCCGGUA GUAGAGGA	1564
933	ACCUCCUC CUGAUGAG X CGAA ACUACCGG	1257	CCGGUAGUA GAGGAGGU	1565
942	UCCAUCAC CUGAUGAG X CGAA ACCUCCUC	1258	GAGGAGGUA GUGAUGGA	1566

Pos	RZ	SEQ ID. No.	Substrate	SEQ ID. No.
985	UCCCCGAG CUGAUGAG X CGAA ACACGCUG	1259	CAGCGUGUC CUCGGGGA	1567
988	UCCUCCCC CUGAUGAG X CGAA AGGACACG	1260	CGUGUCCUC GGGGAGGA	1568
1000	AAUGUGGG CUGAUGAG X CGAA ACUUCCUC	1261	GAGGAAGUC CCCACAUU	1569
1008	UGACUUGG CUGAUGAG X CGAA AUGUGGGG	1262	CCCCACAUU CCAAGUCA	1570
1009	GUGACUUG CUGAUGAG X CGAA AAUGUGGG	1263	CCCACAUUC CAAGUCAC	1571
1015	CUGCUGGU CUGAUGAG X CGAA ACUUGGAA	1264	UUCCAAGUC ACCAGCAG	1572
1042	CGGCCAAG CUGAUGAG X CGAA ACUUCCGC	1265	GCGGAAGUC CUUGGCCG	1573
1045	CAUCGGCC CUGAUGAG X CGAA AGGACUUC	1266	GAAGUCCUU GGCCGAUG	1574
1081	ANUCCCGG CUGAUGAG X CGAA ACCCCAGG	1267	CCUGGGGUA CCGGGANU	1575
1090	AAUAGCCU CUGAUGAG X CGAA ANUCCCGG	1268	CCGGGANUC AGGCUAUU	1576
1096	CCCAGUAA CUGAUGAG X CGAA AGCCUGAN	1269	NUCAGGCUA UUACUGGG	1577
1098	GUCCCGAG CUGAUGAG X CGAA AUAGCCUG	1270	CAGGCUAUU ACUGGGAG	1578
1099	CCUCCAG CUGAUGAG X CGAA AAUAGCCU	1271	AGGCUAUUA CUGGGAGG	1579
1109	CUGGGUGG CUGAUGAG X CGAA ACCUCCCA	1272	UGGGAGGUA CCACCCAG	1580
1142	CCCGUCCC CUGAUGAG X CGAA AUCCUCUU	1273	AAGAGGAUC GGGAGGGG	1581
1153	UGCCAAAC CUGAUGAG X CGAA AGCCCGUC	1274	GACGGGCUC GUUUGGCA	1582
1156	CGGUGCCA CUGAUGAG X CGAA ACGAGCCC	1275	GGGCUUGUU UGGCACCG	1583
1157	ACGGUGCC CUGAUGAG X CGAA AACGAGCC	1276	GGCUCGUUU GGCACCGU	1584
1168	GCCCUCCA CUGAUGAG X CGAA ACACGGUG	1277	CACCGUGUU UCGAGGGC	1585
1169	CGCCUCUG CUGAUGAG X CGAA AACACGGU	1278	ACCGUGUUU CGAGGGCG	1586
1170	CCGCCUC CUGAUGAG X CGAA AAACACGG	1279	CCGUGUUUC GAGGGCGG	1587
1208	GACACCUU CUGAUGAG X CGAA AGCACCUU	1280	AAGGUGCUC AAGGUGUC	1588
1216	UGGGCUGG CUGAUGAG X CGAA ACACCUUG	1281	CAAGGUGUC CCAGCCCA	1589
1245	AUUCUUGA CUGAUGAG X CGAA AGCCUGGG	1282	CCCAGGCUU UCAAGAAU	1590
1246	CAUUCUUG CUGAUGAG X CGAA AAGCCUGG	1283	CCAGGCUUU CAAGAAUG	1591
1247	UCAUUCUU CUGAUGAG X CGAA AAAGCCUG	1284	CAGGCUUUC AAGAAUGA	1592
1268	GUCUCCU CUGAUGAG X CGAA AGCACCUG	1285	CAGGUGCUC AGGAAGAC	1593
1286	AAGAUGUU CUGAUGAG X CGAA ACAUGUCG	1286	CGACAUGUC AACAUUUU	1594
1292	AACAGCAA CUGAUGAG X CGAA AUGUUGAC	1287	GUCAACAUC UUGCUGUU	1595
1294	UAAACAGC CUGAUGAG X CGAA AGAUGUUG	1288	CAACAUCUU GCUGUUUA	1596
1300	AGCCCAUA CUGAUGAG X CGAA ACAGCAAG	1289	CUUGCUGUU UAUGGCUU	1597
1301	AAGCCCAU CUGAUGAG X CGAA AACAGCAA	1290	UUGCUGUUU AUGGCUU	1598
1302	GAAGCCCA CUGAUGAG X CGAA AAACAGCA	1291	UGCUGUUUA UGGGCUUC	1599
1309	GGGUCAUG CUGAUGAG X CGAA AGCCCAUA	1292	UAUGGCUU CAUGACCC	1600
1310	CGGGUCAU CUGAUGAG X CGAA AAGCCCAU	1293	AUGGCUUC AUGACCCG	1601
1327	UGAUGGCA CUGAUGAG X CGAA AUCCCGGC	1294	GCCGGGAUU UGCCAUCA	1602
1328	AUGAUGGC CUGAUGAG X CGAA AAUCCCGG	1295	CCGGGAUUU GCCAUCAU	1603
1334	UGUGUGAU CUGAUGAG X CGAA AUGGCAAA	1296	UUUGCCAUC AUCACACA	1604
1337	CACUGUGU CUGAUGAG X CGAA AUGAUGGC	1297	GCCAUCAUC ACACAGUG	1605
1357	AGAGGCUG CUGAUGAG X CGAA AGCCCUCA	1298	UGAGGGCUC CAGCCUCU	1606
1364	UGAUGGUA CUGAUGAG X CGAA AGGCUGGA	1299	UCCAGCCUC UACCAUCA	1607
1366	GGUGAUGG CUGAUGAG X CGAA AGAGGCUG	1300	CAGCCUCUA CCAUCACC	1608
1371	AUGCAGGU CUGAUGAG X CGAA AUGGUAGA	1301	UCUACCAUC ACCUGCAU	1609
1396	CCAUGUCG CUGAUGAG X CGAA AGCGUGUG	1302	CACACGCUU CGACAUGG	1610
1397	ACCAUGUC CUGAUGAG X CGAA AAGCGUGU	1303	ACACGCUUC GACAUGGU	1611
1406	AUGAGCUG CUGAUGAG X CGAA ACCAUGUC	1304	GACAUGGUC CAGCUCAU	1612
1412	ACGUCGAU CUGAUGAG X CGAA AGCUGGAC	1305	GUCCAGCUC AUCGACGU	1613
1415	GCCACGUC CUGAUGAG X CGAA AUGAGCUG	1306	CAGCUCAUC GACGUGGC	1614
1450	CAUGGAGG CUGAUGAG X CGAA AGUCCAUG	1307	CAUGGACUA CCUCCAUG	1615
1454	UUGGCAUG CUGAUGAG X CGAA AGGUAGUC	1308	GACUACCUC CAUGCCAA	1616
1469	CGGUGGAU CUGAUGAG X CGAA AUGUUCUU	1309	AAGAACAUC AUCCACCG	1617
1472	UCUCGGUG CUGAUGAG X CGAA AUGAUGUU	1310	AACAUCAUC CACGAGA	1618
1482	AGACUUGA CUGAUGAG X CGAA AUCUCGGU	1311	ACCGAGAUC UCAAGUCU	1619
1484	UUAGACUU CUGAUGAG X CGAA AGAUCUCG	1312	CGAGAUCUC AAGUCUAA	1620

Pos	RZ	SEQ ID. No.	Substrate	SEQ ID. No.
1489	UGUUGUUA CUGAUGAG X CGAA ACUUGAGA	1313	UCUCAAGUC UAACAACA	1621
1491	GAUGUUGU CUGAUGAG X CGAA AGACUUGA	1314	UCAAGUCUA ACAACAUC	1622
1499	UGUAGGAA CUGAUGAG X CGAA AUGUUGUU	1315	AACAACAUC UUCCUACA	1623
1501	CAUGUAGG CUGAUGAG X CGAA AGAUGUUG	1316	CAACAUCUU CCUACAUG	1624
1502	UCAUGUAG CUGAUGAG X CGAA AAGAUUUU	1317	AACAUCUUC CUACAUGA	1625
1505	CCCUCAUG CUGAUGAG X CGAA AGGAAGAU	1318	AUCUCCUA CAUGAGGG	1626
1517	UUCACCGU CUGAUGAG X CGAA AGCCCCUC	1319	GAGGGGCUC ACGGUGAA	1627
1529	AAGUCACC CUGAUGAG X CGAA AUCUUCAC	1320	GUGAAGAU CUGGACUU	1628
1537	CCAAGCCA CUGAUGAG X CGAA AGUCACCG	1321	CGGUGACUU UGGCUUGG	1629
1538	GCCAAGCC CUGAUGAG X CGAA AAGUCACC	1322	GGUGACUUU GGCUUGGC	1630
1543	CUGUGGCC CUGAUGAG X CGAA AGCCAAAG	1323	CUUUGGCUU GGCCACAG	1631
1560	GCUCACUC CUGAUGAG X CGAA AGUCUUCA	1324	UGAAGACUC GAUGGAGC	1632
1582	GCUGCUC CUGAUGAG X CGAA AGGGCUGG	1325	CCAGCCCUU GGAGCAGC	1633
1594	CAGAUCCU CUGAUGAG X CGAA AGGGCUGC	1326	GCAGCCUC AGGAUCUG	1634
1600	ACAGCACA CUGAUGAG X CGAA AUCCUGAG	1327	CUCAGGAUC UGUGCUGU	1635
1628	UGCAUACG CUGAUGAG X CGAA AUCACCUC	1328	GAGGUGAUC CGUAUGCA	1636
1632	GUCCUGCA CUGAUGAG X CGAA ACGGAUCA	1329	UGAUCCGUA UGCAGGAC	1637
1651	GGAAGCUG CUGAUGAG X CGAA AGGGGUUC	1330	GAACCCUA CAGCUUCC	1638
1657	GCUCUGG CUGAUGAG X CGAA AGCUGUAG	1331	CUACAGCUU CCAGUCAG	1639
1658	UCUGACUG CUGAUGAG X CGAA AAGCUGUA	1332	UACAGCUUC CAGUCAGA	1640
1663	AGACGUCU CUGAUGAG X CGAA ACUGGAAG	1333	CUUCCAGUC AGACGUCU	1641
1670	UAGGCAUA CUGAUGAG X CGAA ACGUCUGA	1334	UCAGACGUC UAUGCCUA	1642
1672	CGUAGGCA CUGAUGAG X CGAA AGACGUCU	1335	AGACGUCUA UGCCUACG	1643
1678	CAACCCCG CUGAUGAG X CGAA AGGCAUAG	1336	CUAUGCCUA CGGGGUUG	1644
1685	UAGAGCAC CUGAUGAG X CGAA ACCCCGUA	1337	UACGGGGUU GUGCUCUA	1645
1691	AGCUCGUA CUGAUGAG X CGAA AGCACAAC	1338	GUUGGUCUC UACGAGCU	1646
1693	UAAGCUCG CUGAUGAG X CGAA AGAGCACA	1339	UGUGCUCUA CGAGCUUA	1647
1700	CCAGUCAU CUGAUGAG X CGAA AGCUCGUA	1340	UACGAGCUU AUGACUGG	1648
1701	GCCAGUCA CUGAUGAG X CGAA AAGCUCGU	1341	ACGAGCUUA UGACUGGC	1649
1711	AAGGCAGU CUGAUGAG X CGAA AGCCAGUC	1342	GACUGGCUC ACUGCCUU	1650
1719	GUGGCUGU CUGAUGAG X CGAA AGGCAGUG	1343	CACUGCCUU ACAGCCAC	1651
1720	UGUGGCUG CUGAUGAG X CGAA AAGGCAGU	1344	ACUGCCUUA CAGCCACA	1652
1730	CGGCAGCC CUGAUGAG X CGAA AUGUGGCU	1345	AGCCACAUU GGCUGCCG	1653
1748	AUAAAGAU CUGAUGAG X CGAA AUCUGGUC	1346	GACCAGAUU AUCUUUAU	1654
1749	CAUAAAGA CUGAUGAG X CGAA AAUCUGGU	1347	ACCAGAUUA UCUUUAUG	1655
1751	ACCAUAAA CUGAUGAG X CGAA AUAAUCUG	1348	CAGAUUAUC UUUUAUGG	1656
1753	CCACCAUA CUGAUGAG X CGAA AGAUAAUC	1349	GAUUAUCUU UAUGGUGG	1657
1754	CCCACCAU CUGAUGAG X CGAA AAGAUAUU	1350	AUUAUCUUU AUGGUGGG	1658
1755	GCCCACCA CUGAUGAG X CGAA AAAGAUAU	1351	UUUAUCUUU UGGUGGGC	1659
1771	GGGACAGA CUGAUGAG X CGAA AGCCACGG	1352	CCGUGGCUA UCUGUCCC	1660
1773	CGGGGACA CUGAUGAG X CGAA AUAGCCAC	1353	GUGGCUAUC UGUCCCCG	1661
1777	GGUCCGGG CUGAUGAG X CGAA ACAGAUAG	1354	CUAUCUGUC CCCGACC	1662
1787	AUUUUGCU CUGAUGAG X CGAA AGGUCCGG	1355	CCGACCUC AGCAAAAU	1663
1796	UUGCUGGA CUGAUGAG X CGAA AUUUUGCU	1356	AGCAAAAU UCCAGCAA	1664
1798	AGUUGCUG CUGAUGAG X CGAA AGAUUUUG	1357	CAAAAUUC CAGCAACU	1665
1834	GGCAGUCA CUGAUGAG X CGAA ACAGCAGG	1358	CCUGCUGUC UGACUGCC	1666
1844	UGGAACUU CUGAUGAG X CGAA AGGCAGUC	1359	GACUGCCUC AAGUCCA	1667
1849	CCCGCUGG CUGAUGAG X CGAA ACUUGAGG	1360	CCUCAAGUU CCAGCGGG	1668
1850	UCCCGCUG CUGAUGAG X CGAA AACUUGAG	1361	CUCAAGUUC CAGCGGGA	1669
1871	UGGGGGAA CUGAUGAG X CGAA AGGGGCCG	1362	CGGCCCCUC UUCCCCCA	1670
1873	UCUGGGGG CUGAUGAG X CGAA AGAGGGGG	1363	GCCCCUCUU CCCCAGAU	1671
1874	AUCUGGGG CUGAUGAG X CGAA AAGAGGGG	1364	CCCCUCUUC CCCCAGAU	1672
1883	GUGGCCAG CUGAUGAG X CGAA AUCUGGGG	1365	CCCAGAUUC CUGGCCAC	1673
1895	AGCAGCUC CUGAUGAG X CGAA AUUGUGGC	1366	GCCACAAU GAGCUGCU	1674

Pos	RZ	SEQ ID. No.	Substrate	SEQ ID. No.
1912	UGGGGAGU CUGAUGAG X CGAA ACCGUUUC	1367	GCAACGGUC ACUCCCCA	1675
1916	AUCUUGGG CUGAUGAG X CGAA AGUGACCG	1368	CGGUCACUC CCCAAGAU	1676
1925	CUCCGCUC CUGAUGAG X CGAA AUCUUGGG	1369	CCCAAGAUU GAGCGGAG	1677
1939	AGGGUUCC CUGAUGAG X CGAA AGGCACUC	1370	GAGUGCCUC GGAACCCU	1678
1948	GGUGCAAG CUGAUGAG X CGAA AGGGUUC	1371	GGAACCCUC CUUGCACC	1679
1951	UGCGGUGC CUGAUGAG X CGAA AGGAGGGU	1372	ACCCUCCUU GCACCGCA	1680
1975	AGGCAGGC CUGAUGAG X CGAA ACUCAUCG	1373	CGAUGAGUU GCCUGCCU	1681
1988	GCGCUGAG CUGAUGAG X CGAA AGGCAGGC	1374	GCCUGCCUA CUCAGCGC	1682
1991	GCUGCGCU CUGAUGAG X CGAA AGUAGGCA	1375	UGCCUACUC AGCGCAGC	1683
2006	UAAGGCAC CUGAUGAG X CGAA AGGCGGGC	1376	GCCCGCCUU GUGCCUUA	1684
2013	CGGGGCCU CUGAUGAG X CGAA AGGCACAA	1377	UUGUGCCUU AGGCCCG	1685
2014	GCGGGGCC CUGAUGAG X CGAA AAGGCACA	1378	UGUGCCUUA GGCCCCGC	1686
2044	AGGGCUGA CUGAUGAG X CGAA AUUGGCUC	1379	GAGCCAAUC UCAGCCCU	1687
2046	GGAGGGCU CUGAUGAG X CGAA AGAUUGGC	1380	GCCAAUCUC AGCCCUCC	1688
2053	UUGGCGUG CUGAUGAG X CGAA AGGGCUGA	1381	UCAGCCUC CACGCCAA	1689
2069	UGGUGGGC CUGAUGAG X CGAA AGGCUCU	1382	AGGAGCCUU GCCCACC	1690
2084	CGAACAUU CUGAUGAG X CGAA AUUGGCUG	1383	CAGCCAAUC AAUGUUCG	1691
2090	CAGAGACG CUGAUGAG X CGAA ACAUUGAU	1384	AUCAAUGUU CGUCUCUG	1692
2091	GCAGAGAC CUGAUGAG X CGAA AACAUUGA	1385	UCAUGUUC GUCUCUGC	1693
2094	AGGGCAGA CUGAUGAG X CGAA ACGAACAU	1386	AUGUUCGUC UCUGCCCU	1694
2096	UCAGGGCA CUGAUGAG X CGAA AGACGAAC	1387	GUUCGUCUC UGCCCUGA	1695
2113	GGGAUCCU CUGAUGAG X CGAA AGGCAGCA	1388	UGCUGCCUC AGGAUCC	1696
2119	GAAUGGGG CUGAUGAG X CGAA AUCCUGAG	1389	CUCAGGAUC CCCAUUC	1697
2126	GGGUGGGG CUGAUGAG X CGAA AUGGGGA	1390	UCCCCAUU CCCACCC	1698
2127	AGGGUGGG CUGAUGAG X CGAA AAUGGGGG	1391	CCCCAUUC CCCACCCU	1699
2151	CACAUUGG CUGAUGAG X CGAA ACCCCUC	1392	GAGGGGGUC CCCAUGUG	1700
2162	AACUGGAA CUGAUGAG X CGAA AGCACAUG	1393	CAUGUGCUU UCCAGUU	1701
2163	GAACUGGA CUGAUGAG X CGAA AAGCACA	1394	AUGUGCUUU UCCAGUUC	1702
2164	AGAACUGG CUGAUGAG X CGAA AAAGCACA	1395	UGUGCUUUU CCAGUUCU	1703
2165	AAGAACUG CUGAUGAG X CGAA AAAAGCAC	1396	GUGCUUUUC CAGUUCUU	1704
2170	UCCAGAAG CUGAUGAG X CGAA ACUGGAAA	1397	UUCCAGUU CUUCUGGA	1705
2171	UUCAGAA CUGAUGAG X CGAA AACUGGAA	1398	UUCAGUUC UUCUGGAA	1706
2173	AAUUCAG CUGAUGAG X CGAA AGAACUGG	1399	CCAGUUCUU CUGGAAU	1707
2174	CAAUCCA CUGAUGAG X CGAA AAGAACUG	1400	CAGUUCUUC UGGAAUUG	1708
2181	GGUCCCC CUGAUGAG X CGAA AUUCCAGA	1401	UCUGGAAUU GGGGGACC	1709
2214	AUGGAGGA CUGAUGAG X CGAA ACAGGGGG	1402	CCCCUGUC UCCUCCAU	1710
2216	UGAUGGAG CUGAUGAG X CGAA AGACAGGG	1403	CCUGUCUC CUCCAUA	1711
2219	AAAUGAUG CUGAUGAG X CGAA AGGAGACA	1404	UGUCUCCUC CAUCAUU	1712
2223	AACCAAU CUGAUGAG X CGAA AUGGAGGA	1405	UCCUCCAUC AUUUGGUU	1713
2226	GGAAACCA CUGAUGAG X CGAA AUGAUGGA	1406	UCCAUCAU UGUUUUCC	1714
2227	AGGAAACC CUGAUGAG X CGAA AAUGAUGG	1407	CCAUCAUU GGUUUCCU	1715
2231	CAAGAGGA CUGAUGAG X CGAA ACCAAAU	1408	CAUUUGGUU UCCUCUUG	1716
2232	CCAAGAGG CUGAUGAG X CGAA AACCAAU	1409	AUUUGGUU CCUCUUGG	1717
2233	GCCAAGAG CUGAUGAG X CGAA AAACCAA	1410	UUUGGUUUC CUCUUGGC	1718
2236	AAAGCCAA CUGAUGAG X CGAA AGGAAACC	1411	GGUUUCCUC UUGGCUUU	1719
2238	CCAAAGCC CUGAUGAG X CGAA AGAGGAAA	1412	UUUCCUCUU GGCUUUGG	1720
2243	UAUCCCCA CUGAUGAG X CGAA AGCCAAGA	1413	UCUUGGCUU UGGGGAUA	1721
2244	GUAUCCCC CUGAUGAG X CGAA AAGCCAAG	1414	CUUGGCUUU GGGGAUAC	1722
2251	UUUAGAAG CUGAUGAG X CGAA AUCCCCA	1415	UUGGGGAUA CUUCUAAA	1723
2254	AAAUUUAG CUGAUGAG X CGAA AGUAUCCC	1416	GGGAUACUU CUAAAUUU	1724
2255	AAAAUUUA CUGAUGAG X CGAA AAGUAUCC	1417	GGAUACUUC UAAAUUUU	1725
2257	CCAAAAUU CUGAUGAG X CGAA AGAAGUAU	1418	AUACUUCUA AAUUUUGG	1726
2261	GCUCCCAA CUGAUGAG X CGAA AUUUAGAA	1419	UUCUAAAUU UUGGGAGC	1727
2262	AGCUCCCA CUGAUGAG X CGAA AAUUAGA	1420	UCUAAAUUU UGGGAGCU	1728

Pos	RZ	SEQ ID. No.	Substrate	SEQ ID. No.
2263	GAGCUCCC CUGAUGAG X CGAA AAAUUUAG	1421	CUAAAUUUU GGGAGCUC	1729
2271	AGAUGGAG CUGAUGAG X CGAA AGCUCCCA	1422	UGGGAGCUC CUCCAUCU	1730
2274	UGGAGAUG CUGAUGAG X CGAA AGGAGCUC	1423	GAGCUCCUC CAUCUCCA	1731
2278	CCAUUGGA CUGAUGAG X CGAA AUGGAGGA	1424	UCCUCCAUC UCCAAUGG	1732
2280	AGCCAUUG CUGAUGAG X CGAA AGAUGGAG	1425	CUCCAUCUC CAAUGGCU	1733
2294	CUGCCACA CUGAUGAG X CGAA AUCCACAG	1426	GCUGGGAUU UGUGGCAG	1734
2295	CCUGCCAC CUGAUGAG X CGAA AAUCCACAG	1427	CUGGGAUUU GUGGCAGG	1735
2307	CUGAGUGG CUGAUGAG X CGAA AUCCUGC	1428	GCAGGGAUU CCACUCAG	1736
2308	UCUGAGUG CUGAUGAG X CGAA AAUCCUG	1429	CAGGGAUUC CACUCAGA	1737
2313	GAGGUUCU CUGAUGAG X CGAA AGUGGAU	1430	AUUCCACUC AGAACCUC	1738
2321	AUUCGAGA CUGAUGAG X CGAA AGGUUCUG	1431	CAGAACCUC UCUGGAU	1739
2323	AAAUUCCA CUGAUGAG X CGAA AGAGGUUC	1432	GAACCUCUC UGGAAUUU	1740
2330	CAGGCACA CUGAUGAG X CGAA AUUCCAGA	1433	UCUGGAUUU UGUGCCUG	1741
2331	UCAGGCAC CUGAUGAG X CGAA AAUUCACAG	1434	CUGGAUUUU GUGCCUGA	1742
2347	UCCAGUGG CUGAUGAG X CGAA AGGCACAU	1435	AUGUGCCUU CCACUGGA	1743
2348	AUCCAGUG CUGAUGAG X CGAA AAGGCACA	1436	UGUGCCUUC CACUGGAU	1744
2357	AACCCCAA CUGAUGAG X CGAA AUCCAGUG	1437	CACUGGAUU UUGGGGUU	1745
2358	GAACCCCA CUGAUGAG X CGAA AAUCCAGU	1438	ACUGGAUUU UGGGGUUC	1746
2359	GGAACCCC CUGAUGAG X CGAA AAAUCCAG	1439	CUGGAUUUU GGGGUUCC	1747
2365	GUGCUGGG CUGAUGAG X CGAA ACCCCAAA	1440	UUUGGGGUU CCCAGCAC	1748
2366	GGUGCUGG CUGAUGAG X CGAA AACCCCAA	1441	UUGGGGUUC CCAGCACC	1749
2385	CCCCCCAA CUGAUGAG X CGAA AUCCACAU	1442	AUGUGGAUU UUGGGGGG	1750
2386	ACCCCCCA CUGAUGAG X CGAA AAUCCACA	1443	UGUGGAUUU UGGGGGGU	1751
2387	GACCCCCC CUGAUGAG X CGAA AAAUCCAC	1444	GUGGAUUUU GGGGGGUC	1752
2395	ACAAAAGG CUGAUGAG X CGAA ACCCCCCA	1445	UGGGGGGUC CCUUUGU	1753
2399	AGACACAA CUGAUGAG X CGAA AGGGACCC	1446	GGGUCCUUU UUGUGUCU	1754
2400	GAGACACA CUGAUGAG X CGAA AAGGGACC	1447	GGUCCUUU UUGUGUCU	1755
2401	GGAGACAC CUGAUGAG X CGAA AAAGGGAC	1448	GUCCUUUU GUGUCUCC	1756
2406	GCGGGGGA CUGAUGAG X CGAA ACACAAAA	1449	UUUUGUGUC UCCCCCGC	1757
2408	UGGCGGGG CUGAUGAG X CGAA AGACACAA	1450	UUGUGUCUC CCCCGCCA	1758
2418	AGUCCUUG CUGAUGAG X CGAA AUGGCGGG	1451	CCCGCCAUU CAAGGACU	1759
2419	GAGUCCUU CUGAUGAG X CGAA AAUGGCGG	1452	CCGCCAUUC AAGGACUC	1760
2427	AAAGAGAG CUGAUGAG X CGAA AGUCCUUG	1453	CAAGGACUC CUCUCUUU	1761
2430	AAGAAAGA CUGAUGAG X CGAA AGGAGUCC	1454	GGACUCCUC UCUUUCUU	1762
2432	UGAAGAAA CUGAUGAG X CGAA AGAGGAGU	1455	ACUCCUCUC UUUCUUCA	1763
2434	GGUGAAGA CUGAUGAG X CGAA AGAGAGGA	1456	UCCUCUCUU UCUUCACC	1764
2435	UGGUGAAG CUGAUGAG X CGAA AAGAGAGG	1457	CCUCUCUUU CUUCACCA	1765
2436	UUGGUGAA CUGAUGAG X CGAA AAAGAGAG	1458	CUCUCUUUC UUCACCAA	1766
2438	UCUUGGUG CUGAUGAG X CGAA AGAAAGAG	1459	CUCUUCUU CACCAAGA	1767
2439	UUCUUGGU CUGAUGAG X CGAA AAGAAAGA	1460	UCUUCUUC ACCAAGAA	1768

Where "X" represents stem II region of a HH ribozyme (Hertel et al., 1992 Nucleic Acids Res. 20: 3252). The length of stem II may be ≥ 2 base-pairs.

Table XV: Human A-*raf* Hairpin Ribozyme and Target Sequence

nt. Position	Ribozyme Sequence		SEQ ID. No.	Target Sequence		SEQ ID. No.
69	CACAGA	AGAA GCCU ACCAGAGAACA X GUACAUUACCUUGUA	1769	AGCGG	GAC UCUGUG	1841
117	CGUAC	AGAA GCGG ACCAGAGAACA X GUACAUUACCUUGUA	1770	CGCGG	GUU GUAGCG	1842
120	CGCGC	AGAA GCGG ACCAGAGAACA X GUACAUUACCUUGUA	1771	CGGCU	GUA GCGGCG	1843
151	GGGCG	AGAA GGUU ACCAGAGAACA X GUACAUUACCUUGUA	1772	CACCU	GCC CAGCCC	1844
156	AGGUG	AGAA GGGC ACCAGAGAACA X GUACAUUACCUUGUA	1773	GCCCA	GCC CCACCU	1845
167	AGAUG	AGAA GAGG ACCAGAGAACA X GUACAUUACCUUGUA	1774	CCUCA	GCC CAUCUU	1846
268	UUGUUG	AGAA GUUA ACCAGAGAACA X GUACAUUACCUUGUA	1775	UACCU	GCC CAACAA	1847
296	AUCCCG	AGAA GUUA ACCAGAGAACA X GUACAUUACCUUGUA	1776	UGACU	GUC CGGGAU	1848
366	CCACAC	AGAA GUCC ACCAGAGAACA X GUACAUUACCUUGUA	1777	GGACU	GCU GUGUGG	1849
381	UGAUGA	AGAA GUAG ACCAGAGAACA X GUACAUUACCUUGUA	1778	GUACC	GAC UCAUCA	1850
410	GUGCCA	AGAA GUGA ACCAGAGAACA X GUACAUUACCUUGUA	1779	UCACU	GCC UGGGAC	1851
478	AUGGUC	AGAA GGAC ACCAGAGAACA X GUACAUUACCUUGUA	1780	GUGCC	GCU GACCAU	1852
481	UGCAUG	AGAA GCGG ACCAGAGAACA X GUACAUUACCUUGUA	1781	CGGCU	GAC CAUGCA	1853
516	ACGCCA	AGAA GAAG ACCAGAGAACA X GUACAUUACCUUGUA	1782	CUUCA	GCC UGGCGU	1854
537	ACUUA	AGAA GAAG ACCAGAGAACA X GUACAUUACCUUGUA	1783	CUUCU	GCC UUAAGU	1855
550	CCAUGG	AGAA GAAA ACCAGAGAACA X GUACAUUACCUUGUA	1784	UUUCU	GUU CCAUGG	1856
564	UUUGGC	AGAA GAAG ACCAGAGAACA X GUACAUUACCUUGUA	1785	CUUCC	GUU GCCAAA	1857
620	AACACA	AGAA GUGG ACCAGAGAACA X GUACAUUACCUUGUA	1786	CCACA	GUC UGUGUU	1858
652	UGGUAG	AGAA GUUG ACCAGAGAACA X GUACAUUACCUUGUA	1787	CAACA	GUU CUACCA	1859
714	UCAGGG	AGAA GUUC ACCAGAGAACA X GUACAUUACCUUGUA	1788	GAACC	GCC CCUGA	1860
750	UGCGGG	AGAA GGGG ACCAGAGAACA X GUACAUUACCUUGUA	1789	UCCCA	GCC CCGGCA	1861
794	GGCUGG	AGAA GGGG ACCAGAGAACA X GUACAUUACCUUGUA	1790	UCCCU	GCC CCAGCC	1862
825	ACGUGG	AGAA GAUG ACCAGAGAACA X GUACAUUACCUUGUA	1791	CAUCC	GCU CCACGU	1863
866	CAUGGG	AGAA GUGG ACCAGAGAACA X GUACAUUACCUUGUA	1792	CCACG	GCC CCAUG	1864
892	CCAGUG	AGAA GGAU ACCAGAGAACA X GUACAUUACCUUGUA	1793	AUCCA	GCU CACUGG	1865
917	GGCAGC	AGAA GUGC ACCAGAGAACA X GUACAUUACCUUGUA	1794	GCACU	GAU GCUGCC	1866
923	ACUACC	AGAA GCAU ACCAGAGAACA X GUACAUUACCUUGUA	1795	AUGCU	GCC GGUAGU	1867
927	CUCUAC	AGAA GGCA ACCAGAGAACA X GUACAUUACCUUGUA	1796	UGCCG	GUA GUAGAG	1868
969	UGGCGU	AGAA GGGG ACCAGAGAACA X GUACAUUACCUUGUA	1797	CCCCA	GCC CAGCCA	1869
1049	CUUGUC	AGAA GCCA ACCAGAGAACA X GUACAUUACCUUGUA	1798	UGGCC	GAU GACAAG	1870
1126	UUCAGC	AGAA GCAC ACCAGAGAACA X GUACAUUACCUUGUA	1799	GUGCA	GCU GUGAA	1871
1129	CUCUUC	AGAA GCUG ACCAGAGAACA X GUACAUUACCUUGUA	1800	CAGCU	GCU GAAGAG	1872
1219	GCUGUG	AGAA GGGG ACCAGAGAACA X GUACAUUACCUUGUA	1801	UCCCA	GCC CACAGC	1873
1226	CUGCUC	AGAA GUGG ACCAGAGAACA X GUACAUUACCUUGUA	1802	CCACA	GCU GAGCAG	1874
1297	CCCAUA	AGAA GCAA ACCAGAGAACA X GUACAUUACCUUGUA	1803	UUGCU	GUU UAUGGU	1875
1318	AAUCCC	AGAA GGGU ACCAGAGAACA X GUACAUUACCUUGUA	1804	ACCCG	GCC GGGAUU	1876
1359	GGUAGA	AGAA GGAG ACCAGAGAACA X GUACAUUACCUUGUA	1805	CUCCA	GCC UCUACC	1877
1408	UCGAUG	AGAA GGAC ACCAGAGAACA X GUACAUUACCUUGUA	1806	GUCCA	GCU CAUCGA	1878

nt. Position	Ribozyme Sequence	SEQ ID. No.	Target Sequence	SEQ ID. No.
1429	UGGCA AGAA GCG ACCAGAGAACA X GUACAUUACUGGUA	1807	CGGCA GAC UGCCCC	1879
1433	GCCUG AGAA GUC ACCAGAGAACA X GUACAUUACUGGUA	1808	AGACU GCC CAGGGC	1880
1576	UCCAG AGAA GGC ACCAGAGAACA X GUACAUUACUGGUA	1809	GCCCA GCC CUUGGA	1881
1588	CCUGAG AGAA GCUC ACCAGAGAACA X GUACAUUACUGGUA	1810	GAGCA GCC CUAGG	1882
1616	CACUC AGAA GCG ACCAGAGAACA X GUACAUUACUGGUA	1811	UGGCA GCU GAGGUG	1883
1629	CCUGCA AGAA GAUC ACCAGAGAACA X GUACAUUACUGGUA	1812	GAUCC GUA UGACGG	1884
1653	ACUGGA AGAA GUAG ACCAGAGAACA X GUACAUUACUGGUA	1813	CUACA GCU UCCAGU	1885
1664	AUAGAC AGAA GACU ACCAGAGAACA X GUACAUUACUGGUA	1814	AGUCA GAC GUCUUA	1886
1714	CUGUAA AGAA GUGA ACCAGAGAACA X GUACAUUACUGGUA	1815	UCACU GCC UUAACAG	1887
1734	GGUCAC AGAA GCCA ACCAGAGAACA X GUACAUUACUGGUA	1816	UGGCU GCC GUGACC	1888
1744	AGAUA AGAA GGUC ACCAGAGAACA X GUACAUUACUGGUA	1817	GACCA GAU UAUUUU	1889
1774	UCCGGG AGAA GAUA ACCAGAGAACA X GUACAUUACUGGUA	1818	UAUCU GUC CCGGCA	1890
1781	GCUGAG AGAA GGG ACCAGAGAACA X GUACAUUACUGGUA	1819	CCCCG GAC CUCAGC	1891
1806	CCUUGG AGAA GUUG ACCAGAGAACA X GUACAUUACUGGUA	1820	CAACU GCC CCAAGG	1892
1828	UCAGAC AGAA GCG ACCAGAGAACA X GUACAUUACUGGUA	1821	CGCCU GCU GUCUGA	1893
1831	CAGUCA AGAA GCAG ACCAGAGAACA X GUACAUUACUGGUA	1822	CUGCU GUC UGACUG	1894
1835	GAGCA AGAA GACA ACCAGAGAACA X GUACAUUACUGGUA	1823	UGUCU GAC UGCCUC	1895
1839	ACUUGA AGAA GUCA ACCAGAGAACA X GUACAUUACUGGUA	1824	UGACU GCC UCAAGU	1896
1864	AAGAGG AGAA GCUC ACCAGAGAACA X GUACAUUACUGGUA	1825	GAGCG GCC CCUCUU	1897
1879	GCCAGG AGAA GGG ACCAGAGAACA X GUACAUUACUGGUA	1826	CCCCA GAU CCUGGC	1898
1900	CGUUGC AGAA GCUC ACCAGAGAACA X GUACAUUACUGGUA	1827	GAGCU GCU GCAACG	1899
1967	CAACUC AGAA GCCU ACCAGAGAACA X GUACAUUACUGGUA	1828	AGGCC GAU GAGUUG	1900
1979	UAGGCA AGAA GCGA ACCAGAGAACA X GUACAUUACUGGUA	1829	UGCCU GCC UGCCUA	1901
1983	UGAGUA AGAA GGCA ACCAGAGAACA X GUACAUUACUGGUA	1830	UGCCU GCC UACUCA	1902
1997	AAGGGG AGAA GCGC ACCAGAGAACA X GUACAUUACUGGUA	1831	GCGCA GCC CGCCUU	1903
2001	GCACAA AGAA GCGU ACCAGAGAACA X GUACAUUACUGGUA	1832	AGCCC GCC UUGUGC	1904
2020	GGCUUG AGAA GGGC ACCAGAGAACA X GUACAUUACUGGUA	1833	GCCCC GCC CAAGCC	1905
2047	GUGGAG AGAA GAGA ACCAGAGAACA X GUACAUUACUGGUA	1834	UCUCA GCC CUCCAC	1906
2097	CAUCAG AGAA GAGA ACCAGAGAACA X GUACAUUACUGGUA	1835	UCUCU GCC CUGAUG	1907
2102	GGCAGC AGAA GGGC ACCAGAGAACA X GUACAUUACUGGUA	1836	GCCCU GAU GCUGCC	1908
2108	UCCUGA AGAA GCAU ACCAGAGAACA X GUACAUUACUGGUA	1837	AUGCU GCC UCAGGA	1909
2167	CAGRAG AGAA GGAA ACCAGAGAACA X GUACAUUACUGGUA	1838	UUCCA GUU CUUCUG	1910
2211	GGAGGA AGAA GGG ACCAGAGAACA X GUACAUUACUGGUA	1839	CCCCU GUC UCCUCC	1911
2337	AGGCAC AGAA GGCA ACCAGAGAACA X GUACAUUACUGGUA	1840	UGCCU GAU GUGCCU	1912

Where "X" represents stem IV region of a Hairpin ribozyme. The length of stem IV may be 2 base-pairs.

Table XVI: Hammerhead Ribozyme Sites for B-raf

nt. Position	Ribozyme	SEQ ID. No.	Substrate	SEQ ID. No.
17	CGGGCGGG CUGAUGAG X CGAA AGGGGGCC	1913	GGCCCCCUC CCCGCCCG	2354
38	CGGGGCCC CUGAUGAG X CGAA AGCGGCCG	1914	CGGCCGCUC GGGCCCCG	2355
50	AUAACCGA CUGAUGAG X CGAA AGCCGGGG	1915	CCCCGGCUC UCGGUUUA	2356
52	UUAUAACC CUGAUGAG X CGAA AGAGCCGG	1916	CCGGCUCUC GGUUAUAA	2357
56	CAUCUUUA CUGAUGAG X CGAA ACCGAGAG	1917	CUCUCGGUU AUAAGAUG	2358
57	CCAUCUUA CUGAUGAG X CGAA AACCGAGA	1918	UCUCGGUUA UAAGAUGG	2359
59	CGCCAUCU CUGAUGAG X CGAA AUAACCGA	1919	UCGGUUAUA AGAUGGCG	2360
113	GUUGAACA CUGAUGAG X CGAA AGCCUGGC	1920	GCCAGGCUC UGUUCAAC	2361
117	CCCCGUUG CUGAUGAG X CGAA ACAGAGCC	1921	GGCUCUGUU CAACGGGG	2362
118	UCCCCGUU CUGAUGAG X CGAA AACAGAGC	1922	GCUCUGUUC AACGGGGA	2363
165	CAGCCGAA CUGAUGAG X CGAA AGGCGCGG	1923	CGCGGCCUC UUCGGCUG	2364
167	CGCAGCCG CUGAUGAG X CGAA AGAGGCCG	1924	CGGCCUCUU CGGCUGCG	2365
168	CCGCAGCC CUGAUGAG X CGAA AAGAGGCC	1925	GGCCUCUUC GGCUGCGG	2366
187	UCCUCCGG CUGAUGAG X CGAA AUGGCAGG	1926	CCUGCCAUA CCGGAGGA	2367
188	CUCCUCCG CUGAUGAG X CGAA AAUGGCAG	1927	CUGCCAUAU CCGGAGGAG	2368
206	UUGUUUGA CUGAUGAG X CGAA AUUCCACA	1928	UGUGGAAUA UCAAACAA	2369
208	AUUUGUUU CUGAUGAG X CGAA AUUUUCCA	1929	UGGAAUAUC AAACAAAU	2370
220	GUCAACUU CUGAUGAG X CGAA AUCAUUUG	1930	CAAAUGAUU AAGUUGAC	2371
221	UGUCAACU CUGAUGAG X CGAA AAUCAUUU	1931	AAAUGAUUA AGUUGACA	2372
225	CCUGUGUC CUGAUGAG X CGAA ACUUAUUC	1932	GAUUAAGUU GACACAGG	2373
239	GGCCUCUA CUGAUGAG X CGAA AUGUCCCU	1933	AGGAACAUA UAGAGGCC	2374
241	AGGGCCUC CUGAUGAG X CGAA AUAUGUUC	1934	GAACAUAUA GAGGCCCU	2375
250	UUGUCCAA CUGAUGAG X CGAA AGGGCCUC	1935	GAGGCCCUA UUGGACAA	2376
252	AUUUGUCC CUGAUGAG X CGAA AUAGGGCC	1936	GGCCCUAUU GGACAAAU	2377
261	CCCCACCA CUGAUGAG X CGAA AUUUGUCC	1937	GGACAAAUU UGGUGGGG	2378
262	UCCCCACC CUGAUGAG X CGAA AAUUUGUC	1938	GACAAAUUU GGUGGGGA	2379
275	UGGUGGAU CUGAUGAG X CGAA AUGCUCCC	1939	GGGAGCAUA AUCCACCA	2380
278	UGAUGGUG CUGAUGAG X CGAA AUUAUGCU	1940	AGCAUAAUC CACCAUCA	2381
285	GAUAUAUU CUGAUGAG X CGAA AUGGUGGA	1941	UCCACCAUC AAUAUAUC	2382
289	UCCAGAUU CUGAUGAG X CGAA AUUGAUGG	1942	CCAUCAUAU UAUCUGGA	2383
291	CCUCCAGA CUGAUGAG X CGAA AUAUUGAU	1943	AUCAUAUAU UCUGGAGG	2384
293	GGCCUCCA CUGAUGAG X CGAA AUAUAUUG	1944	CAAUUAUAU UGGAGGCC	2385
303	AUUCUUCA CUGAUGAG X CGAA AGGCCUCC	1945	GGAGGCCUA UGAAGAAU	2386
312	UGCUGGUG CUGAUGAG X CGAA AUUCUUCA	1946	UGAAGAAUA CACCAGCA	2387
325	AGUGCAUC CUGAUGAG X CGAA AGCUUGCU	1947	AGCAAGCUA GAUGCACU	2388
334	CUUUGUUG CUGAUGAG X CGAA AGUGCAUC	1948	GAUGCACUC CAACAAAG	2389
354	AUUCCAAU CUGAUGAG X CGAA ACUGUUGU	1949	ACAACAGUU AUUGGAAU	2390
355	GAUCCCAA CUGAUGAG X CGAA AACUGUUG	1950	CAACAGUUA UUGGAAUC	2391
357	GAGAUUCC CUGAUGAG X CGAA AUAACUGU	1951	ACAGUUAUU GGAAUCUC	2392
363	UCCCCAGA CUGAUGAG X CGAA AUUCCAAU	1952	AUUGGAAUC UCUGGGGA	2393
365	GUUCCCCA CUGAUGAG X CGAA AGAUUCCA	1953	UGGAAUCUC UGGGGAAC	2394
383	AACAGAAA CUGAUGAG X CGAA AUCAGUUC	1954	GAACUGAUU UUUCUGUU	2395
384	AAACAGAA CUGAUGAG X CGAA AAUCAGUU	1955	AACUGAUUU UUCUGUUU	2396
385	GAAACAGA CUGAUGAG X CGAA AAAUCAGU	1956	ACUGAUUUU UCUGUUUC	2397
386	AGAAACAG CUGAUGAG X CGAA AAAAUCAG	1957	CUGAUUUUU CUGUUUCU	2398
387	UAGAAACA CUGAUGAG X CGAA AAAAAUCA	1958	UGAUUUUUC UGUUUCUA	2399
391	GAGCUAGA CUGAUGAG X CGAA ACAGAAAA	1959	UUUUCUGUU UCUAGCUC	2400
392	AGAGCUAG CUGAUGAG X CGAA AACAGAAA	1960	UUUCUGUUU CUAGCUCU	2401
393	CAGAGCUA CUGAUGAG X CGAA AAACAGAA	1961	UUCUGUUUC UAGCUCUG	2402
395	UGCAGAGC CUGAUGAG X CGAA AGAAACAG	1962	CUGUUUCUA GCUCUGCA	2403
399	UUGAUGCA CUGAUGAG X CGAA AGCUAGAA	1963	UUCUAGCUC UGCAUCAA	2404
405	UAUCCAUU CUGAUGAG X CGAA AUCCAGAG	1964	CUCUGCAUC AAUGGAUA	2405
413	UGUAACGG CUGAUGAG X CGAA AUCCAUUG	1965	CAAUGGAUA CCGUUAUA	2406

nt. Position	Ribozyme	SEQ ID. No.	Substrate	SEQ ID. No.
418	GAAGAUGU CUGAUGAG X CGAA ACGGUAUC	1966	GAUACCGUU ACAUCUUC	2407
419	AGAAGAUG CUGAUGAG X CGAA AACGGUAU	1967	AUACCGUUA CAUCUUCU	2408
423	AGGAAGAA CUGAUGAG X CGAA AUGUAACG	1968	CGUUACAUC UUCUUCU	2409
425	AGAGGAAG CUGAUGAG X CGAA AGAUGUAA	1969	UUACAUCUU CUUCCUCU	2410
426	AAGAGGAA CUGAUGAG X CGAA AAGUGUA	1970	UACAUCUUC UUCCUCUU	2411
428	AGAAGAGG CUGAUGAG X CGAA AGAAGAU	1971	CAUCUUCUU CCUCUUCU	2412
429	UAGAAGAG CUGAUGAG X CGAA AAGAAGAU	1972	AUCUUCUUC CUCUUCUA	2413
432	GCGUAGAA CUGAUGAG X CGAA AGGAAGAA	1973	UUCUUCUUC UUCUAGCC	2414
434	AAGGCUAG CUGAUGAG X CGAA AGAGGAAG	1974	CUUCCUCUU CUAGCCUU	2415
435	AAAGGCUA CUGAUGAG X CGAA AAGAGGAA	1975	UUCCUCUUC UAGCCUUU	2416
437	UGAAAGGC CUGAUGAG X CGAA AGAAGAGG	1976	CCUCUUCUA GCCUUUA	2417
442	AGCACUGA CUGAUGAG X CGAA AGGCUAGA	1977	UCUAGCCUU UCAGUGCU	2418
443	UAGCACUG CUGAUGAG X CGAA AAGGCUAG	1978	CUAGCCUUU CAGUGCUA	2419
444	GUAGCACU CUGAUGAG X CGAA AAAGGCUA	1979	UAGCCUUUC AGUGCUAC	2420
451	GAUGAAGG CUGAUGAG X CGAA AGCACUGA	1980	UCAGUGCUA CCUUCUUC	2421
455	AAGAGAUG CUGAUGAG X CGAA AGGUAACA	1981	UGCUAACUU CAUCUCUU	2422
456	AAAGAGAU CUGAUGAG X CGAA AAGGUAGC	1982	GCUACCUUC AUCUCUUU	2423
459	CUGAAAGA CUGAUGAG X CGAA AUGAAGGU	1983	ACCUUCAUC UCUUUCAG	2424
461	AACUGAAA CUGAUGAG X CGAA AGAUGAAG	1984	CUUCAUCUC UUUAGUUU	2425
463	AAAACUGA CUGAUGAG X CGAA AGAGAUGA	1985	UCAUCUCUU UCAGUUUU	2426
464	AAAAACUG CUGAUGAG X CGAA AAGAGAUG	1986	CAUCUCUUU CAGUUUUU	2427
465	GAAAAACU CUGAUGAG X CGAA AAAGAGAU	1987	AUCUCUUUC AGUUUUUC	2428
469	UUUUGAAA CUGAUGAG X CGAA ACUGAAAG	1988	CUUUCAGUU UUUCAAAA	2429
470	AUUUUGAA CUGAUGAG X CGAA AACUGAAA	1989	UUUCAGUUU UUCAAAAU	2430
471	GAUUUUGA CUGAUGAG X CGAA AACUGAAA	1990	UUCAGUUUU UCAAAAUC	2431
472	GGAUUUUG CUGAUGAG X CGAA AAAACUGA	1991	UCAGUUUUU CAAAAUCC	2432
473	GGGAUUUU CUGAUGAG X CGAA AAAACUG	1992	CAGUUUUUC AAAAUCCC	2433
479	AUCUGUGG CUGAUGAG X CGAA AUUUUGAA	1993	UUCAAAAUC CCACAGAU	2434
510	UUUGUGGU CUGAUGAG X CGAA ACUUGGGG	1994	CCCCAAGUC ACCACAAA	2435
524	UCUAACGA CUGAUGAG X CGAA AGGUUUUU	1995	AAAAACCUA UCGUUAGA	2436
526	ACUCUAAC CUGAUGAG X CGAA AUAGGUUU	1996	AAACCUAUC GUUAGAGU	2437
529	AAGACUCU CUGAUGAG X CGAA ACGAUAGG	1997	CCUAUCGUU AGAGUCUU	2438
530	GAAGACUC CUGAUGAG X CGAA AACGAUAG	1998	CUAUCGUUA GAGUCUUC	2439
535	GGCAGGAA CUGAUGAG X CGAA ACUCUAAC	1999	GUUAGAGUC UUCUGGCC	2440
537	UGGGCAGG CUGAUGAG X CGAA AGACUCUA	2000	UAGAGUCUU CCUGCCCA	2441
538	UUGGGCAG CUGAUGAG X CGAA AAGACUCU	2001	AGAGUCUUC CUGCCCAA	2442
565	CUUGCAGG CUGAUGAG X CGAA ACCACUGU	2002	ACAGUGGUA CCUGCAAG	2443
583	CGGACUGU CUGAUGAG X CGAA ACUCCACA	2003	UGUGGAGUU ACAGUCCG	2444
584	UCGGACUG CUGAUGAG X CGAA AACUCCAC	2004	GUGGAGUUA CAGUCCGA	2445
589	CUGUCUCG CUGAUGAG X CGAA ACUGUAAC	2005	GUUACAGUC CGAGACAG	2446
599	UUUCUUUA CUGAUGAG X CGAA ACUGUCUC	2006	GAGACAGUC UAAAGAAA	2447
601	GCUUUCUU CUGAUGAG X CGAA AGACUGUC	2007	GACAGUCUA AAGAAAGC	2448
626	UGGGAUUA CUGAUGAG X CGAA ACCUCUCA	2008	UGAGAGGUC UAAUCCCA	2449
628	UCUGGGAU CUGAUGAG X CGAA AGACCUCU	2009	AGAGGUCUA AUCCCAGA	2450
631	CACUCUGG CUGAUGAG X CGAA AUUAGACC	2010	GGUCUAAUC CCAGAGUG	2451
649	AUUCUGUA CUGAUGAG X CGAA ACAGACACA	2011	UGUGCUGUU UACAGAAU	2452
650	AAUUCUGU CUGAUGAG X CGAA AACAGCAC	2012	GUGCUGUUU ACAGAAUU	2453
651	GAAUUCUG CUGAUGAG X CGAA AACAGACA	2013	UGCUGUUUA CAGAAUUC	2454
658	CCAUCCUG CUGAUGAG X CGAA AUUCUGUA	2014	UACAGAAUU CAGGAUGG	2455
659	UCCAUCCU CUGAUGAG X CGAA AAUUCUGU	2015	ACAGAAUUC AGGAUGGA	2456
682	UCCCAACC CUGAUGAG X CGAA AUUGGUUU	2016	AAACCAAUU GGUUGGGA	2457
686	AGUGUCCC CUGAUGAG X CGAA ACCAAUUG	2017	CAAUUGGUU GGGACACU	2458
698	CCAGGAAA CUGAUGAG X CGAA AUCAGUGU	2018	ACACUGAUA UUUCUGG	2459
700	AGCCAGGA CUGAUGAG X CGAA AUAUCAGU	2019	ACUGAUAUU UCCUGGCU	2460
701	AAGCCAGG CUGAUGAG X CGAA AAUAUCAG	2020	CUGAUAUUU CCUGGCUU	2461

nt. Position	Ribozyme	SEQ ID. No.	Substrate	SEQ ID. No.
702	UAAGCCAG CUGAUGAG X CGAA AAAUAUCA	2021	UGAUUUUUC CUGGCUUA	2462
709	UCUCCAGU CUGAUGAG X CGAA AGCCAGGA	2022	UCCUGGCUU ACUGGAGA	2463
710	UUCUCCAG CUGAUGAG X CGAA AAGCCAGG	2023	CCUGGCUUA CUGGAGAA	2464
723	CCACAUGC CUGAUGAG X CGAA AUUCUUCU	2024	AGAAGAAUU GCAUGUGG	2465
738	CAUUCUCC CUGAUGAG X CGAA ACACUUCU	2025	GGAAGUGUU GGAGAAUG	2466
748	GUAAGUGG CUGAUGAG X CGAA ACAUUCUC	2026	GAGAAUGUU CCACUUAU	2467
749	UGUAAGUG CUGAUGAG X CGAA AACAUUCU	2027	AGAAUGUUC CACUUAUA	2468
754	UGUGUUGU CUGAUGAG X CGAA AGUGGAAC	2028	GUUCCACUU ACAACACA	2469
755	GUGUGUUG CUGAUGAG X CGAA AAGUGGAA	2029	UUCACUUA CAACACAC	2470
768	UUCGUACA CUGAUGAG X CGAA AGUUGUGU	2030	ACACAACUU UGUACGAA	2471
769	UUUCGUAC CUGAUGAG X CGAA AAGUUGUG	2031	CACAACUUU GUACGAAA	2472
772	GUUUUUCG CUGAUGAG X CGAA ACAAGUUU	2032	AACUUUGUA CGAAAAAC	2473
783	AGGUGAAA CUGAUGAG X CGAA ACGUUUUU	2033	AAAAACGUU UUUCACCU	2474
784	AAGGUGAA CUGAUGAG X CGAA AACGUUUU	2034	AAAACGUUU UUCACCUU	2475
785	UAAGGUGA CUGAUGAG X CGAA AAACGUUU	2035	AAACGUUUU UCACCUUA	2476
786	CUAAGGUG CUGAUGAG X CGAA AAAACGUU	2036	AACGUUUU CACCUUAG	2477
787	GUUAAGGU CUGAUGAG X CGAA AAAACGUU	2037	ACGUUUUUC ACCUUAAG	2478
792	AAAAGUCU CUGAUGAG X CGAA AGGUGAAA	2038	UUUCACCUU AGCAUUUU	2479
793	CAAAAUGC CUGAUGAG X CGAA AAGGUGAA	2039	UUCACCUUA GCAUUUUG	2480
798	AGUCACAA CUGAUGAG X CGAA AUGCUAAG	2040	CUUAGCAUU UUGUGACU	2481
799	AAGUCACA CUGAUGAG X CGAA AAUGCUGA	2041	UUAGCAUUU UGUGACUU	2482
800	AAAGUCAC CUGAUGAG X CGAA AAAUGCUG	2042	UAGCAUUUU GUGACUUU	2483
807	UUCGACAA CUGAUGAG X CGAA AGUCACAA	2043	UUGUGACUU UUGUCGAA	2484
808	UUUCGACA CUGAUGAG X CGAA AAGUCACA	2044	UGUGACUUU UGUCGAAA	2485
809	CUUUCGAC CUGAUGAG X CGAA AAAGUCAC	2045	GUGACUUUU GUCGAAAG	2486
812	CAGCUUUC CUGAUGAG X CGAA ACAAAAAGU	2046	ACUUUUGUC GAAAGCUG	2487
823	CCUGGGA CUGAUGAG X CGAA AGCAGCUU	2047	AAGCUGCUU UUCAGGGG	2488
824	ACCCUGGA CUGAUGAG X CGAA AAGCAGCU	2048	AGCUGCUUU UCCAGGGU	2489
825	AACCCUGG CUGAUGAG X CGAA AAAGCAGC	2049	GCUGCUUUU CCAGGGUU	2490
826	AAACCCUG CUGAUGAG X CGAA AAAAGCAG	2050	CUGCUUUUC CAGGGUUU	2491
833	ACAGCGGA CUGAUGAG X CGAA ACCCUGGA	2051	UCCAGGGUU UCCGUGU	2492
834	GACAGCGG CUGAUGAG X CGAA AACCCUGG	2052	CCAGGGUUU CCGUGUC	2493
835	UGACAGCG CUGAUGAG X CGAA AAACCCUG	2053	CAGGGUUUC CGUGUCA	2494
842	ACAUGUUU CUGAUGAG X CGAA ACAGCGGA	2054	UCCGUGUC AAACAUGU	2495
854	AAAUUUU CUGAUGAG X CGAA ACCACAUG	2055	CAUGUGGUU AUAAAUUU	2496
855	GAAAUUUA CUGAUGAG X CGAA AACCACAU	2056	AUGUGGUUA UAAAUUUC	2497
857	GUGAAAUU CUGAUGAG X CGAA AUAACCAC	2057	GUGGUUAUA AAUUUCAC	2498
861	GCUGGUGA CUGAUGAG X CGAA AUUUUAUA	2058	UUAUAAAU UCACCAGC	2499
862	CGCUGGUG CUGAUGAG X CGAA AAUUUAUA	2059	UAUAAAUU CACCAGCG	2500
863	ACGUGGUU CUGAUGAG X CGAA AAUUUUUU	2060	AUAAAUUUC ACCAGCGU	2501
872	UGUACUAC CUGAUGAG X CGAA ACGUGGUU	2061	ACCAGCGUU GUAGUACA	2502
875	UUCUGUAC CUGAUGAG X CGAA ACAACGCU	2062	AGCGUUGUA GUACAGAA	2503
878	AACUUCUG CUGAUGAG X CGAA ACUACAAC	2063	GUUGUAGUA CAGAAGUU	2504
886	AUCAGUGG CUGAUGAG X CGAA ACUUCUGU	2064	ACAGAAGUU CCACUGAU	2505
887	CAUCAGUG CUGAUGAG X CGAA AACUUCUG	2065	CAGAAGUUC CACUGAUG	2506
901	UCAUAAUU CUGAUGAG X CGAA ACACACAU	2066	AUGUGUGUU AAUUUAGA	2507
902	GUCAUAAU CUGAUGAG X CGAA AACACACA	2067	UGUGUGUUA AUUAUGAC	2508
905	UUGGUCAU CUGAUGAG X CGAA AUUAACAC	2068	GUGUAAAUU AUGACCAA	2509
906	GUUGGUCA CUGAUGAG X CGAA AAUUUACA	2069	UGUUAAUUA UGACCAAC	2510
916	AGCAAAUC CUGAUGAG X CGAA AGUUGGUC	2070	GACCAACUU GAUUUGCU	2511
920	AAACAGCA CUGAUGAG X CGAA AUCAAGUU	2071	AACUUGAUU UGCUGUUU	2512
921	CAACAGC CUGAUGAG X CGAA AAUCAGU	2072	ACUUGAUUU GCUGUUUG	2513
927	UGGAGACA CUGAUGAG X CGAA ACAGCAA	2073	UUUGCUGUU UGUCUCA	2514
928	UUGGAGAC CUGAUGAG X CGAA AACAGCAA	2074	UUGCUGUUU GUCUCCAA	2515
931	AACUUGGA CUGAUGAG X CGAA ACAACAG	2075	CUGUUUGUC UCCAAGUU	2516

nt. Position	Ribozyme	SEQ ID. No.	Substrate	SEQ ID. No.
933	AGAACUUG CUGAUGAG X CGAA AGACAAAC	2076	GUUUGUCUC CAAGUUCU	2517
939	GUUCAAG CUGAUGAG X CGAA ACUUGGAG	2077	CUCCAAGUU CUUUGAAC	2518
940	UGUUCAAA CUGAUGAG X CGAA AACUUGGA	2078	UCCAAGUUC UUUGAACA	2519
942	GGUGUUA CUGAUGAG X CGAA AGAACUUG	2079	CAAGUUCUU UGAACACC	2520
943	UGGUGUUC CUGAUGAG X CGAA AAGAACUU	2080	AAGUUCUUU GAACACCA	2521
958	UCCUGUGG CUGAUGAG X CGAA AUUGGGUG	2081	CACCCAAUA CCACAGGA	2522
975	CUGCUAAG CUGAUGAG X CGAA ACGCCUCU	2082	AGAGGCGUC CUUAGCAG	2523
978	UCUCUGCU CUGAUGAG X CGAA AGGACGCC	2083	GGCGUCCUU AGCAGAGA	2524
979	GUCUCUGC CUGAUGAG X CGAA AAGGACGC	2084	GCGUCCUUA GCAGAGAC	2525
994	CCAGAUGU CUGAUGAG X CGAA AGGGCAGU	2085	ACUGCCCUA ACAUCUGG	2526
999	AAGAUCCA CUGAUGAG X CGAA AUGUUAGG	2086	CCUAACAUC UGGAUCCU	2527
1005	AAGGGGAU CUGAUGAG X CGAA AUCCAGAU	2087	AUCUGGAUC AUCCCUU	2528
1008	CGGAAGGG CUGAUGAG X CGAA AUGAUCCA	2088	UGGAUCAUC CCCUCCG	2529
1013	GGGUGCGG CUGAUGAG X CGAA AGGGGAUG	2089	CAUCCCUU CCGCACCC	2530
1014	CGGGUGCG CUGAUGAG X CGAA AAGGGGAU	2090	AUCCCUUC CGCACCCG	2531
1026	UAGAGUCC CUGAUGAG X CGAA AGGCGGGU	2091	ACCCGCCUC GGACUCUA	2532
1032	GCCCAAUA CUGAUGAG X CGAA AGUCCGAG	2092	CUCGGACUC UAUUGGGC	2533
1034	GGGCCCAA CUGAUGAG X CGAA AGAGUCCG	2093	CGGACUCUA UUGGGCCC	2534
1036	UGGGGCCC CUGAUGAG X CGAA AUAGAGUC	2094	GACUCUAU UGGCCCCA	2535
1048	CUGGUGAG CUGAUGAG X CGAA AUUUGGGG	2095	CCCCAAAU CUCACCAG	2536
1049	ACUGGUGA CUGAUGAG X CGAA AAUUGGGG	2096	CCCCAAUUC UCACCAGU	2537
1051	GGACUGGU CUGAUGAG X CGAA AGAAUUUG	2097	CAAAUUCUC ACCAGUCC	2538
1058	AGGAGACG CUGAUGAG X CGAA ACUGGUGA	2098	UCACCAGUC CGUCUCCU	2539
1062	UUAAGGA CUGAUGAG X CGAA ACGGACUG	2099	CAGUCCGUC UCCUCAA	2540
1064	UUUGAAG CUGAUGAG X CGAA AGACGGAC	2100	GUCCGUCUC CUUCAA	2541
1067	GAUUUUG CUGAUGAG X CGAA AGGAGACG	2101	CGUCUCCU CAAAUCC	2542
1068	UGGAUUUU CUGAUGAG X CGAA AAGGAGAC	2102	GUCUCCUUC AAAAUCCA	2543
1074	UUGGAUG CUGAUGAG X CGAA AUUUUGAA	2103	UUCAAAUC CAUCCAA	2544
1078	GGAAUUG CUGAUGAG X CGAA AUGGAUUU	2104	AAAUCCAUC CCAAUCC	2545
1079	UGGAUUUG CUGAUGAG X CGAA AAUGGAUU	2105	AAUCCAUC CAAUCCA	2546
1084	GGCUGUG CUGAUGAG X CGAA AUUGGAAU	2106	AUCCAUAU CCACAGCC	2547
1085	GGGUGUG CUGAUGAG X CGAA AAUUGGAA	2107	UCCAUAUC CACAGCCC	2548
1095	CUGGUCGG CUGAUGAG X CGAA AGGGCUGU	2108	ACAGCCCU CCGACCAG	2549
1096	GCUGGUCG CUGAUGAG X CGAA AAGGGCUG	2109	CAGCCCUUC CGACCAGC	2550
1115	AUUUCGAU CUGAUGAG X CGAA AUCUUCAU	2110	AUGAAGAUC AUCGAAU	2551
1118	UUGAUUUC CUGAUGAG X CGAA AUGAUCUU	2111	AAGAUAUC GAAAUCAA	2552
1124	CCCAAUU CUGAUGAG X CGAA AUUUCGAU	2112	AUCGAAUC AAUUGGG	2553
1128	GUUGCCA CUGAUGAG X CGAA AUUGAUUU	2113	AAAUCAAU UGGGCAAC	2554
1129	CGUUGCCC CUGAUGAG X CGAA AAUUGAUU	2114	AAUCAAUU GGGCAACG	2555
1146	CUGAUGAG CUGAUGAG X CGAA AUCGGUCU	2115	AGACCGAUC CUCAUCAG	2556
1149	GAGCUGAU CUGAUGAG X CGAA AGGAUCGG	2116	CCGAUCCUC AUCAGCUC	2557
1152	UGGGAGCU CUGAUGAG X CGAA AUGAGGAU	2117	AUCCUCAUC AGCUCCA	2558
1157	CACAUUGG CUGAUGAG X CGAA AGCUGAUG	2118	CAUCAGCUC CCAAUGUG	2559
1169	UGUGUUUA CUGAUGAG X CGAA AUGCAUAU	2119	AUGUGCAUA UAAACACA	2560
1171	AUUGUUU CUGAUGAG X CGAA AUAUGCAC	2120	GUGCAUAUA AACACAAU	2561
1180	ACAGGUUC CUGAUGAG X CGAA AUUGUGUU	2121	AACACAAUA GAACCGU	2562
1189	UCAAUUU CUGAUGAG X CGAA ACAGGUUC	2122	GAACCGUC AAUAUUGA	2563
1193	GUCAUCAA CUGAUGAG X CGAA AUUGACAG	2123	CUGUCAUA UUGAUGAC	2564
1195	AAGUCAUC CUGAUGAG X CGAA AUAUUGAC	2124	GUCAUAUU GAUGACUU	2565
1203	CUCUUAUC CUGAUGAG X CGAA AGUCAUCA	2125	UGAUGACUU GAUUGAGG	2566
1207	UGGUCUCU CUGAUGAG X CGAA AUCAAGUC	2126	GACUUGAUU AGAGACCA	2567
1208	UUGGUCUC CUGAUGAG X CGAA AAUCAAGU	2127	ACUUGAUUA GAGACCAA	2568
1221	CACCACGA CUGAUGAG X CGAA AUCCUUGG	2128	CCAAGGAUU UCGUGGUG	2569
1222	UCACCACG CUGAUGAG X CGAA AAUCCUUG	2129	CAAGGAUUU CGUGGUGA	2570
1223	AUACCAC CUGAUGAG X CGAA AAUCCUU	2130	AAGGAUUUC GUGGUGAU	2571

nt. Position	Ribozyme	SEQ ID. No.	Substrate	SEQ ID. No.
1239	CUGUGGUU CUGAUGAG X CGAA AUCCUCCA	2131	UGGAGGAUC AACACAG	2572
1250	AGCAGACA CUGAUGAG X CGAA ACCUGUGG	2132	CCACAGGUU UGUCUGCU	2573
1251	UAGCAGAC CUGAUGAG X CGAA AACCUGUG	2133	CACAGGUUU GUCUGCUA	2574
1254	GGGUAGCA CUGAUGAG X CGAA ACAAAACCU	2134	AGGUUUGUC UGCUACCC	2575
1259	AGGGGGGG CUGAUGAG X CGAA AGCAGACA	2135	UGUCUGCUA CCCCCCU	2576
1272	CAGGUAAU CUGAUGAG X CGAA AGGCAGGG	2136	CCCUGCCUC AUUACCUG	2577
1275	AGCCAGGU CUGAUGAG X CGAA AUGAGGCA	2137	UGCCUCAUU ACCUGGCU	2578
1276	GAGCCAGG CUGAUGAG X CGAA AAUGAGGC	2138	GCCUCAUUA CCUGGCUC	2579
1284	UAGUUAGU CUGAUGAG X CGAA AGCCAGGU	2139	ACCUGGCUC ACUACUA	2580
1288	ACGUUAGU CUGAUGAG X CGAA AGUGAGCC	2140	GGCUCACUA ACUACGU	2581
1292	UUUCAGU CUGAUGAG X CGAA AGUUAGUG	2141	CACUAACUA ACGUGAA	2582
1305	AUUUCUGU CUGAUGAG X CGAA AGGCUUUC	2142	GAAAGCCUU ACAGAAU	2583
1306	GAUUUCUG CUGAUGAG X CGAA AAGGCUUU	2143	AAAGCCUUA CAGAAU	2584
1314	GUCCUGGA CUGAUGAG X CGAA AUUUCUGU	2144	ACAGAAU UCCAGGAC	2585
1316	AGGUCCUG CUGAUGAG X CGAA AGAUUUCU	2145	AGAAUUCUC CAGGACCU	2586
1325	UUCUCGU CUGAUGAG X CGAA AGGUCCUG	2146	CAGGACCUC AGCGAGAA	2587
1341	AUGAAGAU CUGAUGAG X CGAA ACUCCUU	2147	AAGGAAGUC AUCUUAU	2588
1344	AGGAUGAA CUGAUGAG X CGAA AUGACUUC	2148	GAAGUCAUC UUCAUCCU	2589
1346	UGAGGAUG CUGAUGAG X CGAA AGAUGACU	2149	AGUCAUUCU CAUCCUCA	2590
1347	CUGAGGAU CUGAUGAG X CGAA AAGAUGAC	2150	GUCAUCUUC AUCCUCAG	2591
1350	CUUCUGAG CUGAUGAG X CGAA AUGAAGAU	2151	AUCUUAUC CUCAGAAG	2592
1353	UGUCUUCU CUGAUGAG X CGAA AGGAUGAA	2152	UUCAUCCUC AGAAGACA	2593
1367	UUUCAUUC CUGAUGAG X CGAA AUUCCUGU	2153	ACAGGAUUC GAAUGAA	2594
1381	CGUCUACC CUGAUGAG X CGAA AGUGUUUU	2154	AAAACACUU GGUAGACG	2595
1385	GUCCCGUC CUGAUGAG X CGAA ACCAAGUG	2155	CACUUGGUA GACGGGAC	2596
1395	CAUCACUC CUGAUGAG X CGAA AGUCCGU	2156	ACGGGACUC GAGUGAUG	2597
1406	AAUCUCCC CUGAUGAG X CGAA AUCAUCAC	2157	GUGAUGAUU GGGAGAUU	2598
1414	CCAUCAGG CUGAUGAG X CGAA AUCUCCA	2158	UGGGAGAUU CCUGAUGG	2599
1415	CCCAUCAG CUGAUGAG X CGAA AAUCUCCC	2159	GGGAGAUUC CUGAUGGG	2600
1429	CCCACUGU CUGAUGAG X CGAA AUCUGCCC	2160	GGGAGAUU ACAGUGGG	2601
1430	UCCCACUG CUGAUGAG X CGAA AAUCUGCC	2161	GGCAGAUUA CAGUGGGA	2602
1447	CCAGAUC CUGAUGAG X CGAA AUUCUUUG	2162	CAAAGAAU GAGUUGG	2603
1452	AUGAUCCA CUGAUGAG X CGAA AUCCA AUU	2163	AAUUGGAUC UGGAUCAU	2604
1458	UCCA AUU CUGAUGAG X CGAA AUCCAGAU	2164	AUCUGGAUC AUUUGGAA	2605
1461	CUGUCCA CUGAUGAG X CGAA AUGAUCCA	2165	UGGAUCAU UGGAACAG	2606
1462	ACUGUCC CUGAUGAG X CGAA AAUGAUCC	2166	GGAUCAUU GGAACAGU	2607
1471	CCCUUGUA CUGAUGAG X CGAA ACUGUCC	2167	GGAACAGUC UACAAGGG	2608
1473	UUCCUUG CUGAUGAG X CGAA AGACUGUU	2168	AACAGUCUA CAAGGGAA	2609
1512	UCACAUUC CUGAUGAG X CGAA ACAUUUUC	2169	GAAAAUGUU GAAUGUGA	2610
1529	CUGAGGUG CUGAUGAG X CGAA AGGUGCUG	2170	CAGCACCUA CACCUCAG	2611
1535	UAACUGCU CUGAUGAG X CGAA AGGUGUAG	2171	CUACACCUC AGCAGUUA	2612
1542	AGGCUUGU CUGAUGAG X CGAA ACUGCUGA	2172	UCAGCAGUU ACAAGCCU	2613
1543	AAGGCUUG CUGAUGAG X CGAA AACUGCUG	2173	CAGCAGUUA CAAGCCUU	2614
1551	CAUUUUUG CUGAUGAG X CGAA AGGCUUGU	2174	ACAAGCCUU CAAAAUG	2615
1552	UCAUUUUU CUGAUGAG X CGAA AAGGCUUG	2175	CAAGCCUUC AAAAAUGA	2616
1564	AGUACUCC CUGAUGAG X CGAA ACUUAUU	2176	AAUGAAGUA GGAGUACU	2617
1570	UUCUGAG CUGAUGAG X CGAA ACUCCUAC	2177	GUAGGAGUA CUCAGGAA	2618
1573	GUUUUCCU CUGAUGAG X CGAA AGUACUCC	2178	GGAGUACUC AGGAAAAC	2619
1595	GAGUAGGA CUGAUGAG X CGAA AUUCACAU	2179	AUGUGAAUA UCCUACUC	2620
1597	AAGAGUAG CUGAUGAG X CGAA AUUAUCAC	2180	GUGAAUAUC CUACUCUU	2621
1600	AUGAAGAG CUGAUGAG X CGAA AGGAUUAU	2181	AAUAUCCUA CUCUUAU	2622
1603	CCCAUGAA CUGAUGAG X CGAA AGUAGGAU	2182	AUCCUACUC UUAUGGG	2623
1605	AGCCCAUG CUGAUGAG X CGAA AGAGUAGG	2183	CCUACUCU CAUGGGCU	2624
1606	UAGCCCAU CUGAUGAG X CGAA AAGAGUAG	2184	CUACUCUUC AUGGGCUA	2625
1614	UUGUGGAA CUGAUGAG X CGAA AGCCCAUG	2185	CAUGGGCUA UCCACAA	2626

nt. Position	Ribozyme	SEQ ID. No.	Substrate	SEQ ID. No.
1616	CUUUGUGG CUGAUGAG X CGAA AUAGCCCA	2186	UGGGCUAUU CCACAAAG	2627
1617	GCUUUGUG CUGAUGAG X CGAA AAUAGCCC	2187	GGGCUAUUC CACAAAGC	2628
1637	GGUAACAA CUGAUGAG X CGAA AGCCAGUU	2188	AACUGGCUA UUGUUACC	2629
1639	UGGGUAAC CUGAUGAG X CGAA AUAGCCAG	2189	CUGGCUAUU GUUACCCA	2630
1642	CACUGGGU CUGAUGAG X CGAA ACAAUAGC	2190	GCUAUUGUU ACCCAGUG	2631
1643	CCACUGGG CUGAUGAG X CGAA AACAAUAG	2191	CUAUUGUUA CCCAGUGG	2632
1662	ACAAGCUG CUGAUGAG X CGAA AGCCCUCA	2192	UGAGGGCUC CAGCUUGU	2633
1668	GGUGAUAC CUGAUGAG X CGAA AGCUGGAG	2193	CUCCAGCUU GUAUCACC	2634
1671	GAUGGUGA CUGAUGAG X CGAA ACAAGCUG	2194	CAGCUUGUA UCACCAUC	2635
1673	GAGAUGGU CUGAUGAG X CGAA AUACAAGC	2195	GCUUGUAUC ACCAUCUC	2636
1679	GAUAUGGA CUGAUGAG X CGAA AUGGUGAU	2196	AUCACCAUC UCCAUAUC	2637
1681	AUGAUUAG CUGAUGAG X CGAA AGAUGGUG	2197	CACCAUCUC CAUAUCAU	2638
1685	CUCAAUGA CUGAUGAG X CGAA AUGGAGAU	2198	AUCUCCAUA UCAUUGAG	2639
1687	GUCUCAAU CUGAUGAG X CGAA AUAUGGAG	2199	CUCCAUAUC AUUGAGAC	2640
1690	UUGGUCUC CUGAUGAG X CGAA AUGAUUAG	2200	CAUAUCAU GAGACCAA	2641
1701	UCAUCUCA CUGAUGAG X CGAA AUUUGGUC	2201	GACCAAAU UGAGAUGA	2642
1702	AUCAUCUC CUGAUGAG X CGAA AAUUGGU	2202	ACCAAAUU GAGAUGAU	2643
1711	AUAAGUUU CUGAUGAG X CGAA AUCAUCUC	2203	GAGAUGAUC AAACUUU	2644
1717	AUAUCUUA CUGAUGAG X CGAA AGUUUGAU	2204	AUCAAAUCU AUAGAUAU	2645
1718	AAUAUCUA CUGAUGAG X CGAA AAGUUUGA	2205	UCAAAUCUA UAGAUAUU	2646
1720	GCAAUAUC CUGAUGAG X CGAA AUAAGUUU	2206	AAACUUAUA GAUAUUGC	2647
1724	UCGUGCAA CUGAUGAG X CGAA AUCUAUAA	2207	UUAUAGAU UUGCACGA	2648
1726	UGUCGUGC CUGAUGAG X CGAA AUAUCUUA	2208	AUAGAUAUU GCACGACA	2649
1754	GUGUAAGU CUGAUGAG X CGAA AUCCAUGC	2209	GCAUGGAUU ACUACAC	2650
1755	CGUGUAAG CUGAUGAG X CGAA AAUCCAUG	2210	CAUGGAUUA CUUACACG	2651
1758	UGGCGUGU CUGAUGAG X CGAA AGUAAUCC	2211	GGAUUACUU ACACGCCA	2652
1759	UUGGCGUG CUGAUGAG X CGAA AAGUAAUC	2212	GAUUACUUA CACGCCAA	2653
1770	GGAUGAUU CUGAUGAG X CGAA ACUUGGCG	2213	CGCCAAGUC AAUCAUCC	2654
1774	CUGUGGAU CUGAUGAG X CGAA AUUGACUU	2214	AAGUCAAU AUCCACAG	2655
1777	UCUCUGUG CUGAUGAG X CGAA AUGAUUGA	2215	UCAAUCAUC CACAGAGA	2656
1789	UUACUCUU CUGAUGAG X CGAA AGGUCUCU	2216	AGAGACCUC AAGAUAA	2657
1796	UAUAUUU CUGAUGAG X CGAA ACUCUUGA	2217	UCAAGAGUA AUAAUUA	2658
1799	AAUAUUAU CUGAUGAG X CGAA AUUACUCU	2218	AGAGUAAUA AUUAUUU	2659
1802	AAGAAUA CUGAUGAG X CGAA AUUAUUAC	2219	GUAAUAAUA UAUUUCU	2660
1804	UGAAGAAA CUGAUGAG X CGAA AUUAUUU	2220	AAUAUUAU UUUCUCA	2661
1806	CAUGAAGA CUGAUGAG X CGAA AUUAUUUA	2221	UAUAUUAU UCUUCAUG	2662
1807	UCAUGAAG CUGAUGAG X CGAA AAUAUAUU	2222	AAUAUAUU CUUCAUGA	2663
1808	UUCAUGAA CUGAUGAG X CGAA AAUAUAU	2223	AUAUAUUU UUCAUGAA	2664
1810	UCUUAUG CUGAUGAG X CGAA AGAAUAU	2224	AUAUUUCU CAUGAAGA	2665
1811	GUCUUAU CUGAUGAG X CGAA AAGAAUA	2225	UAUUUCUUC AUGAAGAC	2666
1822	UUUACUGU CUGAUGAG X CGAA AGGUCUUC	2226	GAAGACCUC ACAGUAAA	2667
1828	CCUAUUUU CUGAUGAG X CGAA ACUGUGAG	2227	CUCACAGUA AAAUAGG	2668
1834	AAAUACCC CUGAUGAG X CGAA AUUUUUAC	2228	GUAAAAUA GGUGAUUU	2669
1841	UAGACCAA CUGAUGAG X CGAA AUCACCUA	2229	UAGGUGAUU UUGUCUA	2670
1842	CUAGACCA CUGAUGAG X CGAA AAUACCU	2230	AGGUGAUUU UGGUCUAG	2671
1843	GCUAGACC CUGAUGAG X CGAA AAUACCC	2231	GGUGAUUUU GGUCUAGC	2672
1847	UGUAGCUA CUGAUGAG X CGAA ACCAAAAU	2232	AUUUUGGUC UAGCUACA	2673
1849	ACUGUAGC CUGAUGAG X CGAA AGACCAA	2233	UUUGGUCUA GCUACAGU	2674
1853	UUUCACUG CUGAUGAG X CGAA AGCUAGAC	2234	GUCUAGCUA CAGUGAAA	2675
1863	UCCAUCGA CUGAUGAG X CGAA AUUUCACU	2235	AGUGAAUUC UCGAUGGA	2676
1865	ACUCCAUC CUGAUGAG X CGAA AGAUUUA	2236	UGAAUUCUC GAUGGAGU	2677
1878	ACUGAUGG CUGAUGAG X CGAA ACCCACUC	2237	GAGUGGGUC CCAUCAGU	2678
1883	UUCAAACU CUGAUGAG X CGAA AUGGGACC	2238	GGUCCCAUC AGUUUGAA	2679
1887	ACUGUUA CUGAUGAG X CGAA ACUGAUGG	2239	CCAUCAGUU UGAACAGU	2680
1888	AACUGUUC CUGAUGAG X CGAA AACUGAUG	2240	CAUCAGUUU GAACAGUU	2681

nt. Position	Ribozyme	SEQ ID. No.	Substrate	SEQ ID. No.
1896	AUCCAGAC CUGAUGAG X CGAA ACUGUUCA	2241	UGAACAGUU GUCUGGAU	2682
1899	UGGAUCCA CUGAUGAG X CGAA ACAACUGU	2242	ACAGUUGUC UGGAUCCA	2683
1905	ACAAAAUG CUGAUGAG X CGAA AUCCAGAC	2243	GUCUGGAUC CAUUUUGU	2684
1909	AUCCACAA CUGAUGAG X CGAA AUGGAUCC	2244	GGAUCCAUU UUGUGGAU	2685
1910	CAUCCACA CUGAUGAG X CGAA AAUGGAUC	2245	GAUCCAUUU UUGUGGAU	2686
1911	CCAUCCAC CUGAUGAG X CGAA AAAUGGAU	2246	AUCCAUUUU GUGGAUGG	2687
1930	AUUCUGAU CUGAUGAG X CGAA ACUUCUGG	2247	CCAGAAGUC AUCAGAAU	2688
1933	UGCAUUCU CUGAUGAG X CGAA AUGACUUC	2248	GAAGUCAUC AGAAUGCA	2689
1946	UGGAUUUU CUGAUGAG X CGAA AUCUUGCA	2249	UGCAAGAUU AAAAUCCA	2690
1952	GCUGUAUG CUGAUGAG X CGAA AUUUUUUU	2250	AUAAAAAUC CAUACAGC	2691
1956	GAAAGCUG CUGAUGAG X CGAA AUGGAUUU	2251	AAAUCCAUA CAGCUUUC	2692
1962	CUGACUGA CUGAUGAG X CGAA AGCUGUAU	2252	AUACAGCUU UCAGUCAG	2693
1963	UCUGACUG CUGAUGAG X CGAA AAGCUGUA	2253	UACAGCUUU CAGUCAGA	2694
1964	AUCUGACU CUGAUGAG X CGAA AAAGCUGU	2254	ACAGCUUUC AGUCAGAU	2695
1968	AUACAUCU CUGAUGAG X CGAA ACUGAAAG	2255	CUUUCAGUC AGAUGUAU	2696
1975	AAUGCAUA CUGAUGAG X CGAA ACAUCUGA	2256	UCAGAUGUA UAUGCAUU	2697
1977	CAAUGCA CUGAUGAG X CGAA AUACAUCU	2257	AGAUGUAUA UGCAUUUG	2698
1983	CAAUCCCA CUGAUGAG X CGAA AUGCAUAU	2258	AUAUGCAUU UGGGAUUG	2699
1984	ACAAUCCC CUGAUGAG X CGAA AAUGCAUA	2259	UAUGCAUUU GGGAUUGU	2700
1990	UACAGAAC CUGAUGAG X CGAA AUCCCAA	2260	UUUGGGAUU GUUCUGUA	2701
1993	UCAUACAG CUGAUGAG X CGAA ACAAUCCC	2261	GGGAUUGUU CUGUAUGA	2702
1994	UUCAUACA CUGAUGAG X CGAA AACAAUCC	2262	GGAUUGUUC UGUUAUGA	2703
1998	UCAAUUCA CUGAUGAG X CGAA ACAGAACA	2263	UGUUCUGUA UGAAUUGA	2704
2004	CAGUCAUC CUGAUGAG X CGAA AUUCAUAC	2264	GUUAUGAUU GAUGACUG	2705
2019	AAUAAGGU CUGAUGAG X CGAA ACUGUCCA	2265	UGGACAGUU ACCUUAUU	2706
2020	GAAUAAGG CUGAUGAG X CGAA AACUGUCC	2266	GGACAGUUA CCUUAUUC	2707
2024	GUUUGAAU CUGAUGAG X CGAA AGGUAACU	2267	AGUUAACUU AUUCAAAC	2708
2025	UGUUGAA CUGAUGAG X CGAA AAGGUAAC	2268	GUUAACCUA UUCAACAA	2709
2027	GAUGUUUG CUGAUGAG X CGAA AUAAGGUA	2269	UACCUUAUU CAAACAUC	2710
2028	UGAUGUUU CUGAUGAG X CGAA AAUAAGGU	2270	ACCUUAUUC AAACAUC	2711
2035	CUGUUGUU CUGAUGAG X CGAA AUGUUUGA	2271	UCAACAUC AACACAG	2712
2053	AUAAAAAU CUGAUGAG X CGAA AUCUGGUC	2272	GACCAGUA AUUUUUUU	2713
2056	ACCAUAAA CUGAUGAG X CGAA AUUAUCUG	2273	CAGUAUUU UUAUGGU	2714
2057	CACCAUAA CUGAUGAG X CGAA AAUUAUCU	2274	AGUAUUUU UUAUGGUG	2715
2058	CCACCAUA CUGAUGAG X CGAA AAUUAUUC	2275	GAUAAUUUU UAUGGUGG	2716
2059	CCCACCAU CUGAUGAG X CGAA AAAAUUUU	2276	AUAAUUUUU AUGGUGGG	2717
2060	UCCACCA CUGAUGAG X CGAA AAAAUUA	2277	UAAUUUUUA UGGUGGGA	2718
2076	GAGACAGG CUGAUGAG X CGAA AUCCUCGU	2278	ACGAGGAU CCUGUCUC	2719
2082	GAUCUGGA CUGAUGAG X CGAA ACAGGUUA	2279	AUACCUGUC UCCAGAUC	2720
2084	GAGAUCUG CUGAUGAG X CGAA AGACAGGU	2280	ACCUGUCUC CAGAUCUC	2721
2090	CUUACUGA CUGAUGAG X CGAA AUCUGGAG	2281	CUCCAGAUC UCAGUAAG	2722
2092	ACCUUACU CUGAUGAG X CGAA AGAUCUGG	2282	CCAGAUCUC AGUAAGGU	2723
2096	CCGUACCU CUGAUGAG X CGAA ACUGAGAU	2283	AUCUCAGUA AGGUACGG	2724
2101	UUACUCCG CUGAUGAG X CGAA ACCUUAUCU	2284	AGUAAGGUA CGGAGUAA	2725
2108	UGGACAGU CUGAUGAG X CGAA ACUCGUA	2285	UACGGAGUA ACUGUCCA	2726
2114	GGCUUUUG CUGAUGAG X CGAA ACAGUUAC	2286	GUAACUGUC CAAAAGCC	2727
2133	CUGCCAUU CUGAUGAG X CGAA AUCUCUUC	2287	GAAGAGAUU AAUGGCAG	2728
2134	UCUGCCAU CUGAUGAG X CGAA AAUCUCUU	2288	AAGAGAUUA AUGGCAGA	2729
2149	UUCUUUUU CUGAUGAG X CGAA AGGCACUC	2289	GAGUGCCUC AAAAAGAA	2730
2176	UGGGGAAA CUGAUGAG X CGAA AGUGGUCU	2290	AGACCACUC UUCCCCA	2731
2178	UUUGGGGA CUGAUGAG X CGAA AGAGUGGU	2291	ACCACUCUU UCCCCAA	2732
2179	AUUUGGG CUGAUGAG X CGAA AAGAGUGG	2292	CCACUCUUU CCCAAAU	2733
2180	AAUUUGGG CUGAUGAG X CGAA AAAGAGUG	2293	CACUCUUUC CCCAAAU	2734
2188	GAGGCGAG CUGAUGAG X CGAA AUUUGGGG	2294	CCCCAAAU CUCGCCUC	2735
2189	AGAGGCGA CUGAUGAG X CGAA AAUUGGGG	2295	CCCCAAUUC UCGCCUCU	2736

nt. Position	Ribozyme	SEQ ID. No.	Substrate	SEQ ID. No.
2191	AUAGAGGC CUGAUGAG X CGAA AGAAUUUG	2296	CAAAUUCUC GCCUCUUAU	2737
2196	GCUCAUA CUGAUGAG X CGAA AGGCGAGA	2297	UCUCGCCUC UAUUGAGC	2738
2198	CAGCUCAA CUGAUGAG X CGAA AGAGGCGA	2298	UCGCCUCUA UUGAGCUG	2739
2200	AGCAGCUC CUGAUGAG X CGAA AUAGAGGC	2299	GCCUCUAU GAGCUGCU	2740
2217	UUGGCAAU CUGAUGAG X CGAA AGCGGGCC	2300	GGCCCGCUC AUUGCCAA	2741
2220	UUUUUGGC CUGAUGAG X CGAA AUGAGCGG	2301	CCGCUCAU GCCAAAAA	2742
2230	CUGCGGUG CUGAUGAG X CGAA AUUUUUGG	2302	CCAAAAAU CACCGCAG	2743
2231	ACUGCGGU CUGAUGAG X CGAA AAUUUUUG	2303	CAAAAAUUC ACCGCAGU	2744
2244	AGGGUUCU CUGAUGAG X CGAA AUGCACUG	2304	CAGUGCAUC AGAACCCU	2745
2253	GAUUCAG CUGAUGAG X CGAA AGGGUUCU	2305	AGAACCCUC CUUGAAUC	2746
2256	CCCAGUUC CUGAUGAG X CGAA AGGAGGGU	2306	ACCCUCCU GAAUCGGG	2747
2261	ACCAGCCC CUGAUGAG X CGAA AUUCAAGG	2307	CCUUGAAUC GGGCUGGU	2748
2270	UGUUUGGA CUGAUGAG X CGAA ACCAGCCC	2308	GGGCUGGUU UCCAAACA	2749
2271	CUGUUUGG CUGAUGAG X CGAA AACCGACC	2309	GGCUGGUUU CCAAACAG	2750
2272	UCUGUUUG CUGAUGAG X CGAA AAACCAGC	2310	GCUGGUUUC CAAACAGA	2751
2285	UAGACUAA CUGAUGAG X CGAA AUCCUCUG	2311	CAGAGGAUU UAGUCUA	2752
2286	AUAGACUA CUGAUGAG X CGAA AAUCCUCU	2312	AGAGGAUUU UAGUCUAU	2753
2287	UAUAGACU CUGAUGAG X CGAA AAAUCCUC	2313	GAGGAUUUU AGUCUAUA	2754
2288	AUAUAGAC CUGAUGAG X CGAA AAAAUCCU	2314	AGGAUUUUU GUCUAUAU	2755
2291	AGCAUAUA CUGAUGAG X CGAA ACUAAAAU	2315	AUUUUAGUC UAUUAGCU	2756
2293	CAAGCAUA CUGAUGAG X CGAA AGACUAAA	2316	UUUAGUCUA UAUGCUGU	2757
2295	CACAAGCA CUGAUGAG X CGAA AUAGACUA	2317	UAGUCUAUA UGCUUGUG	2758
2300	AGAAGCAC CUGAUGAG X CGAA AGCAUAUA	2318	UAUAGCUU GUGCUUCU	2759
2306	UUUUGGAG CUGAUGAG X CGAA AGCACAAG	2319	CUUGUGCUU CUCCAAAA	2760
2307	UUUUUGGA CUGAUGAG X CGAA AAGCACAA	2320	UUGUGCUUC UCCAAAAA	2761
2309	UGUUUUUG CUGAUGAG X CGAA AGAAGCAC	2321	GUGCUUCUC CAAAAACA	2762
2323	CCUGCCUG CUGAUGAG X CGAA AUGGGUGU	2322	ACACCCAUC CAGGCAGG	2763
2337	ACGCACCA CUGAUGAG X CGAA AUCCCCCU	2323	AGGGGGAUA UGGUGCGU	2764
2346	GGACAGGA CUGAUGAG X CGAA ACGCACCA	2324	UGGUGCGUU UCCUGUCC	2765
2347	UGGACAGG CUGAUGAG X CGAA AACGCACC	2325	GGUGCGUUU CCUGUCCA	2766
2348	GUGGACAG CUGAUGAG X CGAA AAACGCAC	2326	GUGCGUUUC CUGUCCAC	2767
2353	UUUCAGUG CUGAUGAG X CGAA ACAGGAAA	2327	UUUCCUGUC CACUGAAA	2768
2379	CUCUCCUG CUGAUGAG X CGAA ACUCUCUC	2328	GAGAGAGUU CAGGAGAG	2769
2380	ACUCUCCU CUGAUGAG X CGAA AACUCUCU	2329	AGAGAGUUC AGGAGAGU	2770
2389	UUUGUUGC CUGAUGAG X CGAA ACUCUCCU	2330	AGGAGAGUA GCAACAAA	2771
2406	UGUUCAUU CUGAUGAG X CGAA AUUUUCCU	2331	AGGAAAAUA AAUGAACA	2772
2416	AGCAAACA CUGAUGAG X CGAA AUGUUCAU	2332	AUGAACUA UGUUUGCU	2773
2420	UAUAAGCA CUGAUGAG X CGAA ACAUAUGU	2333	ACAUAUGUU UGCUAUAU	2774
2421	AUAUAAGC CUGAUGAG X CGAA AACAUUUG	2334	CAUAUGUUU GCUUAUAU	2775
2425	UAACAUAU CUGAUGAG X CGAA AGCAAACA	2335	UGUUGCUU AUAUGUUA	2776
2426	UUAACAUA CUGAUGAG X CGAA AAGCAAAC	2336	GUUUGCUUA UAUGUUAU	2777
2428	AUUUAACA CUGAUGAG X CGAA AUAAGCAA	2337	UUGCUUAUA UGUUAAAU	2778
2432	UUCAAUUU CUGAUGAG X CGAA ACAUAUAA	2338	UUUAUGUU AAAUUGAA	2779
2433	AUUCAAUU CUGAUGAG X CGAA AACAUUAU	2339	UAUAUGUUA AAUUGAAU	2780
2437	UUUUAUUC CUGAUGAG X CGAA AUUUUACA	2340	UGUUAAAU GAAUAAAA	2781
2442	GAGUAUUU CUGAUGAG X CGAA AUUCAAUU	2341	AAUUGAAUA AAAUACUC	2782
2447	AAAGAGAG CUGAUGAG X CGAA AUUUUAUU	2342	AAUAAAAUA CUCUCUUU	2783
2450	AAAAAAGA CUGAUGAG X CGAA AGUAUUUU	2343	AAAAUACUC UCUUUUUU	2784
2452	AAAAAATA CUGAUGAG X CGAA AGAGUAUU	2344	AAUACUCUC UUUUUUUU	2785
2454	UAAAAATA CUGAUGAG X CGAA AGAGAGUA	2345	UACUCUCUU UUUUUUUA	2786
2455	UUAAAAAA CUGAUGAG X CGAA AAGAGAGU	2346	ACUCUCUUU UUUUUUAA	2787
2456	CUUAAAAA CUGAUGAG X CGAA AAAGAGAG	2347	CUCUCUUU UUUUUUAG	2788
2457	CCUAAAAA CUGAUGAG X CGAA AAAAGAGA	2348	UCUCUUUUU UUUUAAGG	2789
2458	ACCUAAAA CUGAUGAG X CGAA AAAAAGAG	2349	CUCUUUUUU UUUUAAGG	2790
2459	CACCUAAA CUGAUGAG X CGAA AAAAAGA	2350	UCUUUUUUU UUAAGGUG	2791

nt. Position	Ribozyme	SEQ ID. No.	Substrate	SEQ ID. No.
2460	CCACCUUA CUGAUGAG X CGAA AAAAAAAG	2351	CUUUUUUUU UAAGGUGG	2792
2461	UCCACCUU CUGAUGAG X CGAA AAAAAAAA	2352	UUUUUUUUU AAGGUGGA	2793
2462	UUCACCU CUGAUGAG X CGAA AAAAAAAA	2353	UUUUUUUUA AGGUGGAA	2794

Where "X" represents stem II region of a HH ribozyme (Hertel et al., 1992 Nucleic Acids Res. 20: 3252). The length of stem II may be ≥ 2 base-pairs.

Table XVII: Human B-raf Hairpin Ribozyme and Target Sequence

nt. Position	Ribozyme Sequence	SEQ ID. No.	Target Sequence	SEQ ID. No.
9	GGAGG AGAA GGA ACCAGAGAAACA X GUACAUUACCUUGUA	2795	UCCCG GCC CCCUC	2846
20	CUGUG AGAA GGA ACCAGAGAAACA X GUACAUUACCUUGUA	2796	UCCCG GCC CGACG	2847
31	CGAGC AGAA GCG ACCAGAGAAACA X GUACAUUACCUUGUA	2797	CAGCG GCC GCUCG	2848
34	GGCCG AGAA GCG ACCAGAGAAACA X GUACAUUACCUUGUA	2798	CGCCG GCU CGGCG	2849
46	ACCGAG AGAA GGG ACCAGAGAAACA X GUACAUUACCUUGUA	2799	CCCG GCU CUCGU	2850
114	CGUUG AGAA GAG ACCAGAGAAACA X GUACAUUACCUUGUA	2800	GCUC GUU CAACG	2851
149	CGGCC AGAA GGC ACCAGAGAAACA X GUACAUUACCUUGUA	2801	CGCG GCC GCGCG	2852
153	GCCGC AGAA GGC ACCAGAGAAACA X GUACAUUACCUUGUA	2802	GGCG GCC CGCGC	2853
160	CGAAG AGAA GCG ACCAGAGAAACA X GUACAUUACCUUGUA	2803	CGCG GCC UCUCG	2854
169	GUCGC AGAA GAG ACCAGAGAAACA X GUACAUUACCUUGUA	2804	CUUC GCU CGGAC	2855
175	GGCAG AGAA GCG ACCAGAGAAACA X GUACAUUACCUUGUA	2805	CUGCG GAC CCUGC	2856
379	AGAAA AGAA GUU ACCAGAGAAACA X GUACAUUACCUUGUA	2806	GAUC GAU UUUUC	2857
388	GUAGA AGAA GAA ACCAGAGAAACA X GUACAUUACCUUGUA	2807	UUUC GUU UCUAG	2858
466	UUGAA AGAA GAA ACCAGAGAAACA X GUACAUUACCUUGUA	2808	UUUA GUU UUUCA	2859
484	UGCAC AGAA GUG ACCAGAGAAACA X GUACAUUACCUUGUA	2809	CCAC GAU GUGCA	2860
540	UUGUG AGAA GGA ACCAGAGAAACA X GUACAUUACCUUGUA	2810	UUUC GCC CAACA	2861
586	GUCUG AGAA GUA ACCAGAGAAACA X GUACAUUACCUUGUA	2811	UUAC GUC CGAGC	2862
596	UCUUA AGAA GUC ACCAGAGAAACA X GUACAUUACCUUGUA	2812	AGAC GUC UAAAG	2863
612	CUAUC AGAA GUC ACCAGAGAAACA X GUACAUUACCUUGUA	2813	GCAC GAU GAUG	2864
646	UCUGA AGAA GCAC ACCAGAGAAACA X GUACAUUACCUUGUA	2814	GUGCU GUU UACAG	2865
819	UGGAA AGAA GCU ACCAGAGAAACA X GUACAUUACCUUGUA	2815	AAGCU GCU UUUCA	2866
836	UUUGAC AGAA GAA ACCAGAGAAACA X GUACAUUACCUUGUA	2816	UUUC GCU GUCAA	2867
891	ACACAC AGAA GUG ACCAGAGAAACA X GUACAUUACCUUGUA	2817	CCAC GAU GUGU	2868
924	GAGAC AGAA GCA ACCAGAGAAACA X GUACAUUACCUUGUA	2818	UUGCU GUU UGUC	2869
988	UGUAG AGAA GUC ACCAGAGAAACA X GUACAUUACCUUGUA	2819	AGACU GCC CUACA	2870
1021	GUCCGA AGAA GGUG ACCAGAGAAACA X GUACAUUACCUUGUA	2820	CACCG GCC UCGAC	2871
1027	AUAGA AGAA GAG ACCAGAGAAACA X GUACAUUACCUUGUA	2821	CCUG GAC UCUAU	2872
1055	GAGAC AGAA GGUG ACCAGAGAAACA X GUACAUUACCUUGUA	2822	CACCA GUC GUCUC	2873
1059	GAAGA AGAA GAC ACCAGAGAAACA X GUACAUUACCUUGUA	2823	AGUC GUC UCCUC	2874
1089	CGAG AGAA GUG ACCAGAGAAACA X GUACAUUACCUUGUA	2824	CCAC GCC CUUCG	2875
1097	CUGUG AGAA GAG ACCAGAGAAACA X GUACAUUACCUUGUA	2825	CUUC GAC CAGC	2876
1105	AUCUC AGAA GUG ACCAGAGAAACA X GUACAUUACCUUGUA	2826	CAGCA GAU GAAGU	2877
1142	AUGAG AGAA GUC ACCAGAGAAACA X GUACAUUACCUUGUA	2827	AGCC GAU CCUCU	2878
1153	AUGGG AGAA GAU ACCAGAGAAACA X GUACAUUACCUUGUA	2828	CAUC GCU CCCAU	2879
1267	UAUGA AGAA GGG ACCAGAGAAACA X GUACAUUACCUUGUA	2829	CCCU GCC UCAUA	2880
1417	CUGCC AGAA GGA ACCAGAGAAACA X GUACAUUACCUUGUA	2830	UUCC GAU GGCAG	2881
1425	ACUGA AGAA GCC ACCAGAGAAACA X GUACAUUACCUUGUA	2831	GGCA GAU UACAGU	2882
1468	CUUGA AGAA GUU ACCAGAGAAACA X GUACAUUACCUUGUA	2832	GAAC GUC UACAAG	2883

nt. Position	Ribozyme Sequence		SEQ ID. No.	Target Sequence	SEQ ID. No.
1664	GAUACA	AGAA GGAG ACCAGAGAAACA X GUACAUUACCUUGUA	2833	CUCCA GCU UGUUAC	2884
1734	UGUGCA	AGAA GUCG ACCAGAGAAACA X GUACAUUACCUUGUA	2834	CGACA GAC UGCACA	2885
1884	UGUACA	AGAA GAUG ACCAGAGAAACA X GUACAUUACCUUGUA	2835	CAUCA GUU UGAACA	2886
1893	CCAGAC	AGAA GUUC ACCAGAGAAACA X GUACAUUACCUUGUA	2836	GAACA GUU GUCUGG	2887
1958	ACUGAA	AGAA GUU ACCAGAGAAACA X GUACAUUACCUUGUA	2837	AUACA GCU UUCAGU	2888
1969	AUAUAC	AGAA GACU ACCAGAGAAACA X GUACAUUACCUUGUA	2838	AGUCA GAU GUUUAU	2889
1995	AUUUCA	AGAA GAAC ACCAGAGAAACA X GUACAUUACCUUGUA	2839	GUUCU GUA UGAUUA	2890
2079	UCUGGA	AGAA GGUA ACCAGAGAAACA X GUACAUUACCUUGUA	2840	UACCU GUC UCCAGA	2891
2086	ACUGAG	AGAA GGAG ACCAGAGAAACA X GUACAUUACCUUGUA	2841	CUCCA GAU CUCAGU	2892
2111	CUUUUG	AGAA GUUA ACCAGAGAAACA X GUACAUUACCUUGUA	2842	UAACU GUC CAAAAG	2893
2205	CGGGCC	AGAA GCUC ACCAGAGAAACA X GUACAUUACCUUGUA	2843	GAGCU GCU GGCCCG	2894
2213	GCAUUG	AGAA GGCC ACCAGAGAAACA X GUACAUUACCUUGUA	2844	GGCCC GCU CAUUGC	2895
2350	UCAGUG	AGAA GGAA ACCAGAGAAACA X GUACAUUACCUUGUA	2845	UUCUU GUC CACUGA	2896

Where "X" represents stem IV region of a Hairpin ribozyme. The length of stem IV may be ≥ 2 base-pairs.

Table XVIII. Hammerhead (HH) Ribozyme target with sequence homology between c-raf and A-raf

nt. Position	Target	Seq I.D. No.
452	AGGAGCU C AUUGUCG	2897
527	UGGCGUU C UGUGACU	2898
583	UGUGGCU A CAAGUUC	2899
668	ACAGUGU C CAGGAUU	2900
857	AUAUGGU C AGCACCA	2901
1096	UCAGGCU A UUACUGG	2902
1098	AGGCUAU U ACUGGGA	2903
1246	CAGGCUU U CAAGAAU	2904
1247	AGGCUUU C AAGAAUG	2905
1309	AUGGGCU U CAUGACC	2906
1327	CCGGGAU U UGCCAUC	2907
1357	GAGGGCU C CAGCCUC	2908
1412	UCCAGCU C AUCGACG	2909
1469	AGAACAU C AUCCACC	2910
1628	AGGUGAU C CGUAUGC	2911
1658	ACAGCUU C CAGUCAG	2912
1663	UUCCAGU C AGACGUC	2913
1748	ACCAGAU U AUCUUUA	2914
1749	CCAGAUU A UCUUUAU	2915
1751	AGAUUUA C UUUAUGG	2916
1753	AUUAUCU U UAUGGUG	2917
1754	UUAUCUU U AUGGUGG	2918
1871	GGCCCCU C UUCCCCC	2919
1874	CCCUCUU C CCCCAGA	2920
1951	CCCUCCU U GCACCGC	2921
2046	CCAAUCU C AGCCCUC	2922
2127	CCCCAUU C CCCACCC	2923
2174	AGUUCUU C UGGAAUU	2924
2251	UGGGGAU A CUUCUAA	2925
2400	GUCCCUU U UGUGUCU	2926
2432	CUCCUCU C UUUCUUC	2927

Table XIX. Hammerhead Ribozyme Target with sequence homology between c-raf and B-raf

nt. Position	Target Sequence	Seq. I. D. No.
17	GCCCCCU C CCCGCC	2928
405	UCUGCAU C AAUGGAU	2929
426	ACAUCUU C UUCCUCU	2930
479	UCAAAAU C CCACAGA	2931
702	GAUAUUU C CUGGCUU	2932
754	UUCCACU U ACAACAC	2933
861	UAUAAAU U UCACCAG	2934
931	UGUUUGU C UCCAAGU	2935
1034	GGACUCU A UUGGGCC	2936
1259	GUCUGCU A CCCCCC	2937
1344	AAGUCAU C UUCAUCC	2938
1603	UCCUACU C UUCAUGG	2939
1662	GAGGGCU C CAGCUUG	2940
1802	UAAUAAU A UAUUUCU	2941
1804	AUAAUAAU A UUUCUUC	2942
1806	AAUAUAAU U UCUUCAU	2943
1807	AUAUAAU U CUUCAUG	2944
1808	UAUAUUU C UUCAUGA	2945
1810	UAUUUCU U CAUGAAG	2946
1834	UAAAAAU A GGUGAUU	2947
1842	GGUGAUU U UGGUCUA	2948
1847	UUUUGGU C UAGCUAC	2949
1956	AAUCCAU A CAGCUUU	2950
2035	CAAACAU C AACAACA	2951
2059	UAAUUUU U AUGGUGG	2952
2090	UCCAGAU C UCAGUAA	2953
2092	CAGAUCU C AGUAAGG	2954
2200	CCUCUAU U GAGCUGC	2955
2256	CCCUCCU U GAAUCGG	2956

Table XX.

Experimental Group	Ribozyme Activity/Target	Dose (mg/kg/day)	Sample Size per dose
RPI.4610	Active/ <i>flt-1</i>	1, 3, 10, 30, 100	10
RPI.4611	Inactive/ <i>flt-1</i>	1, 3, 10, 30, 100	10
RPI.4733	Active/ <i>flk-1</i>	1, 3, 10, 30, 100	10
RPI.4734	Inactive/ <i>flk-1</i>	1, 3, 10, 30, 100	10
Saline	NA	12 μ l/day	10

Claims

1. A method for identification of a nucleic acid molecule capable of modulating a process in a biological system comprising the steps of:
 - 5 a) introducing a random library of a nucleic acid catalyst with a substrate binding domain and a catalytic domain, wherein said substrate binding domain comprises a random sequence, into said biological system under conditions suitable for modulating said process; and
 - 10 b) determining the nucleotide sequence of at least a portion of the substrate binding domain of said nucleic acid catalyst from a said biological system in which the process has been modulated.
2. A method for identifying one or more nucleic acid molecules involved in a process in a biological system comprising the steps of:
 - 15 a) providing a library of a nucleic acid catalyst, with a substrate binding domain and a catalytic domain, wherein said substrate binding domain comprises a random sequence, to said biological system under conditions suitable for said process to be altered;
 - b) identifying any said nucleic acid catalyst present in said biological system where said process has been altered by said any said nucleic acid catalyst; and
 - 20 c) determining the nucleotide sequence of at least a portion of the binding arm of said any said nucleic acid catalyst to allow said identification of said nucleic acid molecule involved in said process in said biological system.
3. A method for identification of a nucleic acid catalyst capable of modulating a process in a biological system comprising the steps of:
 - 25 a) introducing a random library of a nucleic acid catalyst with a substrate binding domain and a catalytic domain, wherein said substrate binding domain comprises

a random sequence, into said biological system under conditions suitable for modulating said process; and

b) identifying said nucleic acid catalyst from said biological system in which the process has been modulated.

- 5 4. The method of any of claims 1-3, wherein said biological system is a bacterial cell.
5. The method of any of claims 1-3, wherein said biological system is of plant origin.
6. The method of any of claims 1-3, wherein said biological system is of
10 mammalian origin.
7. The method of any of claims 1-3, wherein said biological system is of yeast origin.
8. The method of any of claims 1-3, wherein said biological system is *Drosophila*.
9. The method of any of claims 1-3, wherein said nucleic acid catalyst is in a
15 hammerhead motif.
10. The method of any of claims 1-3, wherein said nucleic acid catalyst is in a hairpin motif.
11. The method of any of claims 1-3, wherein said nucleic acid catalyst is in a hepatitis delta virus ribozyme motif.
- 20 12. The method of any of claims 1-3, wherein said nucleic acid catalyst is in group I intron, group II intron, VS ribozyme or RNase P ribozyme motif.
13. The method of any of claims 1-3, wherein said process is selected from the group consisting of growth, proliferation, apoptosis, morphology, angiogenesis, differentiation, migration, viral multiplication, drug resistance, signal

transduction, cell cycle regulation, temperature sensitivity and chemical sensitivity.

14. The method of any of claims 1-3, wherein said random library of nucleic acid catalysts is encoded by an expression vector in a manner which allows
5 expression of said nucleic acid catalysts.

15. The method of claim 14, wherein said expression vector comprises:

a) a transcription initiation region;

b) a transcription termination region;

c) a gene encoding at least one said nucleic acid catalyst; and

10 wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid catalyst.

16. The method of claim 14, wherein said expression vector comprises:

a) a transcription initiation region;

15 b) a transcription termination region;

c) an open reading frame;

d) a gene encoding at least one said nucleic acid catalyst, wherein said gene is operably linked to the 3'-end of said open reading frame; and

20 wherein said gene is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid catalyst.

17. The method of claim 14, wherein said expression vector comprises:

- a) a transcription initiation region;
- b) a transcription termination region;
- c) an intron;
- d) a gene encoding at least one said nucleic acid catalyst; and

5 wherein said gene is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid catalyst.

18. The method of claim 14, wherein said expression vector comprises:

- a) a transcription initiation region;
- 10 b) a transcription termination region;
- c) an intron;
- d) an open reading frame;
- e) a gene encoding at least one said nucleic acid catalyst, wherein said gene is operably linked to the 3'-end of said open reading frame; and


15 wherein said gene is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid catalyst.

19. The method of claim 14, wherein said expression vector is derived from a retrovirus.

20 20. The method of claim 14, wherein said expression vector is derived from an adenovirus.

21. The method of claim 14, wherein said expression vector is derived from an adeno-associated virus.
22. The method of claim 14, wherein said expression vector is derived from an alphavirus.
- 5 23. The method of claim 14, wherein said expression vector is derived from a bacterial plasmid.
24. The method of claim 14, wherein said expression vector is operable linked to a RNA polymerase II promoter element.
25. The method of claim 14, wherein said expression vector is operable linked to a
10 RNA polymerase III promoter element.
26. The method of claim 25, wherein said RNA polymerase III promoter is derived from a transfer RNA gene.
27. The method of claim 25, wherein said RNA polymerase III promoter is derived from a U6 small nuclear RNA gene.
- 15 28. The method of claim 25, wherein the nucleic acid catalyst comprises a sequence at its 5'-end homologous to the terminal 27 nucleotides of encoded by said U6 small nuclear RNA gene.
29. The method of claim 28, wherein said RNA polymerase III promoter is derived from a TRZ RNA gene.
- 20 30. The method of any of claims 1-3, wherein said biological system is of an eukaryotic origin.
31. The method of any of claims 1-3, wherein said biological system is of an prokaryotic origin.


32. The method of any of claims 1-3, wherein said biological system is of an archaeobacterial origin.
33. The method of any of claims 1-3, wherein said substrate binding domain of the nucleic acid catalyst is of length sufficient to form a stable interaction with a target sequence.
34. The method of claim 33, wherein said substrate binding domain is of length between 12 and 100 nucleotides.
35. The method of claim 33, wherein said substrate binding domain is of length between 14 and 24 nucleotides.
36. The method of any of claims 1-3, wherein said nucleic acid catalyst comprises one substrate binding arm.
37. The method of any of claims 1-3, wherein said nucleic acid catalyst comprises two substrate binding arms.
38. The method of claim 37, wherein said substrate binding arms are of similar length.
39. The method of claim 37, wherein said substrate binding arms are of different length.
40. A nucleic acid molecule with an endonuclease activity having the formula **III**:



- wherein, N is independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; o and n are


integers greater than or equal to 1, wherein if (N)_o and (N)_n are nucleotides, (N)_o and (N)_n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent, but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; _____ represents a chemical linkage; and A, C, U and G represent adenosine, cytidine, uridine and guanosine nucleotides, respectively.

41. A nucleic acid molecule with catalytic activity having the formula IV:




wherein, N is independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; o and n are integers greater than or equal to 1, wherein if (N)_o and (N)_n are nucleotides, (N)_o and (N)_n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent, but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; Z3 is 2'-methylthiomethyl uridine; Z4 is 2'-C-allyl uridine; Z7 is 6-methyl uridine; _____ represents a chemical linkage; and A, and G represent adenosine and guanosine nucleotides, respectively.

42. A nucleic acid molecule with catalytic activity having the formula **V**:




wherein, N is independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; o and n are integers greater than or equal to 1, wherein if (N)_o and (N)_n are nucleotides, (N)_o and (N)_n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent, but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; Z₃ is 2'-methylthiomethyl uridine; Z₄ is 2'-methylthiomethyl cytidine; Z₇ is 6-methyl uridine; _____ represents a chemical linkage; and A, and G represent adenosine and guanosine nucleotides, respectively.

43. A nucleic acid molecule with catalytic activity having the formula VI:



- wherein, N is independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; o and n are integers greater than or equal to 1, wherein if (N)_o and (N)_n are nucleotides, (N)_o and (N)_n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent, but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; Z₃ is 2'-methylthiomethyl uridine; Z₄ is 2'-methylthiomethyl cytidine; Z₇ is 2'-C-allyl uridine; _____ represents a chemical linkage; and A, and G represent adenosine and guanosine nucleotides, respectively.

44. A nucleic acid molecule with catalytic activity having the formula VII:



wherein, N is independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; o and n are integers greater than or equal to 1, wherein if (N)_o and (N)_n are nucleotides, (N)_o and (N)_n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent, but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; Z₃ is 2'-methylthiomethyl uridine; Z₄ is 2'-methylthiomethyl cytidine; Z₇ is pyridine-4-one; and — represents a chemical linkage; and A, and G represent adenosine and guanosine nucleotides, respectively.

45. The nucleic acid molecules of any of claims 40-44, wherein said (N)_o and (N)_n are nucleotides and said o and n are integers greater than or equal to 3.
46. The nucleic acid molecules of any of claims 40-44, wherein said L is nucleotide linker.
47. The nucleic acid molecule of any of claims 40-44, wherein said nucleic acid cleaves a separate nucleic acid molecule.

48. The nucleic acid molecule of claim 47, wherein said separate nucleic acid molecule is RNA.
49. The nucleic acid molecule of claim 47, wherein said nucleic acid comprises between 12 and 100 bases complementary to said separate nucleic acid molecule.
- 5 50. The nucleic acid molecule of claim 47, wherein said nucleic acid comprises between 14 and 24 bases complementary to said separate nucleic acid molecule.
51. A cell including the nucleic acid molecule of any of claims 40-44.
52. The cell of claim 17, wherein said cell is a mammalian cell.
53. The cell of claim 18, wherein said cell is a human cell.
- 10 54. An expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid molecule of any of claims 40-44, in a manner which allows expression of that nucleic acid molecule.
55. A cell including the expression vector of claim 54.
56. The cell of claim 55, wherein said cell is a mammalian cell.
- 15 57. The cell of claim 55, wherein said cell is a human cell.
58. A pharmaceutical composition comprising the nucleic acid molecule of any of claims 40-44.
59. A method for modulating expression of a gene in a plant cell by administering to said cell the nucleic acid molecule of any of claims 40-44.
- 20 60. A method for modulating expression of gene in a mammalian cell by administering to said cell the nucleic acid molecule of any of claims 40-44.

61. A method of cleaving a separate nucleic acid comprising, contacting the nucleic acid molecule of any of claims 40-44 with said separate nucleic acid molecule under conditions suitable for the cleavage of said separate nucleic acid molecule.
- 5 62. The method of claim 61, wherein said cleavage is carried out in the presence of a divalent cation.
63. The method of claim 62, wherein said divalent cation is Mg^{2+} .
64. The nucleic acid molecule of claims 40-44, wherein said nucleic acid is chemically synthesized.
65. The expression vector of claim 54, wherein said vector comprises:
- 10 a) a transcription initiation region;
- b) a transcription termination region;
- c) a gene encoding at least one said nucleic acid molecule; and
- wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.
- 15 66. The expression vector of claim 54, wherein said vector comprises:
- a) a transcription initiation region;
- b) a transcription termination region;
- c) an open reading frame;
- 20 d) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and

wherein said gene is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

67. The expression vector of claim 59, wherein said vector comprises:

- 5 a) a transcription initiation region;
- b) a transcription termination region;
- c) an intron;
- d) a gene encoding at least one said nucleic acid molecule; and

10 wherein said gene is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

68. The expression vector of claim 59, wherein said vector comprises:

- a) a transcription initiation region;
- b) a transcription termination region;
- 15 c) an intron;
- d) an open reading frame;
- e) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and

20 wherein said gene is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

69. A method for identifying variants of a nucleic acid catalyst comprising the steps of:
- a) selecting at least three positions within said nucleic acid catalyst to be varied with a predetermined group of different nucleotides;
 - 5 b) synthesizing a first class of different pools of said nucleic acid catalyst, wherein the number of pools synthesized is equal to the number of nucleotides in the predetermined group of different nucleotides, wherein at least one of the positions to be varied in each pool comprises a defined nucleotide selected from the predetermined group of different nucleotides and the remaining positions to be varied comprise a random mixture of nucleotides selected from the
10 predetermined group of different nucleotides;
 - c) testing the different pools of said nucleic acid catalyst under conditions suitable for said pools to show a desired attribute and identifying the pool with said desired attribute and wherein the position with the defined nucleotide in the
15 pool with the desired attribute is made constant in subsequent steps;
 - d) synthesizing a second class of different pools of nucleic acid catalyst, wherein at least one of the positions to be varied in each of the second class of different pools comprises a defined nucleotide selected from the predetermined group of different nucleotides and the remaining positions to be varied comprise a random
20 mixture of nucleotides selected from the predetermined group of different nucleotides;
 - e) testing the second class of different pools of said nucleic acid catalyst under conditions suitable for showing desired attribute and identifying the pool with said desired attribute and wherein the position with the defined nucleotide in the
25 pool with the desired attribute is made constant in subsequent steps; and
 - f) repeating the process similar to steps d and e until every position selected in said nucleic acid catalyst to be varied is made constant.

70. A method for identifying novel nucleic acid molecules in a biological system, comprising the steps of:


a) synthesizing a pool of nucleic acid catalyst with a substrate binding domain and a catalytic domain, wherein said substrate binding domain comprises a random sequence;

b) testing the pools of nucleic acid catalyst under conditions suitable for showing a desired effect in said biological system and identifying the catalyst showing said desired effect;

c) using an oligonucleotide, comprising the sequence of the substrate binding domain of the nucleic acid catalyst showing said desired activity, as a probe, screening said biological system for nucleic acid molecules complementary to said probe; and

d) isolating and sequencing said complementary nucleic acid molecules.

71. A compound having the formula I:



wherein R is independently any nucleoside selected from the group consisting of 2'-*O*-methyl-2,6-diaminopurine riboside; 2'-deoxy-2'-amino-2,6-diaminopurine riboside; 2'-(*N*-alanyl) amino-2'-deoxy-uridine; 2'-(*N*-phenylalanyl)amino-2'-deoxy-uridine; 2'-deoxy-2'-(*N*-β-alanyl) amino ; 2'-deoxy-2'-(lysiyl) amino uridine; 2'-*C*-allyl uridine; 2'-*O*-amino-uridine; 2'-*O*-methylthiomethyl adenosine; 2'-*O*-methylthiomethyl cytidine ; 2'-*O*-methylthiomethyl guanosine; 2'-*O*-methylthiomethyl-uridine; 2'-Deoxy-2'-(*N*-histidyl) amino uridine; 2'-deoxy-2'-amino-5-methyl cytidine; 2'-(*N*-β-carboxamidine-β-alanyl)amino-2'-deoxy-uridine; 2'-deoxy-2'-(*N*-β-alanyl)-guanosine; and 2'-*O*-amino-adenosine.

72. A process for incorporation of the compounds of claim 71 into an oligonucleotide comprising the step of contacting said compound with a mixture comprising a nucleic acid template, an RNA polymerase enzyme, and an enhancer of modified nucleotide triphosphate incorporation, under conditions suitable for the incorporation of said compound into said oligonucleotide.
73. The process of claim 72, wherein said RNA polymerase is a T7 RNA polymerase.
74. The process of claim 72, wherein said RNA polymerase is a mutant T7 RNA polymerase.
75. The process of claim 72, wherein said RNA polymerase is a SP6 RNA polymerase.
76. The process of claim 72, wherein said RNA polymerase is a mutant SP6 RNA polymerase.
77. The process of claim 72, wherein said RNA polymerase is a T3 RNA polymerase.
78. The process of claim 72, wherein said RNA polymerase is a mutant T3 RNA polymerase.
79. The process of claim 72, wherein said enhancer of modified nucleotide triphosphate incorporation is selected from the group consisting of LiCl, methanol, polyethylene glycol, diethyl ether, propanol, methylamine, and ethanol.
80. A process for the synthesis of a pyrimidine nucleotide triphosphate comprising the steps of:
- (a) monophosphorylation, wherein a pyrimidine nucleoside is contacted with a mixture comprising a phosphorylating reagent, a trialkyl phosphate and

dimethylaminopyridine, under conditions suitable for the formation of a pyrimidine nucleotide monophosphate; and

(b) pyrophosphorylation, wherein said pyrimidine monophosphate from step (a) is contacted with a pyrophosphorylating reagent under conditions suitable for the formation of said pyrimidine nucleoside triphosphate.

5

81. The process of claim 80, wherein said pyrimidine nucleoside triphosphate is uridine triphosphate.

82. The process of claim 80, wherein said uridine triphosphate has a 2'-sugar modification.

10

83. The process of claim 82, wherein said uridine triphosphate is 2'-O-methylthiomethyl uridine triphosphate.

84. The process of claim 80, wherein said phosphorylating agent is selected from the group consisting of phosphorus oxychloride, phospho-tris-triazolides and phospho-tris-triimidazolides.

15

85. A process of claim 80, wherein said trialkylphosphate is triethyl phosphate.

86. The process of claim 80, wherein said pyrophosphorylating reagent is tributyl ammonium pyrophosphate.

87. The process of claim 72, wherein said oligonucleotide is RNA.


88. The process of claim 72, wherein said oligonucleotide is an nucleic acid catalyst.

20

89. The process of claim 72, wherein said oligonucleotide is an aptamer.

90. A kit for synthesis of an oligonucleotide comprising an RNA polymerase, an enhancer of modified nucleotide triphosphate incorporation and at least one compound of claim 71.

91. A kit for synthesis of an oligonucleotide comprising a DNA polymerase, an enhancer of modified nucleotide triphosphate incorporation and at least one compound of claim 71.
92. The kit of claim 90, wherein said RNA polymerase is a bacteriophage T7 RNA polymerase.
93. The kit of claim 90, wherein said RNA polymerase is a bacteriophage SP6 RNA polymerase.
94. The kit of claim 90, wherein said RNA polymerase is a bacteriophage T3 RNA polymerase.
95. The kit of claim 90, wherein said RNA polymerase is a mutant T7 RNA polymerase.
96. The kit of claim 90 or 91, wherein said kit comprises at least two compounds of claim 71.
97. A compound having the formula II:



wherein, R_1 is OH, $O-R_3$, wherein R_3 is independently a moiety selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester, $C-R_3$, wherein R_3 is independently a moiety selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester, halo, NHR_4 wherein R_4 is independently a moiety selected from a group consisting of alkyl (C1-22), acyl (C1-22), substituted or unsubstituted aryl), or OCH_2SCH_3 (methylthiomethyl), $ONHR_5$ where R_5 is independently a moiety selected from a group consisting of H, aminoacyl group, peptidyl group, biotinyl group, cholesteryl group, lipoic

acid residue, retinoic acid residue, folic acid residue, ascorbic acid residue, nicotinic acid residue, 6-aminopenicillanic acid residue, 7-aminocephalosporanic acid residue, alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide or ester, $ON=R_6$, where R_6 is independently pyridoxal residue, pyridoxal-5-phosphate residue, 13-cis-retinal residue, 9-cis-retinal residue, alkyl, alkenyl, alkynyl, alkylaryl, carbocyclic alkylaryl, or heterocyclic alkylaryl;

B is independently a nucleotide base or its analog or hydrogen;

X is independently a phosphorus-containing group; and

R_2 is independently blocking group or a phosphorus-containing group.

98. The compound of claim 97, wherein said compound is a nucleotide.
99. The compound of claim 97, wherein said compound is a nucleotide-triphosphate.
100. A polynucleotide comprising the compound of claim 97 at one or more positions.
101. The polynucleotide of claim 100, wherein said polynucleotide is an enzymatic nucleic acid.
102. The enzymatic nucleic acid of claim 101, wherein said nucleic acid is in a hammerhead configuration.
103. The enzymatic nucleic acid of claim 102, wherein said nucleic acid is in a hairpin configuration.
104. The enzymatic nucleic acid of claim 102, wherein said nucleic acid is in a hepatitis delta virus, group I intron, VS RNA, group II intron or RNase P RNA configuration.
105. The compound of claim 97, wherein said compound is xylo riboadenosine.

106. The compound of claim 97, wherein said compound is xylo riboguanosine.
107. The compound of claim 97, wherein said compound is xylo ribonucleoside phosphoramidite.
108. The compound of claim 107, wherein said compound is xylo riboguanosine phosphoramidite.
- 5 109. The compound of claim 107, wherein said compound is xylo riboadenosine phosphoramidite.
110. A mammalian cell comprising the compound of claim 97.
111. The mammalian cell of claim 14, wherein said cell is a human cell.
- 10 112. A mammalian cell comprising the compound of claim 101.
113. The mammalian cell of claim 112, wherein said cell is a human cell.
114. A method of making a polynucleotide of claim 100.
115. A method of modulating gene expression using a polynucleotide of claim 100.
116. A pharmaceutical composition comprising a compound of claim 97.
- 15 117. A pharmaceutical composition comprising a polynucleotide of claim 101.
118. The compound of claim 97, wherein said compound is used as an antiviral agent.
119. A process for the synthesis of a xylo ribonucleoside phosphoramidite comprising the steps of:
- 20 a) oxidation of a 2' and 5'-protected ribonucleoside using an oxidant followed by reduction using a reducing agent under conditions suitable for the formation of 2' and 5'-protected xylofuranosyl nucleoside; and

b) phosphitylation under conditions suitable for the formation of xylofuranosyl nucleoside phosphoramidite.;

120. The process of claim 119, wherein said oxidation is carried out in the presence of chromium oxide, pyridine, and acetic anhydride.
- 5 121. The process of claim 119, wherein said oxidation is carried out in the presence of dimethylsulfoxide and acetic anhydride.
122. The process of claim 119, wherein said oxidation is carried out in the presence of Dess-Martin reagent (periodinane).
- 10 123. The process of claim 119, wherein said reduction is carried out in the presence of triacetoxy sodium borohydride.
124. The process of claim 119, wherein said reduction is carried out in the presence of sodium borohydride
125. The process of claim 119, wherein said reduction is carried out in the presence of lithium borohydride,
- 15 126. A process for one pot deprotection of RNA comprising protecting groups, comprising the steps of:
- a) contacting said RNA with a mixture of anhydrous alkylamine, trialkylamine and a polar organic reagent in a predetermined proportions, at room temperature for about between 30 and 100 min under conditions suitable for the removal of nucleic acid base and phosphate protecting groups from said RNA; and
- 20 b) contacting the resulting RNA from step a with an anhydrous triethylamine-hydrogen fluoride at about between 50 °C-70 °C under conditions suitable for the removal of a 2'-OH protecting group.
127. The process of claim 126 wherein said RNA is an enzymatic RNA molecule.

128. The process of claim 128, wherein said enzymatic RNA molecule is in a hammerhead motif.
- 129 The process of claim 126, wherein said polar organic reagent is dimethylsulfoxide
130. The process of claim 126, wherein said anhydrous alkylamine is anhydrous methyl
5 amine.
131. The process of claim 126, wherein said anhydrous alkylamine is anhydrous ethylamine.
132. The process of claim 126, wherein said trialkylamine is triethylamine.
133. The process of claim 129, wherein the predetermined proportion of anhydrous
10 alkylamine, trialkylamine and dimethylsulfoxide in said mixture is 10, 3 and 13, respectively.
134. A process for one pot deprotection of RNA comprising protecting groups, comprising the steps of:
- 15 a) contacting said RNA with a mixture of anhydrous methylamine, triethylamine and dimethylsulfoxide in proportions of 10, 3 and 13, respectively, at room temperature for about 90 min under conditions suitable for the removal of nucleic acid base and phosphate protecting groups from said RNA; and
- 20 b) contacting the resulting RNA from step a with an anhydrous triethylamine•hydrogen fluoride at about between 65°C under conditions suitable for the removal of a 2'-OH protecting group.
- 135 The process of claim 134 wherein said RNA is an enzymatic RNA molecule.
136. The process of claim 135, wherein said enzymatic RNA molecule is in a hammerhead motif.

- 137 A process for one pot deprotection of RNA comprising protecting groups, comprising the steps of:
- a) contacting said RNA with a mixture of anhydrous alkylamine and a polar organic reagent in a predetermined proportions, at room temperature for about between 30 and 100 min under conditions suitable for the removal of nucleic acid base and phosphate protecting groups from said RNA; and
- b) contacting the resulting RNA with a anhydrous triethylamine•hydrogen fluoride at about between 50 °C-70 °C under conditions suitable for the removal of 2'-OH protecting group.
138. The process of claim 137 wherein said RNA is an enzymatic RNA molecule.
139. The process of claim 138, wherein said enzymatic RNA molecule is in a hammerhead motif.
140. The process of claim 137, wherein said polar organic reagent is dimethylsulfoxide
141. The process of claim 137, wherein said anhydrous alkylamine is anhydrous methyl amine.
142. The process of claim 137, wherein said anhydrous alkylamine is anhydrous ethylamine.
143. An nucleic acid catalyst with RNA cleaving activity, wherein said nucleic acid catalyst modulates the expression of a Raf gene.
144. The nucleic acid catalyst of claim 143, wherein said nucleic acid catalyst is in a hammerhead configuration.
145. The nucleic acid catalyst of claim 144, wherein said nucleic acid catalyst comprises a stem II region of length greater than or equal to 2 base pairs.

146. The nucleic acid catalyst of claim 143, wherein said nucleic acid catalyst is in a hairpin configuration.
147. The nucleic acid catalyst of claim 143, wherein said enzymatic nucleic acid is in a hepatitis δ virus, group I intron, group II intron, VS nucleic acid or RNase P
5 nucleic acid configuration.
148. The enzymatic nucleic acid of claim 146, wherein said nucleic acid catalyst comprises a stem II region of length between three and seven base-pairs.
149. The nucleic acid catalyst of claim 143, wherein said nucleic acid comprises between 12 and 100 bases complementary to said RNA.
- 10 150. The nucleic acid catalyst of claim 143, wherein said nucleic acid comprises between 14 and 24 bases complementary to said mRNA.
151. The nucleic acid catalyst of claim 144, wherein said nucleic acid catalyst consists essentially of any sequence defined as Seq ID Nos 502-1102, 1153-1460 and 1913-2353.
- 15 152. A mammalian cell including an nucleic acid catalyst of any of claim 143.
153. The mammalian cell of claim 152, wherein said mammalian cell is a human cell.
154. An expression vector comprising nucleic acid sequence encoding at least one nucleic acid catalyst of claim 143, in a manner which allows expression of that nucleic acid catalyst.
- 20 155. A mammalian cell including an expression vector of claim 154.
156. The mammalian cell of claim 155, wherein said mammalian cell is a human cell.
157. A method for treatment of cancer, restenosis, psoriasis and rheumatoid arthritis comprising the step of administering to a patient the nucleic acid catalyst of claim 143.

158. A method for treatment of cancer, restenosis, psoriasis and rheumatoid arthritis comprising the step of administering to a patient the expression vector of claim 154.
159. A method for treatment of cancer comprising the steps of: a) isolating cells from a patient; b) administering to said cells the nucleic acid catalyst of claim 143; and c) introducing said cells back into said patient.
160. A pharmaceutical composition comprising the nucleic acid catalyst of claim 143.
161. A method of treatment of a patient having a condition associated with the level of c-raf, wherein said patient is administered the nucleic acid catalyst of claim 143.
162. A method of treatment of a patient having a condition associated with the level of c-raf, comprising contacting cells of said patient with the nucleic acid molecule of claim 143, and further comprising the use of one or more drug therapies.
163. The nucleic acid catalyst of claim 144, wherein said nucleic acid molecule comprises at least five ribose residues, and wherein said nucleic acid comprises phosphorothioate linkages at at least three of the 5' terminal nucleotides, and wherein said nucleic acid comprises a 2'-C-allyl modification at position No. 4 of said nucleic acid, and wherein said nucleic acid comprises at least ten 2'-O-methyl modifications, and wherein said nucleic acid comprises a 3'- end modification.
164. The enzymatic nucleic acid of claim 163, wherein said nucleic acid comprises a 3'-3' linked inverted ribose moiety at said 3' end.
165. The nucleic acid catalyst of claim 144, wherein said nucleic acid molecule comprises at least five ribose residues, and wherein said nucleic acid molecule comprises phosphorothioate linkages at at least three of the 5' terminal nucleotides, and wherein said nucleic acid comprises a 2'-amino modification at position No. 4 and/or at position No. 7 of said nucleic acid molecule, wherein said

nucleic acid molecule comprises at least ten 2'-*O*-methyl modifications, and wherein said nucleic acid comprises a 3'- end modification.

166. The nucleic acid catalyst of claim 144, wherein said nucleic acid molecule comprises at least five ribose residues, and wherein said nucleic acid molecule comprises phosphorothioate linkages at at least three of the 5' terminal nucleotides, and wherein said nucleic acid molecule comprises an abasic substitution at position No. 4 and/or at position No. 7 of said nucleic acid molecule, wherein said nucleic acid comprises at least ten 2'-*O*-methyl modifications, and wherein said nucleic acid molecule comprises a 3'-end modification.
167. The nucleic acid catalyst of claim 144, wherein said nucleic acid molecule comprises of at least five ribose residues, and wherein said nucleic acid comprises phosphorothioate linkages at at least three of the 5' terminal nucleotides, and wherein said nucleic acid molecule comprises a 6-methyl uridine substitution at position No. 4 and/or at position No. 7 of said nucleic acid molecule, wherein said nucleic acid molecule comprises at least ten 2'-*O*-methyl modifications, and wherein said nucleic acid molecule comprises a 3' end modification.
168. A method for modulating expression of c-raf gene in a mammalian cell by administering to said cell the nucleic acid catalyst of claim 143.
169. A method of cleaving a separate RNA molecule comprising, contacting the nucleic acid catalyst of claim 143 with said separate RNA molecule under conditions suitable for the cleavage of said separate RNA molecule.
170. The method of claim 169, wherein said cleavage is carried out in the presence of a divalent cation.
171. The method of claim 170, wherein said divalent cation is Mg^{2+} .

172. The nucleic acid molecule of claim 143, wherein said nucleic acid is chemically synthesized.

173. The expression vector of claim 154, wherein said vector comprises:

a) a transcription initiation region;

5 b) a transcription termination region;

c) a gene encoding at least one said nucleic acid molecule; and

wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

10 174. The expression vector of claim 154, wherein said vector comprises:

a) a transcription initiation region;

b) a transcription termination region;

c) an open reading frame;

15 d) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and

wherein said gene is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

175. The expression vector of claim 154, wherein said vector comprises:

20 a) a transcription initiation region;

b) a transcription termination region;

c) an intron;

d) a gene encoding at least one said nucleic acid molecule; and

wherein said gene is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

5 176. The expression vector of claim 154, wherein said vector comprises:

a) a transcription initiation region;

b) a transcription termination region;

c) an intron;

d) an open reading frame;

10 e) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and

wherein said gene is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

15 177. The nucleic acid catalyst of claim 144, wherein said enzymatic nucleic acid comprises sequences that are complementary to any of sequences defined as Seq ID Nos 1-501, 1461-1768 and 2354-2794.

178. The nucleic acid catalyst of claim 146, wherein said nucleic acid catalyst consists essentially of any sequence defined as Seq ID Nos 1003-1077, 1769-1840 and
20 2795-2845.

179. The nucleic acid catalyst of claim 146, wherein said enzymatic nucleic acid comprises sequences that are complementary to any of sequences defined as Seq ID Nos 1078-1152, 1841-1912 and 2846-2896.

180. The nucleic acid catalyst of claim 144, wherein said enzymatic nucleic acid comprises sequences complementary to any of sequences defined as Seq ID Nos 2897-2956.
181. The nucleic acid catalyst of claim 143, wherein said Raf gene is c-Raf-1 gene.
- 5 182. The nucleic acid catalyst of claim 143, wherein said Raf gene is A-Raf gene.
183. The nucleic acid catalyst of claim 143, wherein said Raf gene is B-Raf gene.
184. The nucleic acid catalyst of claim 143, wherein said enzymatic nucleic acid is a DNA enzyme.
185. The nucleic acid catalyst of claim 143, wherein said enzymatic nucleic acid
10 comprises at least one 2'-sugar modification.
186. The nucleic acid catalyst of claim 143, wherein said enzymatic nucleic acid comprises at least one nucleic acid base modification.
187. The nucleic acid catalyst of claim 143, wherein said enzymatic nucleic acid comprises at least one phosphorothioate modification.
- 15 188. A method of treatment of a systemic disease in a patient comprising the step of systemically administering to said patient a nucleic acid catalyst which specifically cleaves RNA associated with said disease, under conditions in which said RNA in said patient is cleaved and a therapeutic result is attained.
189. The method of claim 188, wherein said disease is selected from the group
20 consisting of cancer, inflammation, psoriasis, non-hepatic ascites and infectious disease.
190. The method of claim 189, wherein said treatment of said cancer is characterised by a decrease in tumor metastasis.

191. The method of claim 189, wherein said treatment of said cancer is characterised by a decrease in tumor volume.
192. The method of claim 189, wherein said treatment of said cancer is characterised by a decrease in the progression of primary tumor.
- 5 193. The method of claim 188, wherein said nucleic acid catalyst is chemically modified.
194. The method of claim 188, wherein said nucleic acid catalyst is in a hammerhead motif.
- 10 195. The method of claim 194, wherein said hammerhead nucleic acid catalyst comprises 2'-C-allyl modification at position 4, phosphorothioate linkages at four 5'-terminal positions and inverted abasic nucleotide at the 3'-end of said nucleic acid molecule.
196. The method of claim 188, wherein said systemic administration is by intravenous administration of said nucleic acid catalyst into said patient.
- 15 197. The method of claim 188, wherein said systemic administration is by a bolus administration of said nucleic acid catalyst into said patient.
198. The method of claim 188, wherein said systemic administration is by continuous infusion of said nucleic acid catalyst into said patient.


Figure 1: Ribozyme Motifs

Figure 2: Accessible Site and Target Discovery




Figure 3. Hammerhead
Ribozyme




Figure 4. A Scheme for the Synthesis of Defined Ribozyme Libraries




Figure 5. Design and Synthesis of a Random Hammerhead Ribozyme Library (A), and Theoretical Complexities of a Random Hammerhead Library With Different Arm-Lengths (B)




Figure 6. Strategy for Discovery of Therapeutic Gene Targets Using Random Ribozyme Libraries




Figure 7. Example of How Random Ribozyme Libraries Could Be used To Discover Critical Genes Involved in ICAM Expression




Figure 8. Ribozyme Cloning Strategy: Design of Oligonucleotides Encoding Ribozyme Sequences and Preparation for Cloning




Figure 9. Sequence Analysis of a Ribozyme Expression Vector Library




Figure 10. Sequence analysis of PNP-targeted ribozymes in SupT1 human T following 6-thioguanosine-selection







Figure 11A: Pol II and Pol III RZ Constructs

Figure 11B: Ribozyme transcription Units Based on U1 snRNA




Wild Type


stable, exported to cytoplasm; binds SM, 2,2,7mG cap, goes back to nucleus (protein A1 binding)



stable, exported to cytoplasm (protein A1 binding)



stable, exported to cytoplasm



stable, exported to cytoplasm; binds SM, 2,2,7mG cap, goes back to nucleus (protein A1 binding)

Figure 11C: Retroviral Vector Encoding Ribozymes







Figure 11D: U6+27 Hammerhead Ribozyme Transcription Unit***Hammerhead Ribozyme***

Figure 12: A Combinatorial Approach to the Screening of Ribozyme Variants



**Figure 13: Starting Ribozyme Motif for Variation
(Hammerhead Motif/HH Motif)**



↓ Positions 3, 4 and 7 are being varied in one example





Figure 14: Screening for Variants of HH-A Ribozyme

Figure 15: Examples of Nucleotide Analogs (n) Used in Library (Class 1 Pool) Construction



226/164-PCT

Figure 16: Activity of HH-A Variant Ribozymes




Figure 17A: HH-A Variants






Figure 17B: Novel Ribozyme Variants



N= independently a nucleotide or a non-nucleotide linker, which may be same or different;
M and Q are independently oligonucleotides of length sufficient to stably interact (e.g., by forming hydrogen bonds with complementary nucleotides in the target) with a target nucleic acid molecule (the target can be an RNA, DNA or RNA/DNA mixed polymers); o and n are integers greater than or equal to 1 and preferably less than about 100, wherein if (N)_o and (N)_n are nucleotides, (N)_o and (N)_n are optionally able to interact by hydrogen bond interaction;
L is a linker which may be present or absent (i.e., the molecule is assembled from two separate molecules), but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; and
— represents a chemical linkage (e.g. a phosphate ester linkage, amide linkage or others known in the art).
A, C, U and G represent adenosine, cytidine, uridine and guanosine nucleotides, respectively, which may be modified or unmodified.

Figure 18: Formula for a novel Ribozyme Motif



N= independently a nucleotide or a non-nucleotide linker, which may be same or different;

M and Q are independently oligonucleotides of length sufficient to stably interact (*e.g.*, by forming hydrogen bonds with complementary nucleotides in the target) with a target nucleic acid molecule (the target can be an RNA, DNA or RNA/DNA mixed polymers);
 o and n are integers greater than or equal to 1 and preferably less than about 100,
 wherein if (N)_o and (N)_n are nucleotides, (N)_o and (N)_n are optionally able to interact by hydrogen bond interaction;

L is a linker which may be present or absent (*i.e.*, the molecule is assembled from two separate molecules), but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; and

— represents a chemical linkage(*e.g.* a phosphate ester linkage, amide linkage or others known in the art).

A, C, U and G represent adenosine, cytidine, uridine and guanosine nucleotides, respectively, which may be modified or unmodified.

Figure 20: Screening for Loop-II Variants of Hammerhead Ribozyme B (HH-B)




Figure 21: Activity of HH-B Variant Ribozymes




Figure 22: RNA Cleavage by Loop II
Variant HH-B Ribozyme




Figure 23: Screening for Ribozyme Binding Arm Sequence Variants-Target Discovery

Hammerhead Ribozyme Model System





Figure 24: Screening for Ribozyme Catalytic Domains




**Figure 25: Accessible Sites Within a Bcl-2 Transcript
Determined Using Combinatorial *In Vitro* Screen.**

<u>Seq. ID No.</u>	<u>Sequence of Site</u>	<u>Site</u>	<u>Est. Size</u>
1	TTGCTTT TCCTCT	78	80
2	GTTCCTT TTCCTC	77	80
3	GTGCCTA TCTGAG	795	800
4	GCTCCTC TAGACT	25	30
5	CGCCCTT CACCGC	462	480
6	AGCTCTT CAGGGA	504	480
7	TCTCTTA GACTCG	32	30
8	CTGAGTA CCTGAA	630	650
9	TTGAGTT CGGTGG	549	550
10	TGAAGTA CATCCA	144	160
11	TGTTGGTC CACCTG	370	370
12	CCCCATC CAGCCG	266	264
13	CTGGATC CAGGAT	658	680

Bcl-2 transcript is 975 nts. in length. Transcript was generated from a cDNA clone. 101 potential ribozyme sites (NUH rule); combinatorial screen identified 13 accessible sites *in vitro*.


Fig.26: Accessible Sites Within a K-ras Transcript Determined Using Combinatorial *In Vitro* Screen.



<u>Seq.ID No.</u>	<u>Sequence of Site</u>	<u>Site</u>	<u>Est. Size</u>
14	CAGGCTC AGGAGT	494	500
15	AATACTA AATCAT	365	370
16	TTGTGTA TTIGCC	346	350
17	AGGAGT ACAGTGC	294	300
18	TGTGGTA GTTGGG	127	120
19	GGTAGTT GGAGCT	130	130
20	GGGTGTT GACCAT	559	570
21	AGGAGTT ATGGGA	512	530
22	GCAGGTC AAGAGG	284	280
23	AAGAGTA AAGGAC	412	410
24	GTTGATT TGCCAT	348	360
25	AGATATT CACCAT	382	390
26	CATTATA GAGAAC	392	390
27	ATTCATT GAGACC	529	540
28	CACCATT ATAGAG	389	390

Kras transcript is 796 nts. in length. Transcript was generated from a cDNA clone (rat). 144 potential ribozyme sites (NUH rule); combinatorial screen identified 15 accessible sites *in vitro*.

Fig. 27. Accessible Sites Within a Urokinase Plasminogen Activator Transcript Determined Using Combinatorial *In Vitro* Screening.



<u>Seq.ID No.</u>	<u>Sequence of Site</u>	<u>Site</u>	<u>Est. Size</u>
29	GTCACIT [†] TTACCG	27	30
30	GCCGCTT GTCCAA	223	220
31	GGGCCTA AAGCCG	214	210
32	CACTGTC CTCAG	94	100
33	GCTTGTC CAAGAG	226	230
34	GGCCATC TACAGG	385	400
35	CACCATC GAGAAC	358	370

UPA transcript is 400 nts. in length. Transcript was generated from a PCR generated fragment (contains a T7 promoter). 45 potential ribozyme sites (NUH rule); combinatorial screen identified 7 accessible sites *in vitro*.

Figure 28. RPA Demonstrating Inhibition of Cellular Bcl-2 mRNA Using Bcl-2 Directed Ribozymes.





Figure 30: Synthesis of a Xylo ribonucleoside phosphoramidite

Scheme 1



B = standard or modified nucleotide base or H




Figure 31A: Xylo Nucleotide-Substituted Hammerhead Ribozymes

Figure 31B: Xylo Nucleotide-Substituted Hammerhead Ribozymes



Overlay of chromatograms of RPI.3703 or "two-pot" deprotected RPI.3703 ribozyme
RPI.3703 g₅u₅u₅ u₅uc ccu GAu Gag gcc gaa agg ccG aaA uuc uccB 200 nmole scale

One-pot	Two-pot
Base Deprotection: 400 µL MA/EtOH/TEA 400 µL DMSO 90 min @ RT	Base Deprotection: 1 mL MA/H ₂ O 10 min @ 65 °C Dry down
Silyl Deprotection: 100 µl TEA:3HF 15 min @ 65 °C	Silyl Deprotection: 300 µl TEA:3HF/NMP 90 min @ 65 °C
Quench: 1mL 1.5M NH ₄ HCO ₃	Quench: 1mL 1.5M NH ₄ HCO ₃



Recovery: One-Pot = 32 O.D.u 260 nm
Two-Pot = 30 O.D.u 260 nm

HPLC Purity: One-Pot = 46%
Two-Pot = 43%

Figure 33


MA/EtOH/TEA : Polar Organic
1 : 1

Organics & Conditions

DMSO, DMF, MeOH,
hexamethylphosphoramide
N-methyl-2-pyrrolidinone
2-methoxyethyl ether


at

65° C for 30 min



Only DMSO permitted the release of oligo.

Figure 34

Figure 35: Ras-Dependent Signal Transduction cascade

Adapted from *Genes V*, Lewin, 1994 Oxford University Press, New York, pp 1211

Figure 36: Structure of ribozyme directed to site 1120 and its substrate RNA sequence




Figure 37: c-raf Ribozyme-Mediated Inhibition of Smooth Cell Proliferation




Figure 38: c-raf Ribozyme-Mediated Inhibition of Smooth Cell Proliferation




Figure 39. Effects of *flt-1* ribozymes (active/inactive) on LLC-HM primary tumor growth in mice. A, 1, B, 3, C, 10, D, 30, E, 100 mg/kg/day *flt-1* ribozyme dose. Treatment begins on day 3 and continues through day 17. Data are reported as mean tumor volume \pm SEM.




Figure 40. Effects of *flt-1* ribozymes on LLC-HM primary tumor volume immediately following the cessation of treatment. RPI.4610 is catalytically active/RPI.4611 is catalytically inactive. Shaded region denotes saline control SEM. Data are reported as mean tumor volume \pm SEM. * $p < 0.05$ with respect to control by Dunnett's, ** $p < 0.05$ with respect to inactive by Tukey-Kramer.




Figure 41. Effects of *flt-1* ribozymes on lung metastatic indices (number of metastases and lung mass). A. Number of lung metastases. B. Lung mass. Data are presented as mean number of metastases or lung mass \pm SEM. Shaded region denotes saline control SEM. * $p < 0.05$ with respect to saline control by Dunnetts, † $p < 0.05$ with respect to saline control by Student's t.




Figure 42. Effects of *flk-1* ribozymes (active/inactive) on LLC-HM primary tumor growth in mice. A. 1, B. 3, C. 10, D. 30, E. 100 mg/kg/day *flk-1* ribozyme dose. Treatment begins on day 3 and continues through day 17. Data are reported as mean tumor volume \pm SEM.




Figure 43. Effects of *flk-1* ribozymes on LLC-HM primary tumor volume immediately following the cessation of treatment. RPI.4733 is catalytically active/RPI.4634 is catalytically inactive. Shaded region denotes saline control SEM. Data are reported as mean tumor volume \pm SEM. * $p < 0.05$ with respect to control by Dunnett's, ** $p < 0.05$ with respect to inactive by Tukey-Kramer.





Figure 44. Effects of *flk-1* ribozymes on lung metastatic indices (number of metastases and lung mass). A. Number of lung metastases. B. Lung mass. Data are presented as mean number of metastases or lung mass \pm SEM. Shaded region denotes saline control SEM. * $p < 0.05$ with respect to saline control by Dunnett's, † $p < 0.05$ with respect to saline control by Student's t, ** $p < 0.05$ with respect to inactive control.





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C12N 9/00, C07H 19/10, 19/20, 19/04, 21/00, C12N 9/12, 15/10</p>	A3	<p>(11) International Publication Number: WO 98/50530</p> <p>(43) International Publication Date: 12 November 1998 (12.11.98)</p>																							
<p>(21) International Application Number: PCT/US98/09249</p> <p>(22) International Filing Date: 5 May 1998 (05.05.98)</p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr><td style="width: 30%;">60/046,059</td><td style="width: 40%;">9 May 1997 (09.05.97)</td><td style="width: 30%;">US</td></tr> <tr><td>60/049,002</td><td>9 June 1997 (09.06.97)</td><td>US</td></tr> <tr><td>60/051,718</td><td>3 July 1997 (03.07.97)</td><td>US</td></tr> <tr><td>60/056,808</td><td>22 August 1997 (22.08.97)</td><td>US</td></tr> <tr><td>60/061,324</td><td>2 October 1997 (02.10.97)</td><td>US</td></tr> <tr><td>60/061,321</td><td>2 October 1997 (02.10.97)</td><td>US</td></tr> <tr><td>60/064,866</td><td>5 November 1997 (05.11.97)</td><td>US</td></tr> <tr><td>60/068,212</td><td>19 December 1997 (19.12.97)</td><td>US</td></tr> </table> <p>(71) Applicant (for all designated States except US): RIBOZYME PHARMACEUTICALS, INC. [US/US]; 2950 Wilderness Place, Boulder, CO 80301 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): JARVIS, Thale [US/US]; 3720 Smuggler Place, Boulder, CO 80301 (US). MAT- ULIC-ADAMIC, Jasenka [YU/YU]; 760 South 42nd Street, Boulder, CO 80303 (US). REYNOLDS, Mark [US/US]; 4184 N. Larkspur Court, Lafayette, CO 80026 (US). KISICH, Kevin [US/US]; 2451 Jonquil Circle, Lafayette, CO 80026 (US). BELLON, Laurent [FR/FR]; 2946 Glenwood Drive, Boulder, CO 80301 (US). PARRY, Tom [US/US]; 12610 Utica Street, Broomfield, CO 80020 (US). BEIGELMAN, Leonid [US/US]; 5530 Colt Drive, Longmont, CO 80503 (US). MCSWIGGEN, James, A. [US/US]; 4866 Franklin Drive, Boulder, CO 80301 (US). KARPEISKY, Alexander [US/US]; 420 Vernier Avenue, Lafayette, CO 80024 (US). BURGIN, Alex [US/US];</p>	60/046,059	9 May 1997 (09.05.97)	US	60/049,002	9 June 1997 (09.06.97)	US	60/051,718	3 July 1997 (03.07.97)	US	60/056,808	22 August 1997 (22.08.97)	US	60/061,324	2 October 1997 (02.10.97)	US	60/061,321	2 October 1997 (02.10.97)	US	60/064,866	5 November 1997 (05.11.97)	US	60/068,212	19 December 1997 (19.12.97)	US	<p>832 Caminito Estrella, Chula Vista, CA 91910 (US). THOMPSON, James [US/US]; 2925 Glenwood Drive #103, Boulder, CO 80301 (US). WORKMAN, Christopher, T. [US/US]; 3910 Longwood, Boulder, CO 80303 (US). BEAUDRY, Amber [US/US]; 711 E. Genesee Street, Lafayette, CO 80026 (US). SWEEDLER, David [US/US]; 956 St. Andrews Lane, Louisville, CO 80027 (US).</p> <p>(74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 29 July 1999 (29.07.99)</p>
60/046,059	9 May 1997 (09.05.97)	US																							
60/049,002	9 June 1997 (09.06.97)	US																							
60/051,718	3 July 1997 (03.07.97)	US																							
60/056,808	22 August 1997 (22.08.97)	US																							
60/061,324	2 October 1997 (02.10.97)	US																							
60/061,321	2 October 1997 (02.10.97)	US																							
60/064,866	5 November 1997 (05.11.97)	US																							
60/068,212	19 December 1997 (19.12.97)	US																							
<p>(54) Title: ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE</p>																									
<p>(57) Abstract</p> <p>Nucleic acid catalysts which modulate the expression of Raf gene; method of delivery, screening, identification, synthesis, deprotection, purification, of nucleic acid catalysts and processes for identification of nucleic acid molecules is described.</p>																									

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/09249

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N9/00 C07H19/10 C07H19/20 C07H19/04 C07H21/00
C12N9/12 C12N15/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 44 24 762 C (MAX PLANCK GESELLSCHAFT) 27 July 1995 cited in the application see column 2, line 45 - column 6, line 10 ---	1,2,6,9, 13-15, 25,30, 33,34, 37-39,70
X	WO 93 23569 A (RIBOZYME PHARM INC) 25 November 1993 cited in the application see page 129 - page 152 --- -/--	1-39

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 January 1999

Date of mailing of the international search report

03.06.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Kok, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/09249

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JARVIS T C ET AL: "INHIBITION OF VASCULAR SMOOTH MUSCLE CELL PROLIFERATION BY HAMMERHEAD RIBOZYMES TARGETTING C-MYB" JOURNAL OF CELLULAR BIOCHEMISTRY., vol. 19A, 1995, page 221 XP002024063 US see the whole document ---	1,2
A	US 5 616 459 A (KRAMER FRED R ET AL) 1 April 1997 cited in the application see the whole document ---	1-39
A	COTTEN M: "THE IN VIVO APPLICATION OF RIBOZYMES" TRENDS IN BIOTECHNOLOGY., vol. 8, no. 7, 1 July 1990, pages 174-178, XP000133091 CAMBRIDGE GB see the whole document ---	14-29
A	WO 95 23225 A (RIBOZYME PHARM INC) 31 August 1995 see page 1 - page 7 see page 81 - page 111; figures 30-39 ---	9-12, 15-21, 24-29
A	WO 96 18736 A (RIBOZYME PHARM INC) 20 June 1996 see abstract ---	1
E	WO 98 32880 A (IMMUSOL INC) 30 July 1998 see page 4 - page 8 see page 21 - page 54 -----	1-4,10, 13-16, 21,25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/09249

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims 1-39, 70.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-39 70

A method for identifying a nucleic acid catalyst capable of modulating a process in a biological system

2. Claims: 40-69

Nucleic acid molecules with an endonuclease activity having the formula III to VII, their preparation and their use

3. Claims: 71-79 87-96

Nucleoside triphosphates having formula I and their use

4. Claims: 80-86

A process for the synthesis of a pyrimidine nucleoside triphosphate

5. Claims: 97-125

Compounds having formula II, methods for their preparation and their use.

6. Claims: 126-142

A process for one pot deprotection of RNA

7. Claims: 143-187

A nucleic acid catalyst with RNA cleaving activity, which modulates the expression of a Raf gene

8. Claims: 188-198

A method of treatment of a systemic disease in a patient comprising the step of administering a nucleic acid catalyst which specifically cleaves RNA

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/09249

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 4424762 C	27-07-1995	WO 9601314 A EP 0776363 A	18-01-1996 04-06-1997
WO 9323569 A	25-11-1993	US 5496698 A AU 4221593 A AU 687736 B AU 4222993 A CA 2135646 A EP 0642589 A JP 8500481 T MX 9302726 A US 5622854 A US 5693535 A US 5610054 A US 5869253 A US 5795778 A US 5525468 A US 5646020 A US 5686599 A US 5804683 A US 5631360 A US 5831071 A US 5891684 A US 5879938 A US 5767263 A US 5672511 A	05-03-1996 13-12-1993 05-03-1998 13-12-1993 25-11-1993 15-03-1995 23-01-1996 31-08-1994 22-04-1997 02-12-1997 11-03-1997 09-02-1999 18-08-1998 11-06-1996 08-07-1997 11-11-1997 08-09-1998 20-05-1997 03-11-1996 06-04-1999 09-03-1999 16-06-1998 30-09-1997
US 5616459 A	01-04-1997	AU 651380 B AU 8517591 A CA 2087519 A EP 0600877 A WO 9201806 A	21-07-1994 18-02-1992 17-01-1992 15-06-1994 06-02-1992
WO 9523225 A	31-08-1995	US 5639647 A US 5658780 A US 5837542 A US 5811300 A US 5616488 A US 5631359 A US 5693532 A US 5783425 A US 5714383 A AU 1821495 A CA 2183992 A EP 0746614 A JP 9509323 T US 5627053 A US 5686599 A US 5804683 A US 5631360 A US 5831071 A AU 1817595 A US 5837855 A	17-06-1997 19-08-1997 17-11-1998 22-09-1998 01-04-1997 20-05-1997 02-12-1997 21-07-1998 03-02-1998 01-06-1995 31-08-1995 11-12-1996 22-09-1997 06-05-1997 11-11-1997 08-09-1998 20-05-1997 03-11-1998 11-09-1995 17-11-1998
WO 9618736 A	20-06-1996	US 5891683 A US 5891684 A US 5612215 A US 5716824 A	06-04-1999 06-04-1999 18-03-1997 10-02-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/09249

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9618736 A		US 5627053 A	06-05-1997
		US 5672501 A	30-09-1997
		AU 4412096 A	03-07-1996
		CA 2207593 A	20-06-1996
		EP 0799313 A	08-10-1997
		US 5731295 A	24-03-1998
		US 5879938 A	09-03-1999
		US 5767263 A	16-06-1998
		US 5672511 A	30-09-1997
		US 5840876 A	24-11-1998
WO 9832880 A	30-07-1998	AU 5927598 A	18-08-1998